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1 Introduction and task formulation 
Chirality is the property of an object that does not allow to result in itself after implementation of any 
symmetry operation. Two enantiomersi of a chiral object, for instance a chiral molecule, behave to 
each other like an image and a mirror image (Figure 1). 
When a prochiral compound is transformed into a chiral one, both enantiomers can be formed.ii They 
have same physical and chemical properties like melting point, boiling point or solubility,iii but they 
have the characteristic to rotate linear polarized light with the same amplitude but to opposite 
directions. When enantiomers interact with other chiral compounds, diastereomers are formed. 
However, these diastereomers have different physical and chemical properties. Everywhere in living 
nature consisting mainly of homochiral compounds, the formation of such diastereomers plays a 
crucial role. Typical examples are the interaction of chiral aroma compounds with chiral receptors in 
the human nose (mainly proteins) or the effect of chiral pharmaceuticals on any biological chiral 
receptors in the body. Another example is the interaction of chiral agrochemicals with chiral receptors 
in plants. An instance of a chiral drug, in which both enantiomers have different therapeutic effects, is 
illustrated in Figure 2. Darvon is an analgesic agent; its enantiomer Novrad has an antitussive effect. 
This situation has led to a revolution in the pharmaceutical industry, because now the individual effect 
of each enantiomer has to be tested and proved.iv With the help of the eudismic ratio,i statements about 
                                                     
i  These are compounds with the same chemical constitution, but they cannot be aligned due to a different physical 
configuration. 
ii  The 1:1-mixture of two enantiomers is called “racemate” or “racemic mixture”. 
iii  Noteworthy, at a level of very small energies, differences of about 10-14 J/mol have been calculated, which is one possible 
rationalization for the development of homochirality on earth.[1] 
iv The discussion about the effect of both enantiomers of thalidomide was crucial for this consideration.  
 
Figure 1. Chirality of a 
molecule: both compounds 
behave to each other like an 
image and a mirror image and 
cannot be aligned. 
 
Figure 2. Enantiomers and their different properties: Darvon and Novrad. 
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the pharmacological activity of the mixture of both enantiomers of a drug can be made. It also explains 
why it is often so important to prepare exclusively one stereoisomer. 
There are many different opportunities to obtain enantiomerically pure compounds, which proved to 
be successful in recent years. One of the oldest but still powerful method is resolution of 
diastereomers. Starting from the produced racemic mixture, both enantiomers are converted into 
diastereomers with the help of enantiomerically pure chiral excipients.ii These diastereomers can be 
separated by crystallization or chromatography. The corresponding pure enantiomer is finally yielded 
by separation from its excipient. Unfortunately, the maximum yield of the desired enantiomer can only 
reach 50 %, because usually one form is needed and the other is unwanted (waste). 
It is spoken of the chiral pool when naturally occurring chiral building blocks are used to constitute 
the desired optically pure compounds. However, these compounds are limited to their natural 
occurrence and fixed configuration of the starting material. 
The stoichiometric asymmetric synthesis utilizes a chiral auxiliaryiii that enables the substrate to be 
bound and consequently converted diastereoselectively. After separation from the auxiliary, the 
desired product occurs enantiomerically pure. But, this way is often uneconomical, since 
stoichiometric amounts of a chiral excipient are required and its separation turns out to be problematic. 
The most effective method for the preparation of enantiomerically pure compounds is asymmetric 
catalysis. With the help of a relatively small amount of a chiral catalyst (e.g. enzyme, metal complex 
etc.), substrates can be converted into one required enantiomer with excellent stereoselectivity. 
Supplementary, mild and thus economical reaction conditions make an application on industrial-scale 
very attractive. 
Enantioselective hydrogenation as well as enantioselective hydroformylation are two important kinds 
of catalysis to obtain enantiomerically pure compounds. Depending on the reagent, they undergo 
different pathways in their catalytic cycles, as illustrated in Scheme 1. 
The -alkyl-metal-complex is considered as a pivotal intermediate for the whole dissertation. It can 
react with hydrogen to form the saturated compound. Reaction with syngas leads to the aldehyde. 
                                                                                                                                                                     
i  The eudismic ratio describes the difference in the pharmalogical activity of both enantiomers in a drug. It represents the 
quotient of the activity or affinity of the pharmacological effective enantiomer (eutomer) to the activity or affinity of the 
less or non-effective enantiomer (distomer). 
ii  Usually chiral excipients are compounds of natural origin, for instance tartaric acid, sugars, alkaloides, etc. 
iii  A chiral auxiliary is a chemical compound, what is incorporated into a reaction to control the stereoselectivity. After 
completion of the reaction the auxiliary is separated from the product and can be reused. 
 
Scheme 1. Starting from the olefin, the -alkyl-metal-complex is formed by addition of the 
catalyst. This complex reacts either with hydrogen to yield an alkane (hydrogenation) or with 
carbon monoxide and hydrogen to generate an aldehyde (hydroformylation). In the case of 
-hydride elimination, isomerization occurs. 
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-Hydride elimination affords the isomerized olefin. By application of prochiral compounds, 
hydrogenation and hydroformylation, respectively, give rise to chiral products. 
Despite of the usage of different reaction gases (hydrogen and a mixture of carbon monoxide and 
hydrogen [e.g. syngas]) and of leading to different reaction products (alkanes and aldehydes), 
enantioselective hydrogenation and enantioselective hydroformylation have following similarities: 
 metal catalysts are used (e.g. rhodium, ruthenium, cobalt, iridium, palladium) 
 olefins are used as substrates 
 chelating chiral phosphorus ligands (especially trivalent phosphorus compounds) are used 
 high enantioselectivities can be reached 
 high atom economy: small molecules are added and practically no waste is produced 
 hydrogenation can occur as a side reaction accompanied by the hydroformylation 
These facts make clear that both ways of catalysis are of special interest for synthesis chemists, 
because starting from the same substrates a vast variety of products can be achieved by minor changes 
of reaction conditions. 
The task of this dissertation was to test and explore the ability to hydrogenate and hydroformylate 
1,1-disubstituted olefins and to reach a significant enantiomeric excess (ee) of the resulting chiral 
products. The particular challenge was that substrates chosen herein were seldom or never in the 
focus of asymmetric catalysis. The results should be optimized by varying the reaction conditions 
and by the synthesis and application of novel chiral ligands. Thus, the goal was to find elegant or 
alternative routes to a range of enantiomerically pure compounds by catalysis.  
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2 General section 
2.1 Hydrogenation 
Hydrogenation, in general, is the addition of hydrogen to a multiple (double or triple) bond of an 
organic molecule in the presence of a catalyst (Scheme 2). 
It is not necessarily limited to carbon-carbon multiple bonds, but also for carbon-heteroatom multiple 
bonds, e.g. carbon-nitrogen and carbon-oxygen bonds. As a hydrogen source molecular hydrogen is 
usually applied, but other hydrogen donors (isopropanol, formic acid derivatives) have been utilized in 
transfer hydrogenation. The H-H bond energy is 434 kJ/mol,[2] therefore a catalyst is required to lower 
the dissociation energy. Usually, it is distinguished between heterogeneous and homogeneous 
hydrogenation. While for heterogeneous hydrogenation the catalyst is not soluble in the reaction 
medium and at least two phases exist, the latter is characterized by existence of the catalyst and the 
substrate in one phase.i 
On a large industrial-scale, the heterogeneously catalyzed hydrogenation is of greater importance 
compared to the homogeneous. However, when stereoselectivity is aimed in a reaction, homogeneous 
catalysis is the first choice.[3] This preference can be rationalized by the better reproducibility of 
molecular defined catalyst preparation and reaction. Depending on the nature of the substrate and on 
the choice of the catalyst, the homogeneously catalyzed hydrogenation can be divided into an 
asymmetric and non-asymmetric version. 
 
 
2.1.1 Principles and generals 
Asymmetric hydrogenation is meant when a prochiral substrate (e.g. olefin, ketone or imine) is 
transferred into a saturated chiral product with formation of at least one stereogenic center. As 
catalysts a wide range of transition metal complexes have been used. Rhodium, ruthenium and iridium 
are proved to be especially powerful for this purpose. 
Polar groups, located next to the double bond, are beneficial for the asymmetric hydrogenation of 
olefins since such groups allow an efficient electronic and steric stereodifferentiation.ii On the other 
hand, such heteroatoms may additionally coordinate to the metal center. As a result, chelates are 
formed, which further reduce the conformational flexibility. 
1,1-Disubstituted, 1,1,2-trisubstituted (internal) and 1,1,2,2-tetrasubstituted olefins can be 
hydrogenated enantioselectively. The mechanism for the Rh-catalyzed hydrogenation of 
1,1-disubstituted olefins[5] differs from the Ru-catalyzed hydrogenation in the manner of the addition 
of hydrogen as shown by Noyori for the example of prochiral (2-acetamidomethyl)acrylate (MAA).[5a]  
                                                     
i  It should be taken into consideration that a system consisting of a gas and a liquid also represents a two-phase system, 
which should be assigned to heterogeneous catalysis. Usually, this differentiation is not done in catalysis.  
ii  However, there are some examples of the successful Ir-catalyzed enantioselective hydrogenation of unfunctionalized 
substrates. Unlike Rh- and Ru-diphosphine-complexes they do not require the presence of a coordinating group near the 
C=C bond, so even purely alkyl-substituted olefins could be hydrogenated with high enantioselectivity. Recent works were 
published by Pfaltz, Andersson and Diéguez.[4] 
 
Scheme 2. Hydrogenation of alkynes to alkenes and finally to 
alkanes. 
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In principle, both enantiomers can be yielded equally. What stereoisomer is favored most can be 
qualitatively explained with the stereodifferenting manner of coordination of the substrate to the 
catalyst. With the help of the quadrant rule,[6] the favorable orientation of the coordinated olefin is 
concluded. This can be clarified with the example of (R,R)-Me-DuPhos, a diphosphine in which two 
phosphorus atoms are part of a chiral phosphacycloalkane. The phosphine units are connected by an 
achiral scaffold.[7] If one imagines the rhodium catalyst bearing the bidentate ligand and divide it into 
four quadrants, both methyl groups of each ring can be assigned to one quadrant (Figure 3). 
In the case of (R,R)-Me-DuPhos, quadrant 1 as well as quadrant 4 are “occupied”; the two others are 
“empty”. Depending on what side the substrate approaches, two diastereomers can be formed.i In a 
consequence, steric repulsion is minimized when the substrate coordinates in such a way that larger 
substituents do not interact with one of the blocked quadrants. Thus, only one substrate-complex is 
favored that finally leads to a single enantiomer. However, this model does not explain why more 
steric hindered ligands do not mandatorily generate highest enantioselectivities for a substrate.  
A quantitative concept, derived from kinetic investigations, is the famous Halpern-mechanism,ii which 
differentiates between two diastereomeric catalyst-substrate-complexes.[8] This so-called major-minor 
concept is based on the assumption that both diastereomers are formed at the beginning of the catalytic 
cycle: the thermodynamically favored (major) complex and the thermodynamically unfavored (minor) 
complex. Since the former is much more stable toward the reaction with hydrogen, it reacts more 
slowly to the corresponding enantiomeric product than the latter. In the result, the predominantly 
formed enantiomer derives from the minor-pathway.[5a,8] 
 
 
2.1.2 Enantioselective hydrogenation of olefins in industry 
Up to now, a large number of large- or small-scale processes, applying asymmetric hydrogenation, 
have been conducted in industry.[9] Until 2012, the synthesis of chiral Metolachlor,iii one of the most 
important grass herbicides for use in maize, represented the largest process for asymmetric catalysis 
(Scheme 3).[10] 
The stereoselective hydrogenation of MEA-imine to (S)-NAA marks the key step in the synthesis of 
(S)-Metolachlor developed by Ciba-Geigy. Starting from MEA-imine, what is derived from the 
reaction of methoxyacetone and 2-methyl-6-ethyl aniline (MEA), the (S)-NAA can be attained in 
                                                     
i  In the case of a C2-symmetric ligand (e.g (R,R)-Me-DuPhos), both possibilities for the coordination of the ligand result in 
the same geometry of the catalyst. 
ii  The Halpern-mechanism is also called “major-minor concept”. 
iii  For both enantiomers of Metolachlor it exists also two atropisomers resulted by a chiral axis. Both atropisomers of 
(S)-Metolachlor exhibit the same biological activity, while the other ones (for (R)-Metolachlor) are inactive.  
 
Figure 3. (R,R)-Me-DuPhos, the quadrant rule of the ligand coordinated to rhodium and the two orientations how the 
substrate can coordinate. 
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79 %ee with almost full conversion. The target benchmarki was significantly exceeded through a 
TOF >400’000 h-1 and a TON >2’000’000. 
Since 2012, the hydrogenation of citral to achieve citronellal has superseded the Metolachlor-process 
as the largest industrial process with more than 20’000 t/a. This is the key step for the synthesis of 
L-menthol at BASF (Scheme 4). Remarkably, a typical “hydroformylation catalyst” is used, which is 
prepared from a reaction of the precursor with CO. Also in the subsequent hydrogenation, a small 
concentration of CO in the hydrogen stream has to be maintained.[11] 
A very recent example, which is of particular economic and medicinal importance, is the 
diastereoselective hydrogenation of Artemisinic acid. The substrate is produced with the assistance of 
genetically modified yeast. Subsequent hydrogenation with a diphenyl-diphosphine-based ruthenium 
catalyst gives the product in high diastereoselectivity that is then converted to Artemisinin.ii  
                                                     
i  The main goal for the synthesis of (S)-Metolachlor was to reach TOF’s >10’000 h-1, TON’s >50’000 and ee’s ≥80 %.  
ii  The development of the technical process was financed by the Bill-and-Melinda-Gates-foundation and shall contribute to 
the reconvalescence of millions of humans suffer from Malaria in Africa. 
 
Scheme 3. Stereoselective hydrogenation of MEA-imine to (S)-NAA and subsequent transformation into 
(S)-Metolachlor. 
 
Scheme 4. Enantioselective hydrogenation of citral to Citronellal and final conversion to 
L-Menthol. 
Chapter 2: General section 
- 7 - 
Also 1,1-disubstituted olefins, considered in this thesis, are used as starting material for the production 
of enantiomerically pure hydrogenation products, such as L-DOPA[12] (Figure 5). The syntheses of 
(S)-Naproxen and (S)-Ibuprofen (Figure 5), which could be also realized by asymmetric 
hydrogenation, do not play an important role on an industrial-scale due to the poor accessibility of the 
substrates. 
 
 
 
2.2 Hydroformylation 
The hydroformylationi is formally a reaction of an alkene with hydrogen (H2) and carbon monoxide 
(CO) under formation of an aldehyde (Scheme 5). 
                                                     
i  The hydroformylation is also known as “oxo synthesis”. 
 
Figure 4. Synthesis of Artemisinin: the diastereoselective hydrogenation of Artemisinic acid to yield 
Dihydroartemisinic acid represents the key step. 
 
Figure 5. L-DOPA, (S)-Naproxen and (S)-Ibuprofen derived from 1,1-disubstituted olefins as precursors. 
 
Scheme 5. Hydroformylation of olefins. 
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This reaction was discovered by Roelen at Ruhrchemie in 1938[13] in the framework of investigation 
on the Fischer-Tropsch-synthesis and is nowadays one of the biggest and most important reactions in 
homogeneous catalysis worldwide with ca. 10.8 Mt/a (2002).[14]  
Its products (aldehydes, alcohols, esters) are applied in many fields of daily life, especially as 
detergents and surfactants, as plasticizers in the polymer chemistry or as cosmetics (Figure 6).[15] 
 
 
2.2.1 Principles and generals 
Contrary to the hydrogenation, in hydroformylation the double bond is not attacked by two (equal) 
atoms (H), but is formally linked to a hydrogen atom and a formyl group. Due to this fact, two 
regioisomers can result for a terminal olefin with a carbon chain number longer than two (when 
isomerization is omitted): linear aldehydes, whereby the carbonyl group is linked to the terminal 
position (n-aldehydes), or branched (iso-) aldehydes, which result from an attack on the interior side of 
the double bond. The generally accepted catalysis mechanism was established by Wilkinson and 
co-workers (Scheme 6, dissociative mechanism).[16] 
 
Figure 6. Hydroformylation products and their application. 
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Starting from the triganol bipyramidal complex HRh(PPh3)3(CO), the quadratic planar hydride-
complex HRh(PPh3)2(CO) (a) is formed by dissociation of one PPh3-molecule. One coordination side 
is now vacant to bind the alkene under formation of a -complex (b). The -complex is formed by 
insertion. At this point, two routes are possible depending on what carbon atom the metal-alkyl bond is 
established. Without isomerization the n-alkyl-metal-complex leads in the last step to the terminal 
aldehyde, whereas the branched intermediate gives rise to the iso-aldehyde (c or c'). When a further 
CO-molecule is taken up, the trigonal bipyramidal complex is formed (d or d'). Insertion of CO results 
in the formation of the quadratic planar Rh(PPh3)2(CO)(acyl)-complex (carbonylation to e or e'). 
Oxidative addition of hydrogen gives complex f and f', respectively. On hydrogenolysis, the linear or 
the branched aldehyde are liberated and the unsaturated HRh(PPh3)2(CO)-complex (a) is regenerated 
that closes the catalytic cycle. 
What regioisomer is mostly favored depends on many factors, such as nature of the ancillary ligand, 
reaction conditions and structure of the substrate. 
One can assume that bulky ligands as well as an increased concentration of ligand lead to an enhanced 
amount of linear aldehyde. Steric congestion around the rhodium results in an overfull complex that 
consequently coordinates to the less hindered side of the olefin. Usually, the formyl group is not linked 
 
Scheme 6. Dissociative mechanism for the hydroformylation of a terminal olefin and the formation of regioisomers 
according to Wilkinson. 
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to a tertiary C-atom, which is expressed in Keulemans’ rule.[17] However, this empirical rule could be 
disproved for a few examples.[18] 
As already pointed out, organic ligands have a great influence on the success of the reaction. They can 
determine reactivity, regioselectivity as well as stereoselectivity and affect the amount of side products 
(chemoselectivity), too. Most important parameters are their sterically demanding and electronic 
properties. Tolman developed a model to measure the steric demand that enables a comparison of 
several ligands with regard to their size. This concept of a cone angle () is based on the measurement 
of the angle, what emerges between the arms of the axis from metal to the outer edge of one 
substituent, starting from the metal as apex.[19] Originally, the distance between the metal center and 
the coordinating atom, that bears all substituents, is defined as 2.28 Å (Figure 7). 
The steric demand of bidentate ligands can be described with the natural bite angle (n), which was 
suggested by Casey and Whiteker.[20] Hereby, the angle, spanned between both donor atoms and the 
metal, is measured while the chelating ligand coordinates (Figure 7). The concept was proved in detail 
with xanthene-based diphosphines (XantPhos-type ligands).[21] 
In Figure 8 are given some bite angles of characteristic bidentate ligands.[22] 
The bite angle has an decisive influence on the regioselectivity.[23] The larger it is, the more increases 
the possibility that the ligand adopts ee-coordination (equatorial-equatorial), whereas ea-coordination 
(equatorial-apical) is especially favored when the ligand has only a small bite angle.[22a] 
When chiral ligands are used, asymmetric hydroformylation (AHF) can be achieved.[24] The goal is to 
get predominantly a single enantiomer. Depending on the alkenes (monosubstituted, 1,2-, or 
1,1-disubstituted) submitted to the reaction, different chiral aldehydes can be obtained. For terminal 
 
Figure 7. Tolman’s cone angle () and the natural 
bite angle (n). 
 
Figure 8. Bite angles of selected bidentate ligands. 
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olefins only the branched product is chiral, whereas the linear aldehyde is achiral. Internal and also 
1,1-disubstituted olefins can give chiral products for both regioisomers (Scheme 7). 
 
 
2.2.2 Asymmetric hydroformylation 
During the last three decades, asymmetric hydroformylation[18a,25] has been developed as an elegant 
process[26] to convert prochiral olefins into enantiomerically pure aldehydes in one step. They serve as 
a lucrative starting material for a large number of interesting compounds. Despite of great 
investigations and a huge number of chiral phosphorus ligands,[25a,b] that have been established in 
rhodium-catalyzed asymmetric hydroformylation, the range of potential substrates is limited to 
monosubstituted[25a,27] and 1,2-disubstituted[28] olefins. 
 
 
2.2.2.1 Potential industrial application of asymmetric hydroformylation 
Today, asymmetric hydroformylation does not play a considerable role in industry. Main reasons are 
the low productivity of the catalysts and, in several cases, the poor accessibility of the substrates. 
Nevertheless, some approaches, developed on small-scale, desire attention. For example, 
(R)-Flurbiprofen, (S)-Ketoprofen and (S)-Tiaprofenic acid (Figure 9) could be synthesized starting 
from the relevant vinyl aromatics by hydroformylation and final oxidation.[29] This method could 
represent an alternative compared to the enantioselective hydrogenation (see above), because starting 
vinyl compounds can be synthesized with much less efforts in comparison to relevant 2-substituted 
acrylates. In the same manner, the preparation of enantiopure Naproxen and Ibuprofen has been taken 
into consideration. 
 
Scheme 7. (Asymmetric) hydroformylation of terminal, internal and 1,1-disubstituted 
olefins and their hydroformylation products. 
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The competition for the optimal asymmetric access can also be illustrated with the so-called “Roche 
aldehyde” in hand. Usually, this compound is prepared by asymmetric hydrogenation and subsequent 
two step conversion of the formed “Roche ester”.[30] An approach, which is based on the asymmetric 
hydroformylation, should be shorter.i Indeed, with a Rh catalyst, based on (S,S,S)-BisDiazaPhos, the 
branched aldehyde was achieved, starting from the corresponding O-silylether, in excellent 
enantioselectivities (up to 97 %). In 2012, this synthesis route was up-scaled[31] (Scheme 8). 
Also, the asymmetric hydroformylation of structurally related allyl cyanide gives access to some 
important pharmaceuticals developed by Merck and Ono Pharmaceuticals. Researchers from 
Dowpharma, using a Rh/(R,R)-Kelliphite catalyst under mild conditions, were able to achieve a b/l 
ratio of 20/1 and an enantioselectivity of 80 % for the desired chiral aldehyde. (Scheme 9).[27a] Thus, 
prior results, obtained from Rh/(R,S)-BINAPHOS, could be improved enormously.ii Up-scaling to ca. 
1 mol-scale of substrate was possible after optimization of the reaction conditions. 
                                                     
i  A price of $0.04/g for allyl alcohol compared to that of the “Roche ester” ($14/g) emphasizes the importance of asymmetric 
hydroformylation to yield the “Roche aldehyde”.[31]  
ii  The rhodium-catalyzed hydroformylation of allyl cyanide gave only a b/l ratio of 72/28 and 66 %ee with (R,S)-BINAPHOS 
as ligand.[32]  
 
Figure 9. Examples for the application of enantioselective hydroformylation: (R)-Flurbiprofen, 
(S)-Ketoprofen and (S)-Tiaprofenic acid. 
 
Scheme 8. An alternative synthetic strategy to the “Roche aldehyde” by asymmetric hydroformylation. 
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Asymmetric hydroformylation of vinyl acetate is another example of potential application in fine 
chemistry. The reaction on a 150-180 g-scale was performed with a rhodium catalyst based on 
(S,S,S)-BisDiazaPhos and proceeds with >90 % conversion and a TOF of 19’400 h-1 
(TON = 99’962).[33] Starting from the chiral aldehyde, obtained with 96.8 %ee, subsequent 
transformations, e.g. to chiral 1,2-amino alcohols, were possible (Scheme 10). 
 
 
2.2.2.2 Enantioselective hydroformylation of 1,1-disubstituted olefins 
Up to now, the enantioselective hydroformylation of 1,1-disubstituted substrates was much less 
investigated.[18b-d,24,28a,34] First work was done by Consiglio and Morandini in 1985.[34a] 
Hydroformylation of -methyl styrene using both, PtCl2/SnCl2 and different rhodium catalysts, led 
either with (S,S)-ChiraPhos or (R,R)-DIOP to poor ee-values of maximum 21 %. Although 
extraordinarily long reaction times (up to 70 h) were applied, only low to moderate conversions were 
noted. In 2004, Takahashi obtained 3-phenylbutanal as product deriving from -methyl styrene with 
[(Rh(cod)2(OAc)]2 and a self-prepared diphosphite ligand in 46.2 %ee, what is highest up to now.[34b] 
However, the conversion was quite poor (15 %). 
In 1987, Stille and co-workers described the reaction of methyl methacrylate with syngas.[34c] A 
[(‒)-BPPM]PtCl2/SnCl2 catalyst was employed,[35] which required strongly elevated syngas pressures 
(18.3 MPa) and also long reaction times (50 h) to provide the linear aldehyde with low to moderate 
enantioselectivities, but little conversions. Both parameters showed opposing tendencies: increasing 
the conversion by changing the ratio of partial pressures of hydrogen to carbon monoxide lowered the 
enantioselectivity and vice versa. Also a few (hydrogenation) by-products were observed, but the 
selectivity still remained superb. 
 
Scheme 9. Asymmetric hydroformylation of allyl cyanide and subsequent steps to pharmaceutically interesting compounds. 
 
Scheme 10. Asymmetric hydroformylation of vinyl acetate and subsequent 
transformation. 
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In the same year, Kollár et al. expanded the scope for the asymmetric hydroformylation of 
1,1-disubstituted olefins to -alkyl acrylates as well as itaconates.[34d] However, the reaction was still 
performed with a PtCl2/SnCl2 catalyst using chiral DIOP as ligand that likewise required high syngas 
pressures (8 MPa) to be stable. Lowering the temperature from 100 °C to 50 °C resulted in much 
better enantioselectivities (up to 82 %), but enormously affected the yield of the chiral aldehyde. 
Furthermore, under these conditions, also competitive and undesirable hydrogenation became more 
significant. 
In 1988, Kollár published the results of the asymmetric hydroformylation of different substrates, 
including -methyl styrene, methyl methacrylate and methyl itaconate, based on a platinum-tin 
catalyst using BDPP as ligand. Next to significant amounts of hydrogenation products, low yields of 
the desired aldehydes were obtained with mediocre enantioselectivities.[34e]  
In 1990, this working group published some results for the asymmetric hydroformylation of a few 
acrylates and acrylamides while testing some Pt, Pd and Rh catalysts. However, medium success with 
respect to enantioselectivity was achieved.[34f]  
In the same year, Gladiali reported the first rhodium-catalyzed asymmetric hydroformylation of 
(2-acetamidomethyl)acrylate, but surprisingly, only the branched aldehyde was formed (against 
Keulemans’ rule) with a good yield (up to 90 %) and enantioselectivity of about 50 %. Improved ee’s 
could be realized with a lower temperature (30 °C), what required a much longer reaction time and 
was accompanied with a loss of reactivity.[18a-c]  
The great breakthrough in the rhodium-catalyzed hydroformylation of 1,1-disubstituted olefins was 
realized by Landis and co-workers in 2010.[28a] They established the hydroformylation of a N-(1-
alkyl)vinyl phthalimide as a novel and efficient route to a chiral 3-aminoaldehyde. The catalyst was 
prepared from Rh(acac)(CO)2 with a self-prepared (S,S,S)-BisDiazaPhos as ligand. The rhodium 
catalyst allowed a mild reaction regime with low syngas pressure (1 MPa) and moderate temperature, 
what led to high selectivity to the linear chiral aldehyde in good enantioselectivity (up to 74 %). Next 
to the aldehyde, significant amounts of the isomerization product were detected (Scheme 11). 
Wang and Buchwald showed that the regioselectivity is dependent on the nature of the substrate. 
However, high enantioselectivities could be reached in both cases.[18d,24a] 
A wide scope of -alkyl acrylates were submitted to the rhodium-catalyzed reaction with 
(R,R)-BenzP* and (R,R)-QuinoxP* as ligands.[24a,34g] Primarily, they achieved only low yields of 
aldehyde with a large amount of hydrogenated substrate, what they could counteract with a higher 
ratio of the hydrogen to carbon monoxide partial pressure without losing any enantioselectivity. With 
this reaction system ee-values up to 94 % were reached that was highest until then (Scheme 12). 
 
Scheme 11. Asymmetric hydroformylation of a N-(1-alkyl)vinyl phthalimide. 
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Furthermore, Wang and Buchwald found a highly enantioselective way for the synthesis of optically 
pure 2-trifluoromethyllactic acidi (TFMLA) based on enantioselective hydroformylation (Scheme 
13).[18d] 
As main product the internal aldehyde was found against Keulemans’ rule. Applying both 
commercially available P-chiral ligands (R,R,S,S)-DuanPhos and (R,R)-QuinoxP* they could reach 
ee’s up to 92 %. For the lactic acid derivative, that can be utilized for the production of the so-called 
Soloshonok acid, it was possible to raise the enantiomeric excess to >99 % by crystallization. 
Quite recently, Zhang and co-workers presented an elegant catalytic route to 3-amino acids based on 
the rhodium-catalyzed asymmetric hydroformylation of prochiral allyl phthalimides (Scheme 14).[24b] 
While testing commercially available ligands they found (S,S)-Ph-BPE as the most appropriate: 
excellent ee-values up to 95 % were achieved, albeit a relative high amount of rhodium (2 mol%) and 
a high loading with ligand (10 mol%) were used. However, moderate conversions and significant 
hydrogenation rates still remained a problem. 
Not least, this substrate class is extremely difficult to be converted enantioselectively. Controlling the 
chemo-, regio- and stereoselectivity, it is still a great challenge to be solved. 
 
 
 
2.3 Ligands 
2.3.1 Phosphines 
Chiral phosphines were the first ligands introduced for the asymmetric hydrogenation by the pioneers 
Horner and Knowles.[36] Through the years, more and more phosphine ligands with either a 
                                                     
i Soloshonok acid is a nucleophilic glycine equivalent for the synthesis of -amino acids. 
 
Scheme 12. Asymmetric hydroformylation of -alkyl acrylates.  
 
Scheme 13. Asymmetric hydroformylation to produce Soloshonok acid. 
 
Scheme 14. Asymmetric hydroformylation of prochiral allyl phthalimides.  
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stereogenic phosphorus atom[37] or stereogenic centers located at their backbone[38] have been applied 
for the asymmetric hydrogenation. By using other forms of chirality, deriving form e.g. a chiral 
axis,[39] a wide scope of ligands could be prepared. This type of ligand is easily tuneable with respect 
to the electronic properties and steric demand.[40] Since the early 1990s, phospholane ligands[41] have 
been of interest to the asymmetric hydrogenation. By modification of the phospholane rings by polar 
groups,i an opportunity was created to improve their solubility in the solvent.[38a,42] 
Quite recently, ligands like diphospholane (S,S,S)-BisDiazaPhos[43] and also P-chiral 
(R,R)-QuinoxP*[44] and (R,R)-BenzP*[45] (Figure 10) were efficiently used in asymmetric 
hydroformylation. 
 
 
2.3.2 Phosphites 
As generally known, in contrast to phosphines, organophosphite ligands are weak -donors, but strong 
-acceptors. This property facilitates the dissociation of CO from a metal center and the subsequent 
insertion into the Rh-acyl bond. As a consequence, the rate of hydroformylation is enhanced.[25c] 
Their relatively simple synthesis from alcohols and their stability toward oxidation make them 
valuable for an application. However, this type of ligands is usually more prone to hydrolysis. 
Noteworthy, the number of commercially available and successfully applied chiral diphosphite 
ligands[25a] is limited up to now. 
In 1992, Babin and Whiteker from Union Carbide reported a chiral diphosphite named 
(R,R)-Chiraphite (Figure 11).[46] It is prepared from (2R,4R)-pentane-2,4-diol and bears bulky achiral 
biphenols at the phosphorus atoms. By varying the biphenol substituents, bearing different sterically 
demanding and electronical groups in ortho- and para-position at the P-atoms, the ligand library could 
be easily expanded. (R,R)-Chiraphite-based rhodium-complexes manage the enantioselective 
hydroformylation of various alkenes with ee’s up to 90 %.[46] 
When the chirality was shifted from the backbone to the substituent at the phosphorus, further classes 
of chiral diphosphites became available. (S,S)-Kelliphite (Figure 11) with an achiral biphenol as 
backbone and bulky biphenols at the phosphorus atoms, deriving from chiral BIPHEN-H2, was first 
mentioned by Whiteker in 2004.[27a] Compared to its relatives it was most efficient with respect to 
regio- and enantioselectivities in asymmetric hydroformylation of allyl cyanide[27a] as well as vinyl 
acetate.[47] 
                                                     
i  Chiral BasPhos and RoPhos (Börner) are two examples of ligands, which show an increased solubility in water in 
comparison to chiral Me-Duphos due to additional polar groups at the phospholane units. 
 
Figure 10. Ligands for asymmetric hydroformylation: (S,S,S)-BisDiazaPhos, (R,R)-QuinoxP* and 
(R,R)-BenzP*. 
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2.3.3 Phosphine-phosphites and -phosphoramidites 
A breakthrough in asymmetric hydroformylation was achieved by Takaya and Nozaki by introducing 
BINAPHOS in 1991 (Figure 12), a chiral phosphine-phosphite with binaphthyl backbone.[48] This 
ligand shows excellent ee’s for a wide range of substrates[28b,48-49] and combines high 
enantioselectivity, as known from phosphines, with the superior activity, a property of the phosphite 
moiety.[22a] 
Zhang and co-workers published the phosphine-phosphoramidite YanPhos (Figure 12) derived from 
BINAPHOS, where one oxygen atom was replaced by an EtN-fragment.[50] It even shows better 
stereodifferentiation for many substrates. Unfortunately, regioselectivities were as moderate as for 
hydroformylation of both, styrene and vinyl acetate, executed by BINAPHOS. 
The recently introduced (Sax,S,S)-BobPhosi by Clarke is a non-symmetric phosphine-phosphite ligand 
that possesses a chiral axis as well chiral phospholane unit. With this ligand high enantioselectivities 
up to 93 % could be attained for the branched aldehyde starting from different terminal alkenes[51] as 
well as an unusually high regioselectivity in the enantioselective hydroformylation of vinyl arenes 
(b/l = 79, 92 %ee).[52] 
 
 
                                                     
i  The name “BobPhos” is derived from “Best of both of phosphorus ligands” and means a combination of both advantages 
coming from the BIPHEN-H2-scaffold of Kelliphite and the phospholane unit of Ph-BPE. Since Rh/Kelliphite is high 
active under mild conditions even for internal aldehydes, Rh/Ph-BPE displays a robust catalyst precursor that gives high 
enantioselectivies for terminal alkenes.  
 
Figure 11. Commercially available chiral diphosphites: (R,R)-Chiraphite and (S,S)-Kelliphite. 
 
Figure 12. Chiral phosphine-phosphite and -phosphoramidite ligands: (R,S)-BINAPHOS, (R,S)-YanPhos and 
(Sax,S,S)-BobPhos. 
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2.4 Isomerization 
Isomerization of olefins frequently accompanies hydrogenation and hydroformylation. Functional 
groups can support the migration of an olefin. Hereby, three principal mechanisms can be 
differentiated: the metal hydride addition-elimination mechanism (alkyl mechanism),[53] reaction via a 
-allyl metal hydride intermediate (allyl mechanism)[54] and isomerization of allylamines or allyl 
alcohols. For the topic, considered herein, the latter is of greater relevance and shown in Scheme 15.[55] 
It can also be used in an asymmetric version.[56] 
Starting from the cationic quadratic planar complex Rh(PP-ligand)(S)2, one solvent molecule S is 
replaced by the amine. In a consequence, the -complex (a) is formed. By dissociation of the second 
solvent ligand -hydride elimination occurs and one hydride is transferred to rhodium. As a result, the 
-complex (b) is generated. Due to the conjugation of the double bond, facile rearrangement happens 
and the hydride is retransferred to the coordinated amine. Both, the nitrogen and the olefin coordinate 
simultaneously to the rhodium (c). When a further allylamine binds to the metal (d), the enamine is 
released and the -complex (b) is formed back by -hydride elimination to restart the catalytic cycle. 
 
Scheme 15. Mechanism of the rhodium-catalyzed isomerization with 
allylamine. 
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3 Results and discussion 
3.1 Hydrogenation 
3.1.1 Preparation of lactic acid derivatives 
For the last years, the demand of enantiomerically pure lactic acid has increased enormously. Its 
importance as a building block for the synthesis of biodegradable chiral polylactic acids (PLAs) can be 
explained by a range of applications similar to the one of polyethylene terephthalate (PET).[57] 
Nowadays, enantiopure lactic acid is generally derived from sugar feedstocks by fermentation. 
Undoubtedly, chemical synthesis and particularly asymmetric hydrogenation present an interesting 
alternative to this route, especially in terms of efficiency and sustainability. The latter has found a 
broad range of application in industry as environmentally friendly technology in the synthesis of chiral 
compounds.[9a,58] Homogeneous catalysts, such as rhodium, ruthenium and iridium, based on chiral 
phosphorus ligands play a crucial role for this task.[59] 
Enantiopure lactic acid and its derivatives have been synthesized via asymmetric hydrogenation 
starting from corresponding pyruvates.[60] Burk recently published the results of a highly 
enantioselective hydrogenation of the unsaturated lactate precursor -acetoxy ethyl acrylate (up to 
>99 %ee using DuPhos as ligand).[61] Schäffner et al. were able to extend the ligand library to a wide 
range of structurally related compounds and reached ee-values up to 98 %.[62] With Rh catalysts based 
on ligands of the catASium®M series, full conversions were achieved in propylene carbonate (PC) as 
economically benign solvent (Scheme 16). 
 
 
3.1.1.1 Synthesis of 2-trimethylsilyloxy methyl acrylate and crotonate 
Prochiral 2-trimethylsilyloxy methyl acrylate was prepared from readily available methyl pyruvate and 
chlorotrimethylsilane in the presence of triethylamine according to the procedure of Bäckvall.[63] The 
silicon attacks the oxygen and, consequently, the double bond rearranges under formation of the 
corresponding TMS-protected compound 1a. After filtration from ammonium chloride and aqueous 
work-up, the desired product 1a could be obtained from Kugelrohr distillation as colorless oil in 99 % 
yield. 
Starting from methyl 2-oxobutanoate, the homologue O-trimethylsilyl-protected olefin 1b is yielded in 
94 % after Kugelrohr distillation as colorless oil (Scheme 17). Both compounds tend to polymerize, 
but can be stored at 5 °C for a few days. 
 
Scheme 16. Asymmetric hydrogenation of lactic acid 
precursors. 
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3.1.1.2 Asymmetric hydrogenation of 2-trimethylsilyloxy methyl acrylate and crotonate 
2-Trimethylsilyloxy methyl acrylate 1a served as a test substrate for the asymmetric hydrogenation 
using a variety of catalysts and conditions (Scheme 18). The absolute configuration of the 
hydrogenation product was compared to enantiomerically pure O-TMS-protected methyl lactates 
prepared by an alternative pathwayi (Table 1). 
Table 1. Initial trials of the asymmetric hydrogenation of prochiral 1a with [Rh(PP-ligand)(cod)]BF4.a 
Entry Ligand eeb [%] 
1 (R,R)-DIPAMP rac 
2 (R)-BINAP rac 
3 (S,S)-Me-BPE n.d.c 
4 (S,S)-Me-DuPhos 1 (S) 
5 catASium®MQF(R) 6 (R) 
6 (R)-MeO-BIPHEP 2 (R) 
7 1,1'-Bis[(2R,5R)-2,5-di-isopropylphospholano]ferrocene 3 (R) 
8 (R,S)-dppftbp 1 (S) 
a 1.0 mmol of 1a, [Rh(PP-ligand)(cod)]BF4 10.0 µmol, H2, 4 mL of THF, 40 °C, 1.5 MPa, S/Rh = 100, 20 h. 
b Full conversion was observed in all cases, determined by 1H NMR spectroscopy; ee-values were determined by GC 
analysis; absolute configurations were compared to synthesized enantiomerically pure O-silylated methyl lactates. 
c No hydrogenation product could be detected by 1H NMR spectroscopy due to decomposition. 
The asymmetric hydrogenation of 1a was performed in THF at a temperature of 40 °C and under a 
hydrogen atmosphere of 1.5 MPa. In all cases, full conversion could be detected via NMR. However, 
lactates, which were achieved from the hydrogenation with rhodium catalysts, based on ligands like 
(R,R)-DIPAMP or (R)-BINAP, were obtained as racemates (entries 1,2). Rh/Me-DuPhos, as a 
preferred catalyst for the enantioselective hydrogenation of structurally related -acetoxy acrylates,[61] 
was also unable to induce any significant stereoselectivity (entry 4). Ligands, that have different 
electronic and steric properties, such as catASium®MQF(R) (entry 5) and (R)-MeO-BIPHEP (entry 6), 
respectively, do not crucially affect the stereodiferrentiation. Subsequently, we switched to ruthenium 
and iridium as metals (Table 2). 
                                                     
i  Enantiomerically pure (S)- and (R)-O-TMS-protected methyl lactate, respectively, was prepared by reaction of its 
corresponding chiral lactate with TMSCl in the presence of Et3N.  
 
Scheme 17. Preparation of prochiral 2-trimethylsilyloxy methyl acrylate 
1a and 2-trimethylsilyloxy methyl crotonate 1b: (i) 1.6 eq Et3N, DCM, 
r.t., 18 h. 
 
Scheme 18. Hydrogenation of prochiral 
2-trimethylsilyloxy methyl acrylate 1a. 
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Table 2. Initial trials of the asymmetric hydrogenation of 1a with ruthenium and iridium.a 
Entry Precatalyst T [°C] p [MPa] Yieldb [%] eec [%] 
1 (R)-BINAP-RuCl2 40 1.5 6 31 (S) 
2 [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl 40 1.5 48 56 (S) 
3 Crabtree’s catalyst 40 1.5 57 1 (S) 
4 (R)-BINAP-RuCl2 50 5.0 98 47 (S) 
5 [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl 50 5.0 >99 53 (S) 
6 Crabtree’s catalyst 50 5.0 54 rac 
7d (R)-BINAP-RuCl2 60 10.0 >99 52 
8e (R)-BINAP-RuCl2 60 10.0 >99 49 
9d [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl 60 10.0 >99 52 
10e [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl 60 10.0 >99 45 
a 1.0 mmol of 1a, precatalyst 10.0 µmol, H2, 4 mL of THF, T, p, S/Rh = 100, 20 h. 
b Yields were determined by 1H NMR spectroscopy. 
c Ee-values were determined by GC analysis; absolute configurations were compared to synthesized enantiomerically pure 
O-silylated methyl lactates. 
d Reaction was performed in DCM. 
e Reaction was performed in toluene. 
Starting with ruthenium, (R)-BINAP as well as (R)-C3-TunePhos were tested with substrate 1a. Under 
the same conditions, the yield of the product was quite low in comparison with that from the rhodium-
catalyzed reaction, although promising ee-values of 31 % and 56 %, respectively, were reached. 
Encouraged by this result, an attempt to promote the reaction with higher temperature and higher 
hydrogen pressure was made. The yield of the desired chiral lactate could be improved from 6 % to 
98 % with (R)-BINAP-RuCl2 as precatalyst, while the enantioselectivity reached 47 % (entry 4). For 
the reaction with [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl, a higher conversion was detected, too, but 
the ee-value slightly dropped (entry 5). At both temperatures, almost no effect on the yield and ee-
value in the hydrogenation of 1a could be noted when Crabtree’s iridium catalyst was employed 
(entries 3,6). 
Additionally, the reaction was run with both ruthenium catalysts at a higher temperature, higher 
hydrogen partial pressure and in two solvents. At a temperature of 60 °C and a hydrogen atmosphere 
of 10 MPa, the enantiomeric excesses were approximately of the same values for both ligands in DCM 
and toluene, respectively. 
The Ru-catalyzed hydrogenation of 1a, using (R)-C3-TunePhos, was also tested in a range of solvents 
owning varied polarity (Table 3). 
Table 3. Screening of solvents for the asymmetric hydrogenation of 1a with [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl.a 
Entry Solvent eeb [%] 
1 THF 53 (S) 
2 Toluene 55 (S) 
3 EtOAc 55 (S) 
4 MeOH 3 (R) 
5 CF3CH2OH 28 (S) 
a 1.0 mmol of 1a, [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl 10.0 µmol, H2, 4 mL of solvent, 50 °C, 5.0 MPa, S/Rh = 100, 20 h. 
b Full conversion was observed in all cases, determined by 1H NMR spectroscopy; ee-values were determined by GC 
analysis; absolute configurations were compared to synthesized enantiomerically pure O-silylated methyl lactates. 
Unpolar solvents, such as toluene, do not have a significant influence on the enantioselectivity of the 
reaction (entry 2), as opposed to THF. When the more polar solvent EtOAc is used, the enantiomeric 
excess is still at the same level (of 55 %ee). For the effect of solvents it can be concluded that the more 
polar it is the lower the ee-value of the product is (entries 4,5). Protic solvents do affect the 
stereoselectivity negatively. Interestingly, for methanol the opposite stereoisomer is favored, even 
though to only a minor degree. This makes clear that the solvent has an enormous influence on the 
success of the reaction. 
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With this result in hands, we screened the most successful precatalysts, [Ru(p-cymene)((R)-C3-
TunePhos)Cl]Cl as well as (R)-BINAP-RuCl2, in the asymmetric hydroformylation of 1b (Scheme 19, 
Table 4). 
Table 4. Asymmetric hydrogenation of 1b with [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl and (R)-BINAP-RuCl2 in different 
solvents.a 
Entry Precatalyst Solvent Conversionb [%] 
1 [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl THF – 
2 [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl EtOAc – 
3 [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl Toluene – 
4 [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl PC – 
5 (R)-BINAP-RuCl2 THF – 
6 (R)-BINAP-RuCl2 EtOAc – 
7 (R)-BINAP-RuCl2 Toluene – 
8 (R)-BINAP-RuCl2 PC – 
a 0.5 mmol of 1b, precatalyst 5.0 µmol, H2, 4 mL of solvent, 50 °C, 8.0 MPa, S/Rh = 100, 20 h. 
b No conversion was determined in any case by 1H NMR spectroscopy. 
To our amazement, both ruthenium catalysts showed no activity in the asymmetric hydrogenation of 
2-trimethylsilyloxy methyl crotonate 1b at 50 °C and 8 MPa hydrogen pressure in all tested solvents. 
Thus, we moved to other catalytic systems developed from ruthenium precursors, while using THF as 
solvent (Table 5). 
Table 5. Asymmetric hydrogenation of 1b with different catalysts in THF.a 
Entry Precatalyst Yieldb [%] eec [%] 
1 [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl 9 6 (–) 
2 RuCl3 + (R)-4-Tol-BINAP <5 6 (–) 
3 RuCl2(C6H6) + (R)-4-Tol-BINAP 8 11 (–) 
4 Ru(methylallyl)2(cod) + (R)-4-Tol-BINAP –d n.d. 
5 Ru(CF3COO)2(cod) + (R)-4-Tol-BINAP –d n.d. 
6 RuCl3 + (R)-MeO-BIPHEP <5 9 (+) 
7 RuCl2(C6H6) + (R)-MeO-BIPHEP <5 4 (–) 
8 Ru(methylallyl)2(cod) + (R)-MeO-BIPHEP 28 12 (+) 
9 Ru(CF3COO)2(cod) + (R)-MeO-BIPHEP –d n.d. 
10 [Rh((S)-BINAP)(cod)]BF4 9 3 (+) 
11 [Rh(catASium®MQF(R))(cod)]BF4 41 5 (–) 
12 [Rh(A)(cod)]BF4e 82 rac 
13 [Rh(B)(cod)]BF4e 16 1 (–) 
a 0.5 mmol of 1b, precatalyst 5.0 µmol, H2, 4 mL of THF, 80 °C, 8.0 MPa, S/Rh = 100, 20 h. 
b Yields were determined by 1H NMR spectroscopy. 
c Ee-values were determined by GC analysis. 
d No O-TMS-protected hydrogenation product could be detected by 1H NMR spectroscopy due to decomposition. 
e Ligands A and B were recently prepared in the research group of Prof. Börner and shown in Chapter 5.3. 
Unfortunately, [Ru(p-cymene)((R)-C3-TunePhos)Cl]Cl gave only a low yield and a negligible 
enantioselectivity of 6 % (entry 1). When (R)-4-Tol-BINAP was tested with different Ru precursors, it 
was not able to decisively raise both, yield and ee-value (entries 2-5), or the product decomposed. 
 
Scheme 19. Hydrogenation of prochiral 2-trimethylsilyloxy 
methyl crotonate 1b. 
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Hydrogenation with (R)-MeO-BIPHEP catalyst did also not succeed with respect to conversion and 
the enantiomeric excess was still poor (entries 6-9). 
The rhodium-catalyzed hydrogenation of 1b was also verified. [Rh(catASium®MQF(R))(cod)]BF4 and 
[Rh(A)(cod)]BF4 yielded best conversions up to 82 % (entry 12), but the stereodiscrimination was 
poor in all cases (entries 10-13). 
It can be summarized that the asymmetric hydrogenation of O-trimethylsilyoxy methyl acrylate was 
accomplished successfully to reach complete conversion. With a Ru catalyst the corresponding 
O-TMS-protected lactate was obtained in 55 %ee that was attained for the first time for this type of 
product. When the crotonate was applied to the reaction instead of the acrylate, no conversion was 
noted. Adapting more drastic conditions, conversions up to 82 % could be reached, but the 
stereodifferentiation still remained low. The relatively small difference in the structure of both 
substrates seems to have a great influence on reactivity as well as enantioselectivity. 
 
 
3.1.2 Preparation of chiral N,O-acetals 
Chiral N,O-acetals often represent essential fragments of a whole range of natural products and 
pharmaceuticals.[64] The stereochemical importance of the N,O-acetal subunit, related to the biological 
activity, is significant and well known today.[64-65] 
(–)-Quinocarcin as one representative, found in a culture broth of Streptomyces melunovinuceus, is a 
pentacyclic tetrahydroisoquinoline alkaloid that contains a chiral oxazolidine subsequence (Figure 
13).[66] This compound shows activity against Gram-positive bacteria in vitro and is moreover 
antiproliferative against lymphocytic leukemia.[66a-d] Therefore, it is a promising candidate as 
antitumor antibiotic.[66a,b,e] Psymberin and Myclamide individuals, belonging to the pederin family, 
possess a N,O-acetal substructure as well, but only the oxygen is part of a ring and nitrogen is 
exocyclic.[67] For example, Myclamide E, what belongs to the family of protein synthesis 
inhibitors,[65a,68] can be isolated from the sponge Mycale hentscheli.[69] The myclamide family shows 
remarkable cytotoxic,[70] antitumor,[68a,b] antiviral,[69] immunosuppressive,[71] antifungal and 
nematocidal activities.[72] (–)-Zampanolide[73] and Perinadine A[74] have an acyclic hemiaminal and 
N,O-acetal structure, respectively, where both heteroatoms are part of the ring structure. 
Next to their natural occurrence, N,O-acetals are used as key intermediates as well. These compounds 
can be transformed into reactive N-imines and subsequently easily attacked by various nucleophiles. In 
this context, they play an important role for the synthesis of Discorhabdin A.[75] 
Although some different methods[76] were already developed for the preparation of N,O-acetals, 
however, the synthesis of chiral acyclic[64] and cyclic[77] N,O-aminal derivatives is limited to an 
enantioselective Mannich-type reaction catalyzed by a chiral Brønsted acid,[78] up to now. 
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The hydrogenation of N,O-ketene acetals,i that can be easily prepared with commercially available 
reagents, still remains hardly touched so far. In literature there are only two examples for the 
diastereoselective hydrogenation of a N,O-ketene acetal on Pd/C.[79] 
Hartley et al. examined the heterogeneous hydrogenation of N-acyl-oxazolone to get chiral 
oxazolidinones. Disappointingly, the isolated yield of this mixture of diastereomers was only 44 %.[79a] 
A substituted 1,3-oxazolidine was hydrogenated heterogeneously by Easton and co-workers with 
Pd/C. They investigated the stepwise hydrogenation of a N,O-ketene acetal possessing an additional 
C-C double bond, but only a low yield of the product was reached.[79b]  
The asymmetric hydrogenation of N,O-ketene acetals has never been accomplished before. It 
illustrates a great challenge, but could also open new possibilities to get enantiopure N,O-acetals. Via 
asymmetric hydrogenation we intended to incorporate a chiral group into a substrate that operates as 
auxiliary, in order to achieve a diastereoselective alkylation afterwards (Scheme 20). 
 
 
                                                     
i  A N,O-ketene acetal is an olefin that bears an electron donating nitrogen and an oxygen atom at the same carbon of the 
double bond. 
 
Figure 13. N,O-Acetals as fragments in naturally occurring compounds: (–)-Quinocarcin, Psymberin, Myclamide E, 
(‒)-Zampanolide and Perinadine A. 
 
Scheme 20. Generation of a chemical auxiliary via asymmetric hydrogenation followed by 
diastereoselective alkylation. 
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3.1.2.1 Synthesis of N,O-ketene acetals 
At first, it was tried to prepare a prochiral N,O-ketene acetal from malonyl chloride and 2-pyrrolidone 
in toluene under reflux for 5 h. Either trials with or without aqueous work-up failed. It can be 
speculated that additional water acts as a nucleophile and leads to ring opening of the resulting 
N,O-ketene acetal. Subsequently, it was necessary to perform the reaction without aqueous work-up. 
The reaction in the presence of triethylamine as a base and stirring for 24 h at room temperature was 
likewise not successful: the starting amide was recovered. Using malonyl diethylester instead of the 
more reactive chloride, what does not release hydrogen chloride gas, could not be accomplished. 
Obviously, the 1,3-dicarbonyl compound is stabilized by a shift of the double bond, what makes it less 
reactive (Scheme 21). 
Changing from malonyl to 2,2-dimethyl malonyl and oxalyl chloride, this rearrangement was 
prevented, but the desired products could only be obtained in traces from the reaction with 
2-pyrrolidone and triethylamine at room temperature (Scheme 21, the reaction with oxalyl chloride is 
omitted). Furthermore, without aqueous work-up, triethylammonium chloride could not be separated 
completely from the product by filtration, what led back to a reaction without using any base to avoid 
annoying salt formation. 
When oxalyl chloride and acetanilide were refluxed in carbon disulfide for 16 h, gas evolution was 
detected. The product was identified as the mono-attacked acyclic intermediate (92 %). To ensure ring 
formation and finally to yield the desired N,O-ketene acetal the reaction time was prolonged to 24 h 
and benzene was used as solvent with a higher boiling point (Scheme 22). 
Starting from acetanilide and oxalyl chloride in benzene, a brownish precipitate evolved when the 
reaction mixture was heated under reflux for 24 h. In addition, gas evolution could be obtained. After 
cooling to room temperature, the solvent was evaporated to yield a puce solid. Purification of the raw 
 
Scheme 21. Trials for the preparation of a N,O-ketene acetal: (i) toluene, reflux, 5 h or  
3.0 eq Et3N, toluene, r.t., 24 h; (ii) toluene, reflux, 9 h. 
 
Scheme 22. Synthesis of N,O-ketene acetals 3a,b: (i) CS2, reflux, 16 h; (ii) benzene, 
reflux, 24 h. 
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material by column chromatography over silica did not yield final N,O-ketene acetal 3a, due to 
decomposition. For that reason, the solid was distilled under vacuum to give 78 % of 3a as a white 
solid. 
Employing the same procedure for the symmetric diacetamidei and oxalyl chloride gave 77 % of 3b as 
a white solid. Both compounds are moisture-sensitive,ii but can be stored under argon at 5 °C.   
Because reactions with unsymmetric imides would always result in a mixture of both regioisomeres, 
which is laborious to separate, it was tried to prepare a N-unsubstituted N,O-ketene acetal while 
substitution at the nitrogen should be realized in a further step. Indeed, no product could be isolated 
from the reaction of oxalyl chloride and acetamide (Scheme 23). 
 
 
3.1.2.2 Asymmetric hydrogenation of N,O-ketene acetals 
The studies were initiated by running the hydrogenation with N,O-ketene acetals 3a,b, what possess a 
phenyl and an acetyl group, respectively, at the nitrogen atom. First of all, the racemic products were 
isolated from the hydrogenation with heterogeneous rhodium on charcoal (Scheme 24). 
The starting material was dissolved in THF and hydrogenated with 2.5 mol% Rh/C catalyst at room 
temperature and under 0.3 MPa of hydrogen atmosphere for 20 h. The pure product could be obtained 
quantitatively after separation from the catalyst by filtration and evaporation of the solvent. 
Ketene acetals are not stable toward Lewis acids[76a] and undergo ring opening in the presence of a 
catalytic amount of acid and a nucleophile.[79b,81] Consequently, especially the proper choice of the 
solvent is very important. For the asymmetric hydrogenation of this substrate aprotic polar solvents, 
such as THF or DCM, reveal to be appropriate. They enable the complete solubility of both, substrate 
and catalyst. Moreover, they are not acidic like methanol and do not react as a nucleophile to cleave 
the N,O-ketene acetal via ring opening. 
As described before, the N,O-ketene acetals are moisture-sensitive and decomposition can already 
appear after prolonged standing. For this purpose, a blank test was run to verify the robustness toward 
the reaction conditions. First of all, 1 mmol of the olefin 3b and 1 mol% of the achiral catalyst 
[Rh(dppb)(cod)]BF4 were dissolved in 4 mL of DCM and the solution was stirred at room temperature 
under an atmosphere of argon (0.1 MPa) for 20 h. It could be noticed that the initial yellowish solution 
                                                     
i  Diacetamide was prepared by the reaction of acetamide and acetyl chloride with pyridine as base to yield 85 % of a white 
solid according to the procedure of Al-Awadi et. al.[80] 
ii  Both N,O-ketene acetals have a slight odor of acetic acid while standing on air. 
 
Scheme 23. Synthesis of a N-unsubstituted N,O-ketene acetal: (i) benzene, reflux, 
24 h. 
 
Scheme 24. Hydrogenation of N,O-ketene acetals 
3a,b. 
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became yellow, but it was possible to recover the starting material completely. It could be confirmed 
that the substrate and a homogeneous rhodium catalyst are stable together in solution, even though 
traces of already formed (acetic) acid are present. 
In addition, it was examined, whether the olefin is stable under increased temperature under a 
hydrogen atmosphere. Two samples of ketene acetal 3b (each of 1 mmol) were dissolved in THF, 
temperate to 40 °C and 60 °C, respectively, and stirred for 15 h under 5 MPa of an H2-atmosphere. As 
a result, only traces of the corresponding hydrogenation product 4b could be detected by 1H NMR 
while the N,O-ketene acetal 3b remained stable and was recovered quantitatively.  
In an initial test series, an achiral homogeneous rhodium precatalyst [Rh(dppb)(cod)]BF4 was used to 
determine the activity toward the transformation of 3b (Table 6). 
Table 6. Hydrogenation of 3b with 1 mol% [Rh(dppb)(cod)]BF4 in THF.a 
Entry T [°C] p [MPa] Yieldb [%] 
1 40 5.0 Traces 
2 40 8.0 Traces 
3 60 1.0 – 
4 60 2.0 – 
5 60 5.0 Traces 
6 60 8.0 Traces 
a 1.0 mmol of 3b, [Rh(dppb)(cod)]BF4 10.0 µmol, H2, 4 mL of THF, T, p, S/Rh = 100, 3 h. 
b Yields were determined by 1H NMR spectroscopy. 
In principle, almost no conversion could be detected with 1 mol% of [Rh(dppb)(cod)]BF4 precatalyst 
at 40 °C and pressures of 5 MPa and 8 MPa, respectively (entries 1,2). At a temperature of 60 °C, but 
lower pressures, no product can be determined. Even at higher pressures of 5 MPa or 8 MPa, only 
traces of the desired N,O-acetal 4b were found via 1H NMR (entries 5,6). Subsequently, the chiral Rh 
precatalysts [Rh((R)-BINAP)(cod)]BF4 and [Rh((S,S)-Me-DuPhos)(cod)]BF4 were tested in two 
solvents (THF and DCM) at 60 °C and 5 MPa hydrogen pressure (Table 7). 
Table 7. Asymmetric hydrogenation of 3b with 1 mol% [Rh(PP-ligand)(cod)]BF4.a 
Entry Ligand Solvent Yieldb [%] ee [%] 
1 (R)-BINAP THF – n.d. 
2 (R)-BINAP DCM – n.d. 
3 (S,S)-Me-DuPhos THF – n.d. 
4 (S,S)-Me-DuPhos DCM – n.d. 
a 0.5 mmol of 3b, precatalyst 5.0 µmol, H2, 4 mL of solvent, 60 °C, 5.0 MPa, S/Rh = 100, 20 h. 
b No yield was determined in any case by 1H NMR spectroscopy. 
By means of these results it can be seen that no hydrogenation took place in any solvent under the 
given conditions. Consequently, more drastic reaction conditions were chosen. The temperature was 
set to 100 °C and the hydrogen pressure to 10 MPa. THF, having a higher boiling point, was used as 
reaction solvent instead of DCM (Table 8). 
Table 8. Asymmetric hydrogenation of 3b with 1 mol% catalyst in THF.a 
Entry Precatalyst Yieldb [%] ee [%] 
1 [Rh((R)-BINAP)(cod)]BF4 – n.d. 
2 [Rh((R,R)-Me-DuPhos)(cod)]BF4 – n.d. 
3 [Ru(p-cymene)(R)-C3-TunePhos)Cl]Cl – n.d. 
4 (R)-BINAP-RuCl2 – n.d. 
a 0.5 mmol of 3b, precatalyst 5.0 µmol, H2, 4 mL of THF, 100 °C, 10.0 MPa, S/Rh = 100, 20 h. 
b No yield was determined in any case by 1H NMR spectroscopy. 
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Both, rhodium (entries 1,2) as well as ruthenium catalysts (entries 3,4) showed no activity under these 
conditions. Despite of the variation of the temperature, hydrogen pressure and solvent, the desired 
product could not be attained. Only the enhancement of the amount of the catalyst from 1 mol% to 
5 mol% promised first positive results as illustrated in Table 9. 
Table 9. Initial trials of the asymmetric hydrogenation of 3b with 5 mol% catalyst in THF.a 
Entry Precatalyst p [MPa] Yieldb [%] eec [%] 
1d [Rh((R)-BINAP)(cod)]BF4 5.0 36 9 (+) 
2 [Rh((R)-BINAP)(cod)]BF4 8.0 60 8 (+) 
3 [Rh((R)-MeO-BIPHEP)(cod)]BF4 8.0 36 11 (+) 
4 [Rh((S,S)-Me-DuPhos)(cod)]BF4 8.0 8 26 (+) 
5 [Rh((S,S)-Et-BPE)(cod)]BF4 8.0 25 50 (+) 
6 [Rh((S,S)-Et-FerroTANE®)(cod)]BF4 8.0 19 rac 
7 [Rh((R,S)-JosiPhos)(cod)]BF4 8.0 96 70 (+) 
8 [Ru(p-cymene)(R)-C3-TunePhos)Cl]Cl 8.0 2 n.d. 
9 (R)-BINAP-RuCl2 8.0 4 n.d. 
10 Ir((S,S)-Ph2PThrePHOX)(cod) 8.0 Traces n.d. 
a 0.5 mmol of 3b, precatalyst 25.0 µmol, H2, 4 mL of THF, 40 °C, p, S/Rh = 20, 72 h. 
b Yields were determined by 1H NMR spectroscopy. 
c Ee-values were determined by GC analysis. 
d Reaction time was 20 h. 
Taken into account that ee-values frequently can be increased by lowering the temperature, the 
asymmetric hydrogenation of 3b was run in THF at 40 °C. The Rh-catalyzed hydrogenation with 
(R)-BINAP as ligand was performed at 5 MPa and 36 % of the corresponding acetal 4b could be 
detected in 1H NMR, but with only poor enantioselectivity (entry 1). To increase the reactivity, the 
pressure was set to 8 MPa and the reaction time was expanded to 72 h while the temperature remained 
unchanged. The isolated yield could be improved to 60 % without remarkable changes in terms of 
enantioselectivity (entry 2). For further test series, the hydrogen pressure was regulated to 8 MPa 
permanently to ensure satisfying yields. 
The hydrogenation with the structurally similar Rh/(R)-MeO-BIPHEP did not engender any significant 
improvement of the enantioselectivity (11 %ee) and showed even worse results in the reactivity under 
the same conditions (entry 3). [Rh((S)-Me-DuPhos)(cod)]BF4 produced only a very low yield of the 
acetal 4b, but the enantiomeric excess was improved to 26 % (entry 4). A higher ee-value of 50 % was 
reached with a rhodium catalyst based on the structurally similar ligand (S,S)-Et-BPE (entry 5). The 
best result was attained with the Rh/(R,S)-JosiPhos catalyst. A yield of 96 % of product 4b and highest 
enantiomeric excess of 70 % were reached for the first time (entry 7). Two Ru-complexes and one Ir-
complex were also used in the asymmetric hydrogenation of 3b, but without success (entries 8-10). 
Encouraged by the result of the Rh/(R,S)-JosiPhos catalyst, a series of commercially available 
ferrocene-based ligands (Figure 14) was screened for the asymmetric hydrogenation of 3b. 
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The hydrogenation was performed with the previously set conditions (40 °C, 8 MPa hydrogen 
atmosphere) (Table 10). 
Table 10. Screening of ferrocene-based ligands for the asymmetric hydrogenation of 3b with [Rh(cod)2]BF4 in THF.a 
Entry Ferrocene-based ligand Yieldb [%] eec [%] 
1 (R,S)-JosiPhos 90 70 (+) 
2 (R,S)-JosiPhos-1 86 20 (+) 
3 (R,S)-JosiPhos-2 87 17 (–) 
4 (R,S)-JosiPhos-3 51 53 (–) 
5 (S,R)-JosiPhos-4 81 35 (+) 
6 (R,R)-WalPhos-1 97 48 (+) 
7 (S,S,R)-MandyPhos-1 29 14 (+) 
8 (S,S,R)-MandyPhos-2 37 16 (–) 
a 0.5 mmol of 3b, [Rh(cod)2]BF4 25.0 µmol, ferrocene-based ligand 27.5 µmol, H2, 4 mL of THF, 40 °C, 8.0 MPa, 
S/Rh = 20, 72 h. 
b Isolated yields after Kugelrohr distillation. 
c Ee-values were determined by GC analysis. 
Various substituents at the phosphorus atom of the ferrocene-based ligands have different influences 
on the progress of the reaction as well as on the stereoselectivity. Starting with the ligands from the 
JosiPhos family, the runs showed very good conversion rates and yielded up to 90 % of the desired 
product (entries 1-3). An influence of the P-substituents can also be noted. Interestingly, opposed 
stereoisomers are preferably formed while using two ligands with the same stereodescriptor 
(entries 2,3). When steric demanding phenyl groups were linked to the phosphorus, the reactivity 
decreased while a moderate enantioselectivity was reached (53 %, entry 4). 
Changing to the structurally similar WalPhos-type ligand with strongly electron withdrawing CF3-
groups at the phenyl ring, full conversion was observed (entry 6). A yield of 97 % of the product 4b 
was isolated with an ee-value of 48 % (entry 6). 
Hydrogenation, catalyzed by Rh/MandyPhos-type ligands, gave the acetal in only low yield with 
negligible enantiomeric excesses (entries 7,8). 
 
Figure 14. Applied ferrocene-based ligands for the asymmetric hydrogenation of N,O-ketene acetal 3b. 
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The (R,S)-JosiPhos ligand induced the best result with respect to enantioselectivity. Consequently, an 
attempt to optimize the reaction by variation of the solvent was carried out. Because the amount of 
catalyst was significantly high, we attempted to minimize the substrate/rhodium ratio, simultaneously 
(Table 11). 
Table 11. Asymmetric hydrogenation of 3b with [Rh((R,S)-JosiPhos)(cod)]BF4.a 
Entry Solvent S/Rh T [°C] p [MPa] Yieldb [%] eec [%] 
1 THF 20 40 8.0 90 70 (+) 
2 DCM 20 40 8.0 64 45 (+) 
3 EtOAc 20 40 8.0 86 14 (+) 
4 Toluene 20 40 8.0 25 31 (+) 
5 THF 40 50 10.0 10 18 (+) 
6 DCM 40 50 10.0 24 11 (+) 
7 EtOAc 40 50 10.0 23 4 (+) 
8 Toluene 40 50 10.0 19 8 (+) 
a 0.5 mmol of 3b, [Rh((R,S)-JosiPhos)(cod)]BF4 12.5-25.0 µmol H2, 4 mL of solvent, T, p, S/Rh, 72 h. 
b Isolated yields after Kugelrohr distillation. 
c Ee-values were determined by GC analysis. 
It can be seen that the solvent has a dramatic influence on the reaction rate. DCM and EtOAc as well 
as toluene diminish the conversion and seem to have a negative influence on the stereoselectivity of 
the reaction. 
When the amount of catalyst was reduced to 2.5 mol%, the isolated yield of the desired N,O-acetal 4b 
along with its enantiomeric excess declined dramatically in all solvents, even at 50 °C and 10 MPa 
hydrogen pressure. 
In conclusion, this synthesis strategy promotes chiral N,O-acetals, what can be achieved by a simple 
two step preparation from inexpensive bulk chemicals. The asymmetric hydrogenation of one 
representative of the family of N,O-ketene acetals was carried out for the first time and delivered a 
chiral N,O-acetal in 70 %ee and excellent yield of 96 % by using a commercially available Rh catalyst 
under mild conditions. 
The final functionalized N,O-acetals can be processed further and used for the construction of 
biologically active compounds. 
 
 
3.1.3 Preparation of -amino acid derivatives[82] 
For many years, enantiopure 2-amino acids have played an important role in biochemistry and 
medicine. These structures can be found as building blocks in several natural products, but also in 
pharmaceuticals and fine chemicals.[83] 2-Homoalanine, as simplest representative of chiral 2-amino 
acids, is a substructure (unit C) of naturally occurring cyclic depsipeptides and can be found inter alia 
in cryptophycins[84] (Figure 15). These compounds are active as antibiotics and display strong 
cytotoxic activity that is why they are used as promising candidates of anticancer agents.[85] 
Chiral 3-amino-2-methylpropanol, derived from 2-homoalanine by reduction of the carboxyl group, 
can be employed as a synthon for the synthesis of Cyclamenol A.[86] This macrolactame inhibits 
leukocyte adhesion to endothelial cells and is one of rare non-carbohydrates or peptides of this 
class.[87] It possesses an anti-inflammatory and anti-infective activity and is used for symptoms related 
to asthma, arthritis and strokes.[88] 
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Up to now, the synthesis of enantiomerically pure 2-homoalanine derivatives have mainly been 
focused on starting material from the chiral pool,[84a,87] however, alternative routes, such as chiral 
resolution[89] and stereoselective alkylation,[90] exist, too. 
The asymmetric hydrogenation of dehydro 2-homoalanine has an interesting potential, especially on 
large industrial-scale. Compared to a great number of routes to 3-homoalanine derivatives,[83a,91] the 
accessibility of chiral 2-homoalanine and its representatives via catalysis is limited.[92] The 
preparation of those compounds by the asymmetric hydrogenation of functionalized allylamides was 
rarely examined in the past and with varying degree of success.[93]  
Some publications exist, wherein N-phthaloyl-protected olefins were converted with rhodium or 
ruthenium catalysts and high stereoselectivity.[93a-e] Those publications have in common that non-
commercial phosphorus ligands were used, synthesized with much effort. With respect to the 
subsequent cleavage of the large N-phthalimido protecting group, a considerable amount of organic 
waste is produced, what is disadvantageous in terms of atom efficiency and application on industrial-
scale. 
Qiu et al. examined the asymmetric hydrogenation of N-benzyloxy-protected -aminomethyl acrylates 
with commercial [Rh(Et-DuPhos)(cod)]BF4 as precatalyst and reached ee’s up to 83 %.[93f] N-Boc-
protected allylamides were employed in asymmetric hydrogenation by Stephan et al. using a self-
prepared chiral ligand related to DIPAMP, called tBu-SMS-Phos.[93g] 
Furthermore, to the best of our knowledge, there is only one example for the asymmetric 
hydrogenation of N-acetyl derivatives. Robinson et al. performed a reaction with commercially 
available (R,R)-Me-BPE, but reached poor enantioselectivities (up to 33 %). Moreover, long reaction 
times were required.[93h] 
Working group of Börner investigated the preparation of N-benzyl- and N-Boc-protected alkyl 
2-aminomethyl-3-aryl-propanoates via a Rh-catalyzed asymmetric hydrogenation,[93i] but the synthesis 
of simple enantiopure 2-homoalanine by asymmetric hydrogenation still remains a challenge. 
 
 
3.1.3.1 Synthesis of dehydro 2-homoalanine derivatives 
First of all, starting from methyl and ethyl acrylate, respectively, 2-hydroxymethyl acrylates 5a,b 
could be synthesized in a Baylis-Hillmann reaction with an excess of paraformaldehyde.[94] These 
 
Figure 15. Structures of 2-homoalanine and 3-amino-2-methylpropanol as building blocks for natural 
compounds Cryctophycin-1 and Cyclamenol A. 
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compounds were obtained in 43 % (5a) and 70 % (5b) yield, respectively, as colorless, viscous oils 
after column chromatography. Compound 5a served as educt for the synthesis of N-acetyl-protected 
derivative 6a by reaction with acetonitrile in the presence of methanesulfonic acid. The nitrogen 
attacks the terminal side of the C=C bond and the double bond rearranges by elimination of water. 
After aqueous work-up and subsequent flash chromatography, 6a yielded as white solid in 47 %.[95] 
This compound is hygroscopic and can be stored for several days under argon at -20 °C. 
When Baylis-Hillmann adducts 5a,b were reacted with tribromo phosphine, the corresponding 
halogenated olefins 7a,b could be isolated in 89 % and 67 %, respectively.[96] By reaction with di-tert-
butyl iminodicarboxylate, they were transferred into the di-N-Boc-protected derivatives 6b,c, which 
were isolated without further purification (95 % and 99 % yield). When these compounds were treated 
with scandium(III) triflate, the monoprotected compounds 6d,e were formed. Both could be obtained 
in 84 % yield after column chromatography.[97] 
 
 
3.1.3.2 Enantioselective hydrogenation of dehydro 2-homoalanine derivatives 
Methyl 2-(acetamidomethyl)acrylate 6a was exemplarily taken as a test substrate for asymmetric 
hydrogenation. Catalysts were prepared from a commercially available precatalyst of the type 
[Rh(PP-ligand)(cod)]BF4 under hydrogen atmosphere and in the presence of the prochiral substrate 
with a substrate/rhodium ratio (S/Rh) of 100/1 (Scheme 26).  
 
Scheme 25. Synthesis of varying N-protected, prochiral dehydro 2-homoalanine 
derivatives 6a-e: (i) 1.0 eq DABCO, dioxane/water (v:v 1:1), r.t., 72 h; (ii) K2CO3, 
60 °C → 110 °C, 6 h; (iii) Et2O, 0 °C → r.t., 2 h; (iv) 1.5 eq K2CO3, CH3CN, r.t., 72  h; 
(v) THF, r.t., 24 h. 
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Ligands, previously proved for the asymmetric hydrogenation of structurally similar compounds, were 
chosen.[93f,h,i] In general, the reaction with chiral diphospholane ligands showed most promising results 
(Table 12). 
Table 12. Initial trials of the asymmetric hydrogenation of 6a with [Rh(PP-ligand)(cod)]BF4.a 
Entry Ligand Solvent p [MPa] eeb [%] 
1c (S,S,R,R)-TangPhos MeOH 2.5 29 (S) 
2 (S,R)-JosiPhos MeOH 2.5 28 (R) 
3 (S,S)-Et-DuPhos MeOH 2.5 92 (R) 
4 catASium®MQF(R) MeOH 2.5 57 (S) 
5 (S,S)-Me-BPE MeOH 2.5 29 (R) 
6d catASium®MQF(R) MeOH 0.1 21 (S) 
7e catASium®MQF(R) DCM 0.1 89 (S) 
8 catASium®MQF(R) DCM 2.5 >99 (S) 
9 catASium®MQF(R) THF 2.5 23 (S) 
10c (S,S,R,R)-TangPhos DCM 2.5 14 (S) 
11 (S,S)-Me-DuPhos DCM 2.5 5 (R) 
12 (S,S)-Et-DuPhos DCM 2.5 68 (R) 
13 (S,S)-iPr-DuPhos DCM 2.5 rac 
14 (S,S)-Me-BPE DCM 2.5 41 (R) 
a 0.33 mmol of 6a, [Rh(PP-ligand)(cod)]BF4 3.3 µmol, H2, 4 mL of solvent, 25 °C, 0.1 MPa, S/Rh = 100, 20 h. 
b Full conversion was observed in all cases, determined by 1H NMR spectroscopy; ee-values were determined by GC 
analysis. 
c Side product 9a (vide infra) was observed by 1H NMR spectroscopy (6 % and 22 %). 
d Reaction time was 6 h. 
e Reaction time was 20 min. 
All reactions proceeded with full conversion. When the hydrogenation was performed in methanol, 
ligands like (S,S,R,R)-TangPhos and (S,R)-JosiPhos gave only poor enantioselectivities (entries 1,2). 
Hydrogenation with (S,S)-Et-DuPhos as ligand resulted in the best stereodifferentiation with 92 %ee 
(entry 3). Structurally related ligands could not improve the stereoselectivity under the same 
conditions (entries 4,5). Changing to THF and DCM, respectively, enormously affected the 
stereoselectivity. Highest ee-values could be achieved with a Rh[catASium®MQF(R)] precatalyst in 
DCM[91a] (entry 8) when the hydrogen pressure was 2.5 MPa. A comparison between the structurally 
similar ligand DuPhos and catASium®MQF(R) shows only a slight difference in the steric, but the 
more in the electronic structure. While the phosphorus atoms of the DuPhos ligand are attached to a 
benzene ring, catASium®MQF(R) possesses a four-membered ring as backbone bearing four strong 
electron withdrawing fluorine atoms. Therefore, the electron density at the phosphorus is reduced, 
what has a positive effect on the asymmetric hydrogenation. An enantiomeric excess up to >99 % 
could be reached. In some cases, also the isomerized side product 9a was detected (entries 1,10). 
With the Rh[catASium®MQF(R)] precatalyst in hand we tried to optimize other reaction parameters 
(time, pressure of H2, S/Rh) (Table 13). 
 
Scheme 26. Asymmetric hydrogenation of dehydro 
2-homoalanine derivative 6a. 
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Table 13. Optimization of the reaction conditions for the asymmetric hydrogenation of 6a with 
[Rh(catASium®MQF(R))(cod)]BF4 in DCM.a 
Entry S/Rh p [MPa] t [h] Conversionb [%] eec [%] 
1 100 2.5 20 >99 >99 
2 200 2.5 1.5 >99 >99 
3 500 2.5 4.5 >99 >99 
4 500 2.5 0.2 >99 >99 
5d 1000 2.5 4.5 >99 54 
6 1000 5.0 4.5 >99 99 
7d 2000 5.0 20 92 11 
8d 1000 15.0 20 89 69 
9d 1500 15.0 20 83 39 
10d 1750 15.0 20 75 12 
11d 2000 15.0 20 64 18 
12e 300 5.0 3 >99 99 
a 0.33 mmol of 6a, [Rh(catASium®MQF(R))(cod)]BF4 0.17-3.3 µmol, H2, 4 mL of DCM, 25 °C, p, S/Rh, t. 
b Conversions were determined by 1H NMR spectroscopy. 
c Ee-values of the (S)-enantiomer were determined by GC analysis. 
d Side product 9a (vide infra) was observed by 1H NMR spectroscopy (4-15 %). 
e Up-scale to 1.0 g of substrate. 
At first, we reduced the amount of the catalyst and increased the substrate/rhodium ratio from 100/1 to 
500/1, while adjusting the reaction time, simultaneously (entries 1-4). Fortunately, no decline in the 
conversions or enantioselectivities was noted. Even with a ratio of S/Rh = 500 the reaction time could 
be drastically reduced to 20 min without any loss of yield of the desired product (entry 4). Further 
increase of the S/Rh ratio to 1000/1 influenced the selectivity (54 %ee, entry 5). This can be 
rationalized by the fact that the external double bond migrates and isomeric olefins (E)-9a and (Z)-9a 
are formed (the shifts of the signals in 1H NMR can be compared to those of the ethyl ester,[93a] 
(Scheme 27). It can be supposed that these enamides are hydrogenated likewise but with lower 
enantioselectivity, what decreases the overall enantiomeric excess. Both isomers, (E)-9a and (Z)-9a, 
could be identified in the final mixture, what gives evidence for this assumption. 
To avoid any loss of stereoselectivity, when a S/Rh ratio of 1000/1 is used, the H2-pressure was 
increased to 5 MPa (entry 6). With a lower catalyst amount, the conversion and also the 
enantioselectivity declined (entries 7-11). Up-scaling to 1 g of the substrate was successfully 
accomplished at a S/Rh ratio of 300 (entry 12). With the optimized conditions it was possible to 
hydrogenate N-Boc-protected substrates 6b-e (Table 14). 
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Table 14. Scope of the asymmetric hydrogenation of 6b-e with [Rh(catASium®MQF(R))(cod)]BF4 in DCM.a 
Entry Substrate p [MPa] t [h] Conversionb [%] eec [%] 
1 6b 2.5 20 38 77 (+) 
2 6b 5.0 20 55 75 (+) 
3 6c 2.5 20 34 81 (+) 
4 6c 5.0 20 43 73 (+) 
5d 6d 2.5 1 39 91 (S) 
6d 6d 2.5 3 45 90 (S) 
7d 6d 2.5 20 42 87 (S) 
8d 6d 5.0 3 42 83 (S) 
9 6d 5.0 20 >99 83 (S) 
10e 6d 8.0 20 >99 94 (S) 
11d 6d 1.0 3 52 86 (S) 
12d 6e 2.5 1 83 89 (S) 
13 6e 2.5 3 >99 88 (S) 
14 6e 2.5 20 >99 87 (S) 
15 6e 5.0 3 >99 83 (S) 
16 6e 1.0 3 >99 91 (S) 
17 6e 0.1 3 >99 96 (S) 
a 0.33 mmol of substrate, [Rh(catASium®MQF(R))(cod)]BF4 3.3 µmol, H2, 4 mL of DCM, 25 °C, p, S/Rh = 100, t. 
b Conversions were determined by 1H NMR spectroscopy. 
c Absolute configuration of 6b and 6c could not be determined clearly. The sign of the specific rotation was positive. The 
positive sign of the specific rotation for 6d and 6e corresponds to their (S)-enantiomers; ee-values were determined by GC or 
HPLC analysis. 
d Side products 9d and 9e (vide infra) were observed by 1H NMR spectroscopy (3-15 %). 
e S/Rh = 50. 
In general, the asymmetric hydrogenation of di-N-Boc-protected acrylates 6b,c proved to be more 
difficult (entries 1-4). The conversions of these substrates were only moderate although the reactions 
were performed for 20 h. Doubling the pressure from 2.5 to 5 MPa slightly raised the conversion, 
however, affected the enantioselectivity (entries 2,4). For these substrates only moderate ee-values 
could be reached. Changing to the mono-N-Boc-protected substrate 6d led to improved 
enantioselectivities, but the conversions were still low, despite of extension of the reaction times 
(entries 5-7). Full conversion was reached with a hydrogen pressure of 5 MPa without any side 
reactions after 20 h (entry 9). Unfortunately, the enantioselectivity fell to 83 %. The best result (full 
conversion, 94 %ee) was reached with a hydrogen pressure of 8 MPa and a substrate/rhodium ratio of 
50 (entry 10).  
For ethyl acrylate 6e full conversion was already achieved after 3 h at a hydrogen pressure of 2.5 MPa. 
(entry 13). When the H2-pressure was increased to 5 MPa, the enantioselectivity dropped to 83 %. 
Finally, a lower hydrogen pressure of 1 MPa and 0.1 MPa, respectively, had a positive effect on the 
stereoselectivity (91 %ee and 96 %ee). Furthermore, in some cases, the external double bond migrates 
to the internal position to form (E)- and (Z)-isomers as already mentioned for 6a (Scheme 27). These 
corresponding enamides 9d,e could be found in the final mixtures up to 3-15 mol% (entries 
5-8,11,12). This effect could be observed especially in solvents like THF and MeOH. In asymmetric 
hydrogenation this isomerization causes incomplete hydrogenation and also drastically reduced 
enantioselectivities.i Surprisingly, an enantiomeric excess of only 4 % was detected when the 
hydrogenation of 6d was performed with Rh/(S,S)-Et-DuPhos under standard conditions (25 °C, 
2.5 MPa, 20 h) in methanol. 85 % of the substrate were converted, but at least 10 % thereof isomerized 
(not shown in Table 14). 
                                                     
i Such migration was already described by Yamamoto with the related N-methoxycarbonyl substrate.[98] 
Chapter 3: Results and discussion  
- 36 - 
 
 
3.1.3.3 Synthesis of chiral secondary products 
N-Acetyl-protected 3-amino-2-methylpropanol[99] 10a can be generated by reduction of N-acetyl 
derivative 8a. Therefore, this compound served as a model substrate with >99 %ee, which was taken 
from the enantioselective hydrogenation of 6a (Table 12, entry 8). At first, the ester group was 
selectively reduced by using LiAlH4 at 0 °C within 2 h to give corresponding alcohol 10a. Fortunately, 
under these conditions, the N-acetyl group was not affected and the chiral integrity remained almost 
intact (98 %ee, Scheme 28). 
When the reaction time was extended to 4 h, the N-acetyl moiety was also reduced to give (S)-3-
(ethylamino)-2-methylpropan-1-ol (10a', 11 % visible in the crude mixture together with 10a). 
The N-Boc-protected ester 8e (96 %ee, Table 14, entry 17) could be likewise reduced with LiAlH4 at 
0 °C within 5 h to give amino alcohol 10b. The enantiomeric excess of O-acetyl derivative 13, 
obtained by in situ treatment of 10b with acetyl chloride, retained in comparison to ester 8e (95 %ee, 
Scheme 29). 
To remove the N-Boc-protection group of 10b the alcohol was treated with trifluoroacetic acid in 
dichloromethane to yield the corresponding chiral deprotected ammonium salt 12 of the amino alcohol 
with 95-96 %ee. Alternatively, the N-Boc group of ester 8e could be removed firstly when treated with 
HCl/dioxane. Hydrochloride 11 of the amino acid ester was generated this way under complete 
preservation of the enantioselectivity (96 %ee). Followed reduction of the ester group was performed 
 
Scheme 27. Asymmetric hydrogenation of derivatives 6a-e and 
concomitant isomerization. 
 
Scheme 28. Reduction of the ester group of 
chiral hydrogenation product 8a: (i) THF, 
0 °C, 2 h. 
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with LiAlH4 and NaBH4, respectively. Unfortunately, the reaction was accompanied by the formation 
of several by-products and did not yield the corresponding alcohol. 
In conclusion, it was possible to prepare enantiopure 2-methyl--alanine (2-homoalanine) derivatives 
via enantioselective hydrogenation by using the commercially available precatalyst 
([Rh(catASium®MQF(R))(cod)]BF4) under mild conditions. Furthermore, this route tolerates different 
ester groups as well as different N-protecting groups. This fact is especially precious with regard to the 
great variation possibilities for the construction of peptides and potential biologically active 
compounds. 
It was also possible to transform the 2-homoalanine into chiral N-protected 3-amino-2-
methylpropanol derivatives to get a valuable building block. 
 
 
 
3.2 Hydroformylation 
3.2.1 Preparation of functionalized 2-homoalanine derivatives 
The successful asymmetric hydrogenation of dehydro 2-homoalanine derivatives prompted us to 
undertake more investigations, what led to the asymmetric hydroformylation of this substrate class. 
Independently, what side of the double bond is mainly attacked, we expected a chiral carbonyl 
compound that could serve as a building block for a range of interesting functionalized compounds 
(e.g. chiral substituted mixed malonic acid ester). 
 
 
3.2.1.1 Asymmetric hydroformylation of dehydro 2-homoalanine derivatives 
From the hydroformylation of methyl 2-(acetamidomethyl)acrylate 6a, different products can result. 
Next to both aldehydes, 14 (branched aldehyde) and 15 (linear aldehyde), the hydrogenation product 
8a as well as the isomerized olefins (E)-9a and (Z)-9a should be taken into consideration (Scheme 30). 
 
Scheme 29. Further reactions of chiral hydrogenation product 8e: 
(i) THF, 0 °C → r.t., 5 h; (ii) dioxane, r.t., 2 h; (iii) DCM, r.t., 3 h. 
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We started our trials with non-asymmetric hydroformylation and used achiral phosphine and phosphite 
ligands under several conditions (Table 15). 
Table 15. Initial trials of the Rh-catalyzed non-asymmetric hydroformylation of 6a.a 
Entry Ligand T [°C] p [MPa] 14b [%] 15b [%] 
8ab 
[%] 
(E)-9ab 
[%] 
(Z)-9ab 
[%] 
1 PPh3 100 5.0 – – – 17 83 
2 P(OPh)3 60 2.0 5 – – 9 86 
3c BiPhePhos 60 2.0 4 – 15 16 66 
4d P(OPh)3 30 2.0 50 – 4 5 41 
a 1.0 mmol of 6a, Rh(acac)(CO)2 10.0 µmol, ligand 30.0 µmol, CO/H2 = 1:1, 5 mL of toluene, T, p, S/Rh = 100, 21 h. 
b Full conversion was observed in all cases; yields were determined by 1H NMR spectroscopy. 
c Ligand 12.0 µmol. 
d Reaction time was 65 h; ligand 60.0 µmol. 
In a first trial, the hydroformylation was performed at 100 °C and under syngas atmosphere of 5 MPa 
with Rh(acac)(CO)2 and triphenylphosphine as ligand. Although full conversion occurred, neither 
aldehydes nor the hydrogenation product were detected. The substrate was completely converted into 
the isomerized (E)- and (Z)-olefin (entry 1). Under milder conditions (60 °C, 2 MPa syngas), using the 
monodentate ligand triphenylphosphite, 95 % of the isomerization product were generated, but also a 
small amount of the iso-aldehyde could be detected. When the bidentate BiPhePhos was employed, 
15 % of hydrogenation product 8a were formed, but the quantity of the branched aldehyde was still 
low and the linear aldehyde could not be determined at all. Unfortunately, the isomerization products 
represented the main part of the product mixture (82 %, entry 3). 
While reducing the temperature to 30 °C, the reaction time was extended to 65 h to ensure full 
conversion. When Rh/P(OPh3)3 was used, the amount of the isomerized olefins could be reduced to 
5 % ((E)-9a) and 41 % ((Z)-9a), respectively, whereas the amount of the branched aldehyde raised up 
to 50 %. 
When trisubstituted olefin (E)-9a was hydoformylated with the rhodium catalyst, using 
triphenylphosphine at 100 °C and 5 MPa, no reaction occurred and the starting material was recovered 
quantitatively (1H NMR, not shown in Table 15). This makes clear that the isomerized olefin does not 
react further to the aldehyde under the given conditions. 
The asymmetric variant of the hydroformylation of 6a was performed under mild conditions (Table 
16). At first, we accomplished the reaction at 60 °C with a range of commerically available bidentate 
phosphorus ligands. Afterwards, these trials were repeated at 30 °C to see any differences, especially 
in the degree of isomerization and enantioselectivity. 
 
Scheme 30. Hydroformylation of dehydro 2-homoalanine derivative 6a. 
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Table 16. Initial trials of the Rh-catalyzed asymmetric hydroformylation of 6a with commercial ligands.a 
Entry Ligand 
T 
[°C] 
t 
[h] 
Conv.b 
[%] 
14b 
[%] 
15b,c 
[%] 
8ab 
[%] 
(E)-
9ab 
[%] 
(Z)-
9ab 
[%] 
eed 
[%] 
1 (S,S)-DIOP 60 21 100 28 – 2 21 48 18 (+) 
2 
(R,R)-
DIPAMP 
60 21 100 12 – 72 4 12 18 (–) 
3 
(R,R)-Me-
DuPhos 
60 21 95 20 – 25 20 30 1 (–) 
4 
(S,S)-
ChiraPhos 
60 21 100 10 – 57 6 27 n.d. 
5 
(R,R)-
Chiraphite 
60 21 100 4 – 47 10 39 n.d. 
6 
(R,R)-
QuinoxP* 
60 21 99 89 – 6 4 – 10 (–) 
7 
(R,R,S)-
BisDiazaPhos 
60 21 100 13 – – 20 67 2 (–) 
8 (S,S)-DIOP 30 65 70 51 – 2 4 13 33 (+) 
9 
(R,R)-
DIPAMP 
30 65 86 2 – 63 6 15 n.d. 
10 
(R,R)-Me-
DuPhos 
30 65 88 <1 <1 77 4 6 n.d. 
11 
(S,S)-
ChiraPhos 
30 65 79 4 – 42 5 28 n.d. 
12 
(R,R)-
QuinoxP* 
30 65 79 13 <1 35 10 21 1 (+) 
13 
(R,R)-
Chiraphite 
30 65 76 6 <1 44 7 19 n.d. 
14 
(R,R)-
Kelliphite 
30 65 100 4 1 55 10 30 4 (+) 
15 (R,R)-Ph-BPE 30 65 100 4 – 65 6 25 6 (+) 
a 0.5 mmol of 6a, Rh(acac)(CO)2 5.0 µmol, PP-ligand 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, T, 2.0 MPa, S/Rh = 100, t. 
b Conversions and yields were determined by 1H NMR spectroscopy. 
c Due to the small amount in the final mixture, the amount of the linear aldehyde (15) was determined by integration of the 
characteristic signal for the proton of the aldehyde group ( = 9.39 ppm) in 1H NMR spectrum. 
d Ee-values of the branched aldehyde (14) were determined by GC analysis. 
It can be summarized that the hydroformylation reactions, performed at 60 °C, provided almost full 
conversion in all cases (entries 1-7). When (S,S)-DIOP was used as ligand, the isomerization products 
can be observed next to the branched aldehyde. The enantiomeric excess of 14 was poor (18 %ee). 
When (R,R)-DIPAMP was employed to the reaction, the isomerization was suppressed, but 
competitive hydrogenation eventuated (72 %). Hydroformylation with (R,R)-Me-DuPhos as well as 
with (S,S)-ChiraPhos as ligand emerged with either a significant amount of isomerized or 
hydrogenated substrate. Additionally, a disatisfactionary amount of the desired aldehyde and no 
considerable stereodifferentiation could be obtained (entries 3,4). Ligand (R,R)-QuinoxP* induced a 
good selectivity toward the formation of the branched aldehyde, however, the ee-value was negligible 
(10 %ee). Interestingly, only a small amount of the hydrogenation product was detected and 
isomerization hardly occurred (entry 6). The Rh/(R,R,S)-BisDiazaPhos catalyst has a pronounced 
property to isomerize 6a. Furthermore, the yield of almost racemic iso-aldehyde was poor (13 %). 
With a reduced temperature (30 °C), but longer reaction time, full conversion could not be detected in 
any case. For (S,S)-DIOP, these conditions seem to have a positive effect on the yield of the branched 
aldehyde (51 %). Also the enantiomeric excess increased to 33 %. Hydrogenation and also 
isomerization were repressed to minor side reactions. Obviously, a lower temperature suppressed 
isomerization, but it forced hydrogenation in some cases (entries 9-11). 
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For both chiral diphosphines (R,R)-QuinoxP* and (R,R)-Ph-BPE as well as the diphosphites 
(R,R)-Chiraphite and (R,R)-Kelliphite, low temperature does not have a positive effect on the 
enantioselectivity so that almost racemic mixtures were detected (entries 12-15). 
In a short summary it can be concluded that 6a is a poor substrate for asymmetric hydroformylation. 
Because of an additional methylene group, located next to the olefin, the double bond can easily 
rearrange that leads to a three-fold and therefore thermodynamically more stable olefin. The 
isomerized olefin does not undergo hydroformylation. Furthermore, reduction of the temperature had a 
great influence on the conversions of 6a, but required very long reaction times. 
For that reason, we expanded our examination in the asymmetric hydroformylation of -substituted 
styrenes, which cannot isomerize. 
 
 
3.2.2 Preparation of chiral 3-aryl-3-phosphorylated propanals 
For a long time, chiral phosphorus compounds have become more and more important to chemical 
application and attracted special attention. Next to the valuable role of chiral phosphines in the metal-
catalyzed asymmetric catalysis, phosphonic acids are used as pharmaceuticals and pesticides.[100] 
Among a variety of organocatalytic asymmetric hydrophosphination of cinnamaldehyde 
derivatives,[101] the preparation of chiral phosphonates, using this method, were exclusively discussed 
by Córdova and co-workers in 2008.[101a] Although they reached ee’s up to 95 % for corresponding 
phosphine oxides, which were also synthesized, the enantioselectivities for the phosphonates were 
quite low (up to 14 %ee, Figure 16). 
This prompted us to find another route for the preparation of 3-aryl-3-phosphorylated propanals. 
Herein we disclose the first example of the rhodium-catalyzed asymmetric hydroformylation of 
-phosphorylated vinyl arenes. 
 
 
3.2.2.1 Synthesis of -phosphorylated vinyl arenes 
Prochiral phosphonic acids were prepared from substituted acetophenones or 2-acetonaphthone and 
phosphorus trichloride in the presence of concentrated acetic acid under reflux. In case of 2',4',6'-
trimethylacetophenone, no product could be isolated under these conditions. These vinyl compounds 
were transformed into the corresponding esters by stirring with an excess of trialkyl orthoformate at 
50 °C for 2 h, followed by column chromatography, according to the procedure of Genêt.[102] The 
prochiral phosphonates 16a-g were attained as colorless oils and white solids in 41-84 % yield 
(Scheme 31). 
 
Figure 16. Organocatalytic asymmetric hydrophosphination of cinnamaldehyde derivatives by Córdova. 
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For the synthesis of 4-methoxy derivative 16h, another synthesis was used. According to the 
procedure of Ding,[103] trans-4-methoxy--nitrostyrene was reacted with trimethyl phosphite over 9 d 
at room temperature to yield 16h as a yellowish oil after column chromatography in 69 % (Scheme 
32). 
Furthermore, the phosphine oxide derivative 16i was prepared from phenylacetylene and 
diphenylphosphine oxide in the presence of 5 mol% Pd(OAc)2 and dppe (7 mol%). The reaction 
mixture was stirred at 100 °C for 14 h and the product could be obtained after column chromatography 
as a white solid in 73 % yield (Scheme 33).[104] 
 
 
3.2.2.2 Initial asymmetric hydroformylation of dimethyl(1-phenylvinyl)phosphonate 
We initiated our studies with non-asymmetric hydroformylation of dimethyl(1-
phenylvinyl)phosphonate 16a (Scheme 34). Next to both regioisomeric aldehydes, the hydrogenation 
product has to be taken into consideration, but no isomerization can occur. This minimizes the range 
of products and allows a greater variation of reaction conditions (Table 17). 
 
Scheme 31. Preparation of phosphonates 16a-g: (i) HOAc, 0 °C → r.t., 16 h, then H2O, 
reflux, 2 h; (ii) 100 °C, 2 h. 
 
Scheme 32. Preparation of phosphonate 16h: (i) DME, r.t., 9 d. 
 
Scheme 33. Preparation of phosphine oxide 16i: 
(i) 5 mol% Pd(OAc)2, 7 mol% dppe, toluene, 100 °C, 
14 h. 
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Table 17. Initial trials of the Rh-catalyzed non-asymmetric hydroformylation of 16a.a 
Entry Ligand T [°C] p [MPa] Conv.b [%] 17ab [%] 18ab [%] 19ab [%] 
1 – 100 1.0 75 60 – 15 
2c Alkanox® 240 100 1.0 100 85 <1 15 
3 BiPhePhos 100 1.0 93 83 <1 9 
4 XantPhos 100 1.0 >99 90 1 9 
5c Alkanox® 240 100 2.0 95 78 3 14 
6 BiPhePhos 100 2.0 >99 90 <1 9 
7 XantPhos 80 2.0 68 58 3 7 
8 XantPhos 80 1.0 91 81 2 8 
9d BiPhePhos 100 1.0 95 86 – 9 
10c Alkanox® 240 50 2.0 81 24 49 8 
11 BiPhePhos 50 2.0 22 15 5 2 
a 0.5 mmol of 16a, Rh(acac)(CO)2 5.0 µmol, ligand 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, T, p, S/Rh = 100, 21 h. 
b Conversions and yields were determined by 31P NMR spectroscopy. 
c Ligand 15.0 µmol. 
d Reaction was performed with a partial pressure ratio CO/H2 = 2:1. 
Firstly, it was tried to perform the hydroformylation with Rh(acac)(CO)2 and without any organic 
ligand. Surprisingly, at 100 °C and syngas atmosphere (1 MPa), a reaction took place. After 21 h, the 
racemic linear aldehyde as well as the hydrogenation product could be determined with 60 % and 
15 % yield, respectively (entry 1). By using the monodentate ligand Alkanox® 240, full conversion 
was reached with a better chemoselectivity toward the formation of the linear aldehyde (85 %), while 
the hydrogenation was still competitive under these conditions. Rhodium catalysts based on 
BiPhePhos and XantPhos diminished the degree of hydrogenation, while the conversion was kept at 
the same level (entries 3,4). Doubling the syngas pressure to 2 MPa in combination with a reaction 
temperature of 100 °C had no significant effect on the reactivity and yield of the desired product. 
When the ratio of the partial pressures of carbon monoxide to hydrogen was changed to 2:1, the results 
with BiPhePhos remained nearly the same (entry 9). The rate of the reaction faded enormously when 
the temperature was reduced to 50 °C (2 MPa syngas pressure, entry 11). At the same time, an 
increased amount of the branched aldehyde was noted (up to 49 %, entry 10). 
Our work was continued with the asymmetric hydroformylation of the -phosphorylated olefin 16a 
(Table 18). 
 
Scheme 34. Hydroformylation of prochiral 16a. 
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Table 18. Initial trials of the Rh-catalyzed asymmetric hydroformylation of 16a with commercial ligands.a 
Entry Ligand 
T 
[°C] 
p 
[MPa] 
Conv.b 
[%] 
17ab 
[%] 
18ab 
[%] 
19ab 
[%] 
eec [%] 
1 (S,S)-DIOP 100 1.0 95 86 7 2 9 (–) 
2 (R,R)-DIPAMP 100 1.0 60 41 7 13 5 (–) 
3 (R,R)-Me-DuPhos 100 1.0 58 35 6 16 1 (–) 
4 (S,S)-BDPP 100 1.0 80 >33 >7 >14 21 (–) 
5 (R)-MeO-BIPHEP 100 1.0 6 3 <1 2 n.d. 
6 (R)-SynPhos 100 1.0 16 14 <1 2 rac 
7 (R)-DifluorPhos 100 1.0 16 15 – <1 rac 
8 (R)-C3-TunePhos 100 1.0 28 27 – 1 rac 
9 (R)-4-Tol-BINAP 100 1.0 16 13 <1 2 2 (–) 
10 (R,R)-QuinoxP* 100 1.0 98 35 7 56 21 (+) 
11 (S,S)-BenzP* 100 1.0 98 17 7 74 21 (+) 
12 (R,R,S)-BisDiazaPhos 100 1.0 98 83 11 5 3 (+) 
13 (R,R)-Chiraphite 100 1.0 84 72 <1 11 2 (+) 
14 (R,R)-Kelliphite 100 1.0 85 78 <1 6 rac 
15 (R,S)-JosiPhos 100 1.0 23 12 2 9 16 (+) 
16 (S,S)-BDPP 80 1.0 20 11 4 5 5 (–) 
17 (R,R)-Chiraphite 80 1.0 43 37 <1 6 1 (+) 
18 (R,R)-Kelliphite 80 1.0 77 71 <1 5 rac 
19 (R,R)-Ph-BPE 80 1.0 45 2 29 14 37 (+) 
20 (S,S)-DIOP 60 3.0 21 5 16 <1 13 (–) 
21 (S,S)-BDPP 60 3.0 3 <1 2 <1 n.d. 
22 (R,R,S)- Bisdiazaphos 60 3.0 7 3 3 1 13 (+) 
23 (R,R)-Chiraphite 60 3.0 24 19 3 2 rac 
24 (R,R)-Kelliphite 60 3.0 13 11 1 1 rac 
25 (R,R)-Ph-BPE 60 3.0 4 – 4 <1 n.d. 
a 0.5 mmol of 16a, Rh(acac)(CO)2 5.0 µmol, PP-ligand 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, T, p, S/Rh = 100, 21 h. 
b Conversions and yields were determined by 31P NMR spectroscopy. 
c Ee-values of the linear aldehyde (17a) were determined by GC analysis. 
Starting with (S,S)-DIOP, we promptly reached 95 % of conversion with a good chemo- and 
regioselectivity. Unfortunately, the resulting 86 % of the linear aldehyde were only of a low ee-value 
(entry 1). Trials with (R,R)-DIPAMP and (R,R)-Me-DuPhos did not succeed. In the runs at 100 °C and 
1.0 MPa pressure of syngas atmosphere only low conversions were observed with low regioselectivity 
and a high amount of the hydrogenation product (entries 2,3). When the catalysis was examined with 
structurally similiar ligands like (R)-MeO-BIPHEP, (R)-SynPhos, (R)-DifluorPhos or (R)-C3-
TunePhos, no significant difference in the reactivity could be obtained (entries 5-8). The 
hydroformylation yielded low amounts of the aldehydes. In all cases, the ee-values were zero. 
Obviously, electronic differences within ligands do not play any role in the stereodifferentiation. 
Catalysts with P-chiral ligands (R,R)-QuinoxP* and (S,S)-BenzP* produced a huge amount of the 
hydrogenation product. The linear aldehyde arose with an ee-value of 21 % for both runs. Trials with 
the diphosphine ligand (R,R,S)-BisDiazaPhos as well as the chiral diphosphites (R,R)-Chiraphite and 
(R,R)-Kelliphite resulted either in a higher concentration of the branched aldehyde or of the 
hydrogenation product, but almost no stereodiscrimination was noted (entries 12-14). When the 
temperature was reduced to 80 °C, the reactivity of the catalyst decreased for all applied ligands. 
Surprisingly, the enantioselectivity dropped by application of (S,S)-BDPP, too (entry 16). Using (R,R)-
Ph-BPE as ligand, the regioselectivity was reversed. 29 % yield of the branched aldehyde was formed 
compared to only 2 % of the linear one. With this ligand the highest ee-value of 37 % could be 
reached until then.  
Further reduction of the temperature to 60 °C (and an increased syngas pressure to 3 MPa) resulted in 
poor or even no conversion. The increased amount of the branched aldehyde is also indicative and is in 
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accordance with the published results for other hydroformylations.[17a] With (S,S)-DIOP and 
(R,R,S)-BisDiazaPhos a slightly enhanced enantiomeric excess of the linear aldehyde can be 
registered. Due to the poor performance of the commercial ligands, we entered a project aimed to 
synthesize non-commercial as well as new ligands. 
 
 
3.2.2.3 Synthesis of non-commercial and new ligands 
The number of commercially available bidentate ligands, which are successful candidates in 
asymmetric hydroformylation, is limited up to now. With the exception of some diphosphines only 
Chiraphite and Kelliphite represent chiral diphosphites that found application nowadays (see 
Chapter 2.3.2). 
Since diastereomerically pure BINAPHOS is not supplied by fine chemical traders, we prepared it in a 
five-step synthesis[48,105] (Scheme 35). According to the procedure of Hayashi and co-workers[105] the 
hydroxyl groups of enantiomerically pure (R)-BINOL were transformed into triflate groups with 
trifluoroacetic anhydride in the presence of pyridine (pathway i). Resulting bistriflate 20a was isolated 
as white solid in quantitative yield. Compound 20a was then coupled with diphenylphosphine oxidei in 
the presence of Pd(OAc)2 and dppb and in conjunction with an excess of Hünig’s base. 
Monophosphine oxide 20b could be isolated only in low yield (maximum 33 %, pathway ii).ii The 
other triflate group could be converted into a hydroxyl group by treatment with 3 M NaOH in 
dioxane/methanol at room temperature for 16 h. Phosphine oxide 20c was isolated in almost 
quantitative yield as a white solid (pathway iii). The phosphine oxide was reduced to a phosphine 
(20d) by treatment with an excess of trichlorosilane and triethylamine at 100 °C in toluene for 16 h. 
The phosphine yielded in 82 % as a white solid (pathway iv). This compound was reacted with either 
the chlorophosphite of (S)-BINOL or (R)-BINOLiii and a slight excess of triethylamine. The products, 
(R,S)-BINAPHOS (47 %, 20e) and (R,R)-BINAPHOS (40 %, 20f), emerged as white solids after 
column chromatography over alumina (pathway v) as described by Takaya.[48] 
                                                     
i  Diphenylphosphine oxide was prepared by stirring chloro diphenylphosphine in 1 M HCl and isolated as a white solid in 
98 % yield.[106] 
ii  The reaction was repeated a few times with different batches of the starting material. For instance, diphenylphosphine 
oxide from SIGMA ALDRICH® as well as Pd(OAc) from different suppliers were used, but did not lead to any improvement 
of the yield. 
iii  To prepare the chlorophosphite of enantiopure BINOL in situ the diol was suspended in phosphorus trichloride, 2-3 drops 
of NMP were added and the suspension was heated to 75 °C for 5 min until it became clear. Evaporation yielded the 
desired chlorophosphite as a pale yellow solid.[107] 
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In addition, some chiral diphosphite ligands could be prepared based on different aromatic diols. 
(S)- and (R)-BINOL, respectively, was coupled with the chlorophosphites of (R)-BINOL (2.1 eq) 
when the reaction was stirred at room temperature for 16 h in the presence of an excess of 
triethylamine. The (R,S,R)- and (R,R,R)-diphosphite were isolated as white solids in 95 % (21a) and 
93 % (21b) after column chromatography over alumina (Scheme 36). 
When achiral 4,4',6,6'-tetra-tert-butyl-2,2'-biphenoli and 4,4'-di-methoxy-6,6'-di-tert-butyl-2,2'-
biphenolii were employed as backbones to the reaction, non-symmetric diphosphites were obtained. 
The reaction with the chlorophosphite of (R)-BINOL yielded 21c and 21d, respectively, under the 
same conditions as for the prior synthesized diphosphite ligands 21a,b. Compounds 21c and 21d 
showed unexpected two signals in a relation of 1:1 in the 31P NMR, what means that they do not have 
chemical equivalent phosphorus atoms and, consequently, transesterfication might has taken place 
(Scheme 37).[110] Both compounds could be isolated as white solids after column chromatography over 
alumina in 94 % (21c) and 97 % (21d) yield, respectively. 
                                                     
i  4,4',6,6'-Tetra-tert-butyl-2,2'-biphenol was prepared from 2,4-di-tert-butylphenol and MnO2 in heptane. Stirring under 
reflux for 3.5 h yielded an off-white solid in 85 %.[108] 
ii  4,4'-Di-methoxy-6,6'-di-tert-butyl-2,2'-biphenol was prepared from 3-tert-butyl-4-hydroxyanisole, KOH and K3[Fe(CN)6] 
in methanol. Strirring at room temprature for 5 h yielded an off-white solid in 98 %.[109] 
 
Scheme 35. Synthesis of (R,S)- and (R,R)-BINAPHOS (20e and 20f): (i) 3.5 eq pyridine, DCM, 0 °C → r.t., 6 h; (ii) 
5 mol% Pd(OAc)2, 5 mol% dppb, 4.0 eq Hünig’s base, DMSO, 100 °C, 20 h; (iii) dioxane/methanol (v:v 1:1), r.t., 
16 h; (iv) 7.2 eq Et3N, toluene, 100 °C, 16 h; (v) 2.5 eq Et3N, toluene, 0 °C → r.t., 16 h. 
 
Scheme 36. Synthesis of diphosphite ligands 21a,b: (i) 5.0 eq Et3N, toluene, 0 °C → r.t., 16 h. 
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When 4,4'-di-methoxy-6,6'-di-tert-butyl-2,2'-biphenol was reacted with the chlorophosphite of 
(R)-BINOL in the presence of n-BuLi at -20 °C, symmetric diphosphite ligand 21e yielded in 61 % as 
a white solid (Scheme 38). 
Furthermore, new bidentate chiral phosphite-phosphoramidite ligands were prepared on the basis of 
readily accessible amino alcohols and chiral as well as non-chiral diols. 
Although L-(–)-ephedrine was already suggested as a backbone for phosphite-phosphoramidite ligands 
in the literature,[111] they have never been synthesized in combination with enantiomerically pure 
BINOL. We used it as starting material for the construction of phosphite-phosphoramidite 22a. It was 
reacted with 2.1 eq of the chlorophosphite of (S)-BINOL and 5.0 eq of triethylamine. Stirring at room 
temperature for 16 h yielded 22a as a white solid after column chromatography over alumina (52 %, 
Scheme 39). 
 
Scheme 37. Synthesis of diphosphite ligands 21c,d: (i) 5.0 eq Et3N, toluene, 0 °C → r.t., 16 h. 
 
Scheme 38. Synthesis of diphosphite ligand 21e: (i) 1.0 eq n-BuLi, toluene, -20 °C → r.t., 16 h. 
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According to this procedure L-(–)-ephedrine was also treated with the chlorophosphite of (R)-BINOL 
to yield 22b as a white solid (65 %). Because the ligands, derived from (R)-BINOL, were especially 
promising for the asymmetric hydroformylation of 16a (see Chapter 3.2.2.4), other 1,2-amino alcohols 
were taken into consideration (Scheme 40). 
In conclusion, five new phosphite-phosphoramidite compounds 22a-e could be prepared with yields of 
28-81% (Table 19). 
Table 19. Synthesis of phosphite-phosphoramidites 22a-e based on different 1,2-amino alcohols.a 
Entry Amino alcohol R1 R2 R3 BINOL Product Yieldb [%] 
1 
L-(–)-Ephedrine Me Me Ph 
(S)-BINOL 22a 52 
2 (R)-BINOL 22b 65 
3 (R)-2-Aminobutan-1-ol H Et H (R)-BINOL 22c 28 
4 2-(Methylamino)ethanol Me H H (R)-BINOL 22d 36 
5 (–)-Pseudoephedrine Me Me Ph (R)-BINOL 22e 81 
a 1.0 mmol of 1,2-amino alcohol, 2.1 mmol of chlorophosphite of enantiopure BINOL, 5.0 mmol Et3N, toluene, 0 °C → r.t., 
16 h. 
b Isolated yields after column chromatography over alumina. 
Amino sugar-based bidentate ligands have been prepared by Diéguez and co-workers recently.[112] All 
of them have in common that a hydrogen is linked to the nitrogen atom (secondary amine). For this 
 
Scheme 39. Synthesis of phosphite-phosphoramidite 22a with (S)-BINOL based on L-(–)-ephedrine: 
(i) 5.0 eq Et3N, toluene, 0 °C → r.t., 16 h. 
 
Scheme 40. Synthesis of phosphite-phosphoramidites 22b-e with (R)-BINOL based on different 1,2-amino 
alcohols: (i) 5.0 eq Et3N, toluene, 0 °C → r.t., 16 h. 
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reason, we focused on the synthesis of N-alkylated phosphite-phosphoramidites based on 1,2-O-
diprotected -D-xylofuranose. -D-Ribofuranose as backbone faded away from our spotlight due to 
the poor performance in the asymmetric hydroformylation of 16a (see Chapter 3.2.2.4). 
Starting from open-chain D-(+)-xylose, the hydroxyl groups were protected by isopropylidene groups 
according to the procedure of Kartha.[113] Therefore, the sugar was dissolved in acetone and a small 
portion of iodine was added as an activator. Stirring at room temperature for 16 h and common 
aqueous work-up gave 96 % of protected -D-xylofuranose 23a as a yellowish solid (pathway i, 
Scheme 41). In this compound, the original hydroxyl groups are protected by differently sized 1,3-
dioxo rings. Because a six-membered 2,2-dimethyl-1,3-dioxane is less stable than a five-membered 
2,2-dimethyl-1,3-dioxolane toward acidic conditions,[114] selective deprotection is possible.i The acetal, 
involving C-3 and C-5, could be cleaved when 23a was stirred in an aqueous solution of sulphuric acid 
at room temperature for 16 h. Neutralization and filtration over Celite yielded 1,2-O-diprotected -D-
xylofuranose 23b as a yellowish viscous oil (92 %, pathway ii).[115] Subsequent transformation of the 
hydroxyl group at C-5 into a leaving group (tosylate) was realized when 23b was stirred with tosyl 
chloride in pyridine at room temperature for 16 h. After aqueous work-up a mixture of mono- und 
ditosylated crude product could be obtained, what was separated by recrystallization. At -20 °C the 
monotosylated compound 23c precipitated and could be isolated as a white solid in 60 % yield after 
filtration (pathway iii).[116],ii 
The amino xylose derivatives 24b-g were prepared from protected 5-tosyl--D-xylofuranose 23c and a 
variety of primary amines. A SN2-reaction occurs at C-5 that is attacked by the nucleophilic amine. 
The reaction was either performed without a solvent at 60 °C (for 24b)[117] or in isopropanol under 
reflux (for 24c-g).[118] Aqueous work-up (except for 24b) and column chromatography yielded 24b-g 
as yellowish solids (pathway iv). The yields are given in Table 20. Product 24g was synthesized and 
characterized for the first time. 
                                                     
i  “Orthogonality” or “orthogonal protection” is a strategy for the deprotection of functional groups independendly of each 
other. 
ii  A large quantity of 23c was provided by the research group of Prof. Diéguez at Universitat Rovira í Virgili in 
Tarragona/Spain. 
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Table 20. Synthesis of amino xylose derivatitives 24b-g based on xylose derivative 23c.a 
Entry Amine R Product Yieldb [%] 
1c Isopropylamine iPr 24b 61 
2 tert-Butylamine tBu 24c 41 
3 Cyclohexylamine cHex 24d 63 
4 Aniline Ph 24e 86 
5 Benzylamine Bn 24f 61 
6 (S)--Methyl-benzylamine (S)--Me-Bn 24g 99 
a 10.0-15.0 mmol of 23c, 40.0-60.0 mmol of amine, isopropanol, 60 °C, 24 h. 
b Isolated yields after column chromatography over silica. 
c A large excess of amine was used instead of a solvent. Reaction was performed under reflux. 
Amino xylose derivatives 24b-g served as starting material for a range of new bidentate phosphite-
phosphoramidite ligands. According to the procedure of Diéguez et al.[112a,b] it was first tried to couple 
the N- as well as O-moiety, simultaneously, with the chlorophosphite of enantiopure BINOL using 
pyridine as a base. Starting from 24b, 12 eq of pyridine and 2.2 eq of the chlorophosphite of 
(S)-BINOL, only the signal for the chlorophosphite could be detected in 31P NMR after stirring at 
room temperature for 16 h. Therefore, the solution was heated to 100 °C and stirred for the same time 
again. In 31P NMR a signal at  = 145.3 ppm appeared, what was assigned to the O-phosphorylated 
product. Based on these results it can be concluded that the alkylated N-moiety of the amino xylose is 
not acidic enough to be deprotonated by pyridine, even at higher temperature. Consequently, it 
required a change to a stronger base, e.g. triethylamine. Amino alcohol 24b was reacted with the 
(S)-BINOL chlorophosphite in the presence of 5 eq of triethylamine at room temperature for 16 h. 
After column chromatography over basic silica, phosphite-phosphoramidite 25b could be isolated as a 
white solid (35 %). The 31P NMR spectrum was characterized by a doublet at  = 151.4 ppm and a 
doublet at  = 153.3 ppm for the phosphite- and phosphoramidite-P. 
Increasing the reaction temperature to 50 °C, the yield of 25b could be raised to 76 %. With this 
improvement, 12 new phosphite-phosphoramidites (25a-g and 26b,d-g) were synthesized with yields 
up to 97 % (Scheme 42, Table 21). 
 
Scheme 41. Synthesis of amino xylose derivatives 24b-g: (i) I2, r.t., 16 h; (ii) 0.8 % H2SO4, MeOH, 
r.t., 16 h; (iii) pyridine, DCM, 0 °C → r.t., 16 h; (iv) neat, 60 °C, 24 h or isopropanol, reflux, 24 h. 
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Table 21. Synthesis of phosphite-phosphoramidites 25a-g and 26b,d-g based on amino xylose derivatives 24a-g.a,i 
Entry Amino xylose R BINOL Product Yieldb [%] 
1 24a Me (S)-BINOL 25a 85 
2c 
24b iPr 
(S)-BINOL 25b 35 
3 (S)-BINOL 25b 76 
4 (R)-BINOL 26b 90 
5 24c tBu (S)-BINOL 25c 29 
6 
24d cHex 
(S)-BINOL 25d 97 
7 (R)-BINOL 26d 97 
8 
24e Ph 
(S)-BINOL 25e 33 
9 (R)-BINOL 26e 33 
10 
24f Bn 
(S)-BINOL 25f 81 
11 (R)-BINOL 26f 85 
12 
24g (S)--Me-Bn 
(S)-BINOL 25g 89 
13 (R)-BINOL 26g 62 
a 1.0 mmol of 24a-g, 2.2 mmol of chlorophosphite of enantiopure BINOL, 5.0 mmol Et3N, toluene, 0 °C → 50 °C, 16 h. 
b Isolated yields after column chromatography over basic silica. 
c The reaction was stirred at room temperature for 16 h. 
Additionally, phosphite-phosphoramidites with non-equal substituents at both phosphorus atoms were 
prepared based on amino xyloses 24b,g. Introducing two different groups makes a reaction over two 
steps necessary. At first, the monophosphite was prepared followed by the coupling of the second 
chlorophosphite to the N-moiety. 
Starting from amino xylose 24b, 4.6 eq of pyridine and 1.1 eq of the chlorophosphite of 
(S)-BIPHEN-H2ii in toluene, the reaction was stirred at 80 °C for 16 h. Column chromatography over 
silica with 2 % of triethylamine in toluene yielded 85 % of a white solid. The added base is necessary, 
inter alia, to ensure that the generated ammonium group of the xylose is retransformed into an amino 
                                                     
i  Amino-xylose 24a was provided by the research group of Prof. Diéguez at Universitat Rovira í Virgili in Tarragona/Spain. 
ii  To prepare the chlorophosphite of enantiopure BIPHEN-H2 or bisDBP, respectively, in situ, the aromatic diol was 
dissolved in toluene, an excess of pyridine was added and the solution was stirred for 16 h at 80 °C. Filtration from the 
pyridinium salt, followed by evaporation of the solvent yielded the desired chlorophosphite as a pale yellow solid. 
 
Scheme 42. Synthesis of xylose-based phospite-phosphoramidites 25a-g and 26b,d-g: (i) 5.0 eq Et3N, 
toluene, 0 °C → 50 °C, 16 h. 
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group.i One can assume that pyridine is less basic than the amino group of the sugar so that the 
N-moiety of the xylose is preferentially protonated during the reaction. To isolate phosphite 27a, 
instead of its ammonium salt, a stronger base than pyridine is needed for the deprotonation. According 
to this procedure three new monophosphites 27a-cii were prepared as white solids in 62-85 % yield 
(Table 22, entries 1-3). 
With amino sugar 24g, monophosphites 27d,e could only be isolated as crude ammonium salts (Table 
22, entries 4,5). Purification by recrystallization as well as column chromatography (with additional 
Et3N) failed. For that reason they were directly used for further reactions. 
Table 22. Synthesis of monophosphites 27a-e based on amino xylose derivatives 24a,g.a 
Entry Amino xylose R Aromatic diol Product Yieldb [%] 
1 
24a iPr 
(S)-BIPHEN-H2 27a 85 
2 (R)-BIPHEN-H2 27b 76 
3 bisDBP 27c 62 
4 
24g (S)--Me-Bn 
(S)-BINOL 27d 99c 
5 (R)-BINOL 27e 98c 
a 2.0 mmol of 24a,g, 2.2 mmol of chlorophosphite of (enantiopure) aromatic diol, 4.6 mmol pyridine, toluene, r.t. → 80 °C, 
16 h. 
b Isolated yields after column chromatography over alumina. 
c The crude product of the ammonium salt was isolated without further purification. 
Monophosphites 27a-e were used as starting material for the synthesis of mixed phosphite-
phosphoramidites. Corresponding to the preparation of phosphite-phosphoramidites 25a-g and 
                                                     
i  The pyridine keeps the reaction medium basic and works partly as a proton sponge, too. 
ii  The three monophosphite ligands 27a-c were synthesized in cooperation with Marc Magre Rosich from research group of 
Prof. Diéguez at Universitat Rovira í Virgili in Tarragona/Spain. 
 
Scheme 43. Synthesis of xylose-based monophosphites 27a-c and 27d,e: (i) 4.6 eq pyridine, toluene, 
0 °C → 80 °C, 16 h. 
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26b,d-g, respectively (see above), the reaction was performed with 5.0 eq of triethylamine and 1.1 eq 
of the chlorophosphite of enantiopure BINOL. Stirring at 50 °C for 16 h yielded 28a-f as white solids 
(starting from 27a-c) after column chromatography over silica. 
To prepare phosphite-phosphoramidite xyloses with varying BINOL units at the phosphorus of the 
O-side and different diols at the phosphorus of the N-moiety, crude products 27d,e were treated with 
2.0 eq of triethylamine and stirred at 50 °C for 16 h. Precipitated ammonium chloride could be 
removed by filtration. The 1H NMR spectrum of the crude material reveals that both singlets at 
 = 11.01 ppm and 11.40 ppm disappeared and thus an evidence for the free amino function. 
Purification by recrystallization or by column chromatography failed so that they were directly 
converted into the corresponding phosphite-phosphoramidites 28g-i (see above, Scheme 44, Table 23). 
 
Scheme 44. Synthesis of xylose-based mixed phosphite-phosphoramidites 28a-i: (i) 4.0 eq Et3N, toluene, 
0 °C → 50 °C, 16 h. 
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Table 23. Synthesis of mixed phosphite-phosphoamidites 28a-i based on monophosphites 27a-e.a 
Entry Monophosphite R Aromatic diol Product Yieldb [%] 
1 
27a (S)-BIPHEN-H2 
(S)-BINOL 28a 43 
2 (R)-BINOL 28b 76 
3 
27b (R)-BIPHEN-H2 
(S)-BINOL 28c 62 
4 (R)-BINOL 28d 73 
5 
27c bisDBP 
(S)-BINOL 28e 71 
6 (R)-BINOL 28f 89 
7 
27d (S)-BINOL 
(R)-BINOL 28g 35c 
8 bisDBP 28h 24c 
9 
27e (R)-BINOL 
(S)-BINOL 28i 21c 
10 bisDBP 28j –c 
a 0.33-0.5 mmol of 27a-e, 0.36-0.55 mmol of chlorophosphite of (enantiopure) aromatic diol, 1.6-2.6 mmol Et3N, toluene, 
0 °C → 50 °C, 16 h. 
b Isolated yields after column chromatography over basic silica. 
c Isolated yield over two steps after column chromatography over basic silica. 
 
 
3.2.2.4 Asymmetric hydroformylation with non-commercial and new ligands 
After widening the set of ligands, we continued the hydroformylation trials of 16a. All conditions 
remained the same as chosen for the preliminary attempts of asymmetric hydroformylation discussed 
above (see Chapter 3.2.2.2). 
At first, (R,S)- and (R,R)-BINAPHOS (20e and 20f) and the ligands, derived from 1,2-amino alcohols, 
were tested (Table 24). 
Table 24. Screening of the Rh-catalyzed asymmetric hydroformylation of 16a with self-prepared phosphorus ligands.a 
Entry Ligand p [MPa] Conv.b [%] 17ab [%] 18ab [%] 19ab [%] eec [%] 
1 20e 1.0 57 51 3 3 41 (+) 
2 20f 1.0 42 39 1 2 3 (–) 
3 22a 1.0 69 64 1 4 23 (–) 
4 22b 1.0 99 96 1 1 46 (+) 
5 22c 1.0 69 64 1 5 24 (+) 
6 22d 1.0 63 59 1 3 26 (+) 
7 22e 1.0 97 93 2 2 24 (+) 
8d 22b 1.0 63 60 1 2 34 (+) 
9e 22b 1.0 31 28 1 2 43 (+) 
10 22b 0.5 99 96 <1 3 44 (+) 
11 22b 5.0 67 52 13 2 32 (+) 
12f 22b 3.0 36 25 11 <1 51 (+) 
13g 22b 1.0 11 6 5 <1 47 (+) 
a 0.5 mmol of 16a, Rh(acac)(CO)2 5.0 µmol, PP-ligand 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, 80 °C, p, S/Rh = 100, 21 h. 
b Conversions and yields were determined by 31P NMR spectroscopy. 
c Ee-values of the linear aldehyde (17a) were determined by GC analysis. 
d The reaction was performed in EtOAc. 
e The reaction was performed in DCM. 
f The reaction was performed at 60 °C. 
g The reaction was performed at room temperature for 63 h. 
The rhodium-catalyzed reaction with (R,S)-BINAPHOS (20e) revealed only a mediocre 
enantioselectivity (41 %ee) with a poor conversion rate (entry 1). Diastereomeric (R,R)-BINAPHOS 
20f showed even worse results in both aspects (entry 2). 
The reaction with 22a gave only a moderate conversion (69 %) with low enantioselectivity of 23 %ee. 
However, the rhodium catalyst with L-(–)-ephedrine-based phosphite-phosphoramidite 22b showed 
first promising results. The highest ee-value of 46 %, quantitative conversion and excellent selectivity 
to the linear aldehyde could be reached for the first time (entry 3). Encouraged by this result, 
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structurally related ligands 22c-e, bearing (R)-BINOL, were employed. They induced good to very 
good chemo- and regioselectivities to the linear aldehyde on the one hand, but the enantioselectivities 
were still poor (entries 5-7). A comparison of the results of ligands 22b and 22e shows that a change 
of the configuration at carbon C-1 (L-(–)-ephedrine and (–)-pseudoephedrine) affected the 
enantioselectivity. Furthermore, the hydroformylation, using 22b, was also performed in EtOAc and 
DCM, but led to no improvement (entries 8,9). Therefore, we switched back to toluene as solvent and 
ran the asymmetric hydroformylation at different pressures. At a syngas pressure of 0.5 MPa, no 
changes of reactivity as well as enantioselectivity could be noted (entry 10). A higher pressure had a 
negative influence (entry 11). A lower temperature had a slightly positive effect on the 
stereodiscrimination, but the reactivity decreased, simultaneously (entries 12,13). 
During these screenings it was also possible to perform the asymmetric hydroformylation of 16a in the 
research group of Prof. Diéguez (Table 25). The provided set of sugar-based ligands is illustrated in 
Figure 17. 
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Figure 17. Provided set of sugar-based ligands used in the asymmetric hydroformylation of 16a. 
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Table 25. Screening of the Rh-catalyzed asymmetric hydroformylation of 16a with sugar-based phosphorus ligands L1-8.a 
Entry Ligand Conv.b [%] 17ab [%] 18ab [%] 19ab [%] eec [%] 
1 L1b 33 27 1 5 1 (+) 
2 L2b 70 63 2 5 rac 
3 L2c 18 15 2 2 17 (+) 
4 L2d 100 81 <1 19 rac 
5 L2e 100 98 <1 2 37 (–) 
6 L2f 100 98 <1 1 30 (+) 
7 L3c 85 58 – 27 2 (+) 
8 L4c 81 68 – 13 5 (–) 
9 L5c 76 54 – 22 2 (+) 
10 L6a >99 96 <1 3 7 (–) 
11 L6b 59 52 1 6 rac 
12 L6c 52 45 1 6 rac 
13 L6e 100 >99 <1 1 46 (–) 
14 L6f 100 98 <1 2 9 (–) 
15 L6g 66 51 <1 14 4 (+) 
16 L6h 100 81 – 19 3 (+) 
17 L7b 48 40 4 4 6 (+) 
18 L7c 49 40 5 4 14 (+) 
19 L8d 2 1 – <1 n.d. 
20 L8e 77 74 <1 3 4 (+) 
21 L8f 100 96 <1 4 11 (–) 
22 L8g 3 2 – 1 25 (+) 
23d L6e 85 82 3 <1 51 (–) 
24e L6e 24 21 2 – 56 (–) 
25e L2e 35 33 1 <1 45 (–) 
a 0.5 mmol of 16a, Rh(acac)(CO)2 5.0 µmol, PP-ligand 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, 80 °C, 1.0 MPa, 
S/Rh = 100, 21 h. 
b Conversions and yields were determined by 31P NMR spectroscopy. 
c Ee-values of the linear aldehyde (17a) were determined by GC analysis. 
d The reaction was performed at 60 °C. 
e The reaction was performed at 40 °C. 
The asymmetric hydroformylation was first started with the diphosphite ligand L1b, based on -D-
ribofuranose, what bears a non-chiral biphenol at both phosphorus atoms.i An almost racemic mixture 
of the linear aldehyde with a comparatively high amount of hydrogenation product could be obtained 
and, furthermore, the conversion was low (33 %). To see any influence of an additional stereogenic 
center at the C-5 carbon ligands of type L2 were employed to the reaction. The -D-allofuranose-
based ligands showed either modest to poor conversion rates (entries 2,3) or disappointing 
chemoselectivity (entry 4). In all cases, the ee-values were pretty low. However, trials performed with 
L2e and L2f, respectively, showed excellent yields of the linear aldehyde and moreover promising 
ee’s. 
When phosphite-phosphoramidite ligands L3c, L4c and L5c (with an opposing chirality at C-3) were 
used, low ee-values yielded. Moreover, hydrogenation became a strong competitive reaction 
(entries 7-9). 
Changing to -D-xylofuranose-based ligands L6 resulted in excellent conversion for some trials 
(entries 10,13,14,16), but ee-values still remained low except for ligand L6e. Highest chemo-, regio- 
and stereoselectivity (46 %ee) could be observed. Surprisingly, when ligands L6g,h were applied, 
having TMS-groups at the 3,3'-positions of the BINOLs, the enantioselectivity was affected. 
Additionally, it promoted the hydrogenation (entries 15,16). Structurally related ligands L7 and L8 
                                                     
i  However, due to the chirality of the sugar backbone, it can be assumed that, especially in the metal-complexes, a certain 
configuration is preferred. This effect of tropos ligands, becoming atropos, has been observed for example with chiral Ru-
diamine-complexes bearing 2,2'-biphenyl diphosphines as a counter-ligand.[119] 
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gave only small to moderate conversions (except for L8f). The additional methyl group at C-5, 
independently on the carbon atom configuration, seems to have a negative influence on the 
enantioselectivities of 17a (entries 17-22). 
At last, further trials with ligands L2e and L6e at lower temperatures (60 °C and 40 °C) were 
performed and showed best ee-values. The enantioselectivities slightly increased from 46 %ee to 
56 %ee and from 37 %ee to 45 %ee, respectively. Certainly, the conversion rates stagnated, but no 
loss of chemo- and regioselectivity could be determined (entries 23-25). 
Based on the promising results achieved with L6e, structurally related phosphite-phosphoramidites 
were synthesized (see Chapter 3.2.2.3) and tested for the asymmetric hydroformylation of 16a (Table 
26). 
Table 26. Screening of the Rh-catalyzed asymmetric hydroformylation of 16a with self-prepared xylose-based phosphite-
phosphoramidite ligands 25a,b,d-g and 26b,d-g.a 
Entry Ligand Conv. [%] 17ab [%] 18ab [%] 19ab [%] eec [%] 
1 25a 97 93 1 2 6 (+) 
2 25b >99 97 <1 2 12 (+) 
3 25d 99 95 <1 3 11 (+) 
4 25e 96 92 2 2 6 (+) 
5 25f >99 97 1 2 12 (+) 
6 25g >99 97 <1 2 19 (+) 
7 26b 100 96 1 3 55 (–) 
8 26d 98 94 1 4 46 (–) 
9 26e 100 97 <1 3 48 (–) 
10 26f 100 96 <1 3 53 (–) 
11 26g 100 96 <1 3 52 (–) 
a 0.5 mmol of 16a, Rh(acac)(CO)2 5.0 µmol, PP-ligand 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, 80 °C, 1.0 MPa, 
S/Rh = 100, 21 h. 
b Conversions and yields were determined by 31P NMR spectroscopy. 
c Ee-values of the linear aldehyde (17a) were determined by GC analysis. 
Using ligands 25a,b,d-g, based on (S)-BINOL, excellent conversions and regioselectivities to the 
linear aldehyde were observed, whereas hydrogenation could be suppressed. Unfortunately, the 
stereodifferentiation was negligible (entries 1-6). The reaction with ligands 26b,d-g, bearing the 
(R)-BINOL fragment, led to moderate ee-values (up to 55 %). Different alkyl substituents at the 
nitrogen have only a small influence on the conversion, regio- and enantioselectivity. Optimizations 
were undertaken while using 26f as ligand (Table 27). 
Table 27. Optimization of the Rh-catalyzed asymmetric hydroformylation of 16a with ligand 26f.a 
Entry T [°C] Conv.b [%] 17ab [%] 18ab [%] 19ab [%] eec [%] 
1d 80 100 96 <1 3 53 (–) 
2e 80 25 23 <1 2 57 (–) 
3 60 95 89 3 3 61 (–) 
4 50 90 84 3 3 62 (–) 
5 40 54 48 4 2 63 (–) 
a 0.5 mmol of 16a, Rh(acac)(CO)2 5.0 µmol, 26f 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, T, 1.0 MPa, S/Rh = 100, 21 h. 
b Conversions and yields were determined by 31P NMR spectroscopy. 
c Ee-values of the linear aldehyde (17a) were determined by GC analysis. 
d Reaction was performed in EtOAc. 
e Reaction was performed in DCM. 
The reaction, performed in EtOAc, gave almost the same results as in toluene from any point of view. 
When DCM was used as solvent the conversion decreased dramatically to 25 %, although the 
enantioselectivity slightly increased (entry 2). When the temperature was lowered to 60 °C, the 
reactivity remained almost unchanged, while the stereoselectivity could be improved to 61 % 
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(entry 3). Further temperature decrease to 50 °C was accompanied by a slight decline of conversion, 
but did not influence the ee-value. At 40 °C, the yield of the linear aldehyde seriously dropped to 48 % 
(entries 4,5). 
In the end, mixed phosphite-phosphoramidite ligands 28a-g,i were also tested in the asymmetric 
hydroformylation of 16a (Table 28). 
Table 28. Screening of the Rh-catalyzed asymmetric hydroformylation of 16a with self-prepared xylose-based mixed 
phosphite-phosphoramidite ligands 28a-g,i.a 
Entry Ligand Conv.b [%] 17ab [%] 18ab [%] 19ab [%] eec [%] 
1 28a 49 44 – 5 7 (–) 
2 28b 47 42 <1 5 5 (–) 
3 28c 53 50 1 2 10 (–) 
4 28d 83 75 1 7 1 (+) 
5 28e 54 50 <1 3 4 (+) 
6 28f 64 59 <1 5 12 (–) 
7 28g >99 89 <1 10 12 (–) 
8 28i 97 80 – 17 31 (+) 
a 0.5 mmol of 16a, Rh(acac)(CO)2 5.0 µmol, PP-ligand 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, 80 °C, 1.0 MPa, 
S/Rh = 100, 21 h. 
b Conversions and yields were determined by 31P NMR spectroscopy. 
c Ee-values of the linear aldehyde (17a) were determined by GC analysis. 
All ligands with different diol rests at both phosphorus atoms generated significant amounts of the 
hydrogenation product. Moreover, they showed disappointingly low activities, except for 28g,i. With 
these two ligands, almost full conversions resulted. A considerable stereodifferentiation could not be 
obtained in any case (maximum 31 %ee).  
The product, dimethyl (3-oxo-1-phenylpropyl)phosphonate 17a, has a slightly acidic hydrogen atom at 
the chiral center. For that reason, it should be taken into consideration that the enantioselectivity might 
deteriorate during the reaction. To ensure that this undesired side reaction does not happen samples 
were taken at certain periods and examined with regard to conversion, yields and especially ee-values. 
A model reaction of the asymmetric hydroformylation of 16a was performed with Rh(acac)(CO)2 and 
26f in toluene at 80 °C under 1 MPa syngas atmosphere (according to Table 26, entry 10). 
Figure 18. Conversion and yields of the products of the asymmetric hydroformylation of 16a with 
Rh(acac)(CO)2 and 26f over time. 
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The diagram shows the dependence of the conversion and the yield as a function of reaction time. At a 
time point of 2 h, 82 % of the starting material were consumed and after approximately 8 h almost full 
conversion was reached (the black curve). The level of the branched aldehyde was constantly low 
(<1 %, the red curve) over the whole reaction time. After 2 h, the hydrogenation adjusted to an amount 
of ca. 3 % of the final product mixture (the green curve). The -aldehyde is formed at the beginning of 
the reaction and after 7-8 h, no changes in the formation rate could be detected (the blue curve). 
Furthermore it can be noted that no decomposition of any product took place after 8 h of reaction (at 
80 °C and syngas atmosphere). Additionally, the enantiomeric excess of linear aldehyde 17a was 
verified at each time. 
It can be concluded that the ee-value remained almost constant after a time of 2 h. When full 
conversion of the substrate was reached (after ca. 7-8 h), e.g. when the maximum amount of the linear 
aldehyde was formed, the ee-value did not change (52-53 %) so that racemization of 17a can be 
excluded. 
 
 
3.2.2.5 HP-NMR experiments 
Furthermore, it was also possible to record HP-NMR spectra of the catalytic active speciesi for the 
representative ligand 26f. Therefore, HRh(26f)(CO)2 29 was prepared in situ under hydroformylation 
conditions to analyze, what configuration the ligand adopts in the complex (Scheme 45). 
1.0 Eq of phosphite-phosphoramidite ligand 26f was added to 1.0 eq of Rh(acac)(CO)2 in C6D6. This 
solution was purged with 1.0 MPa syngas and shaken at 80 °C for 21 h. Subsequently, the solution 
                                                     
i  HP-NMR experiments were performed in cooperation with Dr. Baumann at Leibniz-Institut für Katalyse e.V. in 
Rostock/Germany and Prof. Diéguez at Universitat Rovira í Virgili in Tarragona/Spain. 
 
Figure 19. Enantiomeric excess of 17a as product of the asymmetric hydroformylation of 16a with 
Rh(acac)(CO)2 and 26f over time 
 
Scheme 45. Formation of the catalytically active hydridorhodium 
phosphite-phosphoramidite dicarbonyl-complex HRh(26f)(CO)2 29. 
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was measured under atmospheric pressure and indicated the formation of HRh(26f)(CO)2-complex 29 
(Table 29). The 1H NMR spectrum, shown in Figure 21, illustrates the characteristic region for the 
hydride. 
 
 
Figure 20. 31P NMR for the hydridorhodium phosphite-phosphoramidite dicarbonyl-complex HRh(26f)(CO)2 29. 
 
Figure 21. 1H NMR for the hydridorhodium phosphite-phosphoramidite dicarbonyl-complex HRh(26f)(CO)2 29. 
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Table 29. 1H and 31P NMR data for HRh(26f)(CO)2-complex 29.a 
(P(1)) (P(2)) 1JP(1)-Rh 1JP(2)-Rh 2JP(1)-P(2) (H) 2JH-P(1) 2JH-P(2) 1JH-Rh 
171.9 (dd) 180.9 (dd) 190.1 233.3 124.7 -9.61 (ddd) 88.0 6.0 2.0 
a Prepared in toluene-d8; NMR spectra were recorded under atmospheric conditions at room temperature; chemical shift  in 
ppm; coupling constant J in Hz. 
In 31P NMR spectrum a set of two double doublets can be seen. They result from two non-equivalent 
phosphorus atoms, which couple to each other and also to rhodium. The signals appear at 
(P(1)) = 171.9 ppm and at (P(2)) = 180.9 ppm. The coupling constants for 31P(1)-103Rh is 
1JP(1)-Rh = 190.1 Hz, what neither corresponds to a complete equatorial nor to a complete apical 
coordination.[21a] The coupling constant between 31P(2)-103Rh equals 1JP(2)-Rh = 233.2 Hz and is typical 
for an equatorial coordination of the phosphorus to rhodium.[21a] 
The 31P(1)-31P(2) coupling constant is 2JP(1)-P(2) = 124.7 Hz. This is lower than for an ideal bisequatorial 
coordination of both phosphorus atoms, what ranges between 235-240 Hz,[21a] but higher than for 
equatorial-axial complexes (0-70 Hz). The observation might suggest that there is a dynamic 
equilibrium between ee- and ea-coordination that leads to an averaged value for the chemical shifts () 
and the coupling constant (2JP(1)-P(2), Scheme 46). Another aspect, what has to be considered, is the 
possible formation of a distorted trigonal bipyramidal hydridorhodium dicarbonyl species with 
ee-coordination.[120] 
The reason, why there is only one double doublet for each phosphorus instead of the estimated double 
set of double doublets, is the fast exchange of the position of the phosphorus, which cannot be 
determined on the NMR time scale.[25c] 
In the 1H NMR spectrum, a doublet of double doublets at (H) = -9.60 ppm is visible that can be 
assigned to the apical position of the hydride. The coupling constant for 1H-31P, 2JH-P(1) = 88.0 Hz, is an 
averaged value[25c] between the characteristical one for an equatorial (J < 10 Hz) and an axial 
coordination (J = 140-200 Hz[21a]). Therefore, it can be assigned to the coupling between the hydride 
and the phosphorus P(1). The other coupling constant mounts to 2JH-P(2) = 6.0 Hz. It is typical for an 
equatorial coordination and belongs to the coupling between the hydride and the phosphorus P(2). The 
value of 1H-103Rh is 1JH-Rh = 2.0 Hz is usual.[120a] 
In conclusion, it can be summarized that the values for 2JH-P and 2JP(1)-P(2) indicate a fast exchange 
between ee- and ea-coordination, but no dominant geometry can be supposed. One phosphorus atom 
changes its position and is located at the equatorial as well as the apical position in the trigonal 
bipyramidal-complex. 
 
 
 
Scheme 46. Equilibrium of two rhodium-complexes 
with equatorial-equatorial (ee) and equatorial-apical 
(ea) coordination of the bidentate ligand. 
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3.2.2.6 Scope of the asymmetric hydroformylation of -phosphorylated vinyl arenes  
We tried to expand the scope to a variety of substrates 16b-i for the asymmetric hydroformylation 
(Scheme 47). The reaction was performed with the L-(–)-ephedrine-based ligand 22b and the -D-
xylose- and amino xylose-based ligands L6e and 26f, respectively. A temperature of 80 °C and a 
syngas pressure of 1 MPa were chosen as reaction conditions. 
 
Scheme 47. Scope of the asymmetric hydroformylation of 16b-i. 
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Table 30. Scope of the Rh-catalyzed asymmetric hydroformylation of 16b-i with ligands 22b, L6e and 26f.a 
Entry Substrate Ligand Conv.b [%] 17b [%] 18b [%] 19b [%] eec [%] 
1 16b 22b 72 67 <1 4 n.d.d 
2 16b L6e 90 80 – 10 n.d.d 
3 16b 26f 100 95 1 4 n.d.d 
4 16h 22b 77 75 <1 1 n.d.d 
5 16h L6e 79 75 <1 3 n.d.d 
6 16h 26f 100 99 <1 1 n.d.d 
7 16c 22b 72 60 2 10 n.d.d 
8 16c L6e 97 81 – 16 n.d.d 
9 16c 26f >99 94 1 4 n.d.d 
10 16d 22b 67 62 <1 4 17 (+) 
11 16d L6e 94 89 <1 5 3 (+) 
12 16d 26f 100 96 <1 3 36 (–) 
13 16e 22b 65 58 1 6 17 (+) 
14 16e L6e 98 88 1 10 1 (+) 
15 16e 26f 100 95 1 4 35 (–) 
16 16f 22b 66 57 1 9 19 (+) 
17 16f L6e 97 89 <1 7 2 (+) 
18 16f 26f 100 95 1 4 37 (–) 
19 16g 22b 99 97 <1 2 n.d.d 
20 16g L6e 90 86 <1 3 n.d.d 
21 16g 26f >99 95 <1 5 n.d.d 
22 16i 22b 83 74 – 9 n.d.d 
23 16i L6e 97 67 – 30 n.d.d 
24 16i 26f 100 89 – 11 n.d.d 
a 0.5 mmol of substrate, Rh(acac)(CO)2 5.0 µmol, PP-ligand 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, 80 °C, 1.0 MPa, 
S/Rh = 100, 21 h. 
b Conversions and yields were determined by 31P NMR spectroscopy. 
c Ee-values of the linear aldehyde (17) were determined by GC analysis. 
d Up to now, the degree of enantioselectivity could not be determined, even not by application of different GC and HPLC 
columns. 
As a general tendency, best conversions of the substrates and yields to the corresponding aldehydes 
were observed with 26f. 
The hydroformylation of substrates 16b and 16h, which have electron donating groups (methyl group 
for 16b, [+I-effect] or methoxy group for 16h [+M-effect]) in the para-position of the aryl ring, 
resulted in full conversions with ligand 26f (entries 3,6). Stereoselectivities were not indicated, 
because the enantiomers could not be separated.  
For substrates 16d-f, possessing electron withdrawing groups in the para-position of the aryl ring 
(different halogens, –I-effect), hydroformylation with ligand 22b gave moderate conversions (ca. 
70 %), but low ee-values (entries 10,13,16). Moreover, trials with L6e as ligand resulted in almost full 
conversion, but hydrogenation occurred up to 10 % and the stereodifferentiation was surprisingly 
poor. When ligand 26f was used, very good rates to the linear aldehyde were achieved, however, the 
maximum of the reached enantiomeric excess was only 37 %. 
When diethyl phosphonate 16g was submitted to the reaction, results with these three ligands were 
comparable to those of the dimethyl phosphonate 16a. The ethyl group does not seem to have a great 
influence on conversion, regio-, chemoselectivity. A yield of 95 % for the linear aldehyde was reached 
with ligand 26f. A stereoselectivity was not determined, because both enantiomers could not be 
separated (entries 19-21). In the reaction of phosphine oxide 16i, having a different steric environment 
at the phosphorus atom (phenyl instead of alkoxy groups), the hydrogenation was promoted (up to 
30 %, (entries 22-24). Obviously, the steric demanding phenyl groups shield the double bond so that 
only small molecules (like H2) can attack, what leads to enhanced hydrogenation. 
Chapter 3: Results and discussion  
- 64 - 
3.2.2.7 Outlook 
The synthesis of enantiopure 3-aryl-3-phosphorylated propanals will remain an interesting task since a 
range of interesting structures can be derived. For example, both, phosphine oxide and aldehyde group 
in 17i, could be reduced to give the corresponding hydroxy phosphine compound, which may serve 
itself as ligand or on the way to more sophisticated ligands (Scheme 48). 
Moreover, the aldehyde can also be converted into a variety of functionalized compounds, e.g. 
alcohols, amines and carbon acids and their derivatives. 
 
 
3.2.3 Preparation of enantioenriched 3-phenyl butanal 
3-Phenyl butanal has a grassy, fresh and floral odor.i Together with several derivatives, such as 
Florhydral®,ii it is used as fragrance in all areas of perfumery, due to its great intensity.  
The scaffold of enantiomerically pure 3-phenyl butanal becomes apparent as substructure of 3-aryl -
aminobutyric acid and can be found, for example, in Phenibut (Figure 22). Its (R)-enantiomer is 
pharmacologically active and shows anxiolytic effects in humans and animals. It is used for post-
traumatic stress disorder, anxiety and insomnia, but also for treatment of alcoholism (withdrawal).[121] 
The structurally related derivative (R)-Baclofen is a specific agonist at the GABAB-receptor of 
mammals. It is applied for treatment of spasticity and acts as a muscle relaxant.[122] 
(R)-Rolipram (Figure 22) has an antidepressive,[123] antipsychotic,[124] anti-inflammatory, 
immunosuppressive,[125] and anti-tumor effect.[126] 
                                                     
i  3-Phenyl butanal is also known as hyacinth butanal or Triferal®. 
ii  The chemical name for Florhydral® (floral butanal) is 3-(3-isopropylphenyl)butanal. Currently, Florhydral® is 
predominantly supplied by Givaudan SA.  
 
Scheme 48. Subsequent transformations starting from phosphine oxide 17i. 
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Up to now, a variety of different synthetic strategies for the synthesis of chiral 3-phenyl butanal have 
been tested with more or less success with respect to yield and selectivity. Early research was focused 
on the diastereoselective addition of different organometallic compounds to allylamines,[127] allyl 
ethers,[128] ,-unsaturated aldimines,[129] acetals[130] or oxazolidines[131] using diverse chiral auxiliars. 
Moreover, copper-catalyzed 1,4-addition[132] became attractive, too. 
Another method for the preparation is based on the enantioselective isomerization of -methyl 
cinnamyl alcohol. With  a homogeneous rhodium-complex as catalyst,[133] excellent yields and up to 
75%ee could be reached. However, high amounts of catalyst were needed. The ruthenium-[134] and 
iridium-catalyzed[135] reactions generated high ee’s, but only moderate yields. 
The asymmetric transfer hydrogenation of -methyl cinnamaldehyde, using the Hantzsch ester,[136] 
illustrated another route to yield 3-phenyl butanal with enantioselectivities up to 94 %.[137] In this 
context, other hydrogen sources were employed, too, but competitive hydrogenation to the unsaturated 
alcohol could not be suppressed.[138] 
Asymmetric hydroformylation of -methyl styrene, a cheap and available compound from large 
industrial-scale,i represents a suitable alternative to get chiral 3-phenyl butanal as well as its 
derivatives. 
 
 
3.2.3.1 Asymmetric hydroformylation of -methyl styrene 
The reaction under hydroformylation conditions can give chiral aldehyde 30, branched (achiral) 
aldehyde 31 and hydrogenation product cumene (Scheme 49). In principle, an interesting competition 
in the reaction pathways between the preferred terminal aldehyde, according to Keulemans’ rule, and 
the iso-product due to the -regiodirecting effect of the styrene can be expected (Figure 23).  
Since we aimed to get the chiral product, we started promptly with chiral rhodium catalysts (Table 31). 
                                                     
i  -Methyl styrene is a side product in the cumene process.[139] 
 
Figure 22. Chiral pharmaceuticals derived from 3-phenyl butanal: 
(R)-Phenibut, (R)-Baclofen and (R)-Rolipram. 
 
Figure 23. Regioselective binding of the 
CHO-group. 
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Table 31. Initial trials of the Rh-catalyzed asymmetric hydroformylation of -methyl styrene with commercial ligands.a 
Entry Ligand Conv.b [%] 30b [%] 31b [%] Cumeneb [%] eec [%] 
1 (S,S)-DIOP 94 90 1 3 rac 
2 (S,S)-BDPP 83 80 1 3 rac 
3 (R)-SynPhos 71 69 1 1 1 (–) 
4 (R,R)-Me-DuPhos 35 31 1 3 rac 
5 (S,S)-ChiraPhos 76 66 <1 10 1 (+) 
6 (R,R)-DIPAMP 18 14 1 3 rac 
7 (R)-DifluorPhos 69 64 2 3 rac 
8 (R,R)-Ph-BPE 70 65 2 3 9 (+) 
9 (R,R)-QuinoxP* 43 18 14 11 15 (–) 
10 (S,S)-BenzP* 100 86 – 14 rac 
11 (R,R)-Chiraphite 87 85 1 2 1 (+) 
12 (R,R)-Kelliphite 95 92 <1 3 1 (–) 
a 0.5 mmol of -methyl styrene, Rh(acac)(CO)2 5.0 µmol, PP-ligand 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, 80 °C, 
1.0 MPa, S/Rh = 100, 21 h. 
b Conversions and yields were determined by 1H NMR spectroscopy. 
c Ee-values of the linear aldehyde (30) were determined by GC analysis. 
According to the hydroformylation of 16a we adopted the conditions (amount of catalyst, temperature, 
pressure, time) and started with Rh(acac)(CO)2 and commercially available chiral ligands. At 80 °C 
and under 1 MPa syngas atmosphere, conversions from 18 % to 94 % were obtained (entries 1-7). The 
formation of the linear aldehyde was privileged, however, small amounts of the branched aldehyde 
and the hydrogenation product were found in all cases. With rhodium catalysis, based on these ligands, 
it was not able to induce any chirality in the final product; almost racemic mixtures of 3-phenyl 
butanal were determined. 
When recently successful ligands in the asymmetric hydroformylation (see Chapter 2.2.2.2) were 
applied, no improvements could be achieved: with (R,R)-Ph-BPE a moderate conversion (70 %) with 
poor enantioselectivity (9 %ee) was obtained (entry 8). (R,R)-QuinoxP* and (S,S)-BenzP* gave the 
linear aldehyde in only 15 %ee and as a racemic mixture, respectively (entries 9,10). 
The reaction with diphosphites, such as (R,R)-Chiraphite and (R,R)-Kelliphite, resulted in good 
conversions and excellent regioselectivities. Nevertheless, both ligands were not able to induce 
considerable enantioselectivities as well (entries 11,12). The unsatisfying results prompted us to 
switch to our self-prepared ligands (Table 32). 
 
Scheme 49. Asymmetric hydroformylation of -methyl styrene. 
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Table 32. Screening of the Rh-catalyzed asymmetric hydroformylation of -methyl styrene with self-prepared diphosphite 
ligands 21a-e and phosphite-phosphoramidite ligand 22b.a 
Entry Ligand Conv.b [%] 30b [%] 31b [%] Cumeneb [%] eec [%] 
1 21a 97 97 <1 – 2 (+) 
2 21b 97 96 1 – 33 (–) 
3 21c 76 75 1 – 8 (–) 
4 21d 74 73 1 – 4 (–) 
5 21e 91 90 <1 1 18 (–) 
6 22b 87 85 2 – 10 (–) 
a 0.5 mmol of -methyl styrene, Rh(acac)(CO)2 5.0 µmol, PP-ligand 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, 80 °C, 
1.0 MPa, S/Rh = 100, 21 h. 
b Conversions and yields were determined by 1H NMR spectroscopy. 
c Ee-values of the linear aldehyde (30) were determined by GC analysis. 
We started our trials with chiral diphosphites 21a-e and obtained conversions up to 97 %. However, 
the rhodium catalysts, based on these structurally related ligands, varied in reactivity and 
stereodifferentiation. Excellent chemo- and regioselectivities were attained in all cases (entries 1-5). 
When 21b was employed, a good enantioselectivity for the linear aldehyde was observed (33 %ee). 
L-(–)-Ephedrine-based phosphite-phosphoramidite 22b gave a satisfying conversion accompanied by a 
poor ee-value of 10 % (entry 6). 
Finally, we performed the asymmetric hydroformylation of -methyl styrene using the xylose-based 
ligands (Table 33). 
Table 33. Screening of the Rh-catalyzed asymmetric hydroformylation of -methyl styrene with self-prepared xylose-based 
phosphite-phosphoramidite ligands 25a,d-g, 26d-g and 28a-g,i.a 
Entry Ligand Conv.b [%] 30b [%] 31b [%] Cumeneb [%] eec [%] 
1 25a 83 81 1 1 23 (+) 
2 25d 92 88 1 3 10 (+) 
3 25e 88 86 1 1 12 (+) 
4 25f 82 80 1 1 36 (+) 
5 25g 96 95 <1 – 39 (+) 
6 26d 86 83 2 1 14 (–) 
7 26e 93 91 1 1 8 (–) 
8 26f 91 89 2 – 14 (–) 
9 26g 91 87 2 2 20 (–) 
10 28a 67 63 1 3 11 (–) 
11 28b 65 63 1 <1 9 (–) 
12 28c 74 72 2 – 15 (–) 
13 28d 96 93 1 2 rac 
14 28e 46 45 1 – 2 (–) 
15 28f 58 57 <1 – 5 (–) 
16 28g 98 92 1 5 16 (–) 
17 28i 91 87 1 3 18 (+) 
a 0.5 mmol of -methyl styrene, Rh(acac)(CO)2 5.0 µmol, PP-ligand 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, 80 °C, 
1.0 MPa, S/Rh = 100, 21 h. 
b Conversions and yields were determined by 1H NMR spectroscopy. 
c Ee-values of the linear aldehyde (30) were determined by GC analysis. 
First of all, it could be noted that the substituents at the N-moiety of ligands 25 and 26 have a crucial 
effect on the hydroformylation of -methyl styrene and this fact is in contrast to the reaction of 16a. 
When a rhodium catalyst was used, what is based on 26a (containing N-Me), 23 %ee for the linear 
aldehyde were reached (entry 1). Ligands with more sterically demanding substituents at the nitrogen 
atom, such as cyclohexyl and phenyl (represented in 25d and 25e, respectively), gave lower 
enantioselectivities (entries 2,3). Surprisingly, ligand 25f, bearing a benzyl group at the nitrogen, 
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managed to induce a stereoselectivity of 36 % (entry 4) that could be slightly exceeded by application 
of 25g (39 %ee, entry 5).  
For all these ligands, conversions up to 96 % and very good yields (up to 95 %) to the desired 
3-phenyl butanal were attained. 
Hydroformylation with ligands, bearing (R)-BINOLs at both phosphorus atoms (26d-g), showed 
similar results with respect to reactivity and regioselectivity. However, lower enantioselectivities were 
detected in all cases (entries 6-9). 
When mixed xylose-based phosphite-phosphoramidites were used, varying conversions were obtained 
depending on the substituents at the phosphorus atoms. Among these trials, only ligands 28d and 28g 
induced high yields of linear aldehyde (93 % and 92 %, respectively, entries 13,16). Unfortunately, no 
general tendency can be recognized, how the substituents at the phosphorus atoms are related to 
reactivity as well as to the stereocontrol of the chiral catalyst. 
Summarizing, it can be said that -methyl styrene was hydroformylated yielding 95 % of the desired 
linear aldehyde. This product could be obtained in 39 %ee using the self-prepared ligand 25g. 
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4 Summary and outlook 
The general aim of this thesis consisted in the examination of the asymmetric hydrogenation and the 
hydroformylation of 1,1-disubstituted olefins as an alternative approach to the synthesis of new or 
known chemical compounds or substructures. 
First part of this dissertation was devoted to the asymmetric hydrogenation of functionalized olefins. 
With the hydrogenation of trimethylsilylated dehydro lactate, a new strategy to the synthesis of an 
O-protected lactic acid derivative could be established. In this context, different catalyst precursors 
were tested and the performance of the superior system was optimized with respect to yield and 
stereodifferentiation. Catalysts, recently applied for structurally related substrates, did not perform 
successfully. Noteworthy, a corresponding three-fold substituted olefin did not react under the 
optimized conditions. Even a more severe reaction regime afforded only inferior results. A broader 
catalyst screening, preferentially based on high-throughput screening, could probably give more 
promising results. Unfortunately, such devices were not accessible during this thesis.  
In addition, the stereoselective hydrogenation of a cyclic N,O-ketene acetal was examined, what 
represented a great challenge, since this class of olefins was not hydrogenated asymmetrically, yet.  
Among numerous catalyst precursors tested, a (R,S)-JosiPhos-based rhodium system gave superior 
results after optimization of the reaction parameters. By evaluation of further ligands within this 
ferrocene-based ligand family, no improvements could be achieved. Resulting cyclic N,O-acetal was 
isolated in an excellent yield with good enantioselectivity. 
A further aspect of this thesis was the asymmetric hydrogenation of dehydro 2-homoalanine 
derivatives. One compound of this class served as a model substrate and was treated with rhodium 
catalysts using a variety of ligands. With the help of a commercially available ligand, developed in the 
research group of Prof. Börner, an excellent enantioselectivity and yield could be reached. Further 
trials with other substrates of this class could be worked out. They showed convincing results as well 
and proved the wide range of application of this method. In addition, two newly generated 
2-homoalanine derivatives served as starting material for further transformations. Selectively, the 
ester- as well as the N-protecting group could be reduced and further converted, respectively, under 
preservation of the chiral center to finally yield chiral 1,3-amino alcohols (Scheme 50). 
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A further part of this thesis consisted of the synthesis of novel, chiral phosphorus ligands and their 
application in the asymmetric hydroformylation of 1,1-disubstituted olefins. Next to the preparation of 
non-commercial ligands, such as (R,S)- and (R,R)-BINAPHOS, chiral diphosphites, based on various 
aromatic diols, were synthesized. The preparation of phosphite-phosphoramidites, derived from 
1,2-amino alcohols, was successful and provided five new ligands, which were tested in asymmetric 
hydroformylation. Furthermore, in cooperation with the research group of Prof. Diéguez (Universitat 
Rovira í Virgili in Tarragona/Spain), six xylose-based amines were prepared in a four-step synthesis, 
which were then used as starting material for the synthesis of bidentate phosphite-phosphoramidite 
ligands on the other hand (12 new compounds). A two-step reaction enabled at first the preparation of 
monophosphites (three new compounds), which were then converted into mixed phosphite-
phosphoramidites. In this manner, nine new ligands were synthesized and tested in asymmetric 
hydroformylation (Scheme 51). 
 
Scheme 50. Asymmetric hydrogenation of 1,1-disubstituted olefins and 
subsequent transformations. 
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By means of a precatalysts based on a self-prepared xylose-based phosphite-phosphoramidite ligand, 
HP-NMR experiments were undertaken. The resulting data provided information about the formed 
hydridorhodium-complex and led to some assumptions of the preferred coordination geometry of the 
bidentate ligand to the metal. 
The asymmetric hydroformylation of a dehydro 2-homoalanine derivative led mainly to 
isomerization. The desired branched aldehyde could be obtained in maximum 33 %ee. 
Furthermore, an -phosphorylated styrene derivative was hydroformylated to yield predominately the 
linear aldehyde. By screening of a set of sugar-based ligands, the desired product resulted 
convincingly. Optimization, with respect to the conditions and also the application of new self-
prepared ligands, led to an excellent yield and promising stereoselectivity. The scope could be 
extended to eight different substituted -phosphorylated vinyl arenes and one phosphine oxide 
derivative. 
The asymmetric hydroformylation of -methyl styrene delivered the linear aldehyde in a very good 
yield and a moderate enantioselectivity while the reaction was performed with a self-prepared xylose-
based phosphite-phosphoramidite ligand (Scheme 52). 
In this context, all substrates, with the exception of -methyl styrene, were self-prepared. 
 
Scheme 51. Synthesis of new diphosphites and phosphite-phosphoramidites. 
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In this thesis performed hydrogenation and hydroformylation reactions display a practical alternative 
to already existing synthesis strategies. Because of the relatively simple transition between both types 
of reaction, a wide range of various compounds can be easily achieved. Regarding to 1,1-disubstituted 
olefins, it becomes clear that these compounds possess a great potential, especially in the field of 
enantioselective hydroformylation. However, up to now, it is a great challenge to handle reactivity as 
well as chemo-, regio- and stereoselectivity that requires additional investigations in future.
 
Scheme 52. Asymmetric hydroformylation of 1,1-
disubstituted olefins. 
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5  Appendix 
5.1 Experimental section 
5.1.1 Materials and methods 
5.1.1.1 General remarks 
All non-aqueous reactions were carried out in oven-dried glassware under an argon atmosphere in 
order to exclude oxygen and/or water (Schlenk techniques were applied). Solvents for the reactions 
were dried and distilled by standard methods or purchased in extra dry quality from SIGMA ALDRICH®. 
All chemicals, which were employed, were purchased from a commercial source (SIGMA ALDRICH®, 
ALFA AESAR®, ABCR) and used as received. 
 
 
5.1.1.2 Methods for the compound characterization and analysis 
1H NMR spectroscopy: 
Bruker AVANCE 300 III (f = 300 MHz) and Bruker AVANCE 250 II (f = 250 MHz). All chemical 
shifts  are given in ppm. All coupling constants are indicated as J and given in Hz. References: 
tetramethylsilane TMS ( = 0.00 ppm) was taken as internal standard. Chemical shifts for deuterated 
solvents:  = 7.26 ppm for CDCl3,  = 7.16 ppm for C6D6,  = 5.32 ppm for CD2Cl2 and  = 3.31 ppm 
for CD3OD. Peak characterization: s = singlet, d = doublet, dd = double doublet, ddd = doublet of 
double doublet, t = triplet, q = quartet, dq = double quartet, m = multiplet, br = broad. Aromatic 
hydrogen atoms are abbreviated as CH-Ar. 
 
 
13C NMR spectroscopy: 
Bruker AVANCE 300 III (f = 75 MHz) and Bruker AVANCE 250 II (f = 63 MHz). All chemical 
shifts  are given in ppm. All coupling constants are indicated as J and given in Hz. References: 
tetramethylsilane TMS ( = 0.00 ppm) was taken as internal standard. Chemical shifts for deuterated 
solvents:  = 77.00 ppm for CDCl3 and  = 128.06 ppm for C6D6,  = 54.00 ppm for CD2Cl2 and 
 = 49.15 ppm for CD3OD. Peak characterization: s = singlet, d = doublet, dd = double doublet, 
t = triplet, q = quartet, m = multiplet, br = broad. DEPT method was used for determining the presence 
of primary, secondary, tertiary and quaternary carbon atoms. Aromatic carbon atoms are abbreviated 
as CHAr and CAr. 
 
 
19F NMR spectroscopy: 
Bruker AVANCE 300 III (f = 282 MHz). All chemical shifts  are given in ppm. All coupling 
constants are indicated as J and given in Hz. References: trichlorofluoromethane CFCl3 ( = 0.00 ppm) 
was taken as internal standard. Peak characterization: s = singlet, d = doublet. 
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31P NMR spectroscopy: 
Bruker AVANCE 300 III (f = 121 MHz) and Bruker AVANCE 250 II (f = 101 MHz). All chemical 
shifts  are given in ppm. All coupling constants are indicated as J and given in Hz. References: 
phosphoric acid H3PO4 ( = 0.00 ppm) was taken as internal standard. Peak characterization: 
s = singlet, d = doublet, dd = double doublet, br = broad. 
 
 
Mass spectrometry (MS): 
Finnigan MAT 95-XP (ThermoElectron, EI, 70 eV) and Agilent-6890 with Agilent-5973 mass 
spectrometer. 
 
 
High resolution mass spectrometry (HRMS): 
Agilent 6210 E1969A TOF. Only the measurements with an average deviation from the theoretical 
mass of ± 2 mDa were accounted as correct. 
 
 
Gas chromatography (GC): 
Agilent-7890A with flame ionization detector (FID). 
 
 
High pressure liquid chromatography (HPLC): 
HP 1100 (Hewlett Packard) with diode array detector (DAD). 
 
 
Elemental analysis (EA): 
C/H/N/S-Microanalysator TruSpec CHNS (Leco). 
 
 
Polarimetry: 
Gyromat-HP High Precision Digital Automatic Polarimeter (Kernchen, Germany). The length of the 
cuvettes were l1 = 10 mm and l2 = 20 mm; the wavelength is  = 589 nm. 
 
 
Melting point determination (mp): 
Micro-Hot-Stage Galen™ III Cambridge Instruments. The melting points were not corrected. 
 
 
5.1.2 Synthesis methods 
5.1.2.1 Synthesis of 2-[(trimethylsilyl)oxy] esters 
General procedure for the synthesis of ,-unsaturated methyl esters 1a,b 
The -keto ester (1.0 eq) is dissolved in dichloromethane (1 mL/1.0 mmol substrate) and 
chlorotrimethylsilane (1.4 eq) is added. Then, triethylamine (1.6 eq) is added dropwise to the solution, 
which is stirred at room temperature for 16 h. After this time, pentane is added and the organic layer is 
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washed with water (twice) and brine. The organic phase is dried over Na2SO4, concentrated in vacuo 
and purified by distillation to give 1a,b. 
 
Methyl 2-[(trimethylsilyl)oxy]acrylate (1a)[140] 
Starting from methyl pyruvate (5.11 g, 50 mmol) and TMSCl (7.10 g, 65 mmol) in 
DCM (50 mL), the product 1a was isolated as a colorless oil (8.63 g, 99 %) after 
distillation (T = 53 °C, p = 15 mbar). 
1H NMR (300 MHz, CDCl3):  (ppm) = 0.23 (s, 9H, Si(CH3)3), 3.77 (s, 3H, OCH3), 4.88 (d, 1H, 
HA-CH2, 2JH-H = 1.2 Hz), 5.51 (d, 1H, HB-CH2, 2JH-H = 1.2 Hz). 
13C NMR (75 MHz, CDCl3):  (ppm) = -0.1 (Si(CH3)3), 52.1 (OCH3), 104.0 (CH2), 146.9 (CCH2), 
164.9 (C=O). 
 
Methyl 2-[(trimethylsilyl)oxy]but-2-enoate (1b) 
Starting from methyl 2-oxobutanoate (1.74 g, 15 mmol) and TMSCl (2.68 g, 
21 mmol) in DCM (15 mL), the product 1b was isolated as a colorless oil (2.65 g, 
94 %) after distillation (T = 74 °C, p = 30 mbar). 
Anal. calcd for C8H16O3Si: C, 51.03; H, 8.56. Found: C, 51.06; H, 8.59 %. 
HRMS (ESI) calculated for C8H17O3Si: 189.09415, found 189.09402. 
1H NMR (300 MHz, CDCl3):  (ppm) = 0.21 (s, 9H, Si(CH3)3), 1.70 (d, 3H, CH3, 3JH-H = 7.1 Hz), 3.74 
(s, 3H, OCH3), 6.13 (d, 1H, CH, 3JH-H = 7.1 Hz). 
13C NMR (75 MHz, CDCl3):  (ppm) = 0.4 (Si(CH3)3), 11.3 (CH3), 51.8 (OCH3), 118.4 (CH), 141.3 
(C-O), 165.2 (C=O). 
 
 
General procedure for the synthesis of 2-[(trimethylsilyl)oxy] esters 2a,b 
The substrate (1.0 eq) and the Rh precatalyst (1 mol%) are transferred into a glass vial, which is placed 
into a stainless steel autoclave. The solvent (4 mL/1.0 mmol substrate) is added under an argon 
atmosphere and the autoclave is purged with argon (three times) followed by hydrogen (three times). 
The indicated reaction conditions (H2-pressure, temperature and reaction time) are adjusted by an 
automatic program. After stirring for the adjusted time, the mixture is concentrated under reduced 
pressure. The enantiomeric excess is determined by GC analysis. A racemic mixture of 2b, as sample 
for the quantitative and qualitative analysis, is prepared by the hydrogenation of 1b with 10 % Pd/C in 
THF. 
 
Methyl 2-[(trimethylsilyl)oxy]propanoate (2a)[141] 
Anal. calcd for C7H16O3Si: C, 47.69; H, 9.15. Found: C, 47.73; H, 9.26 %. 
1H NMR (300 MHz, CDCl3):  (ppm) = -0.06 (s, 9H, Si(CH3)3), 1.14 (d, 3H, CH3, 
3JH-H = 6.8 Hz), 3.45 (s, 3H, OCH3), 4.06 (q, 1H, CH, 3JH-H = 6.8 Hz). 
13C NMR (75 MHz, CDCl3):  (ppm) = -0.1 (Si(CH3)3), 21.4 (CH3), 51.7 (OCH3), 68.2 (CH), 174.1 
(C=O). 
Separation of enantiomers by GC on Chiraldex -PM (50 m×0.25 mm), 80/15-8-180; tR = 10.5 min for 
(+)-enantiomer and tR = 10.7 min for (–)-enantiomer. 
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Methyl 2-[(trimethylsilyl)oxy]butanoate (2b) 
Anal. calcd for C8H18O3Si: C, 50.49; H, 9.53. Found: C, 50.30; H, 9.51 %. 
HRMS (ESI) calculated for C8H19O3Si: 191.32060, found 191.32073. 
1H NMR (300 MHz, CDCl3):  (ppm) = 0.13 (s, 9H, Si(CH3)3), 0.93 (t, 3H, CH3, 
3JH-H = 7.2 Hz), 1.68-1.73 (m, 2H, CH2), 3.72 (s, 3H, OCH3), 4.11 (dd, 1H, CH, 3JH-A = 7.5 Hz, 
3JH-B = 4.9 Hz). 
13C NMR (75 MHz, CDCl3):  (ppm) = 0.2 (Si(CH3)3), 10.4 (CH3), 24.4 (CH2), 51.9 (OCH3), 68.5 
(CH), 173.9 (C=O). 
Separation of enantiomers by GC on Chiraldex -PM (50 m×0.25 mm), 75/20-8-180; tR = 17.0 min for 
(+)-enantiomer and tR = 17.3 min for (–)-enantiomer. 
 
 
5.1.2.2 Synthesis of N,O-acetals 
General procedure for the synthesis of 2-methylene-3-substituted-oxazolidine-4,5-diones 3a,b 
The corresponding amide (1.0 eq) is dissolved in benzene (0.5 mL/1.0 mmol amide) and heated to 
60 °C. Oxalyl chloride (1.08 eq) is added dropwise and the mixture is then refluxed for 24 h. After this 
time, it is cooled to room temperature and concentrated in vacuo. Kugelrohr distillation of the residue 
gives 3a,b. 
 
2-Methylene-3-phenyloxazolidine-4,5-dione (3a) 
Starting from acetanilide (9.46 g, 70 mmol) and oxalyl chloride (9.52 g, 75 mmol) 
in benzene (35 mL), the product 3a was isolated as a white solid (10.32 g, 78 %) 
after Kugelrohr distillation (T = 120-130 °C, p = 0.1 mbar). 
Anal. calcd for C10H7NO3: C, 63.49; H, 3.73. Found: C, 63.30; H, 3.71 %. 
HRMS (ESI) calculated for C10H8NO3: 190.17487, found 190.17491. 
1H NMR (300 MHz, CDCl3):  (ppm) = 4.16 (d, 1H, HA-CH2, 2JA-B = 4.8 Hz), 4.53 (d, 1H, HB-CH2, 
2JA-B = 4.8 Hz), 7.36-7.40 (m, 2H, CH-Ar), 7.48-7.60 (m, 3H, CH-Ar). 
13C NMR (63 MHz, CDCl3):  (ppm) = 75.5 (CH2), 126.4 (2CHAr), 130.0 (2CHAr), 130.1 (CHAr), 
130.9 (CAr), 147.2 (CCH2), 149.8 (C=O), 154.1 (C=O). 
 
3-Acetyl-2-methyleneoxazolidine-4,5-dione (3b) 
Starting from diacetamide (5.06 g, 50 mmol) and oxalyl chloride (6.80 g, 54 mmol) in 
benzene (25 mL), the product 3b was isolated as a white solid (6.00 g, 77 %) after 
Kugelrohr distillation (T = 120-140 °C, p = 0.2 mbar). 
Anal. calcd for C6H5NO4: C, 46.46; H, 3.25. Found: C, 46.30; H, 3.20 %. 
HRMS (ESI) calculated for C6H6NO4: 156.02914, found 156.02899. 
1H NMR (250 MHz, CDCl3):  (ppm) = 2.70 (s, 1H, CH3), 4.83 (d, 1H, HA-CH2, 2JA-B = 4.1 Hz), 5.56 
(d, 1H, HB-CH2, 2JA-B = 4.2 Hz). 
13C NMR (63 MHz, CDCl3):  (ppm) = 26.2 (CH3), 83.7 (CH2), 142.1 (CCH2), 150.4 (C=O), 152.8 
(C=O), 167.7 (C=O). 
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General procedure for the asymmetric hydrogenation of 2-methylene-3-substituted-oxazolidine-4,5-
diones 3a,b 
The substrate (1.0 eq) and Rh precatalyst (1 mol%) are transferred into a glass vial, which is placed 
into a stainless steel autoclave. The solvent (8 mL/1.0 mmol substrate) is added under an argon 
atmosphere and the autoclave is purged with argon (three times) followed by hydrogen (three times). 
The indicated reaction conditions (H2-pressure, temperature and reaction time) are adjusted by an 
automatic program. After stirring for the adjusted time, the mixture is concentrated under reduced 
pressure. The enantiomeric excess is determined by GC analysis. Racemic mixtures of 4a,b, as 
samples for the quantitative and qualitative analysis, are prepared by the hydrogenation of 3a,b with 
10 % Pd/C in THF. 
 
2-Methyl-3-phenyloxazolidine-4,5-dione (4a) 
Anal. calcd for C10H9NO3: C, 62.82; H, 4.74. Found: C, 62.92; H, 4.80 %. 
HRMS (ESI) calculated for C10H10NO3: 192.06552, found 192.06540. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.65 (d, 3H, CH3, 3JH-H = 5.6 Hz), 6.20 (q, 
1H, CH, 3JH-H = 5.6 Hz), 7.35-7.41 (m, 1H, CH-Ar), 7.45-7.53 (m, 4H, CH-Ar). 
13C NMR (63 MHz, CDCl3):  (ppm) = 20.7 (CH3), 84.8 (CH), 122.2 (2CHAr), 128.2 (CHAr), 129.8 
(2CHAr), 133.4 (CAr), 150.7 (C=O), 158.3 (C=O). 
 
3-Acetyl-2-methyloxazolidine-4,5-dione (4b) 
Anal. calcd for C6H7NO4: C, 45.86; H, 4.49. Found: C, 46.02; H, 4.54 %. 
HRMS (ESI) calculated for C6H8NO4: 158.04478, found 158.04489. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.77 (d, 3H, CHCH3, 3JH-H = 5.1 Hz), 2.64 (s, 
3H, CH3), 6.06 (q, 1H, CH, 3JH-H = 5.1 Hz). 
13C NMR (63 MHz, CDCl3):  (ppm) = 21.3 (CHCH3), 24.8 (CH3), 84.5 (CH), 151.5 (C=O), 157.0 
(C=O), 169.0 (C=O). 
Separation of enantiomers by GC on CP-Chirasil-Dex CB (25 m×0.32 mm), isotherm 150 °C; 
tR = 7.1 min for (+)-enantiomer and tR = 8.5 min for (–)-enantiomer. 
 
 
5.1.2.3 Synthesis of 2-homoalanine derivatives and secondary products 
General procedure for the synthesis of alkyl (2-hydroxymethyl)acrylates 5a,b 
Paraformaldehyde (1.0 eq), alkyl acrylate (3.0 eq) and DABCO (1.0 eq) are dissolved in dioxane:water 
(2 mL/1.0 mmol paraformaldehyde, v:v 1:1) and stirred at room temperature for 72 h. The mixture is 
dissolved in MTBE and the organic phase is separated, washed with water and brine (twice) and 
finally dried over Na2SO4. The organic layer is concentrated in vacuo and purified, if necessary, by 
column chromatography to give 5a,b. 
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Methyl (2-hydroxymethyl)acrylate (5a)[142] 
Starting from paraformaldehyde (9.0 g, 0.3 mol), methyl acrylate (77.5 g, 0.9 mol) 
and DABCO (33.7 g, 0.3 mol) in dioxane:H2O (600 mL), the product was isolated 
as a white solid (15.0 g, 43 %) after column chromatography 
(cyclohexane/EtOAc = 4:1 to 2:1). 
1H NMR (300 MHz, CDCl3):  (ppm) = 2.32 (brs, 1H, OH), 3.80 (s, 3H, OCH3), 4.33 (s, 2H, CH2), 
5.85 (s, 1H, HA-CH2), 6.25 (s, 1H, HB-CH2). 
13C NMR (75 MHz, CDCl3):  (ppm) = 51.9 (OCH3), 62.5 (OCH2), 125.9 (CH2), 139.3 (C), 166.8 
(C=O). 
 
Ethyl (2-hydroxymethyl)acrylate 5b[142] 
Starting from paraformaldehyde (9.0 g, 0.3 mol), ethyl acrylate (90.1 g, 0.9 mol) 
and DABCO (33.7 g, 0.3 mol) in dioxane:H2O (600 mL) the product was isolated as 
a colorless liquid (28.0 g, 70 %). 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.23 (t, 3H, CH3, 3JH-H = 7.1 Hz), 3.11 (brs, 1H, OH), 4.15 (q, 
2H, OCH2, 3JH-H = 7.1 Hz), 4.24 (brs, 2H, OCH2), 5.77 (m, 1H, HA-CH2), 6.17 (m, 1H, HB-CH2). 
13C NMR (75 MHz, CDCl3):  (ppm) = 14.0 (CH3), 60.7 (OCH2), 61.8 (OCH2), 125.1 (CH2), 139.6 
(C), 166.2 (C=O). 
 
Diethyl 2,2'-oxybis(methylene)diacrylate (5b') 
Next to ethyl (2-hydroxymethyl)acrylate 5b, the formation of diethyl 2,2'-
oxybis(methylene)diacrylate 5b' could be observed as a side product (ca. 
9 mol%); this can be cleaved into two molecules of 1b under acidic 
conditions in the next step. 
HRMS (ESI) calculated for C12H19O5 243.1227, found 243.12252. 
HRMS (ESI) calculated for C12H18NaO5 265.10464, found 265.10492. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.22 (t, 6H, 2CH3, 3JH-H = 7.1 Hz), 4.14 (q, 4H, 2OCH2, 
3JH-H = 7.1 Hz), 4.15 (s, 4H, 2OCH2), 5.82 (m, 2H, 2HA-CH2), 6.24 (m, 2H, 2HB-CH2). 
13C NMR (75 MHz, CDCl3):  (ppm) = 14.0 (2CH3), 60.6 (2OCH2), 68.7 (2OCH2), 125.6 (2CH2), 
137.0 (2C), 165.7 (2C=O). 
 
 
Procedure for the synthesis of methyl (2-acetamidomethyl)acrylate (6a) 
Methyl (2-hydroxymethyl)acrylate 5a (7.0 g, 60.3 mmol) is dissolved in acetonitrile (250 mL) and the 
solution was stirred at 60 °C. Methanesulfonic acid (162 mL, 2.5 mol) is dropped into the solution 
within 15 min. The reaction mixture is then heated to 110 °C and stirred for additional 6 h at this 
temperature. The solution is cooled to 0 °C and diluted in water. The pH-value is adjusted to 7-8 by 
adding solid K2CO3. After extraction with diethyl ether (2×100 mL), the organic phase is washed with 
brine (50 mL) and dried over Na2SO4. The organic layer is concentrated in vacuo and purified by flash 
chromatography (cyclohexane/EtOAc = 4:1 to 2:1) to yield 6a as a white solid (4.50 g, 47 %). 
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Anal. calcd for C7H11NO3: C, 53.49; H, 7.05; N, 8.91. Found: C, 53.73; H, 6.97; N, 
8.99 %. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.95 (t, 3H, CH3) 3.74 (s, 3H, OCH3), 4.04 
(brd, 2H, NCH2, 3JH-H = 6.1 Hz), 5.78 (m, 1H, HA-CH2), 6.22 (brs, 1H, NH), 6.22 (m, 1H, HB-CH2). 
13C NMR (75 MHz, CDCl3):  (ppm) = 23.2 (CH3), 40.5 (NCH2), 51.9 (OCH3), 127.1 (CH2), 136.4 
(C), 166.7 (C=O), 169.9 (C=O). 
 
 
General procedure for the synthesis of alkyl (2-bromomethyl)acrylates 7a,b 
Alkyl (2-hydroxymethyl)acrylate 5a,b (2.0 eq) is dissolved in diethyl ether (1 mL/1.0 mmol substrate) 
and phosphorus tribromide (1.0 eq) is added slowly at 0 °C via syringe to the stirred solution. The 
mixture is heated to room temperature and stirred for further 2 h. After cooling to 0 °C, water is slowly 
added. The crude product is extracted with diethyl ether (three times), the combined organic phases 
are washed with brine (twice) and dried over Na2SO4. The organic layer is concentrated in vacuo and 
purified, if necessary, by Kugelrohr disitillation to give 7a,b. 
 
Methyl (2-bromomethyl)acrylate (7a)[96a] 
Starting from methyl (2-hydroxymethyl)acrylate 5a (18.58 g, 160 mmol) and PBr3 
(21.65 g, 80 mmol) in Et2O (80 mL), the product 7a was isolated as a yellowish liquid 
and used without further purification (12.80 g, 89 %). 
1H NMR (300 MHz, CDCl3):  (ppm) = 3.75 (s, 3H, OCH3), 4.12 (s, 2H, CH2Br), 5.91 (1H, m, 
HA-CH2), 6.27 (1H, m, HB-CH2). 
13C NMR (75 MHz, CDCl3):  (ppm) = 29.2 (CH2Br), 52.1 (OCH3), 129.1 (CH2), 137.1 (C), 165.1 
(C=O). 
 
Ethyl (2-bromomethyl)acrylate (7b)[96b] 
Starting from ethyl (2-hydroxymethyl)acrylate 5b (20.82 g, 160 mmol) and PBr3 
(21.65 g, 80.0 mmol) in Et2O (80 mL), the product 7b was isolated as a colorless liquid 
after Kugelrohr distillation (10.30 g, 67 %, T = 81-84 °C, p = 4 mbar). 
Anal. calcd for C6H9BrO2: C, 37.33; H, 4.70; Br, 41.39. Found: C, 37.33; H, 4.53; Br, 41.67 %. 
MS (EI, 70 eV, m/z): 194 [M+2]+, 14; 192 [M]+, 14; 166 [M+2-C2H4]+, 97; 164 [M-C2H4]+, 97; 149 
[M+2-C2H5O]+, 62; 147 [M-C2H5O]+, 62; 113 [M-Br]+, 58; 39 [C3H3]+, 100. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.29 (t, 3H, CH3, 3JH-H = 7.2 Hz), 4.15 (d, 2H, CH2Br, 
JH-H = 0.8 Hz), 4.23 (q, 2H, OCH2, 3JH-H = 7.2 Hz), 5.91 (m, 1H, HA-CH2), 6.29 (m, 1H, HB-CH2). 
13C NMR (75 MHz, CDCl3):  (ppm) = 14.1 (CH3), 29.3 (CH2Br), 61.2 (OCH2) 128.9 (CH2), 137.5 
(C), 164.7 (C=O). 
 
 
General procedure for the synthesis of alkyl 2-{[bis(tert-butoxycarbonyl)amino]methyl}acrylates 6b,c 
Alkyl (2-bromomethyl)acrylate 7a,b (1.0 eq) is added in one portion to a suspension of di-tert-butyl 
iminodicarboxylate (1.0 eq) and K2CO3 (1.5 eq) in acetonitrile (1 mL/1.0 mmol substrate). The 
mixture is stirred at room temperature for 72 h. The solution is treated with brine and extracted with 
 
 
 
Chapter 5: Appendix 
- 80 - 
ethyl acetate (three times). The combined organic phases are washed with water and dried over 
Na2SO4. The organic layer is concentrated in vacuo to give 6b,c. 
 
Methyl 2-{[bis(tert-butoxycarbonyl)amino]methyl}acrylate (6b)[97a] 
Starting from methyl (2-bromomethyl)acrylate 5a (4.42 g, 24.7 mmol), Boc2NH 
(5.37 g, 24.7 mmol) and K2CO3 (5.12 g, 37.1 mmol) in MeCN (25 mL), the product 6b 
was isolated without further purification as an off-white solid (7.40 g, 95 %, 
mp 68-69 °C). 
Anal. calcd for C15H25NO6: C, 57.13; H, 7.99; N, 4.44. Found: C, 57.07; H, 7.76; N, 4.24 %. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.44 (s, 18H, 2C(CH3)3), 3.73 (s, 3H, CH3), 4.41 (t, 2H, 
NCH2, JH-H = 1.8 Hz), 5.52 (m, 1H, HA-CH2), 6.23 (m, 1H, HB-CH2). 
13C NMR (75 MHz, CDCl3):  (ppm) = 27.9 (2C(CH3)3), 46.1 (NCH2), 51.8 (CH3), 82.6 (2C(CH3)3), 
123.4 (CH2), 136.6 (C), 152.1 (2C=O), 166.1 (C=O). 
 
Ethyl 2-{[bis(tert-butoxycarbonyl)amino]methyl}acrylate (6c) 
Starting from ethyl (2-bromomethyl)acrylate 5b (4.73 g, 24.5 mmol), Boc2NH (5.33 g, 
24.5 mmol) and K2CO3 (5.08 g, 36.8 mmol) in MeCN (25 mL), the product 6c was 
isolated without further purification as a colorless oil (8.00 g, 99 %). 
Anal. calcd for C16H27NO6: C, 58.34; H, 8.26; N, 4.25. Found: C, 58.06; H, 8.02; N, 
4.05 %. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.27 (t, 3H, CH3, 3JH-H = 7.2 Hz); 1.44 (s, 18H, 2C(CH3)3), 
4.19 (q, 2H, OCH2, 3JH-H = 7.2 Hz), 4.42 (t, 2H, NCH2, JH-H = 1.8 Hz), 5.50 (m, 1H, HA-CH2), 6.22 (m, 
1H, HB-CH2). 
13C NMR (75 MHz, CDCl3):  (ppm) = 14.1 (CH3), 27.9 (2C(CH3)3), 46.1 (NCH2), 60.7 (OCH2), 82.6 
(2C(CH3)3), 122.9 (CH2), 136.9 (C), 152.1 (2C=O), 165.7 (C=O). 
 
 
General procedure for the synthesis of alkyl 2-{[(tert-butoxycarbonylamino]methyl}acrylate 6d,e 
N-Diprotected acrylate 6b,c (1.0 eq) is dissolved in tetrahydrofuran (5 mL/1.0 mmol substrate) and 
scandium triflate (0.1 eq) is added in one portion. After stirring at room temprature for 3 h, the mixture 
is concentrated in vacuo and ethyl acetate is added. The organic phase is washed with water and dried 
over Na2SO4. The organic layer is concentrated in vacuo and purified by flash chromatography to give 
6d,e. 
 
Methyl 2-{[(tert-butoxycarbonyl)amino]methyl}acrylate (6d)[97a] 
Starting from methyl 2-{[bis(tert-butoxycarbonyl)amino]methyl}acrylate 6b (6.31 g, 
20.0 mmol) and Sc(OTf)3 (984 mg, 2.0 mmol) in THF (100 mL), the product 6d was 
isolated as a pale yellow oil (3.60 g, 84 %) after column chromatography 
(cyclohexane/EtOAc = 4:1). 
Anal. calcd for C10H17NO4: C, 55.80; H, 7.96; N, 6.51. Found: C, 55.54; H, 7.72; N, 6.31 %. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.37 (s, 9H, C(CH3)3), 3.70 (s, 3H, s, CH3), 3.88 (brd, 2H, 
NCH2, 3JH-H = 6.3 Hz), 5.05 (brs, 1H, NH), 5.72 (m, 1H, HA-CH2) 6.18 (m, 1H, HB-CH2). 
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13C NMR (75 MHz, CDCl3):  (ppm) = 28.2 (C(CH3)3), 41.5 (NCH2), 51.8 (OCH3), 79.3 (C(CH3)3), 
126.2 (CH2), 137.0 (C), 155.6 (C=O), 166.5 (C=O). 
 
Ethyl 2-{[(tert-butoxycarbonylamino]methyl}acrylate (6e)[143] 
Starting from ethyl 2-{[bis(tert-butoxycarbonyl)amino]methyl}acrylate 6c (6.59 g, 
20.0 mmol) and Sc(OTf)3 (984 mg, 2.0 mmol) in THF (100 mL), the product 6e was 
isolated as a pale yellow oil (3.90 g, 84 %) after column chromatography 
(cyclohexane/EtOAc = 19:1 to 9:1). 
Anal. calcd for C11H19NO4: C, 57.63; H, 8.35; N, 6.11. Found: C, 57.79; H, 8.13; N, 5.91 %. 
1H NMR (CDCl3):  (ppm) = 1.26 (t, 3H, CH3, 3JH-H = 7.1 Hz,), 1.39 (s, 9H, C(CH3)3), 3.91 (brd, 2H, 
NCH2, 3JH-H = 6.1 Hz), 4.17 (q, 2H, OCH2, 3JH-H = 7.1 Hz), 5.01 (brs, 1H, NH), 5.71 (m, 1H, HA-CH2), 
6.19 (m, 1H, HB-CH2). 
13C NMR (CDCl3):  (ppm) = 14.1 (CH3), 28.3 (C(CH3)3), 41.5 (NCH2), 60.7 (OCH2) 79.4 (C(CH3)3), 
125.9 (CH2), 137.3 (C), 155.6 (C=O), 166.1 (C=O). 
 
 
General procedure for the asymmetric hydrogenation of dehydro 2-amino acrylates 6a-e 
The substrate (1.0 eq) and Rh precatalyst (1 mol%) are transferred into a glass vial, which is placed 
into a stainless steel autoclave. The solvent (12 mL/1.0 mmol substrate) is added under an argon 
atmosphere and the autoclave is purged with argon (three times) followed by hydrogen (three times). 
The indicated reaction conditions (H2-pressure, temperature and reaction time) are adjusted by an 
automatic program. After stirring for the adjusted time, the mixture is concentrated under reduced 
pressure. The enantiomeric excess is determined by HPLC or GC analysis. Racemic mixtures of 8a-e, 
as samples for the quantitative and qualitative analysis, are prepared by the hydrogenation of 6a-e with 
10 % Pd/C in methanol. 
 
(S)-Methyl-3-acetamido-2-methylpropanoate (8a) 
[α]D
24 = +45.5 (c 1.00, CHCl3), >99 %ee. 
HRMS (ESI) calculated for C7H14NO3 160.09682, found 160.09691. 
HRMS (ESI) calculated for C7H13NO3Na 182.07876, found 182.07909. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.14 (d, 3H, CHCH3, 3JH-H = 7.2 Hz), 1.93 (s, 3H, CH3), 2.67 
(m, 1H, CHCH3), 3.24 (m, 1H, HA-NCH2), 3.46 (m, 1H, HB-NCH2), 3.67 (s, 3H, OCH3), 6.21 (brs, 1H, 
NH). 
13C NMR (75 MHz, CDCl3):  (ppm) = 14.8 (CH3), 23.2 (CH3), 39.4 (NCH2), 41.6 (CHCH3), 51.9 
(OCH3), 170.3 (C=O), 176.0 (C=O). 
Separation of enantiomers by GC on Lipodex E (25 m×0.25 mm), 100/30-8-180/10; tR = 15.1 min for 
(+)-enantiomer and tR = 16.6 min for (–)-enantiomer. The assignment of absolute configuration to the 
GC-peaks was determined by deprotection of (S)-8d and subsequent N-acetylation to (S)-8a. 
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Methyl 3-[bis(tert-butoxycarbonyl)amino]-2-methylpropanoate (8b) 
HRMS (ESI) calculated for C15H27NNaO6 340.17306, found 340.17298. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.08 (d, 3H, CHCH3, 3JH-H = 6.8 Hz), 1.44 (s, 
18H, 2C(CH3)3), 2.78 (m, 1H, CHCH3), 3.58 (dd, 1H, HA-NCH2, 2JA-B = 14.1 Hz, 
3JH-A = 6.8 Hz), 3.60 (s, 3H, OCH3), 3.81 (dd, 1H, HB-NCH2, 2JA-B = 14.1 Hz, 3JH-B = 7.6 Hz). 
13C NMR (75 MHz, CDCl3):  (ppm) = 14.5 (CHCH3), 27.9 (2C(CH3)3), 39.1 (CHCH3), 48.6 (NCH2), 
51.6 (OCH3), 82.4 (2C(CH3)3), 152.4 (2C=O), 175.0 (C=O). 
Separation of enantiomers by HPLC on AD-H (150×4.6 mm), heptane/EtOH = 95:5, 
rate = 0.5 mL/min; tR = 7.1 min for (–)-enantiomer and tR = 7.8 min for (+)-enantiomer. 
 
Ethyl 3-[bis(tert-butoxycarbonyl)amino]-2-methylpropanoate (8c) 
HRMS (ESI) calculated for C16H27NNaO6 352.17306, found 352.17298. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.09 (d, 3H, CHCH3, 3JH-H = 7.2 Hz), 1.19 (t, 
3H, CH3, 3JH-H = 7.2 Hz), 1.45 (s, 18H, 2C(CH3)3), 2.77 (m, 1H, CHCH3), 3.59 (dd, 1H, 
HA-CH2, 2JA-B = 14.1 Hz, 3JH-A = 7.1 Hz), 3.81 (dd, 1H, HB-CH2, 2JA-B = 14.1 Hz, 3JH-B = 7.4 Hz), 4.05 
(q, 2H, OCH2, 3JH-H = 7.2 Hz). 
13C NMR (75 MHz, CDCl3):  (ppm) = 14.0 (CH3), 14.5 (CHCH3), 27.9 (2C(CH3)3), 39.0 (CHCH3), 
48.6 (NCH2), 60.4 (OCH2), 82.4 (2C(CH3)3), 152.4 (2C=O), 174.6 (C=O). 
Separation of enantiomers by HPLC on Reprosil 100 (250×4.6 mm), heptane/EtOH = 99:1, 
rate = 0.5 mL/min; tR = 24.5 min for (–)-enantiomer and tR = 28.0 min for (+)-enantiomer. 
 
(S)-Methyl 3-[(tert-butoxycarbonyl)amino]-2-methylpropanoate (8d)[144] 
[α]D
22 = +23.3 (c 1.20, CHCl3), 94 %ee. 
HRMS (ESI) calculated for C10H19NO4Na 240.12063, found 240.12080. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.12 (d, 3H, CHCH3, 3JH-H = 7.2 Hz), 1.39 (s, 
9H, C(CH3)3), 2.63 (m, 1H, CHCH3), 3.15-3.32 (m, 2H, NCH2), 3.65 (s, 3H, OCH3), 4.96 (brs, 1H, 
NH). 
13C NMR (75 MHz, CDCl3):  (ppm) = 14.6 (CHCH3), 28.3 (C(CH3)3), 39.9 (CHCH3), 42.9 (NCH2), 
51.7 (OCH3), 79.2 (C(CH3)3), 155.9 (C=O), 175.7 (C=O). 
Separation of enantiomers by GC on Chiraldex -PM (50 m×0.25 mm), 110/22-8-180; tR = 31.5 min 
for (+)-enantiomer and tR = 31.7 min for (–)-enantiomer. 
 
(S)-Ethyl 3-[(tert-butoxycarbonyl)amino]-2-methylpropanoate (8e) 
[α]D
22 = +20.3 (c 1.00, CHCl3), 96 %ee; [α]D
23 = +27.1 (c 1.00, MeOH), 96 %ee. 
HRMS (ESI) calculated for C11H21NO4Na 254.13628, found 254.13655. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.13 (d, 3H, CHCH3, 3JH-H = 7.2 Hz), 1.22 (t, 
3H, CH3, 3JH-H = 7.2 Hz), 1.39 (s, 9H, C(CH3)3), 2.62 (m, 1H, CHCH3), 3.15-3.33 (m, 2H, NCH2), 4.11 
(q, 2H, OCH2, 3JH-H = 7.2 Hz), 4.93 (brs, 1H, NH). 
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13C NMR (75 MHz, CDCl3):  (ppm) = 14.1 (CH3), 14.6 (CHCH3), 28.3 (C(CH3)3), 39.9 (CHCH3), 
42.9 (NCH2), 60.5 (OCH2), 79.2 (C(CH3)3), 155.9 (C=O), 175.4 (C=O). 
Separation of enantiomers by GC on Lipodex E (25 m×0.25 mm), 90/40-8-180/10; tR = 43.8 min for 
(+)-enantiomer and tR = 44.1 min for (–)-enantiomer. 
 
(E)-Methyl 3-acetamido-2-methylacrylate ((E)-9a) 
In some cases, (E)-methyl 3-acetamido-2-methylacrylate (E)-9a was visible as a 
side product in the final mixture after the hydrogenation of 6a. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.76 (d, 3H, CCH3, 4JH-H = 1.4 Hz), 2.10 (s, 
3H, CH3), 3.66 (s, 3H, OCH3), 7.94 (brd, 1H, NCH, 3JH-H = 11.9 Hz), 8.43 (brs, 1H, NH). 
13C NMR (75 MHz, CDCl3):  (ppm) = 10.6 (CCH3), 23.1 (CH3), 51.4 (OCH3), 107.3 (CCH3), 132.2 
(NCH), 168.4 (C=O), 168.5 (C=O). 
 
(Z)-Methyl 3-acetamido-2-methylacrylate ((Z)-9a) 
In some cases, (Z)-methyl 3-acetamido-2-methylacrylate (Z)-9a was visible as a side 
product in the final mixture after the hydrogenation of 6a. 
1H NMR (CDCl3):  (ppm) = 1.77 (d, 3H, CCH3, 4JH-H = 1.4 Hz), 2.06 (s, 3H, CH3), 
3.70 (s, 3H, OCH3), 7.29 (brd, 1H, NCH, 3JH-H = 11.0 Hz), 10.30 (brs, 1H, NH). 
13C NMR (CDCl3):  (ppm) = 15.8 (CCH3), 23.5 (CH3), 51.4 (OCH3), 104.3 (CCH3), 134.6 (NCH), 
168.1 (C=O), 168.9 (C=O). 
 
(E)-Methyl 3-[(tert-butoxycarbonyl)amino]-2-methylacrylate ((E)-9d) 
In some cases, (E)-methyl 3-[(tert-butoxycarbonyl)amino]-2-methylacrylate 
(E)-9d was visible as a side product in the final mixture after the hydrogenation 
of 6d. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.47 (s, 9H, C(CH3)3), 1.73 (d, 3H, CCH3, 4JH-H = 1.3 Hz), 
3.68 (s, 3H, OCH3), 6.60 (brd, 1H, NCH, 3JH-H = 11.4 Hz). 
13C NMR (75 MHz, CDCl3):  (ppm) = 10.1 (CCH3), 28.3 (C(CH3)3), 51.3 (OCH3), 81.9 (C(CH3)3), 
104.8 (CCH3), 134.2 (NCH), 151.8 (C=O), 168.7 (C=O). 
 
(Z)-Methyl 3-[(tert-butoxycarbonyl)amino]-2-methylacrylate ((Z)-9d) 
In some cases, (Z)-methyl 3-[(tert-butoxycarbonyl)amino]-2-methylacrylate (Z)-9d was 
visible as a side product in the final mixture after the hydrogenation of 6d. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.43 (s, 9H, C(CH3)3), 1.76 (d, 3H, CCH3, 
4JH-H = 1.3 Hz), 3.70 (s, 3H, OCH3), 7.09 (brd, 1H, NCH, 3JH-H = 11.4 Hz). 
13C NMR spectrum could not be analyzed due to the small amount in the final reaction mixture. 
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(E)-Ethyl 3-[(tert-butoxycarbonyl)amino]-2-methylacrylate ((E)-9e) 
In some cases, (E)-Ethyl 3-[(tert-butoxycarbonyl)amino]-2-methylacrylate (E)-9e 
was visible as a side product in the final mixture after the hydrogenation of 4e. 
1H NMR (300 MHz, CD3OD):  (ppm) = 1.28 (t, 3H, CH3, 3JH-H = 7.1 Hz), 1.51 (s, 
9H, C(CH3)3), 1.81 (d, 3H, CCH3, 4JH-H = 1.2 Hz), 4.16 (q, 2H, OCH2, 3JH-H = 7.1 Hz), 7.76 (brd, 1H, 
NCH, 3JH-H = 11.3 Hz). 
13C NMR spectrum could not be analyzed due to its small amount in the final reaction mixture. 
 
(Z)-Ethyl 3-[(tert-butoxycarbonyl)amino]-2-methylacrylate ((Z)-9e) 
In some cases, (Z)-Ethyl 3-[(tert-butoxycarbonyl)amino]-2-methylacrylate (Z)-9e was 
visible as a side product in the final mixture after the hydrogenation of 6e. 
1H NMR (300 MHz, CD3OD):  (ppm) = 1.29 (t, 3H, CH3, 3JH-H = 7.1 Hz), 1.40 (s, 9H, 
C(CH3)3), 1.76 (d, 3H, CCH3, 4JH-H = 1.2 Hz), 4.16 (q, 2H, OCH2, 3JH-H = 7.1 Hz), 6.92 (brs, 1H, 
NCH). 
13C NMR spectrum could not be analyzed due to its small amount in the final reaction mixture. 
 
 
Procedure for the synthesis of (S)-N-(3-hydroxy-2-methylpropyl)acetamide (10a) 
(S)-Methyl 3-acetamido-2-methylpropanoate 8a (318 mg, 2.0 mmol, >99 %ee) is dissolved in 
tetrahydrofuran (15 mL) and LiAlH4 (228 mg, 6.0 mmol) is added slowly at 0 °C. The solution is 
stirred at room temperature for 2 h and then quenched with water (0.3 mL), 2 M NaOH (0.3 mL) and 
finally water (0.9 mL) again. The resulting white precipitate is filtered off and washed several times 
with dichloromethane. The combined organic phases are dried over Na2SO4 and then concentrated in 
vacuo. Column chromatography (EtOAc) yields 10a as a pale yellow oil (150 mg, 57 %). 
[α]D
24 = +21.6 (c 1.00, CHCl3), 98 %ee. 
HRMS (ESI) calculated for C6H14NO2 132.10191, found 132.10210. 
HRMS (ESI) calculated for C6H13NO2Na 154.08385, found 154.08407. 
1H NMR (300 MHz, CDCl3):  (ppm) = 0.83 (d, 3H, CHCH3, 3JH-H = 7.0 Hz), 1.75 (m, 1H, CHCH3), 
3.06 (m, 1H, HA-NCH2), 3.25 (dd, 1H, HB-NCH2, 2JA-B = 11.5 Hz, 3JH-B = 7.1 Hz), 3.30 (m, 1H, 
HA-OCH2), 3.48 (dd, 1H, HB-OCH2, 2JA-B = 11.5 Hz, 3JH-B = 4.3 Hz), 3.78 (brs, 1H, OH), 6.85 (brs, 
1H, NH). 
13C NMR (75 MHz, CDCl3):  (ppm) = 14.5 (CHCH3), 22.8 (C(CH3)3), 35.6 (CHCH3), 42.1 (NCH2), 
64.4 (OCH2), 171.9 (C=O). 
Separation of enantiomers by GC on Lipodex E (25 m×0.25 mm), 100/30-8-180/10; tR = 39.0 min for 
(+)-enantiomer and tR = 39.2 min for (–)-enantiomer. 
 
(S)-3-(Ethylamino)-2-methylpropan-1-ol (10a') 
When the reaction time was extended by further 2 h at room temperature, the reduction of 
the acetyl group became visible in the NMR spectra of the crude mixture and thus the 
formation of (S)-3-(ethylamino)-2-methylpropan-1-ol 10a' (ca. 11 %). 
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1H NMR (300 MHz, CDCl3):  (ppm) = 0.75 (d, 3H, CHCH3, 3JH-H = 6.9 Hz), 1.03 (t, 3H, 
3JH-H = 7.2 Hz, CH3), 1.89 (m, 1H, CHCH3), 2.48-2.67 (m, 4H, CH2NCH2), 2.80 (m, 1H, HA-OCH2), 
3.62 (m, 1H, HB-OCH2). 
13C NMR (75 MHz, CDCl3):  (ppm) = 14.8 (CHCH3), 14.8 (CH3), 33.8 (CHCH3), 44.0 (NCH2), 55.7 
(NCH2), 70.3 (OCH2). 
 
Procedure for the synthesis of (S)-tert-butyl (3-hydroxy-2-methylpropyl)carbamate (10b)[145] 
Ethyl 3-[(tert-butoxycarbonyl)amino]-2-methylpropanoate 8e (694 mg, 3.0 mmol, 96 %ee) is 
dissolved in tetrahydrofuran (30 mL) and LiAlH4 (342 mg, 9.0 mmol) is added slowly at 0 °C. The 
solution is stirred at this temperature for 1 h, warmed to room temperature and stirred for additional 
4 h. The reaction mixture is then quenched with water (0.35 mL), 2 M NaOH (0.35 mL) and finally 
water (1 mL) again. The resulting white precipitate is filtered off and washed several times with 
dichloromethane. The combined organic phases are dried over Na2SO4 and then concentrated in vacuo. 
Column chromatography (cyclohexane/EtOAc = 4:1 to 1:1) yields 10b as a colorless oil (400 mg, 
69 %). Enantiomeric excess is determined by derivatization to 13. 
[α]D
23 = +13.7 (c 1.00, CHCl3), 95 %ee. 
HRMS (ESI) calculated for C9H19NO3Na 212.12571, found 212.12573. 
1H NMR (300 MHz, CDCl3):  (ppm) = 0.83 (d, 3H, CHCH3, 3JH-H = 7.0 Hz), 1.39 (s, 
9H, C(CH3)3), 1.72 (m, 1H, CHCH3), 2.99 (dd, 1H, HA-OCH2, 2JA-B = 14.2 Hz, 3JH-A = 6.8 Hz), 3.19 
(dd, 1H, HB-OCH2, 2JA-B = 14.2 Hz, 3JH-B = 3.8 Hz), 3.30 (dd, 1H, HA-NCH2, 2JA-B = 11.6 Hz, 
3JH-A = 7.0 Hz), 3.50 (dd, 1H, HB-NCH2, 2JA-B = 11.6 Hz, 3JH-B = 4.4 Hz), 3.50 (brs, 1H, OH), 4.93 
(brs, 1H, NH). 
13C NMR (75 MHz, CDCl3):  (ppm) = 14.3 (CHCH3), 28.3 (C(CH3)3), 36.2 (CHCH3), 42.7 (NCH2), 
64.4 (OCH2), 79.6 (C(CH3)3), 157.3 (C=O). 
 
 
Procedure for the synthesis of (S)-ethyl 3-amino-2-methylpropanoate hydrochloride (11) 
To ethyl 3-[(tert-butoxycarbonyl)amino]-2-methylpropanoate 8e (1.30 g, 5.6 mmol, 96 %ee) is added 
a solution of 4 M HCl(g) in dioxane at room temperature. After stirring for 2 h, the solution is 
concentrated in vacuo to yield the crude hydrochloride 11 as a colorless thick syrup (750 mg, 80 %). 
An enantiomeric excess of 96% was determined by GC analysis after derivatization to the N-Boc-
derivative 8e by addition of 3.0 eq of Boc2O/Et3N to a solution of 11 in dichloromethane. 
[α]D
23 = +11.4 (c 0.56, MeOH), 96%ee. 
HRMS (ESI) calculated for C6H14NO2 132.10191, found 132.1021. 
HRMS (ESI) calculated for C6H13NNaO2 154.08385, found 154.08407. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.23 (t, 3H, CH3, 3JH-H = 7.0 Hz), 1.27 (d, 3H, CHCH3, 
3JH-H = 7.0 Hz) 2.95-3.35 (m, 3H, CHCH3 and NCH2), 4.15 (q, 2H, OCH2, 3JH-H = 7.0 Hz), 6.48 (brs, 
1H, OH), 8.10 (brs, 1H, NH3+). 
13C NMR (75 MHz, CDCl3):  (ppm) = 14.0 (CH3), 15.1 (CHCH3), 37.1 (CHCH3), 41.9 (NCH2), 61.4 
(OCH2), 174.0 (C=O). 
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Procedure for the synthesis of (S)-3-amino-2-methylpropan-1-ol trifluoroacetate (12) 
To a solution of (S)-tert-butyl (3-hydroxy-2-methylpropyl)carbamate 10b (189 mg, 1.0 mmol) in 
dichloromethane (5 mL) is added trifluoroacetic acid (1.5 mL). The solution is stirred at room 
temperature for 3 h and then concentrated in vacuo. The crude product 12 is isolated as a colorless, 
viscous oil (164 mg, 81 %). 
[α]D
23 = -8.2 (c 1.00, MeOH). 
Anal. calcd for C6H12F3NO3: C, 35.47; H, 5.95; F, 28.05; N, 6.89. Found: C, 
35.75; H, 5.60; F, 27.87; N, 6.66 %. 
HRMS (ESI) calculated for C4H12NO+ 90.09134, found 90.09184. 
19F NMR (282 MHz, CD3OD):  (ppm) = -76.5 (s). 
1H NMR (300 MHz, CD3OD):  (ppm) = 0.97 (d, 3H, CHCH3, 3JH-H = 6.9 Hz), 2.00 (m, 1H, CHCH3), 
2.85 (dd, 1H, HA-NCH2, 2JA-B = 12.7 Hz, 3JH-A = 6.0 Hz), 3.00 (dd, 1H, HB-NCH2, 2JA-B = 12.7 Hz, 
3JH-B = 7.6 Hz), 3.64 (dd, 1H, HA-OCH2, 2JA-B = 10.8 Hz, 3JH-A = 7.8 Hz), 3.64 (dd, 1H, HB-OCH2, 
2JA-B = 10.8 Hz, 3JH-B = 4.6 Hz). 
13C NMR (75 MHz, CD3OD):  (ppm) = 14.4 (CHCH3), 35.0 (CHCH3), 45.0 (NCH2), 66.6 (OCH2), 
118.2 (q, CF3, JC-F = 287 Hz), 162.9 (q, C=O, JC-F = 38.0 Hz). 
 
 
Procedure for the synthesis of (S)-3-[(tert-butoxycarbonyl)amino]-2-methylpropyl acetate (13) 
Racemic alcohol 10b (75 mg, 0.4 mmol) is dissolved in dichloromethane (2 mL) and the mixture is 
cooled to 0 °C. Triethylamine (60 mg, 0.6 mmol) and then acetyl chloride (39 mg, 0.5 mmol) are 
added at 0 °C. The mixture is stirred for 1 h, warmed to room temperature and stirred for further 2 h. 
The solution is then concentrated in vacuo and the residue is purified by chromatography 
(cyclohexane/EtOAc = 4:1) to yield 13 (40 mg, 46 %) as a colorless oil. 
HRMS (ESI) calculated for C11H21NO4Na 254.13628, found 254.13605. 
1H NMR (300 MHz, CDCl3):  (ppm) = 0.91 (d, 3H, CHCH3, 3JH-H = 6.9 Hz), 1.40 (s, 
9H, C(CH3)3), 1.95 (m, 1H, CHCH3), 1.95 (s, 3H, CH3), 3.04 (brd, 2H, NCH2, 
3JH-H = 6.5 Hz), 3.92 (dd, 1H, HA-OCH2, 2JA-B = 11.2 Hz, 3JH-A = 6.2 Hz), 3.98 (dd, 1H, HB-OCH2, 
2JA-B = 11.2 Hz, 3JH-B = 5.4 Hz), 4.75 (brs, 1H, NH). 
13C NMR (75 MHz, CDCl3):  (ppm) = 14.3 (CH3), 20.8 (CH3), 28.3 (C(CH3)3), 33.4 (CHCH3), 43.3 
(NCH2), 66.7 (OCH2), 79.2 (C(CH3)3), 156.0 (C=O), 171.2 (C=O). 
Separation of enantiomers by GC on Lipodex E (25 m×0.25 mm). 
 
 
5.1.2.4 Synthesis of functionalized 2-homoalanine derivatives 
General procedure for the asymmetric hydroformylation of methyl (2-acetamidomethyl)acrylate (6a) 
The substrate (1.0 eq), Rh(acac)(CO)2 (1 mol%) and the ligand (1.2 mol%) are transferred into a vial, 
which is placed into a stainless steel autoclave. The solvent (8 mL/1.0 mmol substrate) is added under 
an argon atmosphere and the autoclave is purged with argon (three times) followed by syngas (three 
times). The indicated reaction conditions (syngas pressure, temperature and reaction time) are adjusted 
by an automatic program. After stirring for the adjusted time, the mixture is cooled to room 
temperature, depressurized and concentrated in vacuo. The reaction mixture is analyzed by 1H NMR. 
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The enantiomeric excess is determined by GC analysis. A racemic mixture of 14, as sample for the 
quantitative and qualitative analysis, is prepared by the hydroformylation of 6a with 1 mol% 
Rh(acac)(CO)2 and 6 mol% P(OPh)3 in toluene. 
 
Methyl 3-acetamido-2-formyl-2-methylpropanoate (14) 
1H NMR (300 MHz, CDCl3): (ppm) = 1.32 (s, 3H, CCH3), 2.08 (s, 2H, CH2), 1.91 
(s, 3H, CH3), 3.72 (s, 3H, OCH3), 6.29 (brs, 1H, NH), 9.56 (s, 1H, CHO). 
13C NMR spectrum could not be analyzed due to the small amount in the final 
reaction mixture. 
Separation of enantiomers by GC on Lipodex E (25 m×0.25 mm), 100/30-8-180/10; tR = 31.4 min for 
(+)-enantiomer and tR = 31.6 min for (–)-enantiomer. 
 
 
5.1.2.5 Synthesis of 3-aryl-3-phosphorylated propanals 
General procedure for the synthesis of 1-aryl-1-phosphorylated ethenes 16a-g 
The corresponding acetophenone or 2-acetonaphthone (1.0 eq) is placed in 3-necked flask and it is 
cooled to 0 °C. Phosphorus trichloride (1.4 eq) is added via dropping funnel and the mixture is stirred 
at room temperature for 1 h. Then, it is cooled to 0 °C again and acetic acid (2.5 eq) is added via 
dropping funnel. The solution is stirred at room temperature for 16 h. After that time, ice is added so 
that a white solid precipitates. The mixture is stirred at room temperature for 16 h. Water is then 
distillied off (oil bath, 160 °C), hot aqueous HCl (0.4 mL/1.0 mmol substrate) is added in one portion 
and the solution is refluxed for 2 h. After cooling to room temperature, the corresponding phosphonic 
acid precipitates, what is filtered off and dried in vacuo. The solid is used in a further step without 
purification. 
1.0 Eq of the corresponding phosphonic acid is mixed with trimethyl orthoformate and triethyl 
orthoformate (4.5 eq), respectively, and the solution is stirred at 100 °C for 30 min. Then, formed 
methyl formate and methanol (or ethyl formate and ethanol) are distilled off and the solution is 
refluxed for further 90 min. The mixture is cooled to room temperature, concentrated in vacuo and 
purified by column chromatography to give 16a-g. 
 
Dimethyl (1-phenylvinyl)phosphonate (16a)[146] 
Starting from acetophenone (12.2 g, 100 mmol), PCl3 (19.2 g, 140 mmol) and 
HOAc (15.0 g, 250 mmol), (1-phenylvinyl)phosphonic acid could be obtained as an 
off-white solid (16.0 g, 87 %). Starting from the phosphonic acid (5.0 g, 27.2 mmol) 
and trimethyl orthoformate (13.00 g, 122.2 mmol), the product 16a was isolated as a 
yellowish liquid (4.00 g, 69 %) after column chromatography (EtOAc). 
31P{1H} NMR (121 MHz, CDCl3):  (ppm) = 19.8 (s). 
1H NMR (300 MHz, CDCl3):  (ppm) = 3.70 (d, 6H, 2OCH3, 3JH-P = 11.1 Hz), 6.15 (dd, 1H, HA-CH2, 
JA-P = 46.2 Hz, JA-B = 1.4 Hz), 6.30 (dd, 1H, HB-CH2, JB-P = 22.2 Hz, JA-B = 1.4 Hz), 7.27-7.35 (m, 3H, 
CH-Ar), 7.45-7.49 (m, 2H, CH-Ar). 
13C NMR (75 MHz, CDCl3): (ppm) = 52.6 (d, 2OCH3, JC-P = 5.8 Hz), 127.3 (d, 2CHAr, 
JC-P = 5.8 Hz), 128.3 (d, CHAr, JC-P = 0.9 Hz), 128.4 (2CHAr), 132.3 (d, CH2, JC-P = 8.1 Hz), 136.4 (d, 
CAr, JC-P = 11.8 Hz), 138.5 (d, CCH2, JC-P = 175.2 Hz). 
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Dimethyl (1-(p-tolyl)vinyl)phosphonate (16b) 
Starting from 1-(p-tolyl)ethanone (13.4 g, 100 mmol), PCl3 (19.2 g, 
140 mmol) and HOAc (15.0 g, 250 mmol), (1-(p-tolyl)vinyl)phosphonic acid 
could be obtained as an off-white solid (19.8 g, 99 %). Starting from the 
phosphonic acid (4.96 g, 25.0 mmol) and trimethyl orthoformate (11.94 g, 
112.5 mmol), the product 16b was isolated as a yellowish liquid (2.30 g, 
41 %) after column chromatography (EtOAc). 
Anal. calcd for C11H15O3P: C, 58.41; H, 6.68. Found: C, 58.15; H, 6.43 %. 
HRMS (EI) calculated for C11H15O3P 226.07533, found 226.07498. 
31P{1H} NMR (121 MHz, CDCl3):  (ppm) = 20.2 (s). 
1H NMR (300 MHz, CDCl3):  (ppm) = 2.31 (s, 3H, CH3), 3.69 (d, 6H, 2OCH3, 3JH-P = 11.1 Hz), 6.12 
(dd, 1H, HA-CH2, JA-P = 46.4 Hz, JA-B = 1.4 Hz), 6.26 (dd, 1H, HB-CH2, JB-P = 22.1 Hz, JA-B = 1.4 Hz), 
7.12 (d, 2H, CH-Ar, 3JH-H = 7.8 Hz), 7.35-7.39 (m, 2H, CH-Ar). 
13C NMR (63 MHz, CDCl3): (ppm) = 20.9 (CH3), 52.4 (d, 2OCH3, JC-P = 5.8 Hz), 127.0 (d, 2CHAr, 
JC-P = 5.9 Hz), 129.0 (2CHAr), 131.4 (d, CH2, JC-P = 8.1 Hz), 133.3 (d, CAr, JC-P = 11.7 Hz), 138.1 (d, 
CCH2, JC-P = 174.3 Hz), 138.1 (d, CAr, JC-P = 1.2 Hz). 
 
Dimethyl (1-(naphthalen-2-yl)vinyl)phosphonate (16c) 
Starting from 1-(naphthalen-2-yl)ethanone (8.5 g, 50 mmol), PCl3 (9.6 g, 
70 mmol) and HOAc (7.5 g, 125 mmol), (1-(naphthalen-2-yl)vinyl)phosphonic 
acid could be obtained as an off-white solid (11.1 g, 96 %). Starting from the 
phosphonic acid (5.86 g, 25.0 mmol) and trimethyl orthoformate (11.94 g, 
112.5 mmol), the product 16c was isolated as a yellowish liquid (3.80 g, 60 %) 
after column chromatography (EtOAc). 
Anal. calcd for C14H15O3P: C, 64.12; H, 5.77. Found: C, 64.64; H, 6.13 %. 
HRMS (EI) calculated for C14H15O3P 262.07533, found 262.07504. 
31P{1H} NMR (121 MHz, CDCl3):  (ppm) = 19.9 (s). 
1H NMR (300 MHz, CDCl3):  (ppm) = 3.59 (d, 6H, 2OCH3, 3JH-P = 11.1 Hz), 6.12 (dd, 1H, HA-CH2, 
JA-P = 45.9 Hz, JA-B = 1.2 Hz), 6.26 (dd, 1H, HB-CH2, JB-P = 22.0 Hz, JA-B = 1.2 Hz), 7.27-7.30 (m, 2H, 
CH-Ar), 7.44-7.47 (m, 1H, CH-Ar), 7.62-7.71 (m, 3H, CH-Ar), 7.87 (brs, 1H, CH-Ar). 
13C NMR (75 MHz, CDCl3): (ppm) = 52.3 (d, 2OCH3, JC-P = 5.5 Hz), 124.6 (d, CHAr, JC-P = 6.1 Hz), 
126.0 (CHAr), 126.1 (CHAr), 126.4 (d, CHAr, JC-P = 6.1 Hz), 127.2 (CHAr), 127.8 (CHAr), 128.0 (CHAr), 
132.7 (d, CH2, JC-P = 7.7 Hz), 132.7 (CAr), 132.8 (CAr), 133.4 (d, CAr, JC-P = 12.1 Hz), 138.2 (d, CCH2, 
JC-P = 175.0 Hz). 
 
Dimethyl (1-(4-fluorophenyl)vinyl)phosphonate (16d) 
Starting from 1-(4-fluorophenyl)ethanone (6.9 g, 50 mmol), PCl3 (9.6 g, 
70 mmol) and HOAc (7.5 g, 125 mmol), (1-(4-fluorophenyl)vinyl)phosphonic 
acid could be obtained as a white solid (8.8 g, 87 %). Starting from the 
phosphonic acid (5.06 g, 25.0 mmol) and trimethyl orthoformate (11.94 g, 
112.5 mmol), the product 16d was isolated as a yellowish liquid (4.00 g, 70 %) 
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after column chromatography (EtOAc). 
Anal. calcd for C10H12FO3P: C, 52.18; H, 5.25. Found: C, 52.22; H, 5.29 %. 
HRMS (EI) calculated for C10H12FO3P 230.05026, found 230.05011. 
31P{1H} NMR (101 MHz, CDCl3):  (ppm) = 19.4 (s). 
1H NMR (250 MHz, CDCl3):  (ppm) = 3.67 (d, 6H, 2OCH3, 3JH-P = 11.1 Hz), 6.07 (dd, 1H, HA-CH2, 
JA-P = 45.8 Hz, JA-B = 1.2 Hz), 6.24 (dd, 1H, HB-CH2, JB-P = 22.0 Hz, JA-B = 1.2 Hz), 6.93-7.00 (m, 2H, 
CH-Ar), 7.39-7.45 (m, 2H, CH-Ar). 
13C NMR (63 MHz, CDCl3): (ppm) = 52.5 (d, 2OCH3, JC-P = 5.8 Hz), 115.3 (d, 2CHAr, J = 21.7 Hz), 
129.0 (m, 2CHAr), 131.9 (dd, CH2, JC-P = 7.9 Hz, JC-F = 1.1 Hz), 132.3 (dd, CAr, JC-P = 12.1 Hz, 
JC-F = 3.5 Hz), 137.4 (d, CCH2, JC-P = 176.3 Hz), 162.8 (dd, CAr, JC-F = 248.1 Hz, JC-P = 1.3 Hz). 
 
Dimethyl (1-(4-chlorophenyl)vinyl)phosphonate (16e) 
Starting from 1-(4-chlorophenyl)ethanone (15.5 g, 100 mmol), PCl3 (19.2 g, 
140 mmol) and HOAc (15.0 g, 250 mmol), (1-(4-
chlorophenyl)vinyl)phosphonic acid could be obtained as a white solid (20.8 g, 
95 %). Starting from the phosphonic acid (5.47 g, 25.0 mmol) and trimethyl 
orthoformate (11.94 g, 112.5 mmol), the product 16e was isolated as a 
yellowish liquid (5.20 g, 84 %) after column chromatography (EtOAc). 
Anal. calcd for C10H12ClO3P: C, 48.70; H, 4.90. Found: C, 48.64; H, 4.83 %. 
HRMS (EI) calculated for C10H12ClO3P 246.02071, found 246.02024. 
31P{1H} NMR (121 MHz, CDCl3):  (ppm) = 19.2 (s). 
1H NMR (300 MHz, CDCl3):  (ppm) = 3.68 (d, 6H, 2OCH3, 3JH-P = 11.1 Hz), 6.10 (dd, 1H, HA-CH2, 
JA-P = 45.7 Hz, JA-B = 1.3 Hz), 6.26 (dd, 1H, HB-CH2, JB-P = 22.0 Hz, JA-B = 1.2 Hz), 7.24-7.28 (m, 2H, 
CH-Ar), 7.37-7.40 (m, 2H, CH-Ar). 
13C NMR (75 MHz, CDCl3): (ppm) = 52.5 (d, 2OCH3, JC-P = 5.8 Hz), 128.5 (2CHAr), 128.5 (d, 
2CHAr), 132.3 (d, CH2, JC-P = 7.6 Hz), 134.2 (d, CAr, JC-P = 1.2 Hz), 134.7 (d, CAr, JC-P = 12.1 Hz), 
137.4 (d, CCH2, JC-P = 176.6 Hz). 
 
Dimethyl (1-(4-bromophenyl)vinyl)phosphonate (16f) 
Starting from 1-(4-bromophenyl)ethanone (19.9 g, 100 mmol), PCl3 (19.2 g, 
140 mmol) and HOAc (15.0 g, 250 mmol), (1-(4-
bromophenyl)vinyl)phosphonic acid could be obtained as a white solid (26.1 g, 
99 %). Starting from the phosphonic acid (6.58 g, 25.0 mmol) and trimethyl 
orthoformate (11.94 g, 112.5 mmol), the product 16f was isolated as a 
yellowish liquid (4.50 g, 62 %) after column chromatography (EtOAc). 
Anal. calcd for C10H12BrO3P: C, 41.26; H, 4.16. Found: C, 41.57; H, 4.14 %. 
HRMS (EI) calculated for C10H12BrO3P 289.97019, found 289.96088. 
31P{1H} NMR (121 MHz, CDCl3):  (ppm) = 19.1 (s). 
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1H NMR (300 MHz, CDCl3):  (ppm) = 3.70 (d, 6H, 2OCH3, 3JH-P = 11.1 Hz), 6.13 (dd, 1H, HA-CH2, 
JA-P = 45.8 Hz, JA-B = 1.0 Hz), 6.30 (dd, 1H, HB-CH2, JB-P = 22.0 Hz, JA-B = 1.0 Hz), 7.32-7.35 (m, 2H, 
CH-Ar), 7.42-7.45 (m, 2H, CH-Ar). 
13C NMR (75 MHz, CDCl3): (ppm) = 52.6 (d, 2OCH3, JC-P = 6.1 Hz), 122.6 (d, CAr, JC-P = 1.6 Hz), 
128.9 (d, 2CHAr, JC-P = 6.1 Hz), 131.5 (2CHAr), 132.5 (d, CH2, JC-P = 7.7 Hz), 135.2 (d, CAr, 
JC-P = 12.1 Hz), 137.7 (d, CCH2, JC-P = 177.2 Hz). 
 
Diethyl (1-phenylvinyl)phosphonate (16g)[146] 
Starting from the phosphonic acid (4.60 g, 25.0 mmol) and triethyl orthoformate 
(16.67 g, 112.5 mmol), the product 16g was isolated as a yellowish liquid (4.02 g, 
67 %) after column chromatography (EtOAc). 
31P{1H} NMR (121 MHz, CDCl3):  (ppm) = 17.0 (s). 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.27 (t, 6H, 2CH3, 3JH-H = 7.1 Hz), 
4.00-4.19 (m, 4H, 2OCH2), 6.14 (dd, 1H, HA-CH2, JA-P = 45.8 Hz, JA-B = 1.5 Hz), 6.33 (dd, 1H, 
HB-CH2, JB-P = 22.0 Hz, JA-B = 1.5 Hz), 7.24-7.28 (m, 2H, CH-Ar), 7.30-7.37 (m, 3H, CH-Ar), 
7.50-7.54 (m, 2H, CH-Ar). 
13C NMR (75 MHz, CDCl3): (ppm) = 16.2 (d, 2CH3, JC-P = 6.6 Hz), 62.2 (d, 2OCH2, JC-P = 5.5 Hz), 
127.4 (d, 2CHAr, JC-P = 5.5 Hz), 128.2 (CHAr), 128.4 (2CHAr), 131.7 (d, CH2, JC-P = 8.3 Hz), 138.6 (d, 
CCH2, JC-P = 174.4 Hz), 159.7 (d, CAr, JC-P = 1.1 Hz). 
 
 
Procedure for the synthesis of dimethyl (1-(4-methoxyphenyl)vinyl)phosphonate (16h) 
trans-4-Methoxy--nitrostyrene (3.58 g 20.0 mmol) is dissolved in dimethyl ether (20 mL) and 
trimethyl phosphite (2.73 g, 22.0 mmol) is added slowly via syringe. The mixture is stirred at room 
temperature for 9 d. Then, it is concentrated in vacuo and the resulting oil is purified by column 
chromatography (heptane/EtOAc = 3:1) to yield 16h as a yellowish liquid (3.32 g, 69 %). 
Anal. calcd for C11H15O4P: C, 54.55; H, 6.24. Found: C, 54.21; H, 5.95 %. 
HRMS (EI) calculated for C11H15O4P 242.07025, found 242.07003. 
31P{1H} NMR (121 MHz, CDCl3):  (ppm) = 20.4 (s). 
1H NMR (300 MHz, CDCl3):  (ppm) = 3.72 (d, 6H, 2OCH3, 
3JH-P = 11.1 Hz), 3.80 (s, 3H, PhOCH3), 6.11 (dd, 1H, HA-CH2, 
JA-P = 46.4 Hz, JA-B = 1.4 Hz), 6.24 (dd, 1H, HB-CH2, JB-P = 22.1 Hz, JA-B = 1.4 Hz), 6.85-6.88 (m, 2H, 
CH-Ar), 7.42-7.47 (m, 2H, CH-Ar). 
13C NMR (75 MHz, CDCl3): (ppm) = 52.6 (d, 2OCH3, JC-P = 6.1 Hz), 55.2 (PhOCH3), 113.9 
(2CHAr), 128.5 (d, 2CHAr, JC-P = 6.1 Hz), 130.7 (d, CH2, JC-P = 8.8 Hz), 136.7 (d, CAr, JC-P = 11.6 Hz), 
139.8 (d, CCH2, JC-P = 174.4 Hz). 
 
 
Procedure for the synthesis of diphenyl(1-phenylvinyl)phosphine oxide (16i)[147] 
Phenylacetylene (536 mg, 5.3 mmol), diphenylphosphine oxide (1.01 g, 5.0 mmol), palladium(II) 
acetate (56 mg, 0.25 mmol) and dppe (139 mg, 0.35 mmol) are dissolved in toluene (20 mL) and the 
mixture is stirred at 100 °C for 14 h. After cooling to room temperature, it is concentrated in vacuo to 
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yield product 16i as a yellowish liquid (0.88 g, 73 %) after column chromatography 
(heptane/EtOAc = 1:1). 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 30.0 (s). 
1H NMR (300 MHz, CDCl3): (ppm) = 5.76 (dd, 1H, HA-CH2, JA-P = 19.7 Hz, 
JA-B = 1.1 Hz), 6.26 (dd, 1H, HB-CH2, JB-P = 40.2 Hz, JA-B = 1.0 Hz), 7.22-7.28 (m, 3H, 
CH-Ar), 7.41-7.55 (m, 8H, CH-Ar), 7.69-7.77 (m, 4H, CH-Ar). 
13C NMR (75 MHz, CDCl3): (ppm) = 128.2 (d, JC-P = 5.0 Hz), 128.2, 128.3, 128.4, 
128.5, 131.7 (d, 2CAr, JC-P = 104.1 Hz), 131.9 (d, CH2, JC-P = 9.2 Hz), 132.0, 132.1, 144.4 (d, C, 
JC-P = 93.6 Hz). 
 
 
General procedure for the asymmetric hydroformylation of 1-aryl-1-phosphorylated ethenes 16a-i  
The substrate (1.0 eq), Rh(acac)(CO)2 (1 mol%) and the ligand (1.2 mol%) are transferred into a vial, 
which is placed into a stainless steel autoclave. The solvent (8 mL/1.0 mmol substrate) is added under 
an argon atmosphere and the autoclave is purged with argon (three times) followed by syngas (three 
times). The indicated reaction conditions (syngas pressure, temperature and reaction time) are adjusted 
by an automatic program. After stirring for the adjusted time, the mixture is cooled to room 
temperature, depressurized and concentrated in vacuo. The reaction mixture is analyzed by 31P- and 
1H NMR. The enantiomeric excess is determined by GC analysis. Racemic mixtures of 17a-i, as 
samples for the quantitative and qualitative analysis, are prepared by the hydroformylation of 16a-i 
with 1 mol% Rh(acac)(CO)2 and 5 mol% Alkanox® 240 in toluene. 
 
Dimethyl (3-oxo-1-phenylpropyl)phosphonate (17a) 
Anal. calcd for C11H15O4P: C, 54.55; H, 6.24. Found: C, 54.68; H, 6.33 %. 
HRMS (EI) calculated for C11H15O4P 242.07025, found 242.07001. 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 29.6 (s). 
1H NMR (300 MHz, CDCl3): (ppm) = 3.03 (m, 2H, CH2), 3.49 (d, 3H, OCH3, 
3JH-P = 10.6 Hz), 3.68 (d, 3H, OCH3, 3JH-P = 10.8 Hz), 3.70-3.84 (m, 1H, CH), 7.22-7.38 (m, 5H, 
CH-Ar), 9.65 (m, 1H, CHO). 
13C NMR (75 MHz, CDCl3):  (ppm) = 37.1 (d, CH, JC-P = 141.2 Hz), 43.7 (d, CH2, JC-P = 2.4 Hz), 
52.7 (d, OCH3, JC-P = 7.4 Hz), 53.5 (d, OCH3, JC-P = 7.1 Hz), 127.5 (d, CHAr, JC-P = 3.2 Hz), 128.6 (d, 
2CHAr, JC-P = 2.6 Hz), 128.9 (d, 2CHAr, JC-P = 6.5 Hz), 134.8 (d, CAr, JC-P = 7.2 Hz), 198.4 (d, CHO, 
JC-P = 15.1 Hz). 
Separation of enantiomers by GC on Lipodex E (25 m×0.25 mm), 80/30-8-200/10; tR = 55.2 min for 
(+)-enantiomer and tR = 55.6 min for (–)-enantiomer. 
 
Dimethyl (3-oxo-1-(p-tolyl)propyl)phosphonate (17b) 
Anal. calcd for C12H17O4P: C, 56.25; H, 6.69. Found: C, 56.64; H, 6.88 %. 
HRMS (EI) calculated for C12H17O4P 256.08590, found 256.08545. 
31P{1H} NMR (121 MHz, CDCl3):  (ppm) = 29.8 (s). 
1H NMR (300 MHz, CDCl3):  (ppm) = 2.30 (d, 3H, CH3, 3JH-H = 2.0 Hz), 
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3.03-3.14 (m, 2H, CH2), 3.49 (d, 3H, OCH3, 3JH-P = 10.5 Hz), 3.66 (d, 3H, OCH3, 3JH-P = 10.7 Hz), 
3.68-3.78 (m, 1H, CH), 7.08-7.13 (m, 2H, CH-Ar), 7.20-7.24 (m, 2H, CH-Ar), 9.63 (m, 1H, CHO). 
13C NMR (63 MHz, CDCl3):  (ppm) = 21.0 (CH3), 36.9 (d, CH, JC-P = 141.6 Hz), 43.8 (d, CH2, 
JC-P = 2.0 Hz), 52.9 (d, OCH3, JC-P = 7.3 Hz), 53.7 (d, OCH3, JC-P = 7.1 Hz), 128.8 (d, 2CHAr, 
JC-P = 6.6 Hz), 129.5 (d, 2CHAr, JC-P = 2.7 Hz), 131.6 (d, CAr, JC-P = 7.3 Hz), 137.4 (d, CAr, 
JC-P = 3.2 Hz), 198.7 (d, CHO, JC-P = 15.5 Hz). 
 
Dimethyl (1-(naphthalene-2-yl)-3-oxopropyl)phosphonate (17c) 
Anal. calcd for C15H17O4P: C, 61.64; H, 5.86. Found: C, 61.30; H, 5.81 %. 
HRMS (EI) calculated for C15H17O4P 292.08590, found 292.08573. 
31P{1H} NMR (101 MHz, CDCl3): (ppm) = 29.4 (s). 
1H NMR (300 MHz, CDCl3):  (ppm) = 3.20-3.27 (m, 2H, CH2), 3.48 (d, 3H, 
OCH3, 3JH-P = 10.4 Hz), 3.69 (d, 3H, OCH3, 3JH-P = 10.7 Hz), 3.87-4.00 (m, 1H, CH), 7.41-7.51 (m, 
3H, CH-Ar), 7.76-7.82 (m, 4H, CH-Ar), 9.67 (m, 1H, CHO). 
13C NMR (75 MHz, CDCl3):  (ppm) = 37.3 (d, CH, JC-P = 141.2 Hz), 43.9 (d, CH2, JC-P = 2.3 Hz), 
52.8 (d, CH3, JC-P = 7.2 Hz), 53.6 (d, CH3, JC-P = 7.1 Hz), 126.1 (d, CHAr, JC-P = 1.3 Hz), 126.2 (d, 
CHAr, JC-P = 0.9 Hz), 126.7 (d, CHAr, JC-P = 5.3 Hz), 127.5 (d, CHAr, JC-P = 1.2 Hz), 127.7 (d, CHAr, 
JC-P = 1.1 Hz), 127.9 (d, CHAr, JC-P = 8.3 Hz), 128.4 (d, CHAr, JC-P = 2.1 Hz), 132.3 (d, CAr, 
JC-P = 7.3 Hz), 132.6 (d, CAr, JC-P = 2.3 Hz), 133.2 (d, CAr, JC-P = 2.6 Hz), 198.4 (d, CHO, 
JC-P = 15.2 Hz). 
 
Dimethyl (1-(4-fluorophenyl)-3-oxopropyl)phosphonate (17d) 
Anal. calcd for C11H14FO4P: C, 50.78; H, 5.42. Found: C, 50.55; H, 5.11 %. 
HRMS (EI) calculated for C11H14FO4P 260.06083, found 260.06042. 
19F NMR (282 MHz, CDCl3): (ppm) = -114.6 (d, J = 5.1 Hz). 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 29.4 (s). 
1H NMR (300 MHz, CDCl3):  (ppm) = 3.04-3.25 (m, 2H, CH2), 3.54 (d, 3H, OCH3, 3JH-P = 10.6 Hz), 
3.71 (d, 3H, OCH3, 3JH-P = 10.8 Hz), 3.74-3.84 (m, 1H, CH), 6.99-7.07 (m, 2H, CH-Ar), 7.31-7.38 (m, 
2H, CH-Ar), 9.67 (m, 1H, CHO). 
13C NMR (75 MHz, CDCl3):  (ppm) = 36.3 (d, CH, JC-P = 142.1 Hz), 43.9 (d, CH2, JC-P = 1.8 Hz), 
52.9 (d, CH3, JC-P = 7.3 Hz), 53.6 (d, CH3, JC-P = 7.0 Hz), 115.6 (d, 2CHAr, JC-P = 21.5 Hz, 
JC-F = 2.6 Hz), 130.4-130.6 (m, 2CHAr), 162.1 (dd, CAr, JC-F = 246.8 Hz, JC-P = 3.5 Hz), 172.1 (d, CAr, 
JC-P = 19.5 Hz), 198.2 (d, CHO, JC-P = 15.4 Hz). 
Separation of enantiomers by GC on Lipodex E (25 m×0.25 mm), 140/40-6-180/30; tR = 48.2 min for 
(+)-enantiomer and tR = 48.7 min for (–)-enantiomer. 
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Dimethyl (1-(4-chlorophenyl)-3-oxopropyl)phosphonate (17e) 
Anal. calcd for C11H14ClO4P: C, 47.76; H, 5.10. Found: C, 47.87; H, 5.25 %. 
HRMS (EI) calculated for C11H14ClO4P 276.03127, found 276.03208. 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 29.1 (s). 
1H NMR (300 MHz, CDCl3):  (ppm) = 3.03-3.24 (m, 2H, CH2), 3.54 (d, 3H, 
OCH3, 3JH-P = 10.7 Hz), 3.70 (d, 3H, OCH3, 3JH-P = 10.7 Hz), 3.72-3.81 (m, 1H, CH), 7.30 (m, 4H, 
CH-Ar), 9.67 (m, 1H, CHO). 
13C NMR (75 MHz, CDCl3):  (ppm) = 36.6 (d, CH, JC-P = 141.9 Hz), 43.9 (d, CH2, JC-P = 2.2 Hz), 
53.0 (d, CH3, JC-P = 7.4 Hz), 53.8 (d, CH3, JC-P = 6.8 Hz), 129.0 (d, 2CHAr, JC-P = 2.5 Hz), 130.3 (d, 
2CHAr, JC-P = 6.6 Hz), 133.6 (d, CAr, JC-P = 7.5 Hz), 133.6 (m, CAr), 198.1 (d, CHO, JC-P = 15.3 Hz). 
Separation of enantiomers by GC on Lipodex E (25 m×0.25 mm), 140/40-6-180/30; tR = 48.5 min for 
(+)-enantiomer and tR = 49.0 min for (–)-enantiomer. 
 
Dimethyl (1-(4-bromophenyl)-3-oxopropyl)phosphonate (17f) 
Anal. calcd for C11H14BrO4P: C, 41.14; H, 4.39. Found: C, 41.53; H, 4.77 %. 
HRMS (EI) calculated for C11H14BrO4P 319.98076, found 319.98051. 
31P{1H} NMR (101 MHz, CDCl3):  (ppm) = 29.9 (s). 
1H NMR (250 MHz, CDCl3):  (ppm) = 3.01-3.24 (m, 2H, CH2), 3.51 (d, 3H, 
OCH3, 3JH-P = 10.6 Hz), 3.67 (d, 3H, OCH3, 3JH-P = 10.7 Hz), 3.71-3.83 (m, 1H, CH), 7.18-7.25 (m, 
2H, CH-Ar), 7.40-7.45 (m, 2H, CH-Ar), 9.63 (m, 1H, CHO). 
13C NMR (63 MHz, CDCl3):  (ppm) = 36.6 (d, CH, JC-P = 142.1 Hz), 43.7 (d, CH2, JC-P = 2.2 Hz), 
53.0 (d, OCH3, JC-P = 7.4 Hz), 53.7 (d, OCH3, JC-P = 7.1 Hz), 121.6 (d, CAr, JC-P = 4.0 Hz), 130.6 (d, 
2CHAr, JC-P = 6.6 Hz), 131.8 (d, 2CHAr, JC-P = 2.6 Hz), 134.0 (d, CAr, JC-P = 7.3 Hz), 198.0 (d, CHO, 
JC-P = 15.2 Hz). 
Separation of enantiomers by GC on Lipodex E (25 m×0.25 mm), 140/40-6-180/30; tR = 48.6 min for 
(+)-enantiomer and tR = 49.3 min for (–)-enantiomer. 
 
Diethyl (3-oxo-1-phenylpropyl)phosphonate (17g) 
Anal. calcd for C13H19O4P: C, 57.77; H, 7.09. Found: C, 57.51; H, 6.82 %. 
HRMS (EI) calculated for C13H19O4P 270.10155, found 270.10122. 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 27.2 (s). 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.12 (t, 3H, OCH3, 3JH-H = 7.1 Hz), 1.29 
(t, 3H, OCH3, 3JH-H = 7.1 Hz), 3.06-3.26 (m, 2H, CH2), 3.69-4.17 (m, 5H, CH and 2OCH2), 7.23-7.40 
(m, 5H, CH-Ar), 9.68 (m, 1H, CHO). 
13C NMR (63 MHz, CDCl3):  (ppm) = 16.0 (d, CH3, JC-P = 5.8 Hz), 16.3 (d, CH3, JC-P = 5.9 Hz), 37.7 
(d, CH, JC-P = 141.4 Hz), 43.8 (d, CH2, JC-P = 2.3 Hz), 62.1 (d, OCH2, JC-P = 7.4 Hz), 62.8 (d, OCH2, 
JC-P = 7.1 Hz), 127.4 (d, CHAr, JC-P = 3.4 Hz), 128.5 (d, 2CHAr, JC-P = 2.6 Hz), 129.0 (d, 2CHAr, 
JC-P = 6.5 Hz), 135.0 (d, CAr, JC-P = 7.1 Hz), 198.8 (d, CHO, JC-P = 15.3 Hz). 
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Dimethyl (1-(4-methoxyphenyl)-3-oxopropyl)phosphonate (17h) 
Anal. calcd for C12H17O5P: C, 52.94; H, 6.29. Found: C, 52.64; H, 6.08 %. 
HRMS (EI) calculated for C12H17O5P 272.08081, found 272.08058. 
31P{1H} NMR (101 MHz, CDCl3):  (ppm) = 29.8 (s). 
1H NMR (250 MHz, CDCl3):  (ppm) = 3.00-3.21 (m, 2H, CH2), 3.49 (d, 
3H, OCH3, 3JH-P = 10.6 Hz), 3.67 (d, 3H, OCH3, 3JH-P = 10.7 Hz), 3.77 (s, 
3H, PhOCH3), 3.73 (m, 1H, CH), 6.85 (m, 2H, CH-Ar), 7.24-7.28 (m, 2H, CH-Ar), 9.64 (m, 1H, 
CHO). 
13C NMR (63 MHz, CDCl3):  (ppm) = 36.5 (d, CH, JC-P = 142.3 Hz), 43.9 (d, CH2, JC-P = 1.8 Hz), 
52.8 (d, OCH3, JC-P = 7.8 Hz), 53.6 (d, OCH3, JC-P = 7.1 Hz), 55.1 (s, PhOCH3), 114.2 (d, 2CHAr, 
JC-P = 2.5 Hz), 126.5 (d, CAr, JC-P = 7.3 Hz), 130.0 (d, 2CHAr, JC-P = 6.6 Hz), 159.0 (d, CAr, 
JC-P = 3.0 Hz), 198.7 (d, CHO, JC-P = 15.7 Hz). 
 
3-(Diphenylphosphoryl)-3-phenylpropanal (17i) 
Anal. calcd for C21H19O2P: C, 75.44; H, 5.73. Found: C, 75.69; H, 5.81 %. 
HRMS (EI) calculated for C21H19O2P 334.11172, found 334.11159. 
31P{1H} NMR (121 MHz, CDCl3):  (ppm) = 32.9 (s). 
1H NMR (300 MHz, CDCl3): (ppm) = 2.98-3.09 (m, 1H, HA-CH2), 3.33-3.45 
(m, 1H, HB-CH2), 4.20-4.27 (m, 1H, CH), 7.18-7.61 (m, 13H, CH-Ar), 7.92-7.99 (m, 2H, CH-Ar), 
9.64 (m, 1H, CHO). 
13C NMR (75 MHz, CDCl3):  (ppm) = 40.0 (d, CH, JC-P = 68.2 Hz), 43.9 (CH2), 127.3 (d, CHAr, 
JC-P = 2.4 Hz), 128.0 (CHAr), 128.2 (CHAr), 128.4 (CHAr), 128.5 (CHAr), 128.8 (CHAr), 129.0 (CHAr), 
129.7 (CHAr), 129.7 (CHAr), 130.5 (d, CAr, JC-P = 4.8 Hz), 131.0 (CHAr), 131.1 (CHAr), 131.2 (CHAr), 
131.4 (CHAr), 131.5 (d, CHAr, JC-P = 2.7 Hz), 131.8 (CAr), 132.1 (d, CHAr, JC-P = 2.7 Hz), 135.3 (d, CAr, 
JC-P = 5.3 Hz), 198.9 (d, CHO, JC-P = 13.3 Hz). 
 
Dimethyl (1-oxo-2-phenylpropan-2-yl)phosphonate (18a) 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 24.7 (s). 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.77 (d, 3H, CH3, 3JH-P = 15.9 Hz), 3.63 (d, 
3H, OCH3, 3JH-P = 10.8 Hz), 3.72 (d, 3H, OCH3, 3JH-P = 11.0 Hz), 7.33-7.57 (m, 5H, 
CH-Ar), 9.84 (d, 1H, CHO, 3JH-P = 4.0 Hz). 
13C NMR spectrum could not be analyzed due to the small amount in the final 
reaction mixture. 
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Dimethyl (1-oxo-2-(p-tolyl)propan-2-yl)phosphonate (18b) 
31P{1H} NMR (101 MHz, CDCl3): (ppm) = 24.4 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in the 
final reaction mixture. 
 
 
 
Dimethyl (2-(naphthalene-2-yl)-1-oxopropan-2-yl)phosphonate (18c) 
31P{1H} NMR (101 MHz, CDCl3): (ppm) = 26.1 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in the 
final reaction mixture. 
 
 
 
Dimethyl (2-(4-fluorophenyl)-1-oxopropan-2-yl)phosphonate (18d) 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 24.5 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in the 
final reaction mixture. 
 
 
 
Dimethyl (2-(4-chlorophenyl)-1-oxopropan-2-yl)phosphonate (18e) 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 24.2 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in the 
final reaction mixture. 
 
 
 
Dimethyl (2-(4-bromophenyl)-1-oxopropan-2-yl)phosphonate (18f) 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 25.5 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in the 
final reaction mixture. 
 
 
 
Diethyl (1-oxo-2-phenylpropan-2-yl)phosphonate (18g) 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 24.1 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in the final 
reaction mixture. 
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Dimethyl (2-(4-methoxyphenyl)-1-oxopropan-2-yl)phosphonate (18h) 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 25.0 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in 
the final reaction mixture. 
 
 
 
Dimethyl (1-phenylethyl)phosphonate (19a) 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 32.1 (s). 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.60 (dd, 3H, CH3, 3JH-P = 18.6 Hz, 
3JH-H = 7.4 Hz), 3.16-3.30 (m, 1H, CH), 3.54 (d, 3H, OCH3, 3JH-P = 10.5 Hz), 3.69 
(d, 3H, OCH3, 3JH-P = 10.6 Hz), 7.17-7.58 (m, 5H, CH-Ar). 
13C NMR spectrum could not be analyzed due to the small amount in the final 
reaction mixture. 
 
Dimethyl (1-(p-tolyl)ethyl)phosphonate (19b) 
31P{1H} NMR (101 MHz, CDCl3): (ppm) = 32.3 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in the 
final reaction mixture. 
 
 
 
Dimethyl (1-(naphthalene-2-yl)ethyl)phosphonate (19c) 
31P{1H} NMR (101 MHz, CDCl3): (ppm) = 31.9 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in the 
final reaction mixture. 
 
 
Dimethyl (1-(4-fluorophenyl)ethyl)phosphonate (19d) 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 31.7 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in the 
final reaction mixture. 
 
 
 
Dimethyl (1-(4-chlorophenyl)ethyl)phosphonate (19e) 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 31.4 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in the 
final reaction mixture. 
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Dimethyl (1-(4-bromophenyl)ethyl)phosphonate (19f) 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 31.2 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in the 
final reaction mixture. 
 
 
 
Diethyl (1-phenylethyl)phosphonate (19g) 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 29.7 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in the final 
reaction mixture. 
 
 
Dimethyl (1-(4-methoxyphenyl)ethyl)phosphonate (19h) 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 32.4 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in 
the final reaction mixture. 
 
 
 
Diphenyl(1-phenylethyl)phosphine oxide (19i) 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 33.6 (s). 
1H and 13C NMR spectra could not be analyzed due to the small amount in the final 
reaction mixture. 
 
 
 
 
5.1.2.6 Synthesis of bidentate phosphorus ligands 
Procedure for the synthesis of (R)-(1,1'-binaphthalene)-2,2'-diyl bis(trifluoromethanesulfonate) 
(20a)[105] 
(R)-BINOL (2.00 g, 7.0 mmol) is dissolved in dichloromethane (45 mL) and pyridine (2.0 mL, 
25.0 mmol) is added. The solution is cooled to 0 °C and trifluoroacetic anhydride (2.5 mL, 15.0 mmol) 
is added dropwise. Thus, the mixture is stirred at room temperature for 6 h, concentrated in vacuo and 
dissolved in ethyl acetate (50 mL). The organic layer is washed with 5 % aqueous HCl, saturated 
NaHCO3-solution and finally with brine (each 10 mL). The organic phase is dried over Na2SO4, 
concentrated in vacuo and purified by column chromatography (heptane/dichloromethane = 1:1) to 
give 20a as a white solid (3.85 g, 100 %). 
19F NMR (282 MHz, CDCl3): (ppm) = -74.6 (s). 
1H NMR (300 MHz, CDCl3): (ppm) = 7.24-7.27 (m, 2H, CH-Ar), 7.39-7.44 (m, 
2H, CH-Ar), 7.56-7.64 (m, 4H, CH-Ar), 8.01 (m, 2H, CH-Ar), 8.15 (m, 2H, 
CH-Ar). 
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Procedure for the synthesis of (R)-2'-(diphenylphosphoryl)-[1,1'-binaphthalen]-2-yl 
trifluoromethanesulfonate (20b)[105] 
In a pressure tube the derivative 20a (4.80 g, 8.7 mmol), diphenylphosphine oxide (3.52, 17.4 mmol), 
palladium(II) acetate (99 mg, 0.44 mmol) and dppb (186 mg, 0.44 mmol) are dissolved in dimethyl 
sulfoxide (40 mL) and Hünig’s base (4.51 g, 34.9 mmol) is added in one portion. The solution is 
heated to 100 °C and stirred for 20 h. After cooling to room temperature, the resulting solution is 
dissolved in ethyl acetate (50 mL) and washed with water (2×20 mL). The organic layer is dried over 
Na2SO4 and concentrated in vacuo. Column chromatography (hexane/EtOAc = 1:1) yields 20b as a 
white solid (1.73 g, 33 %). 
19F NMR (282 MHz, CDCl3): (ppm) = -74.6 (s). 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 28.1 (s). 
1H NMR (250 MHz, C6D6): (ppm) = 7.00 (m, CH-Ar), 7.14-8.03 (m, 21H, 
CH-Ar). 
 
 
Procedure for the synthesis of (R)-(2'-hydroxy-[1,1'-binaphthalen]-2-yl)diphenylphosphine oxide 
(20c)[105] 
Phosphine oxide 20b (520 mg, 0.86 mmol) is dissolved in dioxane:methanol (6 mL, v:v 2:1) and 3 M 
NaOH-solution (5 mL) is added. The reaction mixture is stirred at room temperature for 16 h. The 
resulting solution is acidified with concentrated aqueous HCl to pH = 1 and then extracted with ethyl 
acetate (2×10 mL). The organic layer is dried over Na2SO4, concentrated in vacuo and purified by 
column chromatography (heptane:EtOAc = 1:1) to give 20c as a white solid (390 mg, 96 %). 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 30.8 (s). 
1H NMR (300 MHz, CDCl3): (ppm) = 6.43 (m, 1H, CH-Ar), 6.68-7.98 (m, 21H, 
CH-Ar). 
 
 
 
 
Procedure for the synthesis of (R)-2'-(diphenylphosphino)-[1,1'-binaphthalen]-2-ol (20d)[105] 
Phosphine oxide 20c (275 mg, 0.58 mmol) is dissolved in toluene (6 mL) and triethylamine is added 
(431 mg, 4.26 mmol). The solution is cooled to 0 °C and trichlorosilane (402 mg, 2.97 mmol) is added 
dropwise. The reaction mixture is warmed to 100 °C and stirred for 16 h. After cooling to room 
temperature, the resulting solution is dissolved in diethyl ether (5 mL) and quenched with a few drops 
of saturated NaHCO3-solution. The layer is filtrated over Celite, dried over Na2SO4 and concentrated 
in vacuo. Column chromatography (heptane:EtOAc = 3:1) yields 20d as a white solid (217 mg, 82 %). 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = -13.2 (s). 
1H NMR (300 MHz, CDCl3): (ppm) = 6.75 (d, 1H, CH-Ar), 6.99-7.36 (m, 15H, 
CH-Ar), 7.45-7.55 (m, 2H, CH-Ar), 7.80 (m, 1H, CH-Ar), 7.89-7.96 (m, 3H, 
CH-Ar). 
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General procedure for the synthesis of (R,S)- and (R,R)-BINAPHOS 20e,f 
1.05 Eq of enantiopure BINOL are suspended in phosphorus trichloride (1.5 mL/1.0 mmol BINOL), 
2-3 drops of N-methyl-2-pyrrolidone are added and the solution is heated to 75 °C for 5 min. The 
resulting HCl gas is derived from the reaction vessel by using a bubble counter (slight argon stream!). 
The now clear solution is cooled to room temperature, concentrated and dried azeotropically with 
toluene (three times). Thus, the in situ prepared chlorophosphite is dissolved in toluene 
(5 mL/0.33 mmol BINOL). 1.0 Eq of azeotropically dried phosphine 20d is dissolved in toluene 
(5 mL/0.33 mmol substrate) and triethylamine (2.5 eq) is added. This solution is added slowly to the 
chlorophosphite solution at 0 °C over 5 min and the mixture is kept at this temperature for 5 min. The 
reaction solution is then stirred at room temperature for 16 h. After this time, it is concentrated in 
vacuo and the residue is purified by column chromatography (alumina, toluene) to give 20e,f as a 
white solid. 
 
(R,S)-BINAPHOS (20e)[48] 
Starting from (S)-BINOL (100 mg, 0.35 mmol), phosphine 20d 
(150 mg, 0.33 mmol) and Et3N (88 mg, 0.90 mmol) in toluene 
(10 mL), the product 20e was isolated as a white solid (120 mg, 
47 %). 
31P{1H} NMR (121 MHz, C6D6): (ppm) = -13.6 (d, PPh2, 
JP-P = 26.4 Hz), 146.4 (d, O-P, JP-P = 26.4 Hz). 
1H NMR (300 MHz, C6D6): (ppm) = 6.51-6.54 (m, 1H, CH-Ar), 
6.70-7.76 (m, 33H, CH-Ar). 
 
(R,R)-BINAPHOS (20f)[48] 
Starting from (R)-BINOL (100 mg, 0.35 mmol), phosphine 20d 
(150 mg, 0.33 mmol) and Et3N (88 mg, 0.90 mmol) in toluene 
(10 mL), the product 20f was isolated as a white solid (100 mg, 
39 %). 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = -13.4 (d, PPh2, 
JP-P = 9.0 Hz), 145.0 (d, O-P, JP-P = 9.0 Hz). 
1H NMR (250 MHz, CDCl3): (ppm) = 5.74 (m, 1H, CH-Ar), 
6.68-8.03 (m, 33H, CH-Ar). 
 
 
General procedure for the synthesis of diphosphites 21a-d 
2.1 Eq of enantiopure BINOL are suspended in phosphorus trichloride (1.5 mL/1.0 mmol BINOL), 2-3 
drops of N-methyl-2-pyrrolidone are added and the solution is heated to 75 °C for 5 min. The resulting 
HCl gas is derived from the reaction vessel by using a bubble counter (slight argon stream!). The now 
clear solution is cooled to room temperature, concentrated and dried azeotropically with toluene (three 
times). Thus, the in situ prepared chlorophosphite is dissolved in toluene (10 mL/2.1 mmol BINOL). 
1.0 Eq of azeotropically dried aromatic diol is dissolved in toluene (10 mL/1.0 mmol substrate) and 
triethylamine (5.0 eq) is added. This solution is added slowly to the chlorophosphite solution at 0 °C 
over 5 min and the mixture is kept at this temperature for 5 min. The reaction solution is then stirred at 
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room temperature for 16 h. After this time, it is concentrated in vacuo and the residue is purified by 
column chromatography (alumina, toluene) to give 21a-d as white solids. 
 
(1S)-2,2'-Bis[(11bR)-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yloxy]-1,1'-binaphthalene (21a) 
Starting from (R)-BINOL (601 mg, 2.1 mmol), (S)-BINOL 
(286 mg, 1.0 mmol) and Et3N (506 mg, 5.0 mmol) in toluene 
(20 mL), the product 21a was isolated as a white solid (866 mg, 
95 %, Rf 0.90). 
Anal. calcd for C60H36O6P2: C, 78.77; H, 3.97. Found: C, 78.90; 
H, 4.11 %. 
HRMS (EI) calculated for C60H36O6P2 914.19816, found 
914.19795. 
31P{1H} NMR (101 MHz, CD2Cl2): (ppm) = 145.4 (s). 
1H NMR (250 MHz, CD2Cl2): (ppm) = 5.92 (m, 2H, CH-Ar, 
4JH-H = 8.8 Hz), 7.18-8.17 (m, 34H, CH-Ar). 
13C NMR (63 MHz, CD2Cl2): (ppm) = 121.2 (2CHAr), 121.4 (2CHAr), 121.6 (2CHAr), 122.4 (2CAr), 
123.0 (2CAr), 124.0 (2CAr), 124.9 (2CHAr), 125.2 (2CHAr), 125.5 (2CHAr), 126.1 (4CHAr), 126.3 
(2CHAr), 126.6 (2CHAr), 126.8 (2CHAr), 127.2 (2CHAr), 128.3 (4CHAr), 128.4 (2CHAr), 129.3 (2CHAr), 
130.3 (2CHAr), 130.5 (2CHAr), 131.1 (2CAr), 131.3 (2CAr), 131.6 (2CAr), 132.1 (2CAr), 132.7 (2CAr), 
134.2 (2CAr), 147.0 (2CAr-O), 147.3 (2CAr-O), 148.3 (2CAr-O). 
 
(1R)-2,2'-Bis[(11bR)-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yloxy]-1,1'-binaphthalene 
(21b)[148] 
Starting from (R)-BINOL (601 mg, 2.1 mmol), (R)-BINOL 
(286 mg, 1.0 mmol) and Et3N (506 mg, 5.0 mmol) in toluene 
(20 mL), the product 21b was isolated as a white solid (848 mg, 
93 %, Rf 0.92). 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 144.6 (s). 
1H NMR (300 MHz, CDCl3): (ppm) = 6.45 (m, 2H, CH-Ar, 
4JH-H = 8.9 Hz), 7.07-7.35 (m, 22H, CH-Ar), 7.44 (m, 2H, CH-Ar, 
4JH-H = 8.9 Hz), 7.64-7.90 (m, 10H, CH-Ar). 
13C NMR (63 MHz, CDCl3): (ppm) = 121.1 (m, 2CHAr), 121.7 
(2CHAr), 121.9 (2CHAr), 122.4 (m, 4CAr), 124.3 (m, 2CAr), 124.6 
(2CHAr), 124.9 (2CHAr), 125.1 (2CHAr), 125.8 (2CHAr), 126.1 
(2CHAr), 126.2 (2CHAr), 126.8 (2CHAr), 127.0 (4CHAr), 128.1 (2CHAr), 128.2 (2CHAr), 128.4 (2CHAr), 
129.5 (2CHAr), 130.0 (2CHAr), 130.3 (2CHAr), 130.8 (2CAr), 131.0 (2CAr), 131.4 (2CAr), 132.3 (2CAr), 
132.7 (2CAr), 134.3 (2CAr), 147.0 (2CAr-O), 147.6 (m, 2CAr-O), 148.5 (m, 2CAr-O). 
 
 
 
 
 
 
Chapter 5: Appendix 
- 101 - 
(11bR)-4-{[(R)-2'-((2,4,8,10-Tetra-tert-butyldibenzo[d,f][1,3,2]dioxaphosphepin-6-yl)oxy)-[1,1'-
binaphthalen]-2-yl]oxy}dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine (21c) 
Starting from (R)-BINOL (601 mg, 2.1 mmol), 4,4',6,6'-tetra-tert-
butyl-2,2'-biphenol (411 mg, 1.0 mmol) and Et3N (506 mg, 
5.0 mmol) in toluene (20 mL), the product 21c was isolated as a 
white solid (977 mg, 94 %, Rf 0.91). 
[α]D
26 = -188.0 (c 0.79, CHCl3). 
Anal. calcd for C68H64O6P2: C, 78.59; H, 6.21. Found: C, 78.90; 
H, 6.42 %. 
HRMS (EI) calculated for C68H64O6P2 1038.41726, found 
1038.41702. 
31P{1H} NMR (101 MHz, CD2Cl2):  (ppm) = 135.2 (s), 
144.6 (s). 
1H NMR (250 MHz, CD2Cl2):  (ppm) = 1.00 (s, 9H, C(CH3)3), 1.00 (s, 9H, C(CH3)3), 1.30 (s, 9H, 
C(CH3)3), 1.30 (s, 9H, C(CH3)3), 6.04 (d, 1H, CH-Ar, J = 8.8 Hz), 7.09-7.61 (m, 20H, CHAr), 
7.84-8.12 (m, 7H, CH-Ar). 
13C NMR (63 MHz, C6D6):  (ppm) = 31.2 (d, C(CH3)3, JC-P = 2.4 Hz), 31.2 (d, C(CH3)3, 
JC-P = 2.8 Hz), 31.6 (2C(CH3)3), 34.6 (2C(CH3)3), 35.5 (d, 2C(CH3)3, JC-P = 6.5 Hz), 121.3 (d, CHAr, 
JC-P = 12.2 Hz), 122.1 (d, CHAr, JC-P = 1.0 Hz), 122.4 (CHAr), 122.6 (d, CHAr, JC-P = 9.8 Hz), 123.1 (d, 
CAr, JC-P = 2.5 Hz), 123.2 (d, CAr, JC-P = 3.5 Hz), 123.6 (d, CAr, JC-P = 2.9 Hz), 124.4 (2CHAr), 125.0 (d, 
CAr), 125.0 (CHAr), 125.2 (CHAr), 125.3 (CHAr), 125.5 (CHAr), 126.3 (CHAr), 126.6 (CHAr), 126.8 
(2CHAr), 126.9 (CHAr), 127.0 (CHAr), 127.2 (CHAr), 127.3 (CHAr), 127.4 (CHAr), 127.5 (CHAr), 128.3 
(2CHAr), 128.5 (CHAr), 128.6 (CHAr), 129.9 (CHAr), 129.9 (CHAr), 130.2 (CHAr), 130.6 (CHAr), 131.4 
(CAr), 131.4 (CAr), 131.7 (CAr), 132.0 (CAr), 133.1 (d, CAr, JC-P = 1.4 Hz), 133.4 (d, CAr, JC-P = 1.4 Hz), 
133.7 (d, CAr, JC-P = 4.0 Hz), 133.8 (d, CAr, JC-P = 4.0 Hz), 134.8 (CAr), 134.9 (CAr), 141.1 (d, CAr, 
JC-P = 1.5 Hz), 141.2 (d, CAr, JC-P = 1.4 Hz), 146.2 (d, CAr, JC-P = 3.5 Hz), 146.3 (d, CAr, JC-P = 3.0 Hz), 
146.8 (2CAr), 147.8 (d, CAr, JC-P = 2.0 Hz), 148.6 (d, CAr, JC-P = 5.5 Hz), 148.7 (CAr), 149.0 (d, CAr, 
JC-P = 7.1 Hz). 
 
(11bR)-4-{[(R)-2'-((4,8-Di-tert-butyl-2,10-dimethoxydibenzo[d,f][1,3,2]dioxaphosphepin-6-yl)oxy)-
[1,1'-binaphthalen]-2-yl]oxy}dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine (21d) 
Starting from (R)-BINOL (601 mg, 2.1 mmol), 4,4'-di-
methoxy-6,6'-di-tert-butyl-2,2'-biphenol (359 mg, 1.0 mmol) 
and Et3N (506 mg, 5.0 mmol) in toluene (20 mL), the product 
21d was isolated as a white solid (961 mg, 97 %, Rf 0.92). 
[α]D
26 = -132.1 (c 0.54, CHCl3). 
Anal. calcd for C62H52O8P2: C, 75.45; H, 5.31. Found: C, 75.27; 
H, 5.04 %. 
HRMS (EI) calculated for C62H52O8P2 986.31319, found 
986.31301. 
31P{1H} NMR (121 MHz, CDCl3):  (ppm) = 138.5 (s), 
144.5 (s). 
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1H NMR (300 MHz, CD2Cl2):  (ppm) = 0.97 (s, 9H, C(CH3)3), 1.03 (s, 9H, C(CH3)3), 3.72 (s, 3H, 
OCH3), 3.76 (s, 3H, OCH3), 6.10 (d, 1H, CH-Ar, J = 6.1 Hz), 6.54 (dd, 2H, CH-Ar, J = 5.1 Hz, 
J = 3.1 Hz), 6.78 (dd, 2H, CH-Ar, J = 6.5 Hz, J = 3.1 Hz), 7.13-7.49 (m, 14H, CHAr), 7.58 (d, 1H, 
CH-Ar, J = 8.9 Hz), 7.67 (dd, 1H, CH-Ar, J = 8.9 Hz, J = 1.0 Hz), 7.84-7.95 (m, 5H, CH-Ar), 8.03 (d, 
1H, CH-Ar, J = 8.3 Hz), 8.12 (d, 1H, CH-Ar, J = 8.9 Hz). 
13C NMR (75 MHz, CDCl3):  (ppm) = 30.5 (d, C(CH3)3, JC-P = 2.1 Hz), 30.6 (d, C(CH3)3, 
JC-P = 2.8 Hz), 34.9 (C(CH3)3), 35.0 (C(CH3)3), 55.5 (2OCH3), 112.4 (CHAr), 112.5 (CHAr), 113.9 
(CHAr), 114.2 (CHAr), 120.8 (d, CHAr, JC-P = 10.7 Hz), 121.4 (d, CHAr, JC-P = 10.9 Hz), 121.8 (2CHAr), 
122.3 (d, CAr, JC-P = 2.6 Hz), 122.5 (d, CAr, JC-P = 3.5 Hz), 122.6 (d, CAr, JC-P = 3.1 Hz), 124.1 (d, CAr, 
JC-P = 5.1 Hz), 124.6 (CHAr), 124.8 (CHAr), 125.0 (CHAr), 125.1 (CHAr), 125.8 (CHAr), 126.1 (CHAr), 
126.2 (CHAr), 126.3 (CHAr), 126.5 (CHAr), 126.8 (CHAr), 126.9 (CHAr), 127.0 (CHAr), 127.9 (CHAr), 
128.0 (CHAr), 128.2 (2CHAr), 129.4 (CHAr), 129.6 (CHAr), 129.7 (CHAr), 130.1 (CHAr), 130.7 (CAr), 
130.8 (CAr), 131.1 (CAr), 131.5 (CAr), 132.4 (d, CAr, JC-P = 1.4 Hz), 132.8 (d, CAr, JC-P = 1.1 Hz), 133.3 
(d, CAr, JC-P = 4.0 Hz), 133.5 (d, CAr, JC-P = 4.0 Hz), 134.0 (CAr), 134.3 (CAr), 141.3 (d, CAr), 141.4 (d, 
CAr), 142.7 (2CAr) 147.1 (d, CAr, JC-P = 2.3 Hz), 147.7 (d, CAr, JC-P = 4.9 Hz), 148.0 (d, CAr, 
JC-P = 7.8 Hz), 148.2 (CAr), 155.4 (2CAr). 
 
 
Procedure for the synthesis of (11bR,11c'R)-4,4'-[(3,3'-Di-tert-butyl-5,5'-dimethoxy-[1,1'-biphenyl]-
2,2'-diyl)bis(oxy)]didinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepine (21e) 
294 mg (1.02 mmol) of (R)-BINOL are suspended in phosphorus trichloride (1.5 mL), 2-3 drops of 
N-methyl-2-pyrrolidone are added and the solution is heated to 75 °C for 5 min. The resulting HCl gas 
is derived from the reaction vessel by using a bubble counter (slight argon stream!). The now clear 
solution is cooled to room temperature, concentrated and dried azeotropically with toluene (three 
times). Thus, the in situ prepared chlorophosphite is dissolved in toluene (3 mL). 180 mg (0.5 mmol) 
of azeotropically dried 4,4'-di-methoxy-6,6'-di-tert-butyl-2,2'-biphenol is dissolved in toluene (2 mL) 
and the solution is cooled to -20 °C. n-BuLi (1.6 M in hexane, 0.63 mL, 1.0 mmol) is added and the 
mixture is warmed to room temperature over 30 min and stirred for futher 90 min. This solution is 
added slowly to the chlorophosphite solution and stirred at room temperature for 16 h. After this time, 
it is concentrated in vacuo and the residue is purified by column chromatography (alumina, toluene) to 
give 300 mg of 21e as a white solid (61 %, Rf 0.93). 
[α]D
25 = -106.1 (c 0.59, CHCl3). 
Anal. calcd for C62H52O8P2: C, 75.45; H, 5.31. Found: C, 75.12; 
H, 5.22 %. 
HRMS (EI) calculated for C62H52O8P2 986.31319, found 
986.31299. 
31P{1H} NMR (101 MHz, C6D6):  (ppm) = 146.4 (s), 146.5 
(s). 
1H NMR (250 MHz, C6D6):  (ppm) = 1.33 (s, 9H, C(CH3)3), 
1.63 (s, 9H, C(CH3)3), 3.25 (s, 3H, OCH3), 3.54 (s, 3H, OCH3), 
6.83-7.70 (m, 28H, CH-Ar). 
13C NMR (75 MHz, CDCl3):  (ppm) = 30.4 (C(CH3)3), 31.1 
(C(CH3)3), 35.5 (C(CH3)3), 36.0 (C(CH3)3), 55.2 (OCH3), 55.4 (OCH3), 114.7 (CHAr), 115.8 (CHAr), 
116.4 (2CHAr), 122.2 (CHAr), 122.3 (2CHAr), 123.7 (CHAr), 124.9 (CHAr), 124.9 (d, CAr), 125.0 (d, 
CAr), 125.1 (CHAr), 125.2 (CHAr), 125.2 (d, CAr), 125.2 (CAr), 125.3 (CHAr), 126.2 (CHAr), 126.4 
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(CHAr), 126.5 (CHAr), 126.6 (CHAr), 127.5 (2CHAr), 127.6 (CHAr), 127.6 (CHAr), 128.6 (CHAr), 128.7 
(3CHAr), 129.6 (CHAr), 130.1 (CHAr), 130.5 (CHAr), 130.6 (CHAr), 131.6 (CAr), 131.4 (CAr), 132.0 
(CAr), 132.1 (CAr), 133.0 (CAr), 133.1 (d, CAr), 133.1 (CAr), 133.3 (CAr), 133.4 (2CAr), 143.9 (CAr), 
144.1 (CAr), 144.6 (m, CAr) 145.4 (m, CAr), 147.7 (CAr), 147.8 (CAr), 148.9 (m, CAr), 149.2 (m, CAr), 
155.6 (CAr), 155.8 (CAr). 
 
 
General procedure for the synthesis of 1,2-amino alcohol-based phosphites-phosphoramidites 22a-e 
2.1 Eq of enantiopure BINOL are suspended in phosphorus trichloride (1.5 mL/1.0 mmol BINOL), 2-3 
drops of N-methyl-2-pyrrolidone are added and the solution is heated to 75 °C for 5 min. The resulting 
HCl gas is derived from the reaction vessel by using a bubble counter (slight argon stream!). The now 
clear solution is cooled to room temperature, concentrated and dried azeotropically with toluene (three 
times). Thus, the in situ prepared chlorophosphite is dissolved in toluene (10 mL/2.1 mmol BINOL). 
1.0 Eq of azeotropically dried amino alcohol is dissolved in toluene (10 mL/1.0 mmol substrate) and 
triethylamine (5.0 eq) is added. This solution is added slowly to the chlorophosphite solution at 0 °C 
over 5 min and the mixture is kept at this temperature for 5 min. The reaction solution is then stirred at 
room temperature for 16 h. After this time, it is concentrated in vacuo and the residue is purified by 
column chromatography (alumina, toluene) to give 22a-e as a white solid. 
 
(11bS)-N-{(1R,2S)-1-[(11bS)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yloxy]-1-
phenylpropan-2-yl}-N-methyldinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine (22a) 
Starting from (S)-BINOL (601 mg, 2.1 mmol), (1R,2S)-
(–)-ephedrine (165 mg, 1.0 mmol) and Et3N (506 mg, 
5.0 mmol) in toluene (20 mL), the product 22a was 
isolated as a white solid (412 mg, 52 %, Rf 0.90). 
[α]D
23 = +292.6 (c 0.70, CHCl3). 
Anal. calcd for C50H37NO5P2: C, 75.66; H, 4.70; N, 1.76. 
Found: C, 75.64; H, 5.08; N, 1.96 %. 
HRMS (EI) calculated for C50H37NO5P2 793.21415, found 793.21325. 
31P{1H} NMR (121 MHz, CDCl3): (ppm) = 142.7 (s), 148.5 (s). 
1H NMR (300 MHz, CDCl3): (ppm) = 1.50 (d, 3H, CHCH3, 3JH-H = 6.7 Hz), 2.14 (d, 3H, NCH3, 
3JH-P = 4.0 Hz), 3.77-3.91 (m, 1H, CHCH3), 5.18 (dd, 1H, CHPh, 3JH-P = 8.3 Hz, 3JH-H = 8.3 Hz), 
6.97-7.95 (m, 29H, CH-Ar). 
13C NMR (75 MHz, CDCl3): (ppm) = 16.1 (d, CHCH3, JC-P = 6.3 Hz), 27.6 (d, NCH3, JC-P = 1.3 Hz), 
58.4 (dd, CHCH3, JC-P = 41.7 Hz, JC-P = 4.6 Hz), 79.1 (dd, CHPh, JC-P = 6.1 Hz, JC-P = 6.0 Hz), 121.8 
(CHAr), 121.9 (3CHAr), 122.4 (d, CAr, JC-P = 2.1 Hz), 123.8 (d, CAr, JC-P = 4.7 Hz), 124.3 (d, CAr, 
JC-P = 5.3 Hz), 124.5 (CHAr), 124.7 (CHAr), 124.7 (d, CAr), 124.8 (CHAr), 125.1 (CHAr), 126.0 (CHAr), 
126.0 (CHAr), 126.1 (CHAr), 126.2 (CHAr), 126.9 (CHAr), 127.0 (CHAr), 127.0 (CHAr), 127.1 (CHAr), 
127.4 (2CHAr), 128.2 (CHAr), 128.2 (2CHAr), 128.3 (3CHAr), 128.4 (CHAr), 129.7 (CHAr), 129.9 
(CHAr), 130.1 (CHAr), 130.3 (CHAr), 130.6 (CAr), 130.9 (CAr), 131.3 (CAr), 131.6 (CAr), 132.5 (d, CAr), 
132.5 (d, CAr), 132.7 (d, CAr, JC-P = 1.6 Hz), 132.8 (CAr, JC-P = 1.7 Hz), 139.5 (CAr), 147.4 (d, CAr-O, 
JC-P = 1.3 Hz), 148.2 (d, CAr-O, JC-P = 5.4 Hz), 149.3 (CAr-O), 150.2 (d, CAr-O, JC-P = 5.0 Hz). 
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(11bR)-N-{(1R,2S)-1-[(11bR)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yloxy]-1-
phenylpropan-2-yl}-N-methyldinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine (22b) 
Starting from (R)-BINOL (601 mg, 2.1 mmol), (1R,2S)-
(–)-ephedrine (165 mg, 1.0 mmol) and Et3N (506 mg, 
5.0 mmol) in toluene (20 mL), the product 22b was 
isolated as a white solid (518 mg, 65 %, Rf 0.89). 
[α]D
23 = -290.0 (c 0.70, CHCl3). 
Anal. calcd for C50H37NO5P2: C, 75.66; H, 4.70; N, 
1.76. Found: C, 75.56; H, 4.96; N, 1.78 %. 
HRMS (EI) calculated for C50H37NO5P2 793.21415, found 793.21271. 
31P{1H} NMR (101 MHz, C6D6): (ppm) = 141.5 (s), 143.9 (s). 
1H NMR (250 MHz, C6D6): (ppm) = 1.22 (d, 3H, CHCH3, 3JH-H = 6.8 Hz), 2.21 (d, 3H, NCH3, 
3JH-P = 6.1 Hz), 3.86-4.02 (m, 1H, CHCH3), 5.48 (dd, 1H, CHPh, 3JH-P = 9.9 Hz, 3JH-H = 6.6 Hz), 
6.85-7.66 (m, 29H, CH-Ar). 
13C NMR (63 MHz, C6D6):  (ppm) = 14.8 (d, CHCH3, JC-P = 5.8 Hz), 28.5 (d, NCH3, JC-P = 7.9 Hz), 
58.3 (dd, CHCH3, JC-P = 35.3 Hz, JC-P = 5.0 Hz), 81.7 (dd, CHPh, JC-P = 17.5 Hz, JC-P = 4.9 Hz), 122.2 
(d, CHAr, JC-P = 1.3 Hz), 122.4 (d, CHAr, JC-P = 1.1 Hz), 122.7 (2CHAr), 122.9 (d, CAr, JC-P = 2.3 Hz), 
123.6 (d, CAr, JC-P = 2.6 Hz), 124.5 (d, CAr, JC-P = 5.0 Hz), 124.8 (CHAr), 125.0 (d, CAr), 125.0 (CHAr), 
125.2 (CHAr), 125.3 (CHAr), 126.5 (CHAr), 126.5 (CHAr), 126.6 (CHAr), 126.7 (CHAr), 127.4 (3CHAr), 
127.5 (CHAr), 128.0 (2CHAr), 128.5 (3CHAr), 128.7 (4CHAr), 129.8 (CHAr), 130.0 (CHAr), 130.8 
(CHAr), 130.8 (CHAr), 131.1 (CAr), 131.6 (CAr), 131.9 (CAr), 132.1 (CAr), 133.2 (d, CAr), 133.2 (d, CAr), 
133.4 (d, CAr, JC-P = 1.4 Hz), 133.5 (d, CAr, JC-P = 1.6 Hz), 140.1 (d, CAr, JC-P = 0.9 Hz), 148.1 (d, 
CAr-O, JC-P = 2.1 Hz), 148.7 (d, CAr-O, JC-P = 4.9 Hz), 150.2 (d, CAr-O, JC-P = 0.8 Hz), 150.8 (d, CAr-O, 
JC-P = 6.4 Hz). 
 
(11bR)-N-{(2R)-1-[(11bR)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yloxy]butan-2-
yl}dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine (22c) 
Starting from (R)-BINOL (601 mg, 2.1 mmol),      
(R)-(–)-2-amino-1-butanol (89 mg, 1.0 mmol) and Et3N 
(506 mg, 5.0 mmol) in toluene (20 mL), the product 22c 
was isolated as a white solid (200 mg, 28 %, Rf 0.92). 
[α]D
24 = -492.5 (c 0.45, CHCl3). 
HRMS (EI) calculated for C44H33NO5P2 717.18285, 
found 717.18320. 
31P{1H} (121 MHz, C6D6):  (ppm) = 138.8 (s), 151.4 (s). 
1H NMR (300 MHz, C6D6):  (ppm) = 0.70 (t, 3H, CH3, 3JH-H = 7.4 Hz), 1.06-1.26 (m, 2H, CH2), 
2.92-3.04 (m, 1H, CHCH2), 3.40 (ddd, 1H, HA-CH2, 2JA-B = 10.0 Hz, J = 5.3 Hz, J = 4.3 Hz), 3.79 
(ddd, 1H, HB-CH2, 2JA-B = 10.1 Hz, J = 7.2 Hz, J = 4.3 Hz), 6.89-7.65 (m, 24H, CH-Ar). 
13C NMR (63 MHz, C6D6): (ppm) = 10.4 (CH3), 27.0 (d, CHCH2, JC-P = 3.8 Hz), 53.1 (dd, CHCH2, 
JC-P = 19.7 Hz, JC-P = 4.7 Hz), 68.8 (dd, CH2, JC-P = 3.7 Hz, JC-P = 1.5 Hz), 122.1 (CHAr), 122.2 (d, 
CHAr, JC-P = 1.7 Hz), 122.3 (d, CHAr, JC-P = 1.7 Hz), 122.8 (CHAr), 123.4 (d, CAr, JC-P = 2.5 Hz), 124.2 
(d, CAr, JC-P = 2.4 Hz), 124.6 (d, CAr, JC-P = 5.3 Hz), 124.7 (d, CAr, JC-P = 4.9 Hz), 125.0 (CHAr), 125.0 
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(CHAr), 125.2 (CHAr), 125.3 (CHAr), 126.5 (CHAr), 126.6 (CHAr), 126.7 (CHAr), 126.8 (CHAr), 127.4 
(4CHAr), 128.6 (CHAr), 128.7 (CHAr), 128.7 (CHAr), 128.8 (CHAr), 129.8 (CHAr), 130.5 (CHAr), 130.8 
(CHAr), 131.0 (CHAr), 131.4 (CAr), 131.5 (CAr), 132.0 (d, CAr, JC-P = 0.8 Hz), 132.1 (CAr), 133.3 (d, CAr, 
JC-P = 1.4 Hz), 133.4 (d, 3CAr, JC-P = 1.1 Hz), 148.2 (d, CAr-O, JC-P = 2.1 Hz), 148.6 (d, CAr-O, 
JC-P = 5.2 Hz), 149.6 (d, CAr-O, JC-P = 5.1 Hz), 150.3 (d, CAr-O, JC-P = 1.5 Hz). 
 
(11bR)-N-{2-[(11bR)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yloxy]ethyl}-N-
methyldinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine (22d) 
Starting from (R)-BINOL (601 mg, 2.1 mmol), 
2-(methylamino)ethanol (75 mg, 1.0 mmol) and Et3N 
(506 mg, 5.0 mmol) in toluene (20 mL), the product 22d 
was isolated as a white solid (250 mg, 36 %, Rf 0.84). 
[α]D
24 = -506.7 (c 0.72, CHCl3). 
Anal. calcd for C43H31NO5P2: C, 73.40; H, 4.44; N, 1.99. Found: C, 73.35; H, 3.51; N, 2.21 %. 
HRMS (EI) calculated for C43H31NO5P2 703.16720, found 703.16781. 
31P{1H} (121 MHz, C6D6):  (ppm) = 138.5 (s), 149.4 (s). 
1H NMR (300 MHz, C6D6):  (ppm) = 2.16 (d, 3H, CH3, 3JH-P = 5.4 Hz), 2.60-2.74 (m, 1H, CH2), 
3.06-3.18 (m, 1H, CH2), 3.44-3.53 (m, 1H, CH2), 3.71-3.81 (m, 1H, CH2), 6.90-7.69 (m, 24H, CH-Ar). 
13C NMR (63 MHz, C6D6): (ppm) = 32.6 (d, CH3, JC-P = 4.6 Hz), 50.2 (dd, NCH2), 62.8 (brs, OCH2), 
122.2 (CHAr), 122.2 (d, CHAr, JC-P = 1.5 Hz), 122.4 (d, CHAr, JC-P = 1.4 Hz), 122.7 (CHAr), 123.3 (d, 
CAr, JC-P = 2.6 Hz), 123.4 (d, CAr, JC-P = 2.2 Hz), 124.6 (d, CAr), 124.7 (d, CAr), 124.9 (CHAr), 125.0 
(CHAr), 125.3 (CHAr), 125.3 (CHAr), 126.5 (CHAr), 126.6 (CHAr), 126.8 (2CHAr), 127.4 (4CHAr), 128.6 
(CHAr), 128.7 (CHAr), 128.8 (CHAr), 128.8 (CHAr), 130.4 (CHAr), 130.5 (CHAr), 130.8 (CHAr), 131.0 
(CHAr), 131.3 (CAr), 131.5 (CAr), 132.0 (CAr), 132.1 (CAr), 133.3 (d, CAr), 133.3 (CAr), 133.5 (CAr), 
133.5 (CAr), 148.3 (d, CAr-O, JC-P = 2.3 Hz), 149.7 (d, CAr-O, JC-P = 5.3 Hz), 150.2 (d, CAr-O, 
JC-P = 0.8 Hz), 150.8 (d, CAr-O, JC-P = 5.7 Hz). 
 
(11bR)-N-{(1R,2R)-1-[(11bR)-Dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-yloxy]-1-
phenylpropan-2-yl}-N-methyldinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine (22e) 
Starting from (R)-BINOL (601 mg, 2.1 mmol), (1R,2R)- 
(–)-pseudoephedrine (165 mg, 1.0 mmol) and Et3N 
(506 mg, 5.0 mmol) in toluene (20 mL), the product 22e 
was isolated as a white solid (640 mg, 81 %, Rf 0.90). 
[α]D
25 = -89.7 (c 0.63, CHCl3). 
HRMS (EI) calculated for C50H37NO5P2 793.21415, 
found 793.21475. 
31P{1H} (121 MHz, C6D6):  (ppm) = 138.4 (s), 145.0 (s). 
1H NMR (250 MHz, C6D6):  (ppm) = 0.52 (d, 3H, CHCH3, 3JH-H = 6.1 Hz), 1.50 (d, 3H, NCH3, 
3JH-P = 14.4 Hz), 2.75-2.87 (m, 1H, CHCH3), 4.50 (dd, 1H, CHPh, 3JH-P = 9.5 Hz, 3JH-H = 3.1 Hz), 
6.71-7.95 (m, 29H, CH-Ar). 
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13C NMR (63 MHz, C6D6): (ppm) = 14.4 (d, CHCH3, JC-P = 7.0 Hz), 27.9 (d, NCH3, JC-P = 12.9 Hz), 
61.5 (d, CHCH3, JC-P = 6.0 Hz), 92.6 (d, CHPh, JC-P = 10.1 Hz), 121.0 (d, CHAr, JC-P = 14.1 Hz), 121.9 
(d, CHAr, JC-P = 6.7 Hz), 122.0 (d, CAr, JC-P = 1.8 Hz), 122.5 (CHAr), 123.3 (d, CAr, JC-P = 2.2 Hz), 124.8 
(CHAr), 124.8 (d, CAr), 125.0 (CHAr), 125.0 (d, CAr, JC-P = 5.2 Hz), 125.2 (CHAr), 125.4 (CHAr), 126.1 
(CHAr), 126.3 (d, CHAr, JC-P = 1.6 Hz), 126.6 (CHAr), 126.9 (CHAr), 127.3 (2CHAr), 127.3 (CHAr), 
127.5 (CHAr), 128.2 (CHAr), 128.2 (CHAr), 128.2 (2CHAr), 128.5 (CHAr), 128.6 (4CHAr), 128.7 (CHAr), 
129.8 (CHAr), 130.0 (CHAr), 130.6 (CHAr), 130.7 (CHAr), 131.0 (CAr), 131.5 (CAr), 131.7 (CAr), 132.0 
(CAr), 133.0 (d, CAr, JC-P = 1.4 Hz), 133.4 (d, CAr, JC-P = 1.4 Hz), 134.8 (CAr) 135.0 (CAr), 139.6 (CAr), 
147.7 (d, CAr-O, JC-P = 2.3 Hz), 148.4 (d, CAr-O, JC-P = 4.9 Hz), 148.8 (d, CAr-O, JC-P = 7.2 Hz), 151.4 
(d, CAr-O, JC-P = 5.7 Hz). 
 
 
Procedure for the synthesis of (–)-1,2:3,5-di-O-isopropylidene--D-xylofuranose (23a)[149] 
D-(+)-Xylose (1.5 g, 10.0 mmol) is dissolved in acetone (90 mL) and iodine is added (450 mg, 
1.8 mmol). The reaction mixture is stirred at room temperature for 16 h. After this time, saturated 
Na2S2O3-solution is added until the mixture becomes colorless to yellowish. The organic solvent is 
removed in vacuo and the residue is extracted with dichloromethane (3×20 mL) and dried over 
Na2SO4. Concentration in vacuo yields 2.21 g of 23a (96 %) as a yellowish solid. 
1H NMR (300 MHz, CDCl3): (ppm) = 1.32 (s, 3H, C(CH3)2), 1.37 (s, 3H, 
C(CH3)2), 1.43 (s, 3H, C(CH3)2), 1.49 (s, 3H, C(CH3)2), 4.00-4.11 (m, 3H, H-4 
and 2H-5), 4.31 (d, 1H, H-3, J = 2.5 Hz), 4.52 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 6.02 
(d, 1H, H-1, 3J1-2 = 3.8 Hz). 
13C NMR (75 MHz, CDCl3):  (ppm) = 18.7 (C(CH3)2), 26.2 (C(CH3)2), 26.8 (C(CH3)2), 28.7 
(C(CH3)2), 60.0 (C-5), 71.6 (C-3), 73.2 (C-4), 84.4 (C-2), 97.5 (C(CH3)2), 105.1 (C-1), 111.6 
(C(CH3)2). 
 
 
Procedure for the synthesis of 1,2-O-(methylethylidene)--D-xylofuranose (23b)[149] 
Protected -D-xylose 23a (2.0 g, 8.7 mmol) is dissolved in methanol (12 mL) and aqueous 
H2SO4-solution is added (0.8 %, 12 mL). The reaction mixture is stirred at room temperature for 16 h. 
After this time, solid BaCO3 is added to neutralize the mixture. The solution is filtrated over Celite and 
then washed with methanol and ethyl acetate. Concentration in vacuo yields 1.52 g of 23b (92 %) as a 
yellowish, viscous oil. 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.32 (s, 3H, C(CH3)2), 1.49 (s, 3H, 
C(CH3)2), 3.97-4.11 (m, 2H, 2H-5), 4.17-4.21 (m, 1H, H-4), 4.31 (s, 1H, H-3), 
4.52 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 6.00 (d, 1H, H-1, 3J1-2 = 3.7 Hz). 
13C NMR (75 MHz, CDCl3):  (ppm) = 26.2 (C(CH3)2), 26.7 (C(CH3)2), 60.6 
(C-5), 76.7 (C-3), 79.0 (C-4), 85.4 (C-2), 104.9 (C-1), 111.6 (C(CH3)2). 
 
 
Procedure for the synthesis of 1,2-di-O-isopropylidene-5-O-tosyl--D-xylofuranose (23c)[149] 
Diprotected -D-xylose 23b (1.50 g, 7.9 mmol) is dissolved in pyridine (3.73 g, 47.2 mmol) and 
cooled to 0 °C. To this solution is added dropwise tosyl chloride (1.53 g, 8.0 mmol) in 
dichloromethane (6 mL) via dropping funnel. After complete addition, the reaction mixture is warmed 
to room temperature and stirred for further 16 h. After this time, water is added and the layer is 
 
 
Chapter 5: Appendix 
- 107 - 
extracted with dichloromethane (3×3 mL). The combined organic phases are washed with aqueous 
HCl (0.1 M, 3 mL) and dried with over Na2SO4. Evaporation under reduced pressure yields a residue, 
which consists of mono- and ditosylated product. The crude is dissolved in a small amount of 
dichloromethane, petroleum ether is added and the solution is kept at -20 °C for 2 h. The precipitated 
product 23c could be separated by filtration to yield a white solid (1.63 g, 60 %). 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.31 (s, 3H, C(CH3)2), 1.46 (s, 3H, 
C(CH3)2), 2.47 (s, 3H, CH3), 4.10-4.19 (m, 1H, H-3), 4.27-4.35 (m, 3H, H-4 and 
2H-5), 4.52 (d, 1H, H-2, 3J1-2 = 3.5 Hz), 5.87 (d, 1H, H-1, 3J1-2 = 3.5 Hz), 
7.33-7.82 (m, 4H, CH-Ar). 
13C NMR (75 MHz, CDCl3):  (ppm) = 21.5 (CH3), 26.2 (C(CH3)2), 26.7 
(C(CH3)2), 66.6 (C-5), 74.4 (C-3), 77.5 (C-4), 84.9 (C-2), 104.9 (C-1), 111.8 (C(CH3)2), 128.0 
(2CHAr), 130.0 (2CHAr), 132.1 (CAr), 145.2 (CAr). 
 
 
Procedure for the synthesis of 5-deoxy-5-N-isopropylamino-1,2-O-isopropylidene--D-
xylofuranose (24b)[150] 
1,2-Di-O-isopropylidene-5-O-tosyl--D-xylofuranose 23c (3.45 g, 10.0 mmol) and isopropylamine 
(20 mL) are stirred in a pressure tube at 60 °C for 24 h. The reaction mixture is cooled to room 
temperature and concentrated in vacuo. The residue is taken up in dichloromethane (50 mL), washed 
with saturated NaHCO3-solution, water and finally with brine (each 20 mL). The organic phase is 
dried over Na2SO4, concentrated in vacuo to give 24b as a yellowish solid (1,42 g, 61 %) after column 
chromatography (EtOAc/Et3N = 97:3). 
1H NMR (250 MHz, CDCl3):  (ppm) = 1.07 (d, 6H, CH(CH3)2, 
3JH-H = 6.3 Hz), 1.32 (s, 3H, C(CH3)2), 1.48 (s, 3H, C(CH3)2), 2.77 (m, 1H, 
CH(CH3)2), 2.97 (dd, 1H, HA-5, 2J5A-5B = 12.8 Hz, 3J4-5A = 1.2 Hz), 3.38 (dd, 
1H, HB-5, 2J5A-5B = 12.8 Hz, 3J4-5B = 3.5 Hz), 4.20-4.23 (m, 1H, H-4), 4.28 (d, 
1H, H-3, J = 2.9 Hz), 4.48 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 5.95 (d, 1H, H-1, 
3J1-2 = 3.7 Hz). 
13C NMR (63 MHz, CDCl3):  (ppm) = 22.3 (CH(CH3)2), 22.6 (CH(CH3)2), 26.1 (C(CH3)2), 26.8 
(C(CH3)2), 46.8 (C-5), 48.6 (CH(CH3)2), 76.9 (C-3), 78.2 (C-4), 86.1 (C-2), 105.1 (C-1), 111.3 
(C(CH3)2). 
 
 
General procedure for the synthesis of 5-N-alkylamino-5-deoxy-1,2-O-isopropylidene--D-
xylofuranose 24c-g 
1.0 Eq of 1,2-di-O-isopropylidene-5-O-tosyl--D-xylofuranose 23c and the corresponding amine 
(4.0 eq) are dissolved in isopropanol (2 mL/1.0 mmol substrate). The mixture is heated to reflux and 
stirred for 24 h. After cooling to room temperature, it is concentratetd in vacuo. The residue is treated 
with saturated NaHCO3-solution and extracted with diethyl ether (three times). The combined organic 
phases are dried with Na2SO4 and concentrated in vacuo to give 24c-g after column chromatography 
(EtOAc/Et3N = 9:1). 
 
 
 
 
 
Chapter 5: Appendix 
- 108 - 
5-N-tert-Butylamino-5-deoxy-1,2-O-isopropylidene--D-xylofuranose (24c)[150] 
Starting from tert-butylamine (4.39 g, 60.0 mmol) and 1,2-di-O-
isopropylidene-5-O-tosyl--D-xylofuranose 23c (5.17 g, 15.0 mmol) in 
isopropanol (30 mL), the product 24c was isolated as an off-white solid 
(1.52 g, 41 %). 
1H NMR (250 MHz, CDCl3):  (ppm) = 1.10 (s, 9H, C(CH3)3), 1.31 (s, 3H, 
C(CH3)2), 1.47 (s, 3H, C(CH3)2), 2.95 (dd, 1H, HA-5, 2J5A-5B = 12.7 Hz, 
3J4-5A = 1.2 Hz), 3.35 (dd, 1H, HB-5, 2J5A-5B = 12.7 Hz, 3J4-5B = 3.5 Hz), 4.21-4.24 (m, 1H, H-4), 4.27 
(d, 1H, H-3, J = 2.9 Hz), 4.46 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 5.94 (d, 1H, H-1, 3J1-2 = 3.7 Hz). 
13C NMR (63 MHz, CDCl3):  (ppm) = 26.2 (C(CH3)2), 26.9 (C(CH3)2), 28.4 (C(CH3)3), 41.4 (C-5), 
50.2 (C(CH3)3), 76.9 (C-3), 78.3 (C-4), 86.1 (C-2), 105.1 (C-1), 111.4 (C(CH3)2). 
 
5-Deoxy-5-N-cyclohexylamino-1,2-O-isopropylidene--D-xylofuranose (24d)[150] 
Starting from cyclohexylamine (4.00 g, 40.0 mmol) and 1,2-di-O-
isopropylidene-5-O-tosyl--D-xylofuranose 23c (3.45 g, 10.0 mmol) in 
isopropanol (20 mL), the product 24d was isolated as an off-white solid 
(1.70 g, 63 %). 
1H NMR (250 MHz, CDCl3):  (ppm) = 0.98-1.29 (m, 5H, CH2), 1.31 (s, 
3H, C(CH3)2), 1.47 (s, 3H, C(CH3)2), 1.55-1.61 (m, 1H, CH2), 1.68-1.74 (m, 2H, CH2), 1.82-1.92 (m, 
2H, CH2), 2.35-2.46 (m, 1H, CH(CH2)2, 3.00 (dd, 1H, HA-5, 2J5A-5B = 12.9 Hz, 3J4-5A = 1.3 Hz), 3.46 
(dd, 1H, HB-5, 2J5A-5B = 12.9 Hz, 3J4-5B = 3.5 Hz), 4.19-4.22 (m, 1H, H-4), 4.27 (d, 1H, H-3, 
J = 2.9 Hz), 4.48 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 5.95 (d, 1H, H-1, 3J1-2 = 3.7 Hz). 
13C NMR (63 MHz, CDCl3):  (ppm) = 24.7, 24.7, 25.9 (CH2), 26.2 (C(CH3)2), 26.8 (C(CH3)2), 32.8, 
33.1 (CH2), 45.5 (C-5), 56.3 (CH(CH2)2), 77.0 (C-3), 78.3 (C-4), 86.1 (C-2), 105.1 (C-1), 111.4 
(C(CH3)2). 
 
5-Deoxy-5-N-phenylamino-1,2-O-isopropylidene--D-xylofuranose (24e)[112c] 
Starting from aniline (3.73 g, 40.0 mmol) and 1,2-di-O-isopropylidene-5-
O-tosyl--D-xylofuranose 23c (3.45 g, 10.0 mmol) in isopropanol 
(20 mL), the product 24e was isolated as an off-white solid (2.27 g, 86 %).  
1H NMR (250 MHz, CDCl3):  (ppm) = 1.34 (s, 3H, C(CH3)2), 1.50 (s, 
3H, C(CH3)2), 3.61 (d, 2H, 2H-5, 3J4-5 = 4.0 Hz), 3.90 (s, 1H, NH), 4.32 
(d, 1H, H-3, J = 2.8 Hz), 4.38-4.43 (m, 1H, H-4), 4.55 (d, 1H, H-2, 
3J1-2 = 3.7 Hz), 6.02 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 6.79-6.90 (m, 3H, CH-Ar), 7.20-7.26 (m, 2H, 
CH-Ar). 
13C NMR (63 MHz, CDCl3):  (ppm) = 26.1 (C(CH3)), 26.8 (C(CH3)2), 44.0 (C-5), 77.1 (C-3), 77.3 
(C-4), 85.6 (C-2), 104.9 (C-1), 111.8 (C(CH3)2), 115.4 (CHAr), 120.2 (CHAr), 129.3 (CHAr), 146.7 
(CAr). 
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5-Deoxy-5-N-benzylamino-1,2-O-isopropylidene--D-xylofuranose 24f[150] 
Starting from benzylamine (4.29 g, 40.0 mmol) and 1,2-di-O-
isopropylidene-5-O-tosyl--D-xylofuranose 23c (3.45 g, 10.0 mmol) in 
isopropanol (20 mL), the product 24f was isolated as an off-white solid 
(1.70 g, 61 %). 
1H NMR (250 MHz, CDCl3):  (ppm) = 1.32 (s, 3H, C(CH3)2), 1.47 (s, 
3H, C(CH3)2), 3.00 (dd, 1H, HA-5, 2J5A-5B = 13.0 Hz, 3J4-5A = 1.4 Hz), 3.40 (dd, 1H, HB-5, 
2J5A-5B = 12.9 Hz, 3J4-5B = 3.6 Hz), 3.78 (d, 2H, CH2, J = 3.2 Hz), 4.21-4.23 (m, 1H, H-4), 4.29 (d, 1H, 
H-3, J = 2.2 Hz), 4.50 (d, 1H, H-2, 3J1-2 = 3.6 Hz), 5.95 (d, 1H, H-1, 3J1-2 = 3.6 Hz) 7.26-7.37 (m, 5H, 
CH-Ar). 
13C NMR (75 MHz, CDCl3):  (ppm) = 26.3 (C(CH3)), 27.0 (C(CH3)2), 48.1 (C-5), 54.0 (CH2), 77.3 
(C-3), 78.5 (C-4), 86.3 (C-2), 105.5 (C-1), 111.9 (C(CH3)2), 128.0 (CHAr), 128.7 (CHAr), 129.1 (CHAr), 
139.0 (CAr). 
 
5-Deoxy-5-N-(S)--methybenzylamino-1,2-O-isopropylidene--D-xylofuranose (24g) 
Starting from (S)-(–)--methylbenzylamine (4.85 g, 40.0 mmol) and 1,2-
di-O-isopropylidene-5-O-tosyl--D-xylofuranose 23c (3.45 g, 10.0 mmol) 
in isopropanol (20 mL), the product 24g was isolated as a yellowish, 
viscous oil (2.90 g, 99 %). 
[α]D
26 = +5.0 (c 1.26, CHCl3). 
Anal. calcd for C16H23NO4: C, 65.51; H, 7.90; N, 4.77. Found: C, 65.20; H, 8.01; N, 4.95 %. 
HRMS (ESI) calculated for C16H24NO4 294.16998, found 294.16984. 
HRMS (ESI) calculated for C16H23NO4Na 316.15193, found 316.15178. 
1H NMR (250 MHz, CDCl3):  (ppm) = 1.32 (s, 3H, C(CH3)2), 1.39 (dd, 3H, CHCH3, 3JH-H = 6.7 Hz), 
1.46 (s, 3H, C(CH3)2), 2.90 (dd, 1H, HA-5, 2J5A-5B = 12.9 Hz, 3J4-5A = 1.4 Hz), 3.18 (dd, 1H, HB-5, 
2J5A-5B = 12.9 Hz, 3J4-5B = 3.8 Hz), 3.72 (q, 1H, CHCH3, 3JH-H = 6.7 Hz), 4.17-4.20 (m, 1H, H-4), 4.30 
(d, 1H, H-3, J = 2.9 Hz), 4.51 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 5.95 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 7.20-7.38 
(m, 29H, CH-Ar). 
13C NMR (63 MHz, CDCl3):  (ppm) = 23.2 (CH(CH3)), 26.1 (C(CH3)2), 26.8 (C(CH3)2), 46.3 (C-5), 
58.1 (CHCH3), 76.9 (C-3), 77.2 (C-4), 85.9 (C-2), 105.0 (C-1), 111.4 (C(CH3)2), 126.1 (CHAr), 127.4 
(CHAr), 128.7 (CHAr), 143.7 (CAr). 
 
 
General procedure for the synthesis of amino xylose-based diphosphites 25a-g and 26b,d-g 
2.2 Eq of enantiopure BINOL are suspended in phosphorus trichloride (1.5 mL/1.0 mmol BINOL), 2-3 
drops of N-methyl-2-pyrrolidone are added and the solution is heated to 75 °C for 5 min. The resulting 
HCl gas is derived from the reaction vessel by using a bubble counter (slight argon stream!). The now 
clear solution is cooled to room temperature, concentrated and dried azeotropically with toluene (three 
times). Thus, the in situ prepared chlorophosphite is dissolved in toluene (8 mL/2.2 mmol BINOL) and 
triethylamine is added (5 mmol/2.2 mmol BINOL). 1.0 Eq of azeotropically dried amino sugar 24b-g 
is dissolved in toluene (8 mL/1.0 mmol substrate) and triethylamine (5.0 eq) is added. This solution is 
added slowly to the chlorophosphite solution at 0 °C over 5 min and the mixture is kept at this 
temperature for 5 min. The reaction solution is then stirred at 50 °C for 16 h. After this time, the 
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mixture is cooled to room temperature and concentrated in vacuo. The residue is purified by column 
chromatography (basic silica, toluene) to give 25a-g and 26b,d-g, respectively. 
 
3,5-Bis-(S)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-methylamino-1,2-O-isopropylidene--
D-xylofuranose (25a) 
Starting from (S)-BINOL (630 mg, 2.2 mmol), 5-Deoxy-5-N-
methylamino-1,2-O-isopropylidene--D-xylofuranose (203 mg, 
1.0 mmol) and Et3N (1.01 g, 10.0 mmol) in toluene (16 mL), the 
product 25a was isolated as a white solid (703 mg, 85 %, Rf 0.23). 
[α]D
26 = +335.0 (c 0.53, CHCl3). 
Anal. calcd for C49H39NO8P2: C, 70.75; H, 4.73; N, 1.68. Found: C, 
69.89; H, 5.00; N, 1.55 %. 
HRMS (ESI) calculated for C49H40NO8P2 832.22237, found 
832.22174. 
HRMS (ESI) calculated for C49H39NO8P2Na 854.20431, found 
854.20402. 
31P{1H} NMR (101 MHz, C6D6):  (ppm) = 146.1 (d, JP-P = 4.0 Hz), 154.3 (d, JP-P = 4.0 Hz). 
1H NMR (250 MHz, C6D6): (ppm) = 0.97 (s, 3H, C(CH3)2), 1.36 (s, 3H, C(CH3)2), 2.48 (d, 3H, CH3, 
3JH-P = 5.5 Hz), 3.41 (ddd, 1H, HA-5, 2J5A-5B = 19.2 Hz, J = 14.7 Hz, J = 8.1 Hz), 3.82 (ddd, 1H, HB-5, 
J = 9.9 Hz, J = 3.5 Hz), 4.31 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 4.43-4.49 (m, 1H, H-4), 4.64 (dd, 1H, H-3, 
3J3-P = 9.3 Hz, J = 2.6 Hz), 5.76 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 6.83-7.74 (m, 24H, CH-Ar). 
13C NMR (75 MHz, C6D6):  (ppm) = 26.2 (C(CH3)2), 26.9 (C(CH3)2), 33.9 (d, CH3, JC-P = 3.9 Hz), 
49.5 (d, C-5, J5-P = 36.2 Hz), 78.4 (d, C-3, J3-P = 5.9 Hz), 80.8 (m, C-4), 84.7 (C-2), 105.5 (C-1), 111.8 
(C(CH3)2), 121.9 (CHAr), 122.1 (d, CHAr, JC-P = 1.1 Hz), 122.5 (d, CHAr, JC-P = 1.1 Hz), 122.7 (CHAr), 
123.2 (d, CAr, JC-P = 2.5 Hz), 123.5 (d, CAr, JC-P = 2.5 Hz), 124.7 (d, CAr, JC-P = 1.8 Hz), 124.8 (d, CAr, 
JC-P = 2.3 Hz), 124.9 (CHAr), 125.0 (CHAr), 125.3 (CHAr), 125.5 (CHAr), 126.5 (CHAr), 126.6 (CHAr), 
126.8 (2CHAr), 127.3 (CHAr), 127.3 (CHAr), 127.4 (CHAr), 127.5 (CHAr), 128.7 (CHAr), 128.7 (3CHAr), 
130.6 (CHAr), 130.7 (2CHAr), 131.0 (CHAr), 131.4 (CAr), 131.6 (CAr), 132.0 (CAr), 132.1 (CAr), 133.1 
(d, CAr, JC-P = 1.1 Hz), 133.3 (CAr), 133.4 (d, CAr, JC-P = 1.4 Hz), 133.5 (d, CAr, JC-P = 1.4 Hz), 147.7 (d, 
CAr-O, JC-P = 2.3 Hz),  148.8 (d, CAr-O, JC-P = 6.1 Hz), 150.2 (CAr-O) 150.8 (d, CAr-O, JC-P = 4.5 Hz). 
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3,5-Bis-(S)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-isopropylamino-1,2-O-isopropylidene-
-D-xylofuranose (25b) 
Starting from (S)-BINOL (630 mg, 2.2 mmol), 5-Deoxy-5-N-
isopropylamino-1,2-O-isopropylidene--D-xylofuranose 24b 
(231 mg, 1.0 mmol) and Et3N (1.01 g, 10.0 mmol) in toluene 
(16 mL), the product 25b was isolated as a white solid (653 mg, 
76 %, Rf 0.45). 
[α]D
25 = +427.9 (c 0.58, CHCl3). 
Anal. calcd for C51H43NO8P2: C, 71.24; H, 5.04; N, 1.63. Found: C, 
71.17; H, 5.36; N, 1.14 %. 
HRMS (ESI) calculated for C51H44NO8P2 860.25367, found 
860.25257. 
HRMS (ESI) calculated for C51H43NO8P2Na 882.23561, found 
882.23446. 
31P{1H} NMR (101 MHz, C6D6):  (ppm) = 153.3 (d, JP-P = 5.0 Hz), 154.1 (d, JP-P = 5.0 Hz). 
1H NMR (250 MHz, C6D6):  (ppm) = 0.80 (s, 3H, CH3), 1.30 (s, 3H, CH3), 1.32 (d, 3H, CH(CH3)2, 
3JH-H = 6.8 Hz), 1.33 (d, 3H, CH(CH3)2, 3JH-H = 6.8 Hz), 3.27 (ddd, 1H, HA-5, 2J5A-5B = 15.5 Hz, 
J = 9.4 Hz, J = 6.3 Hz), 3.70 (ddd, 1H, HB-5, 2J5A-5B = 15.5 Hz, J = 6.1 Hz, J = 3.5 Hz), 3.85 (m, 1H, 
CH(CH3)2), 4.08 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 4.49-4.57 (m, 2H, H-3 and H-4), 5.57 (d, 1H, H-1, 
3J1-2 = 3.7 Hz), 6.80-7.76 (m, 24H, CH-Ar). 
13C NMR (63 MHz, C6D6):  = 23.0 (d, CH(CH3)2, JC-P = 9.6 Hz), 23.6 (d, CH(CH3)2, JC-P = 7.0 Hz), 
26.1 (C(CH3)2), 26.8 (C(CH3)2), 43.1 (d, C-5, J5-P = 8.1 Hz), 49.3 (d, CH(CH3)2, JC-P = 25.9 Hz), 78.3 
(d, C-3, J3-P = 10.8 Hz), 82.4 (m, C-4), 84.5 (d, C-2, J2-P = 1.5 Hz), 105.2 (C-1), 111.6 (C(CH3)2), 
122.2 (d, CHAr, JC-P = 1.3 Hz), 122.3 (2CHAr), 122.5 (d, CHAr, JC-P = 1.4 Hz), 123.0 (d, CAr, 
JC-P = 2.2 Hz), 123.4 (d, CAr, JC-P = 2.5 Hz), 124.7 (d, CAr, JC-P = 5.2 Hz), 124.8 (CHAr), 124.9 (d, CAr, 
JC-P = 5.2 Hz), 125.0 (CHAr), 125.2 (CHAr), 125.4 (CHAr), 126.5 (2CHAr), 126.7 (CHAr), 126.7 (CHAr), 
127.3 (CHAr), 127.4 (2CHAr), 128.5 (CHAr), 128.6 (CHAr), 128.7 (CHAr), 128.7 (CHAr), 128.8 (CHAr), 
130.0 (CHAr), 130.7 (CHAr), 130.8 (2CHAr), 131.4 (CAr), 131.6 (CAr), 132.0 (CAr), 132.0 (CAr), 133.1 
(d, CAr, JC-P = 1.3 Hz), 133.4 (2CAr), 133.5 (d, CAr, JC-P = 1.5 Hz), 147.8 (d, CAr-O, JC-P = 3.1 Hz), 
148.5 (d, CAr-O, JC-P = 5.3 Hz), 150.3 (CAr-O), 150.8 (d, CAr-O, JC-P = 4.8 Hz). 
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3,5-Bis-(S)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-tert-butylamino-1,2-O-isopropylidene-
-D-xylofuranose (25c) 
Starting from (S)-BINOL (630 mg, 2.2 mmol), 5-N-tert-butylamino-
5-Deoxy-1,2-O-isopropylidene--D-xylofuranose 24c (245 mg, 
1.0 mmol) and Et3N (1.01 g, 10.0 mmol) in toluene (16 mL), the 
product 25c was isolated as a white solid (250 mg, 29 %, Rf 0.41). 
HRMS (ESI) calculated for C52H46NO8P2 874.26932, found 
874.26741. 
HRMS (ESI) calculated for C52H45NO8P2Na 896.25126, found 
896.24942. 
31P{1H} NMR (101 MHz, C6D6): (ppm) = 140.8 (s), 143.6 (s). 
1H NMR (250 MHz, C6D6):  (ppm) = 0.70 (s, 3H, C(CH3)2), 1.31 (s, 
3H, C(CH3)2), 1.62 (d, 9H, C(CH3)3, 3JH-P = 2.5 Hz), 3.26 (ddd, 1H, 
HA-5, 2J5A-5B = 16.1 Hz), 3.78 (ddd, 1H, HB-5, 2J5A-5B = 16.0 Hz), 3.88 
(d, 1H, H-2, 3J1-2 = 3.7 Hz), 4.54-4.57 (m, 2H, H-3 and H-4), 5.43 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 
6.69-7.75 (m, 24H, CH-Ar). 
13C NMR (63 MHz, C6D6): (ppm) = 25.9 (C(CH3)2), 26.9 (C(CH3)2), 31.6 (d, C(CH3)3, 
JC-P = 15.8 Hz), 42.7 (d, C-5, J5-P = 5.8 Hz), 56.2 (d, C(CH3)3, JC-P = 22.0 Hz), 78.6 (d, C-3, 
J3-P = 12.5 Hz), 84.2 (C-4), 84.3 (C-2), 104.9 (C-1), 111.4 (C(CH3)2), 122.0 (CHAr), 122.2 (CHAr), 
122.4 (CHAr), 122.5 (d, CHAr, JC-P = 1.7 Hz), 122.6 (d, CAr, JC-P = 1.9 Hz), 123.4 (d, CAr, JC-P = 2.7 Hz), 
124.6 (d, CAr, JC-P = 5.4 Hz), 124.7 (CHAr), 125.1 (2CHAr), 125.3 (CHAr), 125.3 (d, CAr), 126.4 (CHAr), 
126.5 (CHAr), 126.6 (CHAr), 126.6 (CHAr), 127.2 (CHAr), 127.4 (CHAr), 127.5 (d, CHAr, JC-P = 2.5 Hz), 
127.8 (CHAr), 128.6 (2CHAr), 128.7 (CHAr), 128.8 (CHAr), 129.7 (CHAr), 130.4 (CHAr) 130.7 (CHAr), 
131.0 (CHAr), 131.5 (CAr), 131.6 (CAr), 132.0 (CAr), 132.0 (d, CAr, JC-P = 0.8 Hz), 133.1 (d, CAr, 
JC-P = 1.5 Hz), 133.4 (d, CAr, JC-P = 1.4 Hz), 133.5 (d, CAr, JC-P = 1.5 Hz), 133.6 (CAr), 147.9 (d, CAr-O, 
JC-P = 3.1 Hz), 148.4 (d, CAr-O, JC-P = 5.8 Hz), 150.5 (CAr-O), 151.3 (d, CAr-O, JC-P = 5.1 Hz). 
 
3,5-Bis-(S)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-cyclohexylamino-1,2-O-
isopropylidene--D-xylofuranose (25d) 
Starting from (S)-BINOL (630 mg, 2.2 mmol), 5-Deoxy-5-N-
cyclohexylamino-1,2-O-isopropylidene--D-xylofuranose 24d 
(272 mg, 1.0 mmol) and Et3N (1.01 g, 10.0 mmol) in toluene 
(16 mL), the product 25d was isolated as a white solid (875 mg, 
97 %, Rf 0.50). 
[α]D
26 = +402.0 (c 0.75, CHCl3). 
Anal. calcd for C54H47NO8P2: C, 72.07; H, 5.26; N, 1.56. Found: C, 
72.10; H, 5.27; N, 1.39 %. 
HRMS (ESI) calculated for C54H48NO8P2 900.28497, found 
900.28466. 
HRMS (ESI) calculated for C54H47NO8P2Na 922.26691, found 
922.2662. 
31P{1H} NMR (101 MHz, C6D6):  (ppm) = 153.6 (d, JP-P = 3.9 Hz), 155.0 (d, JP-P = 3.9 Hz). 
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1H NMR (250 MHz, C6D6):  (ppm) = 0.79 (s, 3H, CH3), 0.88-1.14 (m, 4H, 2CH2), 1.32 (s, 3H, CH3), 
1.55-1.72 (m, 2H, CH2), 1.77-1.93 (m, 2H, CH2), 2.11-2.24 (m, 2H, CH2), 3.24-3.47 (m, 2H, HA-5 and 
CH(CH2)2), 3.73 (ddd, 1H, HB-5, 2J5A-5B = 15.4 Hz, J = 6.0 Hz, J = 3.5 Hz), 4.07 (d, 1H, H-2, 
3J1-2 = 3.7 Hz), 4.52-4.58 (m, 2H, H-3 and H-4), 5.58 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 6.82-7.79 (m, 24H, 
CH-Ar). 
13C NMR (75 MHz, C6D6):  (ppm) = 25.8 (CH2), 26.1 (C(CH3)2), 26.7 (2CH2), 26.9 (C(CH3)2), 34.2 
(d, CH2, JC-P = 9.9 Hz), 35.2 (d, CH2, JC-P = 7.8 Hz), 44.1 (d, C-5, J5-P = 6.1 Hz), 58.6 (d, CH(CH2)2, 
JC-P = 23.0 Hz), 78.3 (d, C-3, J3-P = 10.9 Hz), 82.6 (m, C-4), 84.5 (d, C-2, J2-P = 1.0 Hz), 105.2 (C-1), 
111.6 (C(CH3)2), 122.2 (CHAr), 122.3 (CHAr), 122.3 (CHAr), 122.5 (CHAr), 123.1 (d, CAr, 
JC-P = 2.0 Hz), 123.4 (d, CAr, JC-P = 2.6 Hz), 124.7 (d, CAr, JC-P = 5.3 Hz), 124.8 (CHAr), 125.0 (d, CAr, 
JC-P = 5.3 Hz), 125.0 (CHAr), 125.2 (CHAr), 125.3 (CHAr), 126.5 (2CHAr), 126.7 (CHAr), 126.7 (CHAr), 
127.3 (CHAr), 127.4 (2CHAr), 127.6 (CHAr), 128.6 (CHAr), 128.7 (2CHAr), 128.8 (CHAr), 130.0 (CHAr), 
130.7 (CHAr), 130.8 (2CHAr), 131.4 (CAr), 131.6 (CAr), 132.0 (CAr), 132.0 (CAr), 133.1 (d, CAr, 
JC-P = 1.1 Hz), 133.4 (2CAr), 133.5 (d, CAr, JC-P = 1.4 Hz), 147.8 (d, CAr-O, JC-P = 2.9 Hz), 148.6 (d, 
CAr-O, JC-P = 5.6 Hz), 150.5 (CAr-O), 150.9 (d, CAr-O, JC-P = 4.9 Hz). 
 
3,5-Bis-(S)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-phenylamino-1,2-O-isopropylidene--
D-xylofuranose (25e) 
Starting from (S)-BINOL (630 mg, 2.2 mmol), 5-Deoxy-5-N-
phenylamino-1,2-O-isopropylidene--D-xylofuranose 24e (265 mg, 
1.0 mmol) and Et3N (1.01 g, 10.0 mmol) in toluene (16 mL), the 
product 25e was isolated as a white solid (291 mg, 33 %, Rf 0.27). 
[α]D
25 = +150.9 (c 0.53, CHCl3). 
Anal. calcd for C54H41NO8P2: C, 72.56; H, 4.62; N, 1.57. Found: C, 
72.23; H, 4.44; N, 1.47 %. 
HRMS (EI) calculated for C54H41NO8P2 893.23019, found 893.22940. 
31P{1H} NMR (101 MHz, C6D6):  (ppm) = 146.3 (s), 150.8 (s). 
1H NMR (250 MHz, C6D6):  (ppm) = 0.78 (s, 3H, C(CH3)2), 1.13 (s, 
3H, C(CH3)2), 3.80 (ddd, 1H, HA-5, 2J5A-5B = 14.6 Hz, J = 5.7 Hz, 
J = 3.2 Hz), 4.06-4.15 (m, 1H, HB-5), 4.14 (d, 1H, H-2, 3J1-2 = 3.6 Hz), 4.43-4.46 (m, 1H, H-4), 4.58 
(dd, 1H, H-3, 3J3-P = 8.5 Hz, J = 2.5 Hz), 5.46 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 6.82-7.73 (m, 29H, CH-Ar). 
13C NMR (63 MHz, C6D6):  (ppm) = 26.1 (C(CH3)2), 26.7 (C(CH3)2), 46.7 (C-5), 77.6 (m, C-4), 79.2 
(d, C-3, J3-P = 6.5 Hz), 84.5 (C-2), 104.8 (C-1), 111.6 (C(CH3)2), 122.1 (CHAr), 122.2 (CHAr), 122.3 
(CHAr), 122.5 (CHAr), 122.5 (d, CAr), 123.1 (d, CAr, JC-P = 2.3 Hz), 124.8 (d, CAr, JC-P = 5.4Hz), 124.9 
(d, CAr) 125.0 (CHAr), 125.2 (3CHAr), 125.3 (CHAr), 126.0 (CHAr), 126.2 (CHAr), 126.6 (3CHAr), 126.7 
(CHAr), 127.2 (CHAr), 127.4 (CHAr), 127.6 (CHAr), 128.6 (CHAr) 128.7 (2CHAr), 128.8 (2CHAr), 129.6 
(2CHAr), 130.2 (CHAr), 130.7 (CHAr), 130.8 (CHAr), 131.0 (CHAr), 131.5 (2CAr), 132.1 (CAr), 132.1 
(CAr), 133.0 (d, CAr, JC-P = 1.3 Hz), 133.3 (d, CAr, JC-P = 0.9 Hz), 133.4 (d, CAr, JC-P = 2.0 Hz), 133.5 (d, 
CAr, JC-P = 2.0 Hz), 144.1 (d, CAr, JC-P = 20.0 Hz), 147.8 (d, CAr-O, JC-P = 2.7 Hz), 148.7 (d, CAr-O, 
JC-P = 5.9 Hz), 149.7 (CAr-O), 150.4 (d, CAr-O, JC-P = 5.5 Hz). 
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3,5-Bis-(S)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-benzylamino-1,2-O-isopropylidene--
D-xylofuranose (25f) 
Starting from (S)-BINOL (630 mg, 2.2 mmol), 5-Deoxy-5-N-
benzylamino-1,2-O-isopropylidene--D-xylofuranose 24f (279 mg, 
1.0 mmol) and Et3N (1.01 g, 10.0 mmol) in toluene (16 mL), the 
product 25f was isolated as a white solid (731 mg, 81 %, Rf 0.60). 
[α]D
27 = +319.2 (c 0.80, CHCl3). 
Anal. calcd for C55H43NO8P2: C, 72.76; H, 4.77; N, 1.54. Found: C, 
72.92; H, 4.80; N, 1.50 %. 
HRMS (ESI) calculated for C55H44NO8P2 908.25367, found 
908.25315. 
HRMS (ESI) calculated for C55H43NO8P2Na 930.23561, found 
930.23403. 
31P{1H} NMR (101 MHz, C6D6):  (ppm) = 152.2 (s), 152.3 (s). 
1H NMR (250 MHz, C6D6):  (ppm) = 0.93 (s, 3H, C(CH3)2), 1.40 (s, 3H, C(CH3)2), 3.39 (ddd, 1H, 
HA-5, 2J5A-5B = 19.3 Hz, J = 15.1 Hz, J = 8.3 Hz), 3.61 (ddd, 1H, HB-5, 2J5A-5B = 15.1 Hz), 4.23 (d, 1H, 
H-2, 3J1-2 = 3.8 Hz), 4.30 (dd, 1H, HA-NCH2, 2JA-B = 14.9 Hz, 3JA-P = 10.4 Hz), 4.45 (dd, 1H, H-3, 
3J3-P = 9.4 Hz, J = 2.6 Hz), 4.53-4.61 (dd, 1H, HB-NCH2, 2JA-B = 14.9 Hz, 3JB-P = 6.3 Hz), 4.64-4.69 
(m, 1H, H-4), 5.69 (d, 1H, H-1, 3J1-2 = 3.8 Hz), 6.83-7.74 (m, 29H, CH-Ar). 
13C NMR (63 MHz, C6D6): (ppm) = 26.1 (C(CH3)2), 26.9 (C(CH3)2), 45.0 (d, C-5, J5-P = 23.2 Hz), 
50.3 (d, CH2Ph, JC-P = 14.1 Hz), 78.9 (d, C-3, J3-P = 13.6 Hz), 82.9 (m, C-4), 84.4 (d, C-2, 
J2-P = 1.3 Hz), 105.7 (C-1), 111.8 (C(CH3)2), 122.1 (2CHAr), 122.5 (2CHAr), 123.2 (d, CAr, 
JC-P = 2.5 Hz), 123.3 (d, CAr, JC-P = 2.0 Hz), 124.8 (d, CAr, JC-P = 5.3 Hz), 124.9 (CHAr), 124.9 (d, CAr), 
125.1 (CHAr), 125.2 (CHAr), 125.4 (CHAr), 126.6 (2CHAr), 126.6 (CHAr), 126.8 (CHAr), 127.2 (CHAr), 
127.3 (CHAr), 127.4 (CHAr), 127.4 (CHAr), 127.6 (CHAr), 128.6 (3CHAr), 128.7 (CHAr), 128.7 (CHAr), 
128.8 (CHAr), 129.5 (2CHAr), 130.4 (CHAr), 130.8 (2CHAr), 131.2 (CHAr), 131.4 (CAr), 131.6 (CAr), 
132.0 (CAr), 132.1 (CAr), 133.1 (d, CAr, JC-P = 1.1 Hz), 133.2 (CAr), 133.4 (d, CAr, JC-P = 1.2 Hz), 133.5 
(d, CAr, JC-P = 1.3 Hz), 139.1 (d, CAr, JC-P = 1.3 Hz), 147.7 (d, CAr-O, JC-P = 2.7 Hz), 148.5 (d, CAr-O, 
JC-P = 6.0 Hz), 150.1 (CAr-O), 150.6 (d, CAr-O, JC-P = 4.4 Hz). 
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3,5-Bis-(S)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-(S)--methylbenzylamino-1,2-O-
isopropylidene--D-xylofuranose (25g) 
Starting from (S)-BINOL (630 mg, 2.2 mmol), 5-Deoxy-5-N-(S)--
methylbenzylamino-1,2-O-isopropylidene--D-xylofuranose 24g 
(294 mg, 1.0 mmol) and Et3N (1.01 g, 10.0 mmol) in toluene 
(16 mL), the product 25g was isolated as a white solid (824 mg, 
89 %, Rf 0.36). 
[α]D
23 = +313.8 (c 1.00, CHCl3). 
Anal. calcd for C56H45NO8P2: C, 72.96; H, 4.92; N, 1.52. Found: C, 
72.92; H, 5.88; N, 1.25 %. 
HRMS (ESI) calculated for C56H46NO8P2 922.26932, found 
922.26841. 
HRMS (ESI) calculated for C56H45NO8P2Na 944.25126, found 
944.2514. 
31P{1H} NMR (121 MHz, C6D6):  (ppm) = 149.7 (s), 156.1 (s). 
1H NMR (300 MHz, C6D6):  (ppm) = 0.76 (s, 3H, CH3), 1.26 (s, 3H, CH3), 1.80 (dd, 3H, CHCH3, 
3JH-H = 7.1 Hz, 3JH-P = 3.8 Hz), 3.02 (ddd, 1H, HA-5, 2J5A-5B = 15.2 Hz, J = 7.2 Hz, J = 2.8 Hz), 3.52 
(ddd, 1H, HB-5, 2J5A-5B = 15.2 Hz, 3J5B-P = 2.9 Hz, 3J5A-H = 2.9 Hz), 3.98 (d, 1H, H-2, 3J1-2 = 3.8 Hz), 
4.27 (dd, 1H, H-3, 3J3-P = 8.9 Hz, J = 2.6 Hz), 4.52-4.56 (m, 1H, H-4), 5.06 (dq, 1H, CHCH3, 
3JH-P = 14.2 Hz, 3JH-H = 7.1 Hz), 5.50 (d, 1H, H-1, 3J1-2 = 3.8 Hz), 6.80-7.77 (m, 29H, CH-Ar). 
13C NMR (75 MHz, C6D6):  (ppm) = 23.2 (d, CH(CH3), JC-P = 30.4 Hz), 25.9 (C(CH3)2), 26.8 
(C(CH3)2), 45.5 (C-5), 59.6 (d, CHCH3, JC-P = 23.7 Hz), 78.8 (d, C-3, J3-P = 15.8 Hz), 83.0 (m, C-4), 
84.1 (C-2), 105.5 (C-1), 111.5 (C(CH3)2), 122.0 (CHAr), 122.2 (CHAr), 122.4 (CHAr), 122.5 (CHAr), 
122.7 (d, CAr, JC-P = 2.2 Hz), 123.3 (d, CAr, JC-P = 2.5 Hz), 124.7 (d, CAr), 124.7 (CHAr), 125.0 (d, CAr, 
JC-P = 5.3 Hz), 125.1 (CHAr), 125.2 (CHAr), 125.4 (CHAr), 126.4 (CHAr), 126.5 (CHAr), 126.6 (CHAr), 
126.7 (CHAr), 127.2 (CHAr), 127.3 (CHAr), 127.4 (CHAr), 127.6 (CHAr), 127.7 (CHAr), 128.2 (CHAr), 
128.3 (CHAr), 128.6 (CHAr), 128.7 (2CHAr), 128.9 (3CHAr), 130.1 (CHAr) 130.5 (CHAr), 130.8 (CHAr), 
131.3 (CHAr), 131.3 (CAr) 131.5 (CAr), 132.0 (2CAr), 133.1 (d, CAr, JC-P = 1.3 Hz), 133.3 (CAr), 133.4 
(d, CAr, JC-P = 0.9 Hz), 133.5 (d, CAr, JC-P = 1.6 Hz), 144.9 (d, CAr, JC-P = 1.2 Hz), 147.8 (d, CAr-O, 
JC-P = 3.0 Hz), 148.5 (d, CAr-O, JC-P = 5.9 Hz), 150.4 (CAr-O), 151.0 (d, CAr-O JC-P = 5.1 Hz). 
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3,5-Bis-(R)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-isopropylamino-1,2-O-isopropylidene-
-D-xylofuranose (26b) 
Starting from (R)-BINOL (630 mg, 2.2 mmol), 5-Deoxy-5-N-
isopropylamino-1,2-O-isopropylidene--D-xylofuranose 24b 
(231 mg, 1.0 mmol) and Et3N (1.01 g, 10.0 mmol) in toluene 
(16 mL), the product 26b was isolated as a white solid (777 mg, 
90 %, Rf 0.25). 
[α]D
27 = -392.0 (c 0.71, CHCl3). 
Anal. calcd for C51H43NO8P2: C, 71.24; H, 5.04; N, 1.63. Found: C, 
71.16; H, 5.08; N, 1.10 %. 
HRMS (ESI) calculated for C51H44NO8P2 860.25367, found 
860.25359. 
HRMS (ESI) calculated for C51H43NO8P2Na 882.23561, found 
882.2354. 
31P{1H} NMR (121 MHz, C6D6):  (ppm) = 151.4 (d, JP-P = 8.3 Hz), 153.3 (d, JP-P = 8.4 Hz). 
1H NMR (300 MHz, C6D6):  (ppm) = 1.05 (s, 3H, CH3), 1.08 (d, 3H, CH(CH3)2, 3JH-H = 6.8 Hz), 1.12 
(d, 3H, CH(CH3)2, 3JH-H = 6.7 Hz), 1.39 (s, 3H, CH3), 3.42 (ddd, 1H, HA-5, 2J5A-5B = 16.4 Hz, 
J = 10.1 Hz, J = 6.9 Hz), 3.68-3.82 (m, 2H, HB-5 and CH(CH3)2), 4.43-4.49 (m, 2H, H-3 and H-4), 
4.61 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 5.81 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 6.82-7.80 (m, 24H, CH-Ar). 
13C NMR (75 MHz, C6D6):  (ppm) = 22.3 (d, CH(CH3)2, JC-P = 6.6 Hz), 23.3 (d, CH(CH3)2, 
JC-P = 5.0 Hz), 26.5 (C(CH3)2), 27.1 (C(CH3)2), 42.7 (d, C-5, J5-P = 20.9 Hz), 48.2 (d, CH(CH3)2, 
JC-P = 15.7 Hz), 79.0 (d, C-3, J3-P = 11.9 Hz), 81.8 (m, C-4), 85.0 (d, C-2, J2-P = 3.1 Hz), 105.2 (C-1), 
111.9 (C(CH3)2), 121.8 (CHAr), 122.1 (CHAr), 122.6 (CHAr), 122.8 (CHAr), 123.3 (d, CAr, 
JC-P = 2.2 Hz), 123.4 (d, CAr, JC-P = 2.5 Hz), 124.6 (d, CAr, JC-P = 4.6 Hz), 124.7 (d, CAr, JC-P = 4.9 Hz), 
125.0 (CHAr), 125.1 (CHAr), 125.3 (CHAr), 125.3 (CHAr), 126.5 (CHAr), 126.7 (3CHAr), 127.4 (2CHAr), 
127.5 (2CHAr), 128.6 (CHAr), 128.7 (CHAr), 128.7 (CHAr), 128.7 (CHAr), 130.3 (CHAr), 130.4 (CHAr), 
130.8 (2CHAr), 131.2 (CAr), 131.6 (CAr), 132.0 (CAr), 132.1 (CAr), 133.2 (d, CAr, JC-P = 1.1 Hz), 133.3 
(d, CAr, JC-P = 1.5 Hz), 133.5 (2CAr), 147.6 (d, CAr-O, JC-P = 2.1 Hz), 148.5 (d, CAr-O, JC-P = 5.5 Hz), 
150.4 (d, CAr-O, JC-P = 5.9 Hz), 150.6 (CAr-O). 
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3,5-Bis-(R)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-cyclohexylamino-1,2-O-
isopropylidene--D-xylofuranose (26d) 
Starting from (R)-BINOL (630 mg, 2.2 mmol), 5-Deoxy-5-N-
cyclohexylamino-1,2-O-isopropylidene--D-xylofuranose 24d 
(272 mg, 1.0 mmol) and Et3N (1.01 g, 10.0 mmol) in toluene 
(16 mL), the product 26d was isolated as a white solid (876 mg, 
97 %, Rf 0.33). 
[α]D
22 = -298.6 (c 1.00, CHCl3). 
Anal. calcd for C54H47NO8P2: C, 72.07; H, 5.26; N, 1.56. Found: C, 
72.06; H, 5.12; N, 1.49 %. 
HRMS (ESI) calculated for C54H48NO8P2 900.28497, found 
900.28497. 
HRMS (ESI) calculated for C54H47NO8P2Na 922.26691, found 
922.26696. 
31P{1H} NMR (101 MHz, C6D6):  (ppm) = 151.9 (d, JP-P = 10.1 Hz), 155.0 (d, JP-P = 10.2 Hz). 
1H NMR (250 MHz, C6D6):  (ppm) = 0.73 (m, 3H, 1.5CH2), 1.05 (s, 3H, CH3), 1.23-1.36 (m, 2H, 
CH2), 1.42 (s, 3H, CH3), 1.57-1.70 (m, 3H, 1.5CH2), 1.84-1.95 (m, 2H, CH2), 3.14-3.27 (m, 1H, 
CH(CH2)2), 3.38-3.51 (m, 1H, HA-5), 3.74 (ddd, 1H, HB-5, 2J5A-5B = 15.4 Hz, J = 12.1 Hz, J = 3.3 Hz), 
4.51-4.56 (m, 2H, H-3 and H-4), 4.64 (d, 1H, H-2, 3J1-2 = 3.6 Hz), 5.82 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 
6.82-7.79 (m, 24H, CH-Ar). 
13C NMR (63 MHz, C6D6):  (ppm) = 25.8 (CH2), 26.5 (C(CH3)2), 26.6 (CH2), 26.7 (CH2), 27.1 
(C(CH3)2), 33.9 (d, CH2, JC-P = 7.0 Hz), 34.3 (d, CH2, JC-P = 6.3 Hz), 43.4 (d, C-5, J5-P = 22.0 Hz), 57.3 
(d, CH(CH2)2, JC-P = 12.5 Hz), 78.9 (d, C-3, J3-P = 12.1 Hz), 82.0 (m, C-4), 85.0 (d, C-2, J2-P = 3.3 Hz), 
105.2 (C-1), 111.9 (C(CH3)2), 121.8 (CHAr), 122.1 (CHAr), 122.7 (2CHAr), 123.3 (d, CAr, 
JC-P = 2.2 Hz), 123.4 (d, CAr, JC-P = 2.6 Hz), 124.6 (d, CAr, JC-P = 5.1 Hz), 124.7 (d, CAr, JC-P = 5.5 Hz), 
125.0 (CHAr), 125.0 (CHAr), 125.3 (CHAr), 125.3 (CHAr), 126.5 (CHAr), 126.7 (3CHAr), 127.4 (2CHAr), 
127.5 (2CHAr), 128.4 (CHAr), 128.7 (CHAr), 128.7 (2CHAr), 130.3 (CHAr), 130.4 (CHAr), 130.8 (CHAr), 
130.9 (CHAr), 131.2 (CAr), 131.6 (CAr), 131.9 (CAr), 132.1 (CAr), 133.2 (d, CAr, JC-P = 1.4 Hz), 133.3 (d, 
CAr, JC-P = 1.5 Hz), 133.5 (d, CAr, JC-P = 1.0 Hz), 133.5 (d, CAr, JC-P = 1.6 Hz), 147.7 (d, CAr-O, 
JC-P = 2.0 Hz), 148.5 (d, CAr-O, JC-P = 5.3 Hz), 150.5 (d, CAr-O, JC-P = 5.5 Hz), 150.6 (CAr-O). 
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3,5-Bis-(R)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-phenylamino-1,2-O-isopropylidene--
D-xylofuranose (26e) 
Starting from (R)-BINOL (630 mg, 2.2 mmol), 5-Deoxy-5-N-
phenylamino-1,2-O-isopropylidene--D-xylofuranose 24e (265 mg, 
1.0 mmol) and Et3N (1.01 g, 10.0 mmol) in toluene (16 mL), the 
product 26e was isolated as a white solid (291 mg, 33 %, Rf 0.18). 
[α]D
26 = -265.2 (c 0.50, CHCl3). 
Anal. calcd for C54H41NO8P2: C, 72.56; H, 4.62; N, 1.57. Found: C, 
72.25; H, 4.51; N, 1.66 %. 
HRMS (EI) calculated for C54H41NO8P2 893.23019, found 
893.23177. 
31P{1H} NMR (101 MHz, C6D6):  (ppm) = 146.9 (d, JP-P = 8.9 Hz), 
147.7 (d, JP-P = 9.0 Hz). 
1H NMR (250 MHz, C6D6): (ppm) = 0.89 (s, 3H, C(CH3)2), 1.09 (s, 3H, C(CH3)2), 3.87-4.11 (m, 2H, 
2H-5), 4.33-4.39 (m, 1H, H-4), 4.45 (dd, 1H, H-3, 3J3-P = 9.6 Hz, J = 2.7 Hz), 4.55 (d, 1H, H-2, 
3J1-2 = 3.6 Hz), 5.69 (d, 1H, H-1, 3J1-2 = 3.6 Hz), 6.82-7.70 (m, 29H, CH-Ar). 
13C NMR (63 MHz, C6D6):  (ppm) = 26.4 (C(CH3)2), 26.8 (C(CH3)2), 47.4 (d, C-5, J5-P = 16.1 Hz), 
78.5 (m, C-4), 78.8 (d, C-3, J3-P = 8.5 Hz), 84.9 (d, C-2, J2-P = 2.6 Hz), 104.9 (C-1), 112.0 (C(CH3)2), 
121.6 (CHAr), 122.2 (CHAr), 122.4 (CHAr), 122.5 (CHAr), 123.3 (d, CAr, JC-P = 2.3 Hz), 123.3 (d, CAr, 
JC-P = 2.3 Hz), 124.7 (d, CAr, JC-P = 1.2 Hz CAr), 124.8 (d, CAr, JC-P = 1.0 Hz), 125.0 (CHAr), 125.1 
(CHAr), 125.3 (CHAr), 125.4 (CHAr), 125.8 (CHAr), 126.5 (CHAr), 126.6 (CHAr), 126.8 (CHAr), 126.8 
(CHAr), 127.4 (3CHAr), 127.5 (CHAr), 128.0 (CHAr), 128.1 (CHAr), 128.6 (CHAr), 128.7 (CHAr), 128.7 
(2CHAr), 129.4 (2CHAr), 130.4 (2CHAr), 130.8 (CHAr), 130.9 (CHAr), 131.2 (CAr), 131.5 (CAr), 132.0 
(CAr), 132.1 (CAr), 133.2 (d, CAr, JC-P = 1.0 Hz), 133.3 (d, CAr, JC-P = 1.2 Hz), 133.3 (d, CAr, 
JC-P = 1.6 Hz), 133.5 (d, CAr, JC-P = 1.4 Hz), 143.2 (d, CAr, JC-P = 12.5 Hz), 147.7 (d, CAr-O, 
JC-P = 1.8 Hz), 148.7 (d, CAr-O, JC-P = 5.3 Hz), 149.9 (CAr-O), 150.3 (d, CAr-O, JC-P = 5.6 Hz). 
 
3,5-Bis-(R)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-benzylamino-1,2-O-isopropylidene--
D-xylofuranose (26f) 
Starting from (R)-BINOL (630 mg, 2.2 mmol), 5-Deoxy-5-N-
benzylamino-1,2-O-isopropylidene--D-xylofuranose 24f (279 mg, 
1.0 mmol) and Et3N (1.01 g, 10.0 mmol) in toluene (16 mL), the 
product 26f was isolated as a white solid (770 mg, 85 %, Rf 0.23). 
[α]D
25 = -263.1 (c 0.31, CHCl3). 
Anal. calcd for C55H43NO8P2: C, 72.76; H, 4.77; N, 1.54. Found: C, 
72.85; H, 4.88; N, 1.45 %. 
HRMS (ESI) calculated for C55H44NO8P2 908.25367, found 
908.25397. 
HRMS (ESI) calculated for C55H43NO8P2Na 930.23561, found 
930.23455. 
31P{1H} NMR (101 MHz, C6D6):  (ppm) = 143.6 (d, JP-P = 5.0 Hz), 150.9 (d, JP-P = 5.0 Hz). 
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1H NMR (250 MHz, C6D6):  (ppm) = 1.00 (s, 3H, C(CH3)2), 1.37 (s, 3H, C(CH3)2), 3.42 (ddd, 1H, 
HA-5, 2J5A-5B = 15.1 Hz, J = 2.2 Hz), 3.67 (dd, 1H, HA-NCH2, 2JA-B = 15.4 Hz, J = 4.5 Hz), 3.78-3.92 
(m, 1H, HB-5), 4.37 (dd, 1H, H-3, 3J3-P = 10.2 Hz, J = 2.6 Hz), 4.53-4.61 (m, 2H, HB-NCH2 and H-4), 
4.63 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 5.87 (d, 1H, H-1, 3J1-2 = 3.6 Hz), 6.81-7.70 (m, 27H, CH-Ar), 7.84 
(m, 1H, CH-Ar), 8.05 (m, 1H, CH-Ar). 
13C NMR (75 MHz, C6D6):  (ppm) = 26.3 (C(CH3)2), 27.1 (C(CH3)2), 45.6 (d, C-5, J5-P = 36.5 Hz), 
48.0 (CH2Ph), 76.3 (m, C-4), 79.1 (d, C-3, J3-P = 2.4 Hz), 85.4 (d, C-2, J2-P = 1.9 Hz), 105.2 (C-1), 
111.8 (C(CH3)2), 121.5 (CHAr), 122.0 (CHAr), 122.6 (CHAr), 123.0 (CHAr), 123.0 (d, CAr, 
JC-P = 2.4 Hz), 123.9 (d, CAr, JC-P = 1.9 Hz), 124.6 (d, CAr, JC-P = 1.1 Hz), 124.7 (CAr), 125.0 (CHAr), 
125.0 (CHAr), 125.3 (CHAr), 125.4 (CHAr), 126.4 (CHAr), 126.5 (CHAr), 126.7 (CHAr), 126.8 (CHAr), 
127.3 (CHAr), 127.4 (3CHAr), 127.5 (CHAr), 128.5 (4CHAr), 128.6 (CHAr), 128.7 (CHAr), 128.7 
(2CHAr), 130.6 (2CHAr), 130.7 (CHAr), 130.9 (CHAr), 131.4 (2CAr), 132.0 (CAr), 132.1 (CAr), 133.1 (d, 
CAr, JC-P = 0.9 Hz), 133.3 (d, CAr, JC-P = 1.2 Hz), 133.3 (d, CAr, JC-P = 1.7 Hz), 133.6 (d, CAr, 
JC-P = 1.2 Hz), 138.4 (d, CAr, JC-P = 1.3 Hz), 147.6 (d, CAr-O, JC-P = 1.8 Hz), 148.6 (d, CAr-O, 
JC-P = 5.5 Hz), 150.4 (d, CAr-O, JC-P = 0.9 Hz), 150.7 (d, CAr-O, JC-P = 4.9 Hz). 
 
3,5-Bis-(R)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-(S)--methylbenzylamino-1,2-O-
isopropylidene--D-xylofuranose (26g) 
Starting from (R)-BINOL (630 mg, 2.2 mmol), 5-deoxy-5-N-(S)--
methylbenzylamino-1,2-O-isopropylidene--D-xylofuranose 24g 
(294 mg, 1.0 mmol) and Et3N (1.01 g, 10.0 mmol) in toluene 
(16 mL), the product 26g was isolated as a white solid (570 mg, 
62 %, Rf 0.15). 
[α]D
24 = -386.4 (c 0.73, CHCl3).  
Anal. calcd for C56H45NO8P2: C, 72.96; H, 4.92; N, 1.52. Found: C, 
73.07; H, 4.93; N, 1.44 %. 
HRMS (ESI) calculated for C56H46NO8P2 922.26932, found 
922.26877. 
HRMS (ESI) calculated for C56H45NO8P2Na 944.25126, found 
944.25027. 
31P{1H} NMR (101 MHz, C6D6):  (ppm) = 150.6 (d, JP-P = 17.1 Hz), 151.2 (d, JP-P = 17.1 Hz). 
1H NMR (250 MHz, C6D6):  (ppm) = 1.04 (s, 3H, C(CH3)2), 1.36 (s, 3H, C(CH3)2), 1.53 (d, 3H, 
CHCH3, 3JH-H = 7.2 Hz), 3.39-3.51 (m, 1H, HA-5), 3.64-3.76 (ddd, 1H, HB-5, 2J5A-5B = 15.1 Hz, 
J = 11.3 Hz, J = 3.4 Hz), 4.30-4.34 (m, 2H, H-3 and H-4), 4.55 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 4.90-5.02 
(m, 1H, CHCH3), 5.77 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 6.78-7.81 (m, 29H, CH-Ar). 
13C NMR (63 MHz, C6D6):  (ppm) = 20.7 (d, CHCH3, JC-P = 12.1 Hz), 26.4 (C(CH3)2), 27.2 
(C(CH3)2), 43.6 (d, C-5, J5-P = 18.9 Hz), 54.7 (d, CHCH3, JC-P = 14.0 Hz), 78.6 (d, C-3, J3-P = 11.9 Hz), 
80.7 (m, C-4), 85.0 (d, C-2, J2-P = 2.8 Hz), 105.2 (C-1), 111.8 (C(CH3)2), 121.7 (CHAr), 122.2 (CHAr), 
122.8 (2CHAr), 123.3 (d, CAr, JC-P = 2.6 Hz), 123.3 (d, CAr, JC-P = 2.8 Hz), 124.5 (d, CAr, JC-P = 3.0 Hz), 
124.6 (d, CAr, JC-P = 3.3 Hz), 125.0 (CHAr), 125.1 (CHAr), 125.2 (CHAr), 125.3 (CHAr), 126.5 (CHAr), 
126.6 (CHAr), 126.6 (CHAr), 126.7 (CHAr), 127.2 (CHAr), 127.4 (2CHAr), 127.5 (CHAr), 127.6 (CHAr), 
127.9 (2CHAr), 128.5 (CHAr), 128.6 (3CHAr), 128.7 (CHAr), 128.7 (CHAr), 130.2 (CHAr), 130.3 (CHAr), 
130.7 (CHAr), 130.8 (CHAr), 131.2 (CAr), 131.5 (CAr), 132.0 (2CAr), 133.2 (d, CAr, JC-P = 1.1 Hz), 133.3 
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(d, CAr, JC-P = 1.3 Hz), 133.5 (2CAr), 143.5 (d, CAr, JC-P = 1.7 Hz), 147.6 (d, CAr-O, JC-P = 1.8 Hz), 
148.4 (d, CAr-O, JC-P = 5.0 Hz), 150.2 (d, CAr-O, JC-P = 6.2 Hz), 150.3 (CAr-O). 
 
 
General procedure for the synthesis of amino xylose-based monophosphites 27a-c 
1.1 Eq of the corresponding chlorophosphite of the aromatic diol are dissolved in toluene 
(5 mL/1.1 mmol chlorophosphite) and pyridine (2.3 eq) is added. 1.0 Eq of azeotropically dried amino 
sugar 24b is dissolved in toluene (5 mL/1.0 mmol substrate) and pyridine (2.3 eq) is added. The 
chlorophosphite solution is added slowly to the sugar solution at 0 °C over 5 min and the mixture is 
kept at this temperature for 5 min. The reaction solution is warmed to 80 °C and stirred for 16 h. After 
this time, the mixture is cooled to room temperature and concentrated in vacuo. The residue is purified 
by column chromatography (alumina, toluene/Et3N = 97:3) to give 27a-c.  
 
3-(S)-[(3,3'-Di-tert-butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-deoxy-5-N-
isopropylamino-1,2-O-isopropylidene--D-xylofuranose (27a) 
Starting from (S)-(–)-5,5',6,6'-tetramethyl-3,3'-di-tert-butyl-1,1'-
biphenyl-2,2'-diol (390 mg, 1.1 mmol), 5-Deoxy-5-N-isopropylamino-
1,2-O-isopropylidene--D-xylofuranose 24b (231 mg, 1.0 mmol) and 
pyridine (364 mg, 4.6 mmol) in toluene (10 mL), the product 27a was 
isolated as a white solid (360 mg, 59 %, Rf 0.55). 
[α]D
26 = -329.0 (c 1.00, CHCl3). 
Anal. calcd for C35H52NO6P: C, 68.49; H, 8.54; N, 2.28. Found: C, 
68.33; H, 8.87; N, 2.25 %. 
HRMS (EI) calculated for C35H52NO6P 613.35268, found 613.35339. 
31P{1H} NMR (121 MHz, C6D6):  (ppm) = 140.9 (s). 
1H NMR (300 MHz, C6D6):  (ppm) = 0.92 (d, 3H, CH(CH3)2, 3JH-H = 6.2 Hz), 0.97 (s, 3H, C(CH3)2), 
0.98 (d, 3H, CH(CH3)2, 3JH-H = 6.2 Hz), 1.36 (s, 3H, C(CH3)2), 1.57 (br, 18H, 2C(CH3)3), 1.70 (s, 3H, 
CH3), 1.80 (s, 3H, CH3), 2.05 (s, 3H, CH3), 2.06 (s, 3H, CH3), 2.70 (m, 1H, CH(CH3)2), 3.05 (dd, 1H, 
HA-5, 2J5A-5B = 11.8 Hz, 3J4-5A = 6.3 Hz), 3.11 (dd, 1H, HB-5, 2J5A-5B = 11.8 Hz,  3J4-5B = 6.8 Hz), 4.08 
(d, 1H, H-2, 3J1-2 = 3.7 Hz), 4.42 (ddd, 1H, H-4, 3J3-4 = 2.7 Hz), 4.91 (dd, 1H, H-3, 3J3-P = 8.1 Hz, 
J = 2.7 Hz), 5.78 (d, 1H, H-1, 3J1-2 = 3.8 Hz), 7.21 (s, 1H, CH-Ar), 7.23 (s, 1H, CH-Ar). 
13C NMR (75 MHz, C6D6):  (ppm) = 16.6 (CH3), 16.8 (CH3), 20.4 (CH3), 20.4 (CH3), 23.1 
(CH(CH3)2), 23.4 (CH(CH3)2), 26.0 (C(CH3)2), 26.8 (C(CH3)2), 31.7 (d, C(CH3)3, JC-P = 5.1 Hz), 
31.9 (C(CH3)3), 35.0 (C(CH3)3), 35.2 (C(CH3)3), 46.1 (C-5), 49.3 (CH(CH3)2), 77.9 (C-3), 80.5 (d, 
C-4, J4-P = 5.6 Hz), 84.7 (C-2), 105.3 (C-1), 111.2 (C(CH3)2), 128.3 (CHAr), 128.5 (CHAr), 131.7 (d, 
CAr, JC-P = 3.2 Hz), 132.3 (d, CAr, JC-P = 0.8 Hz), 132.5 (d, CAr, JC-P = 5.2 Hz), 133.0 (CAr), 135.0 (d, 
CAr, JC-P = 0.9 Hz), 135.6 (d, CAr, JC-P = 1.0 Hz), 138.2 (CAr), 138.6 (d, CAr, JC-P = 2.6 Hz), 145.5 (d, 
CAr-O, JC-P = 5.5 Hz), 145.7 (d, CAr-O, JC-P = 2.6 Hz). 
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3-(R)-[(3,3'-Di-tert-butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-deoxy-5-N-
isopropylamino-1,2-O-isopropylidene--D-xylofuranose (27b) 
Starting from (R)-(+)-5,5',6,6'-tetramethyl-3,3'-di-tert-butyl-1,1'-
biphenyl-2,2'-diol (390 mg, 1.1 mmol), 5-Deoxy-5-N-isopropylamino-
1,2-O-isopropylidene--D-xylofuranose 24b (231 mg, 1.0 mmol) and 
pyridine (364 mg, 4.6 mmol) in toluene (10 mL), the product 27b was 
isolated as a white solid (383 mg, 62 %, Rf 0.58). 
[α]D
25 = +334.2 (c 1.00, CHCl3). 
Anal. calcd for C35H52NO6P: C, 68.49; H, 8.54; N, 2.28. Found: C, 
68.42; H, 8.36; N, 2.11 %. 
HRMS (ESI) calculated for C35H53NO6P 614.3605, found 614.36048. 
HRMS (ESI) calculated for C35H52NO6PNa 636.34245, found 636.34294. 
31P{1H} NMR (121 MHz, C6D6):  (ppm) = 144.7 (s). 
1H NMR (300 MHz, C6D6):  (ppm) = 0.77 (d, 3H, CH(CH3)2, 3JH-H = 6.2 Hz), 0.83 (d, 3H, CH(CH3)2, 
3JH-H = 6.2 Hz), 1.09 (s, 3H, C(CH3)2), 1.37 (s, 3H, C(CH3)2), 1.50 (s, 9H, C(CH3)3), 1.56 (s, 9H, 
C(CH3)3), 1.71 (s, 3H, CH3), 1.78 (s, 3H, CH3), 2.05 (s, 3H, CH3), 2.13 (s, 3H, CH3), 2.34 (m, 1H, 
CH(CH3)2), 2.64 (dd, 1H, HA-5, 2J5A-5B = 11.6 Hz, 3J4-5A = 7.3 Hz), 2.71 (dd, 1H, HB-5, 
2J5A-5B = 11.6 Hz, 3J4-5A = 6.5 Hz), 4.57 (ddd, 1H, H-4, 3J3-4 = 2.8 Hz), 4.69 (d, 1H, H-2, 3J1-2 = 3.0 Hz), 
4.79 (dd, 1H, H-3, 3J3-P = 11.4 Hz, J = 2.8 Hz), 5.96 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 7.17 (s, 1H, CH-Ar), 
7.26 (s, 1H, CH-Ar). 
13C NMR (63 MHz, C6D6):  (ppm) = 16.3 (CH3), 16.8 (CH3), 20.4 (CH3), 20.5 (CH3), 23.2 
(CH(CH3)2), 23.3 (CH(CH3)2), 26.5 (C(CH3)2), 27.0 (C(CH3)2), 31.6 (d, C(CH3)3, JC-P = 5.1 Hz), 31.9 
(C(CH3)3), 34.9 (C(CH3)3), 35.2 (C(CH3)3), 45.4 (C-5), 49.0 (CH(CH3)2), 76.9 (d, C-3, J3-P = 7.8 Hz), 
80.8 (d, C-4, J4-P = 2.3 Hz), 85.0 (d, C-2, J2-P = 2.8 Hz), 105.5 (C-1), 112.0 (C(CH3)2), 128.2 (CHAr), 
128.6 (d, CHAr, JC-P = 1.2 Hz), 131.3 (d, CAr, JC-P = 3.3 Hz), 132.2 (d, CAr, JC-P = 1.1 Hz), 132.6 (d, CAr, 
JC-P = 5.2 Hz), 133.0 (d, CAr, JC-P = 0.8 Hz), 134.4 (d, CAr, JC-P = 1.3 Hz), 135.5 (d, CAr, JC-P = 1.2 Hz), 
138.1 (CAr), 138.4 (d, CAr, JC-P = 2.7 Hz), 145.1 (d, CAr-O, JC-P = 2.7 Hz), 145.2 (d, CAr-O, 
JC-P = 6.6 Hz). 
 
3-[(3,3',5,5'-Tetra-tert-butyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-deoxy-5-N-isopropylamino-1,2-O-
isopropylidene--D-xylofuranose (27c) 
Starting from 3,3',5,5'-tetra-tert-butyl-1,1'-biphenyl-2,2'-diol (904 mg, 
2.2 mmol), 5-Deoxy-5-N-isopropylamino-1,2-O-isopropylidene--D-
xylofuranose 24b (462 mg, 2.0 mmol) and pyridine (728 mg, 
9.2 mmol) in toluene (20 mL), the product 27c was isolated as a white 
solid (950 mg, 71 %, Rf 0.50). 
[α]D
25 = +15.5 (c 0.45, CHCl3). 
Anal. calcd for C39H60NO6P: C, 69.93; H, 9.03; N, 2.09. Found: C, 
68.89; H, 8.65; N, 2.23 %. 
HRMS (ESI) calculated for C39H61NO6P 670.4231, found 670.42314. 
HRMS (ESI) calculated for C39H60NO6PNa 692.40505, found 692.40366. 
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31P{1H} NMR (121 MHz, C6D6):  (ppm) = 149.0 (s). 
1H NMR (300 MHz, C6D6):  (ppm) = 0.89 (d, 3H, CH(CH3)2, 3JH-H = 6.2 Hz), 0.91 (d, 3H, CH(CH3)2, 
3JH-H = 6.2 Hz), 1.05 (s, 3H, C(CH3)2), 1.25 (s, 9H, C(CH3)3), 1.29 (s, 9H, C(CH3)3), 1.38 (s, 3H, 
C(CH3)2), 1.57 (br, 18H, 2C(CH3)3), 2.62 (m, 1H, CH(CH3)2), 2.96 (dd, 1H, HA-5, 2J5A-5B = 11.7 Hz, 
3J4-5A = 6.4 Hz), 3.04 (dd, 1H, HB-5, 2J5A-5B = 11.7 Hz, 3J4-5B = 6.9 Hz), 4.48-4.53 (m, 2H, H-2 and 
H-4), 4.92 (dd, 1H, H-3, 3J3-P = 9.8 Hz, J = 2.7 Hz), 5.85 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 7.37 (d, 1H, 
CH-Ar, JH-P = 2.5 Hz), 7.38 (d, 1H, CH-Ar, JH-P = 2.5 Hz), 7.59 (d, 1H, CH-Ar, 5JH-P = 2.5 Hz), 7.61 
(d, 1H, CH-Ar, 5JH-P = 2.5 Hz). 
13C NMR (75 MHz, C6D6):  (ppm) = 23.2 (CH(CH3)2), 23.4 (CH(CH3)2), 26.1 (C(CH3)2), 26.7 
(C(CH3)2), 31.5 (d, C(CH3)3, JC-P = 3.1 Hz), 31.6 (C(CH3)3), 31.6 (2C(CH3)3), 34.7 (C(CH3)3), 
34.7 (C(CH3)3), 35.7 (C(CH3)3), 35.8 (C(CH3)3), 46.1 (C-5), 49.2 (CH(CH3)2), 77.8 (d, C-3, 
J3-P = 4.4 Hz), 80.7 (d, C-4, J4-P = 4.4 Hz), 84.9 (d, C-2, J2-P = 2.0 Hz), 105.3 (C-1), 111.6 (C(CH3)2), 
124.6 (2CHAr), 127.2 (2CHAr), 133.8 (d, CAr), 133.9 (d, CAr), 140.7 (d, CAr, JC-P = 1.2 Hz), 140.9 (d, 
CAr, JC-P = 1.7 Hz), 146.3 (d, CAr-O, JC-P = 6.4 Hz), 146.3 (d, CAr-O, JC-P = 6.0 Hz), 147.2 (d, 2CAr, 
JC-P = 5.7 Hz). 
 
 
General procedure for the synthesis of amino xylose-based diphosphites 28a-f  
1.1 Eq of enantiopure BINOL are suspended in phosphorus trichloride (1.5 mL/1.0 mmol BINOL), 2-3 
drops of N-methyl-2-pyrrolidone are added and the solution is heated to 75 °C for 5 min. The resulting 
HCl gas is derived from the reaction vessel by using a bubble counter (slight argon stream!). The now 
clear solution is cooled to room temperature, concentrated and dried azeotropically with toluene (three 
times). Thus, the in situ prepared chlorophosphite is dissolved in toluene (15 mL/1.1 mmol BINOL) 
and triethylamine is added (2.5 mmol/1.1 mmol BINOL). 1.0 Eq of azeotropically dried amino 
monophosphite 27a-c is dissolved in toluene (15 mL/1.0 mmol substrate) and triethylamine (2.5 eq) is 
added. This solution is added slowly to the chlorophosphite solution at 0 °C over 5 min and the 
mixture is kept at this temperature for 5 min. The reaction solution is stirred at 50 °C for 16 h. After 
this time, the mixture is cooled to room temperature and concentrated in vacuo. The residue is purified 
by column chromatography (basic silica, toluene) to give 28a-f. 
 
3-(S)-[(3,3'-Di-tert-butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-(S)-[(1,1'-
binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-isopropylamino-1,2-O-isopropylidene--D-xylofuranose 
(28a) 
Starting from (S)-BINOL (128 mg, 0.45 mmol), 3-(S)-[(3,3'-di-tert-
butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-
deoxy-5-N-isopropylamino-1,2-O-isopropylidene--D-xylofuranose 
27a (250 mg, 0.41 mmol) and Et3N (206 mg, 2.0 mmol) in toluene 
(12 mL), the product 28a was isolated as a white solid (162 mg, 
43 %, Rf 0.64). 
[α]D
26 = -12.3 (c 0.35, CHCl3). 
Anal. calcd for C55H63NO8P2: C, 71.18; H, 6.84; N, 1.51. Found: C, 
71.15; H, 6.87; N, 1.38 %. 
HRMS (ESI) calculated for C55H64NO8P2 928.41017, found 
928.41011. 
HRMS (ESI) calculated for C55H63NO8P2Na 950.39211, found 
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950.39249. 
HRMS (ESI) calculated for C55H63NO8P2K 966.36605, found 966.36708. 
31P{1H} NMR (121 MHz, C6D6):  (ppm) = 138.3 (s), 153.1 (s). 
1H NMR (300 MHz, C6D6):  (ppm) = 0.93 (d, 3H, CH(CH3)2, 3JH-H = 6.7 Hz), 1.04 (d, 3H, CH(CH3)2, 
3JH-H = 6.8 Hz), 1.06 (s, 3H, C(CH3)2), 1.42 (s, 3H, C(CH3)2), 1.50 (s, 9H, C(CH3)3), 1.51 (s, 9H, 
C(CH3)3), 1.70 (s, 3H, CH3), 1.83 (s, 3H, CH3), 2.05 (s, 3H, CH3), 2.14 (s, 3H, CH3), 3.14 (ddd, 1H, 
HA-5, J = 19.4 Hz, 2J5A-5B = 15.8 Hz, J = 8.3 Hz), 3.44 (ddd, 1H, HB-5, 2J5A-5B = 15.7 Hz, J = 10.6 Hz, 
J = 2.5 Hz), 3.59-3.70 (m, 1H, CH(CH3)2, 3JH-H = 6.7 Hz), 4.57 (d, 1H, H-2, 3J1-2 = 3.0 Hz), 4.64 (dd, 
1H, H-3, 3J3-P = 9.8 Hz, J = 2.6 Hz), 4.71-4.74 (m, 1H, H-4), 5.96 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 
6.87-7.14 (m, 4H, CH-Ar), 7.20 (s, 1H, CH-Ar), 7.25 (s, 1H, CH-Ar), 7.42-7.72 (m, 8H, CH-Ar). 
13C NMR (75 MHz, C6D6):  (ppm) = 16.6 (CH3), 16.8 (CH3), 20.4 (CH3), 20.5 (CH3), 22.3 (d, 
CH(CH3)2, JC-P = 3.0 Hz), 23.1 (d, CH(CH3)2, JC-P = 4.1 Hz), 26.5 (C(CH3)2), 27.1 (C(CH3)2), 31.6 (d, 
C(CH3)3), JC-P = 5.2 Hz), 31.7 (C(CH3)3), 34.9 (C(CH3)3), 35.1 (C(CH3)3), 42.5 (d, C-5, 
J5-P = 30.2 Hz), 47.3 (d, CH(CH3)2, JC-P = 6.3 Hz), 78.2 (d, C-3, JC-P = 4.1 Hz), 82.2 (m, C-4), 84.6 (d, 
C-2, JC-P = 4.2 Hz), 105.3 (C-1), 112.0 (C(CH3)2), 122.6 (d, CHAr, JC-P = 1.3 Hz), 122.8 (d, CAr, 
JC-P = 2.2 Hz), 123.0 (CHAr), 124.8 (CHAr), 124.8 (d, CAr), 124.9 (CHAr), 126.4 (CHAr), 126.5 (CHAr), 
127.5 (CHAr), 127.6 (CHAr), 128.2 (CHAr), 128.7 (3CHAr), 130.1 (CHAr), 130.6 (CHAr), 131.2 (CAr), 
131.4 (d, CAr, JC-P = 3.3 Hz), 131.9 (CAr), 132.3 (CAr), 132.6 (d, CAr, JC-P = 5.3 Hz), 133.0 (CAr), 133.3 
(d, CAr, JC-P = 0.8 Hz), 133.5 (d, CAr, JC-P = 1.5 Hz), 134.7 (d, CAr, JC-P = 0.9 Hz), 135.6 (d, CAr, 
JC-P = 0.9 Hz), 138.0 (CAr), 138.5 (d, CAr, JC-P = 2.7 Hz), 145.3 (d, CAr-O), 145.4 (d, CAr-O), 150.5 
(CAr), 151.0 (d, CAr-O, JC-P = 5.7 Hz). 
 
3-(R)-[(3,3'-Di-tert-butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-(S)-[(1,1'-
binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-isopropylamino-1,2-O-isopropylidene--D-xylofuranose 
(28b) 
Starting from (S)-BINOL (128 mg, 0.45 mmol), 3-(R)-[(3,3'-di-tert-
butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-
deoxy-5-N-isopropylamino-1,2-O-isopropylidene--D-xylofuranose 
27a (250 mg, 0.41 mmol) and Et3N (206 mg, 2.0 mmol) in toluene 
(12 mL), the product 28b was isolated as a white solid (233 mg, 
62 %, Rf 0.52). 
[α]D
26 = +456.4 (c 0.56, CHCl3). 
Anal. calcd for C55H63NO8P2: C, 71.18; H, 6.84; N, 1.51. Found: C, 
71.06; H, 6.80; N, 1.50 %. 
HRMS (ESI) calculated for C55H64NO8P2 928.41017, found 
928.40949. 
HRMS (ESI) calculated for C55H63NO8P2Na 950.39211, found 
950.39192. 
HRMS (ESI) calculated for C55H63NO8P2K 966.36605, found 966.3667. 
31P{1H} NMR (121 MHz, C6D6):  (ppm) = 140.1 (d, JP-P = 9.5 Hz), 149.8 (d, JP-P = 9.5 Hz). 
1H NMR (300 MHz, C6D6):  (ppm) = 0.87 (s, 3H, C(CH3)2), 1.26 (d, 3H, CH(CH3)2, 3JH-H = 6.7 Hz), 
1.30 (d, 3H, CH(CH3)2, 3JH-H = 6.8 Hz), 1.32 (s, 9H, C(CH3)3), 1.36 (s, 3H, C(CH3)2), 1.48 (s, 9H, 
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C(CH3)3), 1.65 (s, 3H, CH3), 1.74 (s, 3H, CH3), 2.00 (s, 3H, CH3), 2.02 (s, 3H, CH3), 3.14 (ddd, 1H, 
HA-5, 2J5A-5B = 15.5 Hz, J = 9.9 Hz, J = 5.2 Hz), 3.65 (ddd, 1H, HB-5, 2J5A-5B = 15.5 Hz, J = 5.9 Hz, 
J = 4.6 Hz), 3.81 (dq, 1H, CH(CH3)2, 3JH-P = 18.5 Hz, 3JH-H = 6.7 Hz), 3.95 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 
4.48-4.52 (m, 1H, H-4), 4.69 (dd, 1H, H-3, 3J3-P = 6.3 Hz, J = 2.4 Hz), 5.49 (d, 1H, H-1, 
3J1-2 = 3.7 Hz), 6.86-6.93 (m, 2H, CH-Ar), 7.00-7.19 (m, 4H, CH-Ar), 7.42-7.79 (m, 8H, CH-Ar). 
13C NMR (75 MHz, C6D6):  (ppm) = 16.5 (CH3), 16.7 (CH3), 20.3 (CH3), 20.3 (CH3), 22.8 (d, 
CH(CH3)2, JC-P = 9.0 Hz), 23.5 (d, CH(CH3)2, JC-P = 6.7 Hz), 25.9 (C(CH3)2), 26.9 (C(CH3)2), 31.6 (d, 
C(CH3)3), JC-P = 5.1 Hz), 31.9 (C(CH3)3), 34.8 (C(CH3)3), 35.1 (C(CH3)3), 42.3 (d, C-5, J5-P = 8.1 Hz), 
49.2 (d, CH(CH3)2, JC-P = 26.4 Hz), 77.3 (C-3), 82.7 (m, C-4), 84.7 (C-2), 105.2 (C-1), 111.2 
(C(CH3)2), 122.3 (CHAr), 122.7 (d, CHAr, JC-P = 1.2 Hz), 123.1 (d, CAr, JC-P = 2.0 Hz), 125.0 (d, CAr), 
124.9 (CHAr), 125.0 (CHAr), 126.4 (CHAr), 126.6 (CHAr), 127.5 (CHAr), 127.6 (CHAr), 128.2 (CHAr), 
128.4 (CHAr), 128.6 (CHAr), 128.8 (CHAr), 130.5 (CHAr), 130.7 (CHAr), 131.3 (CAr), 131.9 (d, CAr, 
JC-P = 3.1 Hz), 132.0 (CAr), 132.1 (d, CAr, JC-P = 0.7 Hz), 132.4 (d, CAr, JC-P = 5.4 Hz), 132.8 (d, CAr, 
JC-P = 0.6 Hz), 133.4 (CAr), 133.5 (d, CAr, JC-P = 1.4 Hz), 134.7 (d, CAr, JC-P = 1.0 Hz), 135.4 (d, CAr, 
JC-P = 0.8 Hz), 138.5 (CAr), 138.6 (d, CAr, JC-P = 2.4 Hz), 145.4 (CAr-O), 145.4 (d, CAr-O), 150.4 
(CAr-O), 150.8 (d, CAr-O, JC-P = 4.7 Hz). 
 
3-(S)-[(3,3'-Di-tert-butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-(R)-[(1,1'-
binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-isopropylamino-1,2-O-isopropylidene--D-xylofuranose 
(28c) 
Starting from (R)-BINOL (103 mg, 0.36 mmol), 3-(S)-[(3,3'-di-tert-
butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-
deoxy-5-N-isopropylamino-1,2-O-isopropylidene--D-xylofuranose 
27b (200 mg, 0.33 mmol) and Et3N (165 mg, 1.6 mmol) in toluene 
(10 mL), the product 28c was isolated as a white solid (230 mg, 
76 %, Rf 0.52). 
[α]D
27 = +23.5 (c 0.52, CHCl3). 
Anal. calcd for C55H63NO8P2: C, 71.18; H, 6.84; N, 1.51. Found: C, 
71.01; H, 6.70; N, 1.59 %. 
HRMS (ESI) calculated for C55H64NO8P2 928.41017, found 
928.40979. 
HRMS (ESI) calculated for C55H63NO8P2Na 950.39211, found 
950.39186. 
31P{1H} NMR (121 MHz, C6D6):  (ppm) = 144.9 (s), 155.8 (s). 
1H NMR (300 MHz, C6D6):  (ppm) = 0.95 (s, 3H, C(CH3)2), 1.07 (d, 3H, CH(CH3)2, 3JH-H = 6.8 Hz), 
1.08 (d, 3H, CH(CH3)2, 3JH-H = 6.7 Hz), 1.41 (s, 3H, C(CH3)2), 1.51 (s, 9H, C(CH3)3), 1.58 (s, 9H, 
C(CH3)3), 1.68 (s, 3H, CH3), 1.79 (s, 3H, CH3), 2.03 (s, 3H, CH3), 2.05 (s, 3H, CH3), 3.62-3.73 (m, 
3H, CH(CH3)2 and 2H-5), 4.12 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 4.59-4.64 (m, 1H, H-4), 4.85 (dd, 1H, H-3, 
3J3-P = 7.0 Hz, J = 2.5 Hz), 5.67 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 6.87-7.14 (m, 4H, CH-Ar), 7.19 (s, 1H, 
CH-Ar), 7.22 (s, 1H, CH-Ar), 7.43-7.74 (m, 8H, CH-Ar). 
13C NMR (75 MHz, C6D6):  (ppm) = 16.5 (CH3), 16.8 (CH3), 20.3 (CH3), 20.4 (CH3), 22.4 (d, 
CH(CH3)2, JC-P = 4.6 Hz), 23.3 (d, CH(CH3)2, JC-P = 5.0 Hz), 26.0 (C(CH3)2), 26.9 (C(CH3)2), 31.7 (d, 
C(CH3)3), JC-P = 5.1 Hz), 31.8 (C(CH3)3), 35.0 (C(CH3)3), 35.1 (C(CH3)3), 42.3 (d, C-5, 
J5-P = 29.4 Hz), 47.5 (d, CH(CH3)2 , JC-P = 7.9 Hz), 77.9 (C-3), 80.7 (m, C-4), 84.8 (d, C-2, 
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JC-P = 2.0 Hz), 105.1 (C-1), 111.2 (C(CH3)2), 122.7 (CHAr), 122.8 (CHAr), 123.0 (d, CAr, JC-P = 2.1 Hz), 
124.7 (d, CAr, JC-P = 5.4 Hz), 124.8 (CHAr), 124.9 (CHAr), 126.4 (CHAr), 126.5 (CHAr), 127.5 (2CHAr), 
128.3 (CHAr), 128.5 (2CHAr), 128.7 (CHAr), 130.0 (CHAr), 130.7 (CHAr), 131.1 (CAr), 131.7 (d, CAr, 
JC-P = 3.1 Hz), 131.9 (CAr), 132.3 (d, CAr, JC-P = 0.7 Hz), 132.4 (d, CAr, JC-P = 5.2 Hz), 133.1 (CAr), 
133.4 (d, CAr, JC-P = 0.9 Hz), 133.5 (d, CAr, JC-P = 1.6 Hz), 134.9 (d, CAr, JC-P = 0.8 Hz), 135.7 (d, CAr, 
JC-P = 0.8 Hz), 138.5 (CAr), 138.6 (d, CAr, JC-P = 2.6 Hz), 145.4 (d, CAr-O, JC-P = 5.6 Hz), 145.6 (d, 
CAr-O, JC-P = 2.6 Hz), 150.6 (CAr-O), 150.8 (d, CAr-O, JC-P = 5.8 Hz). 
 
3-(R)-[(3,3'-Di-tert-butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-(R)-[(1,1'-
binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-isopropylamino-1,2-O-isopropylidene--D-xylofuranose 
(28d) 
Starting from (R)-BINOL (132 mg, 0.46 mmol), 3-(R)-[(3,3'-di-tert-
butyl-5,5',6,6'-tetramethyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-
deoxy-5-N-isopropylamino-1,2-O-isopropylidene--D-xylofuranose 
27b (260 mg, 0.42 mmol) and Et3N (214 mg, 2.2 mmol) in toluene 
(12 mL), the product 28d was isolated as a white solid (285 mg, 
73 %, Rf 0.58). 
[α]D
26 = -356.0 (c 0.42, CHCl3). 
Anal. calcd for C55H63NO8P2: C, 71.18; H, 6.84; N, 1.51. Found: C, 
70.78; H, 6.79; N, 1.51 %. 
HRMS (ESI) calculated for C55H64NO8P2 928.41017, found 
928.41003. 
HRMS (ESI) calculated for C55H63NO8P2Na 950.39211, found 
950.39183. 
31P{1H} NMR (121 MHz, C6D6):  (ppm) = 144.9 (s), 155.8 (s). 
1H NMR (300 MHz, C6D6):  = 0.96 (d, 6H, CH(CH3)2, 3JH-H = 6.6 Hz), 1.07 (s, 3H, C(CH3)2), 1.46 (s, 
3H, C(CH3)2), 1.50 (s, 9H, C(CH3)3), 1.57 (s, 9H, C(CH3)3), 1.69 (s, 3H, CH3), 1.76 (s, 3H, CH3), 2.03 
(s, 3H, CH3), 2.25 (s, 3H, CH3), 3.12 (ddd, 1H, HA-5, 2J5A-5B = 15.8 Hz, J = 10.8 Hz, J = 7.5 Hz), 
3.32-3.44 (ddd, 1H, HB-5, J = 18.0 Hz,  2J5A-5B = 15.8 Hz, J = 2.7 Hz), 3.56 (m, 1H, CH(CH3)2), 
4.54-4.58 (m, 1H, H-4), 4.64 (m, 1H, H-2), 4.65 (dd, 1H, H-3, 3J3-P = 10.0 Hz, J = 2.6 Hz), 5.85 (d, 
1H, H-1, 3J1-2 = 3.7 Hz), 6.87-7.14 (m, 5H, CH-Ar) 7.35 (s, 1H, CH-Ar), 7.46-7.55 (m, 2H, CH-Ar), 
7.52 (s, 1H, CH-Ar), 7.59 (s, 1H, CH-Ar), 7.62-7.67 (m, 2H, CH-Ar), 7.70-7.80 (m, 2H, CH-Ar). 
13C NMR (75 MHz, C6D6):  (ppm) = 16.6 (CH3), 16.8 (CH3), 20.4 (CH3), 20.6 (CH3), 22.4 (d, 
CH(CH3)2, JC-P = 4.2 Hz), 22.8 (d, CH(CH3)2, JC-P = 4.8 Hz), 26.5 (C(CH3)2), 27.1 (C(CH3)2), 31.5 (d, 
C(CH3)3 JC-P = 4.9 Hz) 31.9 (C(CH3)3), 34.9 (C(CH3)3), 35.2 (C(CH3)3), 42.7 (d, C-5, J5-P = 31.6 Hz), 
47.5 (CH(CH3)2), 77.7 (d, C-3, J3-P = 7.1 Hz), 82.1 (br, C-4), 84.9 (d, C-2, J2-P = 4.2 Hz), 105.2 (C-1), 
111.8 (C(CH3)2), 122.6 (d, CHAr, JC-P = 1.2 Hz), 123.0 (CHAr), 123.2 (d, CAr, JC-P = 2.2 Hz), 124.7 (d, 
CAr, JC-P = 5.2 Hz), 124.4 (CHAr), 124.9 (CHAr), 126.4 (CHAr), 126.5 (CHAr), 127.5 (CHAr), 127.5 
(CHAr), 128.2 (CHAr), 128.5 (CHAr), 128.7 (CHAr), 128.8 (CHAr), 129.9 (CHAr), 130.6 (CHAr), 131.1 
(CAr), 131.4 (d, CAr, JC-P = 3.3 Hz), 131.9 (CAr), 132.3 (CAr), 132.6 (d, CAr, JC-P = 5.1 Hz), 133.0 (d, 
CAr, JC-P = 0.7 Hz), 133.4 (d, CAr, JC-P = 0.9 Hz), 133.5 (d, CAr, JC-P = 1.4 Hz), 134.8 (d, CAr, 
JC-P = 1.0 Hz), 135.6 (d, CAr, JC-P = 0.9 Hz), 138.0 (CAr), 138.4 (d, CAr, JC-P = 2.7 Hz), 145.1 (d, CAr-O, 
JC-P = 6.5 Hz), 145.4 (d, CAr-O, JC-P = 2.7 Hz), 150.6 (CAr-O), 150.8 (d, CAr-O, JC-P = 6.0 Hz). 
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3-[(3,3',5,5'-Tetra-tert-butyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-(S)-[(1,1'-binaphthyl-2,2'-
diyl)phosphite]-5-deoxy-5-N-isopropylamino-1,2-O-isopropylidene--D-xylofuranose (28e) 
Starting from (S)-BINOL (158 mg, 0.55 mmol), 3-[(3,3',5,5'-tetra-
tert-butyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-deoxy-5-N-
isopropylamino-1,2-O-isopropylidene--D-xylofuranose 27c 
(335 mg, 0.50 mmol) and Et3N (253 mg, 2.6 mmol) in toluene 
(15 mL), the product 28e was isolated as a white solid (350 mg, 
71 %, Rf 0.67). 
[α]D
25 = +353.8 (c 0.48, CHCl3). 
Anal. calcd for C59H71NO8P2: C, 72.00; H, 7.27; N, 1.42. Found: C, 
71.96; H, 7.67; N, 1.41 %. 
HRMS (ESI) calculated for C59H72NO8P2 984.47277, found 
984.47214. 
HRMS (ESI) calculated for C59H71NO8P2Na 1006.45471, found 
1006.45459. 
31P{1H} NMR (121 MHz, C6D6):  (ppm) = 150.3 (d, JP-P = 5.3 Hz), 153.9 (d, JP-P = 5.3 Hz). 
1H NMR (300 MHz, C6D6):  (ppm) = 0.92 (s, 3H, C(CH3)2), 1.24 (s, 9H, C(CH3)3), 1.26 (s, 9H, 
C(CH3)3), 1.28 (d, 3H, CH(CH3)2, 3JH-H = 6.7 Hz), 1.32 (d, 3H, CH(CH3)2, 3JH-H = 6.7 Hz), 1.36 (s, 9H, 
C(CH3)3), 1.37 (s, 3H, C(CH3)2), 1.53 (s, 9H, C(CH3)3), 3.17 (ddd, 1H, HB-5, 2J5A-5B = 15.6 Hz, 
J = 9.7 Hz, J = 6.1 Hz), 3.58-3.66 (ddd, 1H, HB-5, 2J5A-5B = 15.5 Hz, J = 6.1 Hz, J = 3.5 Hz), 3.84 (m, 
1H, CH(CH3)2), 4.28 (d, 1H, H-2, 3J1-2 = 3.6 Hz), 4.54-4.58 (m, 1H, H-4), 4.66 (dd, 1H, H-3, 
3J3-P = 7.9 Hz, J = 2.4 Hz), 5.51 (d, 1H, H-1, 3J3-P = 3.6 Hz), 6.84-7.14 (m, 4H, CH-Ar), 7.34 (s, 1H, 
CH-Ar), 7.34 (s, 1H, CH-Ar), 7.43-7.65 (m, 9H, CH-Ar), 7.75-7.78 (m, 1H, CH-Ar). 
13C NMR (75 MHz, C6D6):  (ppm) = 22.9 (d, CH(CH3)2, JC-P = 9.2 Hz), 23.6 (d, CH(CH3)2, 
JC-P = 6.9 Hz), 26.4 (C(CH3)2), 27.0 (C(CH3)2), 31.4 (d, C(CH3)3, JC-P = 4.3 Hz), 31.6 (2C(CH3)3), 31.7 
(C(CH3)3), 34.7 (C(CH3)3), 34.7 (C(CH3)3), 35.5 (C(CH3)3, 35.8 (C(CH3)3), 42.8 (d, C-5, 
J5-P = 7.0 Hz), 49.3 (d, CH(CH3)2, JC-P = 26.0 Hz), 77.3 (d, C-3, J3-P = 4.3 Hz), 82.9 (m, C-4), 84.7 
(C-2), 105.3 (C-1), 111.6 (C(CH3)2), 122.3 (CHAr), 122.6 (d, CHAr, JC-P = 1.2 Hz), 123.0 (d, CAr, 
JC-P = 2.1 Hz), 124.4 (CHAr), 124.6 (CHAr), 124.9 (CHAr), 125.0 (d, CAr, JC-P = 5.3 Hz), 125.0 (CHAr), 
126.4 (CHAr), 126.5 (CHAr), 126.9 (CHAr), 127.0 (CHAr), 127.4 (CHAr), 127.6 (CHAr), 128.6 (CHAr), 
128.8 (CHAr), 130.6 (CHAr), 130.7 (CHAr), 131.3 (CAr), 132.0 (CAr), 133.4 (d, CAr), 133.4 (d, CAr), 
133.5 (d, CAr, JC-P = 1.7 Hz), 134.2 (d, CAr, JC-P = 4.7 Hz), 140.9 (CAr), 141.0 (d, CAr, JC-P = 2.1 Hz), 
145.8 (d, CAr-O, JC-P = 4.0 Hz), 146.7 (d, CAr-O, JC-P = 8.7 Hz), 146.8 (CAr), 147.2 (CAr), 150.4 
(CAr-O), 150.8 (d, CAr-O, JC-P = 4.8 Hz). 
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3-[(3,3',5,5'-Tetra-tert-butyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-(R)-[(1,1'-binaphthyl-2,2'-
diyl)phosphite]-5-deoxy-5-N-isopropylamino-1,2-O-isopropylidene--D-xylofuranose (28f) 
Starting from (R)-BINOL (158 mg, 0.55 mmol), 3-[(3,3',5,5'-tetra-
tert-butyl-1,1'-biphenyl-2,2'-diyl)phosphite]-5-deoxy-5-N-
isopropylamino-1,2-O-isopropylidene--D-xylofuranose 27c 
(335 mg, 0.50 mmol) and Et3N (253 mg, 2.5 mmol) in toluene 
(15 mL), the product 28f was isolated as a white solid (440 mg, 89 %, 
Rf 0.67). 
[α]D
27 = -99.7 (c 0.68, CHCl3). 
Anal. calcd for C59H71NO8P2: C, 72.00; H, 7.27; N, 1.42. Found: C, 
72.23; H, 7.98; N, 1.38 %. 
HRMS (ESI) calculated for C59H72NO8P2 984.47277, found 
984.47261. 
HRMS (ESI) calculated for C59H71NO8P2Na 1006.45471, found 
1006.45455. 
31P{1H} NMR (101 MHz, C6D6):  (ppm) = 149.3 (d, JP-P = 9.5 Hz), 154.6 (d, JP-P = 9.6 Hz). 
1H NMR (250 MHz, C6D6):  (ppm) = 1.03 (s, 3H, C(CH3)2), 1.06 (d, 3H, CH(CH3)2, 3JH-H = 7.0 Hz), 
1.06 (d, 3H, CH(CH3)2, 3JH-H = 6.6 Hz), 1.26 (s, 18H, 2C(CH3)3), 1.45 (s, 3H, C(CH3)2), 1.53 (s, 9H, 
C(CH3)3), 1.58 (s, 9H, C(CH3)3), 3.51-3.76 (m, 3H, CH(CH3)2 and 2H-5), 4.53 (d, 1H, H-2, 
3J1-2 = 3.6 Hz), 4.58-4.63 (m, 1H, H-4), 4.78 (dd, 1H, H-3, 3J3 P = 8.6 Hz, J = 2.4 Hz),  5.72 (d, 1H, 
H-1, 3J1-2 = 3.7 Hz), 6.84-7.14 (m, 4H, CH-Ar), 7.31-7.32 (m, 1H, CH-Ar), 7.37-7.38 (m, 1H, CH-Ar), 
7.43-7.63 (m, 8H, CH-Ar), 7.69-7.76 (m, 2H, CH-Ar). 
13C NMR (63 MHz, C6D6):  (ppm) = 22.5 (d, CH(CH3)2, JC-P = 4.9 Hz), 23.3 (d, CH(CH3)2, 
JC-P = 5.1 Hz), 26.5 (C(CH3)2), 27.1 (C(CH3)2), 31.6 (4 C(CH3)3), 34.7 (2C(CH3)3), 35.7 (C(CH3)3), 
35.8 (C(CH3)3), 42.6 (d, C-5, J5-P = 28.9 Hz), 47.6 (d, CH(CH3)2, JC-P = 8.2 Hz), 77.9 (d, C-3, 
J3-P = 3.9 Hz), 81.2 (m, C-4), 84.8 (d, C-2, J2-P = 3.2 Hz), 105.1 (C-1), 111.6 (C(CH3)2), 122.7 (d, 
CHAr, JC-P = 1.4 Hz), 122.9 (CHAr), 123.1 (d, CAr, JC-P = 2.2 Hz), 124.5 (CHAr), 124.6 (CHAr), 124.6 (d, 
CAr), 124.8 (CHAr), 124.9 (CHAr), 126.3 (CHAr), 126.4 (CHAr), 127.1 (CHAr), 127.3 (CHAr), 127.5 
(2CHAr), 128.5 (CHAr), 128.7 (CHAr), 130.0 (CHAr), 130.7 (CHAr), 131.1 (CAr), 131.9 (CAr), 133.4 (d, 
CAr, JC-P = 1.1 Hz), 133.5 (d, CAr, JC-P = 1.5 Hz), 133.7 (d, CAr, JC-P = 3.7 Hz), 133.8 (d, CAr, 
JC-P = 4.0 Hz), 140.8 (CAr), 140.8 (d, CAr), 146.3 (d, CAr-O, JC-P = 4.3 Hz), 146.3 (d, CAr-O, 
JC-P = 5.0 Hz), 147.2 (2CAr), 150.6 (CAr-O), 150.7 (d, CAr-O, JC-P = 6.0 Hz). 
 
 
General procedure for the synthesis of amino xylose-based mixed diphosphites 28g-i 
1.1 Eq of enantiopure BINOL are suspended in phosphorus trichloride (1.5 mL/1.0 mmol BINOL), 2-3 
drops of N-methyl-2-pyrrolidone are added and the solution is heated to 75 °C for 5 min. The resulting 
HCl gas is derived from the reaction vessel by using a bubble counter (slight argon stream!). The now 
clear solution is cooled to room temperature, concentrated and dried azeotropically with toluene (three 
times). Thus, the in situ prepared chlorophosphite is dissolved in toluene (5 mL/1.1 mmol BINOL) and 
pyridine (2.3 eq) is added. 1.0 Eq of azeotropically dried amino sugar 24g is dissolved in toluene 
(5 mL/1.0 mmol substrate) and pyridine (2.3 eq) is added. The chlorophosphite solution is added 
slowly to the sugar solution at 0 °C over 5 min and the mixture is kept at this temperature for 5 min. 
The reaction solution is warmed to 80 °C and stirred for 16 h. After this time, the mixture is cooled to 
room temperature and concentrated in vacuo. Because the residue can not be purified by column 
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chromatography or recrystallization, crude products 27d,e are used in the next step without further 
purification. 
1.1 Eq of the corresponding chlorophosphite of the aromatic diol are dissolved in toluene 
(10 mL/1.1 mmol chlorophosphite) and triethylamine (2.0 eq) is added. 1.0 Eq of the crude 27d,e is 
dissolved in toluene (10 mL/1.0 mmol substrate) and triethylamine (2.0 eq) is added. The 
chlorophosphite solution is added slowly to the sugar solution at 0 °C over 5 min and the mixture is 
kept at this temperature for 5 min. The reaction solution is warmed to 50 °C and stirred for 16 h. After 
this time, the mixture is cooled to room temperature and concentrated in vacuo. The residue is purified 
by column chromatography (basic silica, toluene) to give 28g-i.  
 
3-(S)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-(R)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-
-methyl-benzylamino-1,2-O-isopropylidene--D-xylofuranose (28g) 
Starting from (S)-BINOL (158 mg, 0.55 mmol), (R)-BINOL (158 mg, 
0.55 mmol), 5-Deoxy-5-N-(S)--methylbenzylamino-1,2-O-
isopropylidene--D-xylofuranose 27d (147 mg, 0.5 mmol), pyridine 
(182 mg, 2.3 mmol) and Et3N (202 mg, 2.0 mmol) in toluene, the 
product 28g was isolated as a white solid (161 mg, 35 %, Rf 0.28). 
[α]D
26 = +12.1 (c 0.37, CHCl3). 
Anal. calcd for C56H45NO8P2: C, 72.96; H, 4.92; N, 1.52. Found: C, 
73.09; H, 4.82; N, 1.30 %. 
HRMS (ESI) calculated for C56H46NO8P2 922.26932, found 
922.26902. 
HRMS (ESI) calculated for C56H45NO8P2Na 944.25126, found 
944.2511. 
31P{1H} NMR (121 MHz, C6D6):  (ppm) = 147.4 (d, JP-P = 4.8 Hz), 148.7 (brs). 
1H NMR (300 MHz, C6D6):  (ppm) = 0.96 (s, 3H, C(CH3)2), 1.40 (s, 3H, C(CH3)2), 1.62 (d, 3H, 
CHCH3, 3JH-H = 6.7 Hz), 3.32-3.42 (m, 1H, HA-5), 3.75 (ddd, 1H, HB-5, 2J5A-5B = 15.5 Hz, J = 9.1 Hz, 
J = 2.8 Hz), 4.22-4.26 (m, 2H, H-2 and H-3), 4.36-4.40 (m, 1H, H-4), 4.98 (m, 1H, CHCH3), 5.60 (d, 
1H, H-1, 3J1-2 = 3.7 Hz), 6.81-6.91 (m, 4H, CH-Ar), 7.00-7.16 (m, 5H, CH-Ar), 7.19-7.80 (m, 20H, 
CH-Ar). 
13C NMR (63 MHz, C6D6):  (ppm) = 21.5 (d, CHCH3, JC-P = 15.7 Hz), 26.5 (C(CH3)2), 27.1 
(C(CH3)2), 42.6 (d, C-5, J5-P = 10.9 Hz), 55.6 (CHCH3), 78.8 (d, C-3, J3-P = 13.2 Hz), 81.0 (m, C-4), 
84.7 (d, C-2, J2-P = 2.2 Hz), 105.4 (C-1), 111.5 (C(CH3)2), 121.9 (CHAr), 122.3 (CHAr), 122.6 (CHAr), 
122.7 (CHAr), 123.0 (d, CAr, JC-P = 2.6 Hz), 123.4 (d, CAr, JC-P = 2.2 Hz), 124.5 (d, CAr, JC-P = 5.1 Hz), 
124.7 (d, CAr, JC-P = 5.1 Hz), 125.0 (CHAr), 125.1 (CHAr), 125.1 (CHAr), 125.3 (CHAr), 126.5 (2CHAr), 
126.7 (CHAr), 126.8 (CHAr), 127.2 (2CHAr), 127.5 (2CHAr), 127.6 (CHAr), 127.8 (CHAr), 127.8 (CHAr), 
128.4 (CHAr), 128.6 (4CHAr), 128.7 (CHAr), 130.3 (CHAr), 130.4 (CHAr), 130.7 (CHAr), 131.0 (CHAr), 
131.1 (CAr), 131.6 (CAr), 132.0 (2CAr), 133.0 (d, CAr, JC-P = 1.4 Hz), 133.4 (d, CAr, JC-P = 1.3 Hz), 133.5 
(d, CAr, JC-P = 1.6 Hz), 133.6 (d, CAr, JC-P = 1.2 Hz), 143.8 (d, CAr, JC-P = 1.7 Hz), 147.7 (d, CAr-O, 
JC-P = 2.5 Hz), 148.4 (d, CAr-O, JC-P = 5.3 Hz), 150.1 (d, CAr-O, JC-P = 6.4 Hz), 150.3 (CAr-O). 
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3-(S)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-[(3,3',5,5'-tetra-tert-butyl-1,1'-biphenyl-2,2'-
diyl)phosphite ]-5-deoxy-5-N--methyl-benzylamino-1,2-O-isopropylidene--D-xylofuranose (28h) 
Starting from (S)-BINOL (158 mg, 0.55 mmol), 3,3',5,5'-tetra-
tert-butyl-(1,1'-biphenyl)-2,2'-diol (226 mg, 0.55 mmol), 5-deoxy-
5-N-(S)--methylbenzylamino-1,2-O-isopropylidene--D-
xylofuranose 27d (147 mg, 0.5 mmol), pyridine (182 mg, 
2.3 mmol) and Et3N (202 mg, 2.0 mmol) in toluene, the product 
28h was isolated as a white solid (125 mg, 24 %, Rf 0.58). 
[α]D
24 = +85.7 (c 0.47, CHCl3). 
Anal. calcd for C64H73NO8P2: C, 73.47; H, 7.03; N, 1.34.Found: 
C, 73.77; H, 7.06; N, 1.10 %. 
HRMS (ESI) calculated for C64H74NO8P2 1046.48842, found 
1046.48817. 
HRMS (ESI) calculated for C64H73NO8P2Na 1068.47036, found 
1068.47042. 
HRMS (ESI) calculated for C64H73NO8P2K 1084.4443, found 1084.44515. 
31P{1H} NMR (121 MHz, C6D6):  (ppm) = 126.7 (s), 138.2 (s). 
1H NMR (300 MHz, C6D6):  (ppm) = 1.03-1.06 (m, 6H, C(CH3)2 and CHCH3), 1.23 (s, 9H, C(CH3)3), 
1.26 (s, 3H, C(CH3)2), 1.29 (s, 18H, 2C(CH3)3), 1.43 (s, 9H, C(CH3)3), 2.45 (ddd, 1H, HA-5, 
2J5A-5B = 14.1 Hz, J = 6.1 Hz, J = 1.8 Hz), 2.67-2.71 (m, 1H, HB-5, 2J5A-5B = 14.1 Hz), 3.23-3.32 (m, 
1H, CHCH3), 3.70-3.72 (m, 1H, H-3), 4.38 (brs, 1H, H-4), 4.44 (d, 1H, H-2, 3J1-2 = 3.7 Hz), 5.87 (d, 
1H, H-1, 3J1-2 = 3.7 Hz), 6.83-6.88 (m, 1H, CH-Ar), 6.98-7.11 (m, 7H, CH-Ar), 7.28-7.80 (m, 13H, 
CH-Ar). 
13C NMR (125 MHz, C6D6):  (ppm) = 21.9 (d, CHCH3, JC-P = 19.1 Hz), 26.3 (C(CH3)2), 26.9 
(C(CH3)2), 31.3 (d, C(CH3)3, JC-P = 2.7 Hz), 31.5 (d, C(CH3)3, JC-P = 1.1 Hz), 31.6 (C(CH3)3), 31.6 
(C(CH3)3), 34.6 (C(CH3)3), 34.7 (C(CH3)3), 35.5 (C(CH3)3), 35.6 (C(CH3)3), 39.5 (C-5), 58.5 (d, 
CHCH3, JC-P = 28.8 Hz), 72.2 (d, C-3, J3-P = 3.4 Hz), 73.6 (C-4), 85.3 (d, C-2, J2-P = 3.8 Hz), 105.4 
(C-1), 111.4 (C(CH3)2), 120.3 (d, CHAr, JC-P = 14.1 Hz), 122.1 (d, CAr, JC-P = 1.6 Hz), 122.8 (d, CHAr, 
JC-P = 8.4 Hz), , 124.5 (2CHAr), 124.5 (CHAr), 124.8 (d, CAr, JC-P = 3.1 Hz), 125.2 (CHAr), 126.7 
(CHAr), 126.8 (CHAr), 127.0 (CHAr), 127.0 (CHAr), 127.1 (CHAr), 127.1 (CHAr), 127.1 (CHAr), 127.4 
(2CHAr), 128.2 (CHAr), 128.3 (CHAr),  128.4 (2CHAr), 129.3 (CHAr), 130.2 (CHAr), 130.7 (CAr), 131.4 
(CAr), 133.8 (d, CAr, JC-P = 3.8 Hz), 133.8 (d, CAr, JC-P = 4.4 Hz), 134.7 (CAr), 135.2 (CAr), 140.9 (CAr), 
141.0 (CAr), 143.6 (d, CAr, JC-P = 6.6 Hz), 146.1 (d, CAr-O, JC-P = 6.6 Hz), 146.3 (d, CAr-O, 
JC-P = 6.3 Hz), 146.9 (d, 2CAr, JC-P = 4.7 Hz), 148.4 (d, CAr-O, JC-P = 1.3 Hz), 150.8 (d, CAr-O, 
JC-P = 5.7 Hz). 
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3-(R)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-(S)-[(1,1'-binaphthyl-2,2'-diyl)phosphite]-5-deoxy-5-N-
-methyl-benzylamino-1,2-O-isopropylidene--D-xylofuranose (28i) 
Starting from (R)-BINOL (158 mg, 0.55 mmol), (S)-BINOL (158 mg, 
0.55 mmol), 5-Deoxy-5-N-(S)--methylbenzylamino-1,2-O-
isopropylidene--D-xylofuranose 27e (147 mg, 0.5 mmol), pyridine 
(182 mg, 2.3 mmol) and Et3N (202 mg, 2.0 mmol) in toluene (5 mL), 
the product 28i was isolated as a white solid (97 mg, 21 %, Rf 0.28). 
[α]D
26 = -49.6 (c 0.28, CHCl3). 
Anal. calcd for C56H45NO8P2: C, 72.96; H, 4.92; N, 1.52. Found: C, 
72.54; H, 5.21; N, 1.28 %. 
HRMS (ESI) calculated for C56H46NO8P2 922.26932, found 
922.26866. 
HRMS (ESI) calculated for C56H45NO8P2Na 944.25126, found 
944.2506. 
HRMS (ESI) calculated for C56H45NO8P2K 960.22520, found 960.22543. 
31P{1H} NMR (121 MHz, C6D6):  (ppm) = 133.1 (s), 145.8 (s). 
1H NMR (300 MHz, C6D6):  (ppm) = 1.06 (s, 3H, C(CH3)2), 1.36 (s, 3H, C(CH3)2), 1.88 (dd, 3H, 
CHCH3, 3JH-H = 7.2 Hz, 4JH-P = 3.2 Hz), 3.08 (ddd, 1H, HA-5, 2J5A-5B = 15.2 Hz, J = 7.7 Hz, J = 2.2 Hz), 
3.74 (m, 1H, HB-5), 4.31 (dd, 1H, H-3, 3J3-P = 9.8 Hz, J = 2.8 Hz), 4.49-4.53 (m, 2H, H-2 and H-4), 
5.07-5.20 (m, 1H, CHCH3), 5.79 (d, 1H, H-1, 3J1-2 = 3.7 Hz), 6.60-7.14 (m, 9H, CH-Ar), 7.18-7.83 (m, 
20H, CH-Ar). 
13C NMR (63 MHz, C6D6):  (ppm) = 26.1 (C(CH3)2), 26.7 (C(CH3)2), 30.2 (CHCH3), 45.7 (C-5), 59.2 
(d, CHCH3, JC-P = 22.4 Hz), 79.8 (C-3), 83.3 (m, C-4), 84.4 (d, C-2, J2-P = 1.6 Hz), 105.2 (C-1), 111.7 
(C(CH3)2), 121.8 (CHAr), 122.0 (d, CAr), 122.0 (CHAr), 122.1 (d, CHAr, JC-P = 1.7 Hz), 122.4 (d, CHAr, 
JC-P = 1.5 Hz), 122.7 (d, CAr, JC-P = 2.0 Hz), 124.8 (CHAr), 124.9 (d, CAr), 125.0 (CHAr), 125.2 (CHAr), 
125.4 (CHAr), 125.5 (d, CAr, JC-P = 5.4 Hz), 126.5 (CHAr), 126.6 (2CHAr), 126.6 (CHAr), 127.3 (CHAr), 
127.4 (CHAr), 127.5 (CHAr), 127.6 (CHAr), 127.8 (CHAr), 128.4 (CHAr), 128.6 (CHAr), 128.7 (2CHAr), 
128.8 (2CHAr), 128.8 (2CHAr), 130.5 (CHAr), 130.7 (CHAr), 130.9 (CHAr), 131.0 (CHAr), 131.2 (CAr), 
131.5 (CAr), 132.0 (CAr), 132.1 (CAr), 132.8 (d, CAr, JC-P = 1.1 Hz), 133.2 (d, CAr, JC-P = 1.1 Hz), 133.3 
(d, CAr, JC-P = 1.5 Hz), 133.6 (d, CAr, JC-P = 1.5 Hz), 144.3 (d, CAr, JC-P = 1.3 Hz), 147.3 (d, CAr-O, 
JC-P = 1.2 Hz), 149.4 (d, CAr-O, JC-P = 6.8 Hz), 150.3 (CAr-O), 151.2 (d, CAr-O, JC-P = 5.2 Hz). 
 
 
5.1.2.7 Synthesis of 3-phenylbutanal 
General procedure for the asymmetric hydroformylation of -methyl styrene 
The substrate (1.0 eq), Rh(acac)(CO)2 (1 mol%) and the ligand (1.2 mol%) are transferred into a vial, 
which is placed into a stainless steel autoclave. The solvent (8 mL/1.0  mmol substrate) is added under 
an argon atmosphere and the autoclave is purged with argon (three times) followed by syngas (three 
times). The indicated reaction conditions (syngas pressure, temperature and reaction time) are adjusted 
by an automatic program. After stirring for the adjusted time, the mixture is cooled to room 
temperature, depressurized and concentrated in vacuo. The reaction mixture was analyzed by 
1H NMR. The enantiomeric excess is determined by GC analysis. A racemic mixture of 30, as sample 
for the quantitative and qualitative analysis, is prepared by the hydroformylation of -methyl styrene 
with 1 mol% Rh(acac)(CO)2 and 5 mol% PPh3 in toluene. 
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3-Phenylbutanal (30)[151] 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.32 (d, 3H, CH3, 3JH-H = 6.9 Hz), 2.66 
(ddd, 1H, HA-CH, 2JA-B = 16.9 Hz, 3JH-A = 6.9 Hz, 3JH-A = 2.1 Hz), 2.76 (ddd, 1H, 
HB-CH2, 3JA-B = 16.9 Hz, 3JH-B = 6.7 Hz, 4JH-B = 2.0 Hz), 3.36 (m, 1H, CH), 
7.15-7.34 (m, 5H, CH-Ar), 9.71 (t, 1H, CHO, 3JH-H = 2.1 Hz). 
13C NMR (63 MHz, CDCl3):  (ppm) = 22.4 (CH3), 34.5 (CH), 51.9 (CH2), 126.7 (CHAr), 127.0 
(2CHAr), 128.9 (2CHAr), 145.7 (CAr), 201.9 (CHO). 
Separation of enantiomers by GC on Lipodex E (25 m×0.25 mm), 90/25-6-180; tR = 13.5 min for 
(+)-enantiomer and tR = 13.5 min for (–)-enantiomer. 
 
2-Methyl-2-phenylpropanal (31)[152] 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.47 (s, 6H, 2CH3), 7.26-7.42 (m, 5H, 
CH-Ar), 9.51 (s, 1H, CHO). 
13C NMR spectrum could not be analyzed due to the small amount in the final reaction 
mixture. 
 
Cumene[153] 
1H NMR (300 MHz, CDCl3):  (ppm) = 1.24 (d, 6H, 2CH3, 3JH-H = 6.9 Hz), 2.93 (m, 1H, 
CH), 6.75-7.10 (m, 5H, CH-Ar). 
13C NMR spectrum could not be analyzed due to the small amount in the final reaction 
mixture. 
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5.2 List of abbreviations 
° Degree(s) 
a Year(s) 
 Specific rotation 
Å Angstrom(s) 
Ac Acetyl 
Anal. calcd Analytical calculated 
Ar Aromatic or aryl 
asym. Asymmetric 
b/l Branched to linear 
n Natural bite angle 
eq Equivalent 
BASF Badische Anilin und Sodafabrik 
Bn Benzyl 
Boc tert-Butoxycarbonyl 
br Broad 
Bu Butyl 
n-BuLi normal-Butyl lithium 
c Concentration 
C Carbon 
°C Degree Celsius 
cat. Catalyst 
cHex Cyclohexyl 
conv. Conversion 
D Spectrum line of sodium at 589 nm or deuterium 
d Double or doublet or deuterated 
 Chemical shift 
Da Dalton 
DABCO 1,4-Diazabicyclo[2.2.2]octane 
DCM Dichloromethane 
DEPT Distortionless enhancement by polarization transfer 
DMF N,N-Dimethylformamide 
DMSO Dimethyl sulfoxide 
ea Equatorial-apical 
ee Equatorial-equatorial or enantiomeric excess 
e.g. exempli gratia (for example) 
EI Electron ionization 
ESI Electrospray ionization 
Et Ethyl 
et al. et alii (and others) 
Et3N Triethylamine 
EtOAc Ethyl acetate 
Et2O Diethyl ether 
eV Electronvolt 
f Frequency 
g Gram(s) or gaseous 
GC Gas chromatography 
h Hour(s) 
H Hydrogen or proton 
HPLC High pressure liquid chromatography 
HP-NMR High pressure NMR 
HRMS High resolution mass spectrometry 
Hünig’s base N,N-Diisopropylethylamine 
Hz Hertz 
i iso 
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iPr Isopropyl 
J Coupling constant 
J Joule 
l Length 
L Liter(s) 
 Wavelength 
LDA Lithium diisopropylamide 
m Meter(s) or multiplet 
M Metal 
[M]+ Molpeak 
m/z Mass to charge 
min Minute(s) 
Me Methyl 
MeCN Acetonitrile 
mol Mole(s) 
mp Melting point 
MS Mass spectrometry 
MTBE Methyl tert-butyl ether 
n normal 
n.d. Not determined 
Naph Naphthyl 
NMP N-Methyl-2-pyrrolidone 
NMR Nuclear magnetic resonance 
OTf Triflate (trifluoromethanesulfonate) 
p Pressure 
Pa Pascal 
PC Propylene carbonate 
pH Pondus hydrogenii 
Ph Phenyl 
ppm Part(s) per million 
R Organic rest 
rac Racemic 
Rf Response factor 
r.t. Room temperature 
s Singlet 
S Solvent or substrate 
 Tolman’s cone angle 
t Ton(s) 
t tert or time 
tBu tert-Butyl 
T Temperature 
THF Tetrahydrofuran 
TMS Trimethylsilyl or tetramethylsilane 
TOF Turnover frequency or time of flight 
TON Turnover number 
q Quartet 
v Volume 
vs. versus 
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acac Acetyl acetonato 
Alkanox® 240 Tris(2,4-di-tert-butylphenyl)phosphite 
(S,S)-BDPP (2S,4S)-(+)-2,4-Bis(diphenylphosphino)pentane 
(S,S)-BenzP* (S,S)-(–)-1,2-Bis(tert-butylmethylphosphino)benzene 
(R,R)-BenzP* (R,R)-(+)-1,2-Bis(tert-butylmethylphosphino)benzene 
(S)-BINAP (S)-(–)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthalene 
(R)-BINAP (R)-(+)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthalene 
(R)-4-Tol-BINAP (R)-(+)-2,2'-Bis(di-p-tolylphosphino)-1,1'-binaphthalene 
(R,S)-BINAPHOS 
(11bS)-4-{[(R)-2'-(Diphenylphosphino)-[1,1'-binaphthalen]-2-
yl]oxy}dinaphtho[2,1-d:1',2'-f][1,3,2]dioxophosphepin 
(R,R)-BINAPHOS 
(11bR)-4-{[(R)-2'-(Diphenylphosphino)-[1,1'-binaphthalen]-2-
yl]oxy}dinaphtho[2,1-d:1',2'-f][1,3,2]dioxophosphepin 
(S)-BINOL (S)-(–)-1,1'-Binaphthalene-2,2'-diol 
(R)-BINOL (R)-(+)-1,1'-Binaphthalene-2,2'-diol 
(S)-BIPHEN-H2 (S)-5,5',6,6'-Tetramethyl-3,3'-di-tert-butyl-1,1'-biphenyl-2,2'-diol 
(R)-BIPHEN-H2 (R)-5,5',6,6'-Tetramethyl-3,3'-di-tert-butyl-1,1'-biphenyl-2,2'-diol 
(R)-MeO-BIPHEP (R)-(+)-2,2'-Bis(diphenylphosphino)-6,6'-dimethoxy-1,1'-biphenyl 
BiPhePhos 
6,6'-[(3,3'-Di-tert-butyl-5,5'-dimethoxy-1,1'-biphenyl-2,2'-
diyl)bis(oxy)]bis(dibenzo[d,f][1,3,2]dioxaphosphepin) 
BISBI 2,2'-Bis[(diphenylphosphino)methyl]-1,1'-biphenyl 
bisDBP 3,3',5,5'-Tetra-tert-butyl-1,1'-biphenyl-2,2'-diol 
(S,S,S)-BisDiazaPhos 
2,2',2'',2'''-(1,2-Phenylenebis[(1S,3S)-tetrahydro-5,8-dioxo-1H-
[1,2,4]diazaphopholo[1,2-a]pyridazine-2,1,3(3H)-triyl])tetrakis(N-
[(1S)-1-phenylethyl])benzamide 
(R,R,S)-BisDiazaPhos 
2,2',2'',2'''-(1,2-Phenylenebis[(1R,3R)-tetrahydro-5,8-dioxo-1H-
[1,2,4]diazaphopholo[1,2-a]pyridazine-2,1,3(3H)-triyl])tetrakis(N-
[(1S)-1-phenylethyl])benzamide 
(Sax,S,S)-BobPhos 
(11aS)-4,8-Di-tert-butyl-6-{[(2S,5S)-2,5-diphenylphospholan-1-
yl]methoxy}-1,2,10,11-
tetramethyldibenzo[d,f][1,3,2]dioxophosphepin 
(S,S)-Me-BPE (–)-1,2-Bis[(2S,5S)-2,5-dimethylphospholano]ethane 
(S,S)-Et-BPE (–)-1,2-Bis[(2S,5S)-2,5-dimethylphospholano]ethane 
(S,S)-Ph-BPE (+)-1,2-Bis[(2S,5S)-2,5-diphenylphospholano]ethane 
(R,R)-Ph-BPE (–)-1,2-Bis[(2R,5R)-2,5-diphenylphospholano]ethane 
(–)-BPPM 
(2S,4S)-N-(tert-Butoxycarbonyl)-4-(diphenylphosphino)-2-
[(diphenylphosphino)methyl]pyrrolidine 
catASium®MQF(R) 
(–)-1,2-Bis[(2R,5R)-2,5-dimethylphospholanyl]-3,3,4,4-tetrafluoro-1-
cyclobutene 
(S,S)-Chiraphite 
(–)-6,6'-{[(1S,3S)-1,3-Dimethyl-1,3-propanedyl]bis(oxy)}bis[4,8-
bis(tert-butyl)-2,10-dimethoxy-bibenzo[d,f][1,3,2]dioxaphosphepin 
(R,R)-Chiraphite 
(+)-6,6'-{[(1R,3R)-1,3-Dimethyl-1,3-propanedyl]bis(oxy)}bis[4,8-
bis(tert-butyl)-2,10-dimethoxy-bibenzo[d,f][1,3,2]dioxaphosphepin 
(S,S)-ChiraPhos (2S,4S)-(–)-2,4-Bis(diphenylphosphino)butane 
cod 1,5-Cyclooctadiene 
Crabtree’s catalyst 
(1,5-Cyclooctadiene)(pyridine)(tricyclohexylphosphine)-iridium(I) 
hexafluorophosphate 
(R)-DifluorPhos 
(R)-(–)-5,5'-Bis(diphenylphosphino)-2,2,2',2'-tetrafluoro-4,4'-bi-1,3-
benzodioxole 
(S,S)-DIOP 
(4S,5S)-(+)-4,5-Bis(diphenylphosphinomethyl)-2,2-dimethyl-1,3-
dioxolane 
(R,R)-DIPAMP (R,R)-(–)-1,2-Bis[(2-methoxyphenyl)(phenylphosphino)]ethane 
dppb 1,4-Bis(diphenylphosphino)butane 
dppe 1,4-Bis(diphenylphosphino)ethane 
dppf 1,1'-Bis(diphenylphosphino)ferrocene 
(R,S)-dppftbp 
= (R,S)-JosiPhos-4 
(R)-1-[(S)-2-(Diphenylphosphino)ferrocenyl]ethyldi-tert-
butylphosphine 
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(R,R,S,S)-DuanPhos 
(1R,1'R,2S,2'S)-2,2'-Di-tert-butyl-2,3',2,3'-tetrahydro,1H,1'H-
(1,1')biisophosphindolyl 
(S,S)-Me-DuPhos (+)-1,2-Bis[(2S,5S)-2,5-dimethylphospholano]benzene 
(R,R)-Me-DuPhos (–)-1,2-Bis[(2R,5R)-2,5-dimethylphospholano]benzene 
(S,S)-Et-DuPhos (+)-1,2-Bis[(2S,5S)-2,5-diethylphospholano]benzene 
(S,S)-iPr-DuPhos (–)-1,2-Bis[(2S,5S)-2,5-diisopropylphospholano]benzene 
(S,S)-Et-FerroTANE® (–)-1,1'-Bis[(2S,4S)-2,4-diethylphosphotano]ferocene 
(S,R)-JosiPhos 
(S)-1-[(R)-2-
(Diphenylphosphino)ferrocenyl]ethyldicyclohexylphosphine 
(R,S)-JosiPhos 
(R)-1-[(S)-2-
(Diphenylphosphino)ferrocenyl]ethyldicyclohexylphosphine 
(R,S)-JosiPhos-1 
(R)-1-[(S)-2-(Dicyclohexylphosphino)ferrocenyl]ethyldi-tert-
butylphosphine 
(R,S)-JosiPhos-2 
(R)-1-[(S)-2-
(Dicyclohexylphosphino)ferrocenyl]ethyldicyclohexylphosphine 
(R,S)-JosiPhos-3 
(R)-1-{(S)-2-[Bis(4-methoxy-3,5-
dimethylphenyl)phosphino]ferrocenyl}ethyldi(3,5-xylyl)phosphine 
(S,R)-JosiPhos-4 
(S)-1-[(R)-2-(Diphenylphosphino)ferrocenyl]ethyldi-tert-
butylphosphine 
(S,S)-Kelliphite 
(S,S)-(+)-6,6'-[(1,1'-Biphenyl-2,2'-diyl)bis(oxy)]bis[4,8-di-tert-butyl-
1,2,10,11-tetramethyl]dibenzo[d,f][1,3,2]dioxaphosphepin 
(R,R)-Kelliphite 
(R,R)-(–)-6,6'-[(1,1'-Biphenyl-2,2'-diyl)bis(oxy)]bis[4,8-di-tert-butyl-
1,2,10,11-tetramethyl]dibenzo[d,f][1,3,2]dioxaphosphepin 
(S,S,R)-MandyPhos-1 
(S,S')-1,1'-Bis(dicyclohexylphosphino)-2,2'-bis[(R)--
(dimethylamino)benzyl]ferrocene 
(S,S,R)-MandyPhos-2 
(S,S')-1,1'-Bis[(R)--(dimethylamino)benzyl]-2,2'-
bis[diphenylphosphino)ferrocene 
(R,R)-QuinoxP* (R,R)-(–)-2,3-Bis(tert-butylmethylphosphino)quinoxaline 
(R)-DTBM-SegPhos 
(R)-(–)-5,5'-Bis[di(3,5-di-tert-butyl-4-methoxyphenyl)phosphino]-
4,4'-bi-1,3-benzodioxole 
(R)-SynPhos 
(R)-(+)-6,6'-Bis(diphenylphosphino)-2,2',3,3'-tetrahydro-5,5'-bi-1,4-
benzodioxin 
(S,S,R,R)-TangPhos (1S,1'S,2R,2'R)-1,1'-Di-tert-butyl-(2,2')-diphospholane 
(S,S)- cHex2PThrePHOX 
{Dibenzyl[(4S,5S)-5-methyl-2-phenyl-4,5-dihydro-4-
oxazolyl]methyl}dicyclohexylphosphinite 
(S,S)-Ph2PThrePHOX 
{Dibenzyl[(4S,5S)-5-methyl-2-phenyl-4,5-dihydro-4-
oxazolyl]methyl}diphenylphosphinite 
(R)-C3-TunePhos 
(R)-1,13-Bis(diphenylphosphino)-7,8-dihydro-6H-
dibenzo[f,h][1,5]dioxonin 
(R,R)-WalPhos-1 
(R)-1-{(R)-2-[2-(Diphenylphosphino)phenyl]ferrocenyl}ethylbis[3,5-
bis-(trifluoromethyl)phenyl]phosphine 
XantPhos 4,5-Bis(diphenylphosphino)-9,9-dimethylxanthene 
(R,S)-XyliPhos 
(R)-1-{[(S)-2-Diphenylphosphino]ferrocenyl}ethylbis(3,5-
dimethylphenyl)phosphine 
(R,S)-YanPhos 
(11bS)-N-[(R)-2'-(Diphenylphosphino)-[1,1'-binaphthalen]-2-yl]-N-
ethyldinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin-4-amine 
L1b 
3,5-Bis[(3,3'-di-tert-butyl-5,5'-dimethoxy-1,1'-biphenyl-2,2'- 
diyl)phosphite]-1,2-O-isopropylidene--D-ribofuranose 
L2b 
3,5-Bis[(3,3'-di-tert-butyl-5,5'-dimethoxy-1,1'-biphenyl-2,2'- 
diyl)phosphite]-1,2-O-isopropylidene--D-allofuranose 
L2c 
3,5-Bis[(3,3',5,5'-tetra-tert-butyl-1,1'-biphenyl-2,2'- 
diyl)phosphite]-1,2-O-isopropylidene--D-allofuranose 
L2d 
3,5-Bis[(3,3'-bistrimethylsilyl-1,1'-biphenyl-2,2'-diyl)phosphite]-6-
deoxy-1,2-O-isopropylidene--D-allofuranose 
L2e 
3,5-Bis{[(S)-1,1'-binaphthyl-2,2'-diyl]phosphite}-6-deoxy-1,2-O-
isopropylidene--D-allofuranose 
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L2f 
3,5-Bis{[(R)-1,1'-binaphthyl-2,2'-diyl]phosphite}-6-deoxy-1,2-O-
isopropylidene--D-allofuranose 
L3c 
3,5-Bis[(3,3',5,5'-tetra-tert-butyl-1,1'-biphenyl-2,2'- 
diyl)phosphite]-3-amine-3-deoxy-1,2-O-isopropylidene--D-
ribofuranose 
L4c 
3,5-Bis[(3,3',5,5'-tetra-tert-butyl-1,1'-biphenyl-2,2'- 
diyl)phosphite]-3-amine-3-deoxy-1,2-O-isopropylidene--D-
xylofuranose 
L5c 
3,5-Bis[(3,3',5,5'-tetra-tert-butyl-1,1'-biphenyl-2,2'- 
diyl)phosphite]-5-amine-5-deoxy-1,2-O-isopropylidene--D-
xylofuranose 
L6a 
3,5-Bis[(1,1'-biphenyl-2,2'-diyl)phosphite]-1,2-O-isopropylidene--D-
xylofuranose 
L6b 
3,5-Bis[(3,3'-di-tert-butyl-5,5'-dimethoxy-1,1'-biphenyl-2,2'- 
diyl)phosphite]-1,2-O-isopropylidene--D-xylofuranose 
L6c 
3,5-Bis[(3,3',5,5'-tetra-tert-butyl-1,1'-biphenyl-2,2'- 
diyl)phosphite]-1,2-O-isopropylidene--D-xylofuranose 
L6e 
3,5-Bis{[(S)-1,1'-binaphthyl-2,2'-diyl]phosphite}-1,2-O-
isopropylidene--D-xylofuranose 
L6f 
3,5-Bis{[(R)-1,1'-binaphthyl-2,2'-diyl]phosphite}-1,2-O-
isopropylidene--D-xylofuranose 
L6g 
3,5-Bis{[(S)-3,3'-bistrimethylsilyl-1,1'-binaphthyl-2,2'-
diyl]phosphite}-1,2-O-isopropylidene--D-xylofuranose 
L6h 
3,5-Bis{[(R)-3,3'-bistrimethylsilyl-1,1'-binaphthyl-2,2'-
diyl]phosphite}-1,2-O-isopropylidene--D-xylofuranose 
L7b 
3,5-Bis[(3,3'-di-tert-butyl-5,5'-dimethoxy-1,1'-biphenyl-2,2'- 
diyl)phosphite]-6-deoxy-1,2-O-isopropylidene--L-idofuranose 
L7c 
3,5-Bis[(3,3',5,5'-tetra-tert-butyl-1,1'-biphenyl-2,2'- 
diyl)phosphite]-6-deoxy-1,2-O-isopropylidene--L-idofuranose 
L8d 
3,5-Bis[(3,3'-bistrimethylsilyl-1,1'-biphenyl-2,2'-diyl)phosphite]-6-
deoxy-1,2-O-isopropylidene--D-glucofuranose 
L8e 
3,5-Bis{[(S)-1,1'-binaphthyl-2,2'-diyl]phosphite}-6-deoxy-1,2-O-
isopropylidene--D-glucofuranose 
L8f 
3,5-Bis{[(R)-1,1'-binaphthyl-2,2'-diyl]phosphite}-6-deoxy-1,2-O-
isopropylidene--D-glucofuranose 
L8g 
3,5-Bis{[(S)-3,3'-bistrimethylsilyl-1,1'-binaphthyl-2,2'-
diyl]phosphite}-6-deoxy-1,2-O-isopropylidene--D-glucofuranose 
A 
1,2-Bis[(4R,5S,6S,7R)-5,6-dimethoxy-4,7-dimethyl-1,3,2-
dioxophosphepan-2-yl)ethane 
B (S)-1,4-Bis(diphenylphosphino)butan-2-amine 
C 
{(S)-2-[2-((R,R)-2,5-Dimethylphospholan-1-yl)phenyl]-4-isopropyl-
4,5-dihydrooxazole}(1,5-cyclooctadiene)iridium(I) 
hexafluorophosphate 
D 
Dichloro[(R)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl][(R,R)-1,2-
diphenylethane diamine]ruthenium(II) 
E 
Dichloro[(S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl][(S,S)-1,2-
diphenylethane diamine]ruthenium(II) 
F 
Dichloro[(S)-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl][(R,R)-1,2-
diphenylethane diamine]ruthenium(II) 
G 
(1S,1'S)-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis[phenyl(o-
tolyl)phosphine] 
H 
(1S,1'S)-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis[(2-
methoxyphenyl)(phenyl) phosphine] 
I 
(1S,1'S)-(9,9-Dimethyl-9H-xanthene-4,5-diyl)bis(naphthalen-2-
yl(phenyl)phosphine] 
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5.3 Applied ligands in this dissertation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Applied achiral ligands in this dissertation. 
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Figure 25. Applied ligands in this dissertation. 
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5.4 Supplementary information 
Table 34. Asymmetric hydrogenation of 1a with different catalysts in THF.a 
Entry Catalyst Yieldb [%] eec [%] 
1d Ce 31 1 (S) 
2 De 16 4 (S) 
3 Ee 6 2 (R) 
4 Fe 6 9 (S) 
5 Ir((S,S)-Ph2PThrePHOX)(cod) 69 4 (R) 
6 Ir((S,S)-cHex2PThrePHOX)(cod) 67 4 (S) 
a 1.0 mmol of 1a, catalyst 10.0 µmol, H2, 4 mL of THF, 50 °C, 5.0 MPa, S/Rh = 100, 20 h. 
b Yields were determined by 1H NMR spectroscopy. 
c Ee-values were determined by GC analysis; absolute configurations were compared to synthesized enantiomerically pure 
O-silylated methyl lactate. 
d Reaction was performed at 40 °C and 1.5 MPa. 
e Catalysts C-F were recently prepared in the research group of Prof. Börner and shown in Chapter 5.3. 
 
Table 35. Rh-catalyzed asymmetric hydroformylation of 6a with non-commercial and new ligands.a 
Entry Ligand 
Conv.b 
[%] 
14b 
[%] 
15b,c 
[%] 
8ab 
[%] 
(E)-9ab [%] (Z)-9ab [%] eed [%] 
1 20f 100 1 <1 62 10 26 n.d. 
2 21a 100 30 – 22 24 24 rac 
3 22b 100 11 – 74 5 10 rac 
4 Gf 53 2 <1 32 4 15 n.d. 
a 0.5 mmol of 6a, Rh(acac)(CO)2 5.0 µmol, PP-ligand 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, 30 °C, 2.0 MPa, S/Rh = 100, 
63 h. 
b Conversions and yields were determined by 1H NMR spectroscopy. 
c Due to the small amount in the final mixture, the amount of the linear aldehyde (15) was determined by integration of the 
characteristic signal for the proton of the aldehyde group ( = 9.39 ppm) in 1H NMR spectroscopy. 
d Ee-values of the branched aldehyde (14) were determined by GC analysis. 
f Ligand G was recently prepared in the research group of Prof. Börner and shown in Chapter 5.3. 
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Table 36. Rh-catalyzed asymmetric hydroformylation of 16a.a 
Entry Ligand Conv.b [%] 17ab [%] 18ab [%] 19ab [%] eec [%] 
1d (S,S)-DIOP 64 <1 – 63 n.d. 
2e (S,S)-DIOP 56 48 <1 7 4 (–) 
3f (S,S)-DIOP 50 35 3 11 7 (–) 
4 (S,S)-DIOP/PPh3 (1:1) 72 52 9 11 8 (–) 
5d (R,R)-QuinoxP* 93 36 2 55 10 (–) 
6g (R,R)-QuinoxP* 64 21 8 34 16 (–) 
7h (R,R)-QuinoxP* 17 1 2 14 23 (–) 
8d (S,S)-BenzP* 68 34 4 29 2 (+) 
9 (S,S)-ChiraPhos 42 21 3 18 24 (+) 
10 21a >99 97 <1 3 15 (–) 
11g 21a 67 64 1 2 19 (–) 
12h,i 21a 12 9 3 <1 14 (–) 
13e 21a 62 59 1 2 12 (–) 
14k 21a 39 37 1 1 22 (–) 
15l 21a 79 75 1 3 11 (–) 
16m 21a 66 62 <1 4 3 (–) 
17 21b >99 94 <1 6 6 (–) 
18g 21b 85 80 2 3 8 (–) 
19 21c 69 64 <1 5 14 (–) 
20g 21c 13 12 <1 <1 19 (–) 
21 21d 66 63 <1 2 10 (–) 
22g 21d 16 14 <1 <1 10 (–) 
23g 21e 32 30 <1 1 3 (–) 
24 Gn 65 59 1 5 11 (+) 
25g Gn 45 40 2 2 28 (+) 
26h,o Gn 46 37 6 3 41 (+) 
27g Hn 71 62 2 8 4 (–) 
28g In 89 77 2 10 11 (–) 
a 0.5 mmol of 16a, Rh(acac)(CO)2 5.0 µmol, PP-ligand 6.0 µmol, CO/H2 = 1:1, 5 mL of toluene, 100 °C, 1.0 MPa, 
S/Rh = 100, 21 h. 
b Conversions and yields were determined by 31P NMR spectroscopy. 
c Ee-values of the linear aldehyde (17a) were determined by GC analysis. 
d Reaction was performed with a partial pressure ratio CO/H2 = 1:5. 
e Reaction was performed in THF. 
f Reaction was performed with [Rh(cod)2]BF4. 
g Reaction was performed at 80 °C. 
h Reaction was performed at 60 °C. 
i Reaction was performed under 3.0 MPa. 
k Reaction was performed in DCM. 
l Reaction was performed in EtOAc. 
m Reaction was performed in heptane. 
n Ligands G-I were recently prepared in the research group of Prof. Börner and shown in Chapter 5.3. 
o Rh(acac)(CO)2 25.0 µmol, ligand 30.0 µmol. 
 
 
 
 
 
 
 
Chapter 5: Appendix 
- 142 - 
5.5 References 
[1] Tranter, G. E. Mol. Phys. 1985, 56, 825-838. 
[2] Catalysis from A to Z - A Concise Encyclopedia; Cornils, B., Herrmann, W. A., Schlögl, R., Wong, C.-H., Eds; 
WILEY-VCH: Weinheim, 2003. 
[3] Angewandte homogene Katalyse; Behr, A., Eds; WILEY-VCH: Weinheim, Germany, 2008. 
[4] (a) Pfaltz, A.; Blankenstein, J.; Hilgraf, R.; Hörmann, E.; McIntyre, S.; Menges, F.; Schönleber, M.; Smidt, S. P.; 
Wüstenberg, B.; Zimmermann, N. Adv. Synth. Catal. 2003, 345, 33-45. (b) Cui, X.; Burgess, K. Chem. Rev. 2005, 
105, 3272-3296. (c) Källström, K.; Munslow, I.; Andersson, P. G. Chem. Eur. J. 2006, 12, 3194-3200. 
(d) Roseblade, S. J.; Pfaltz, A. Acc. Chem. Res. 2007, 40, 1402-1411. (e) Mazuela, J.; Verendel, J. J.; Coll, M.; 
Schäffner, B.; Börner, A.; Andersson, P. G.; Pàmies, O.; Diéguez, M. J. Am. Chem. Soc. 2009, 131, 12344-12353. 
[5] (a) Kitamura, M.; Tsukamoto, M.; Bessho, Y.; Yoshimura, M.; Kobs, U.; Widhalm, M.; Noyori, R. J. Am. Chem. 
Soc. 2002, 124, 6649-6667. (b) Gridnev, I. D.; Imamoto, T. Acc. Chem. Res. 2004, 37, 633-643. 
[6] Koenig, K. E.; Sabacky, M. J.; Bachmann, G. L.; Christopfel, W. C.; Barnstorff, H. D.; Friedman, R. B.; Knowles, 
W. S.; Stults, B. R.; Vineyard, B. D.; Weinkauff, D. J. Ann. N.Y. Acad. Sci. 1980, 333, 16-22. 
[7] Blaser, H.-U.; Malan, C.; Pugin, B.; Spindler, F.; Steiner, H.; Studer, M. Adv. Synth. Catal. 2003, 345, 103-151. 
[8] Halpern, J. Science 1982, 217, 401-406. 
[9] (a) Asymmetric Catalysis on Industrial Scale; 1st ed.; Blaser, H. U., Federsel, H.-J., Eds; WILEY-VCH: Weinheim, 
Germany, 2004. (b) Asymmetric Catalysis on Industrial Scale; 2nd ed.; Blaser, H.-U., Federsel, H.-J., Eds; 
WILEY-VCH: Weinheim, Germany, 2010. 
[10] Blaser, H. U.; Hanreich, R.; Schneider, H. D.; Spindler, F.; Steinacher, B. In Asymmetric Catalysis on Industrial 
Scale; 1st ed.; Blaser, H. U., Schmidt, S., Eds; WILEY-VCH: Weinheim, Germany, 2004; pp 55-70. 
[11] (a) Jäkel, C.; Paciello, R.; BASF SE, Christoph Jaekel, Rocco Paciello; WO2006040096, 2006. (b) Schmidt-
Leithoff, J.; Jäkel, C.; Paciello, R.; BASF SE; EP2139835, 2008. (c) Heydrich, G.; Gralla, G.; Rauls, M.; Schmidt-
Leithoff, J.; Ebel, K.; Krause, W.; Oehlenschläger, S.; Jäkel, C.; Friedrich, M.; Bergner, E. J.; Kashani-Shirazi, N.; 
Paciello, R.; BASF; US20100249467, 2009. 
[12] (a) Selke, R. In Asymmetric Catalysis on Industrial Scale; 1st ed.; Blaser, H. U., Schmidt, S., Eds; WILEY-VCH: 
Weinheim, Germany, 2004; pp 39-53. (b) Knowles, W. S. In Asymmetric Catalysis on Industrial Scale; 1st ed.; 
Blaser, H. U., Schmidt, S., Eds; WILEY-VCH: Weinheim, Germany, 2004; pp 23-38. (c) Asymmetric Catalysis on 
Industrial Scale: Challenges, Approaches and Solutions; Blaser, H.-U., Schmidt, E., Eds; WILEY-VCH: 
Weinheim, Germany, 2004. 
[13] Cornils, B.; Herrmann, W. A.; Rasch, M. Angew. Chem. 1994, 106, 2219-2238. 
[14] Industrielle organische Chemie; Arpe, H.-J., Eds; WILEY-VCH: Weinheim, Germany, 2007. 
[15] (a) Whiteker, G. T.; Cobley, C. J. Top. Organomet. Chem. 2012, 42, 35-46. (b) 75 JAHRE OXO-SYNTHESE; Frey, 
G., Dämbkes, G., Eds; Klartext: Essen, Germany, 2013. 
[16] (a) Osborn, J. A.; Wilkinson, G.; Young, J. F. Chem. Commun. (London) 1965, 17-17. (b) Evans, D.; Osborn, J. A.; 
Wilkinson, G. J. Chem. Soc. 1968, 3133-3142. 
[17] (a) Clarke, M. L.; Roff, G. J. Chem. Eur. J. 2006, 12, 7978-7986. (b) Keulemans, A. I. M.; Kwantes, A.; van Bavel, 
T. Recl. Trav. Chim. Pays-Bas 1948, 67, 298-308. 
[18] (a) Botteghi, C.; Paganelli, S.; Schionato, A.; Marchetti, M. Chirality 1991, 3, 355-369. (b) Gladiali, S.; Pinna, L. 
Tetrahedron: Asymmetry 1990, 1, 693-696. (c) Gladiali, S.; Pinna, L. Tetrahedron: Asymmetry 1991, 2, 623-632. 
(d) Wang, X.; Buchwald, S. L. J. Org. Chem. 2013, 78, 3429-3433. 
[19] Tolman, C. A. Chem. Rev. 1977, 77, 313-348. 
[20] (a) Casey, C. P.; Whiteker, G. T. Isr. J. Chem. 1990, 30, 299-304. (b) Casey, C. P.; Whiteker, G. T.; Melville, M. 
G.; Petrovich, L. M.; Gavney Jr, J. A.; Powell, D. R. J. Am. Chem. Soc. 1992, 114, 5535-5543. 
[21] (a) van Leeuwen, P. W.; Kamer, P. C.; Reek, J. N.; Dierkes, P. Chem. Rev. 2000, 100, 2741-2770. (b) Kamer, P. C. 
J.; van Leeuwen, P. W. N. M.; Reek, J. N. H. Acc. Chem. Res. 2001, 34, 895-904. 
[22] (a) Homogenous Catalysis: Understanding the Art; van Leeuwen, P. W. N. M., Eds; Kluwer Academic: Dordrecht, 
2004. (b) Ferrocenes: Ligands, Materials and Biomolecules; Stepnicka, P., Eds; WILEY-VCH: Weinheim, 
Germany, 2008. 
[23] van Leeuwen, P. W. N. M.; Kamer, P. C. J.; Reek, J. N. H. Pure Appl. Chem. 1999, 71, 1443-1452. 
[24] (a) Wang, X.; Buchwald, S. L. J. Am. Chem. Soc. 2011, 133, 19080-19083. (b) Zheng, X.; Cao, B.; Liu, T.-l.; 
Zhang, X. Adv. Synth. Catal. 2013, 355, 679-684. 
[25] (a) Klosin, J.; Landis, C. R. Acc. Chem. Res. 2007, 40, 1251-1259. (b) Gual, A.; Godard, C.; Castillón, S.; Claver, 
C. Tetrahedron: Asymmetry 2010, 21, 1135-1146. (c) Rhodium Catalyzed Hydroformylation; van Leeuwen, P. W. 
N. M., Claver, C., Eds; Kluwer Arcademic: Dordrecht, 2002. (d) Agbossou, F.; Carpentier, J.-F.; Montreux, A. 
Chem. Rev. 1995, 95, 2485-2506. 
[26] (a) Franke, R.; Selent, D.; Börner, A. Chem. Rev. 2012, 112, 5675-5732. (b) Gusevskaya, E. V.; Jiménez-Pinto, J.; 
Börner, A. ChemCatChem 2014, 6, 382-411. 
Chapter 5: Appendix 
- 143 - 
[27] (a) Cobley, C. J.; Gardner, K.; Klosin, J.; Praquin, C.; Hill, C.; Whiteker, G. T.; Zanotti-Gerosa, A.; Petersen, J. L.; 
Abboud, K. A. J. Org. Chem. 2004, 69, 4031-4040. (b) Nozaki, K.; Sakai, N.; Nanno, T.; Higashijima, T.; Mano, 
S.; Horiuchi, T.; Takaya, H.; V, K. U. J. Am. Chem. Soc. 1997, 119, 4413-4423. (c) Nozaki, K.; Itoi, Y.; Shibahara, 
F.; Shirakawa, E.; Ohta, T.; Takaya, H.; Hiyama, T. J. Am. Chem. Soc. 1998, 120, 4051-4052. (d) Cobley, C. J.; 
Froese, R. D. J.; Klosin, J.; Qin, C.; Whiteker, G. T.; Abboud, K. A.; Uni, V.; Gaines, V. Organometallics 2007, 
26, 2986-2999. (e) Erre, G.; Enthaler, S.; Junge, K.; Gladiali, S.; Beller, M. J. Mol. Catal. A: Chem. 2008, 280, 
148-155. (f) Axtell, A. T.; Klosin, J.; Whiteker, G. T.; Cobley, C. J.; Fox, M. E.; Jackson, M.; Abboud, K. A. 
Organometallics 2009, 28, 2993-2999. (g) Robert, T.; Abiri, Z.; Wassenaar, J.; Sandee, A. J.; Romanski, S.; 
Neudörfl, J. r.-M.; Schmalz, H.-G. n.; Reek, J. N. H. Organometallics 2010, 29, 478-483. (h) Wassenaar, J.; de 
Bruin, B.; Reek, J. N. H. Organometallics 2010, 29, 2767-2776. 
[28] (a) McDonald, R. I.; Wong, G. W.; Neupane, R. P.; Stahl, S. S.; Landis, C. R. J. Am. Chem. Soc. 2010, 132, 
14027-14029. (b) Sakai, N.; Nozaki, K.; Takaya, H. J. Chem. Soc., Chem. Commun. 1994, 395-396. (c) Kollár, L.; 
Farkas, E.; Bâtiu, J. J. Mol. Catal. A: Chem. 1997, 115, 283-288. (d) Watkins, A. L.; Hashiguchi, B. G.; Landis, C. 
R. Org. Lett. 2008, 10, 4553-4556. (e) Mazuela, J.; Coll, M.; Pàmies, O.; Diéguez, M. J. Org. Chem. 2009, 74, 
5440-5445. (f) Worthy, A. D.; Joe, C. L.; Lightburn, T. E.; Tan, K. L. J. Am. Chem. Soc. 2010, 132, 14757-14759. 
(g) Chikkali, S. H.; Bellini, R.; Berthon-Gelloz, G.; van der Vlugt, J. I.; de Bruin, B.; Reek, J. N. H. Chem. 
Commun. (Camb.) 2010, 46, 1244-1246. (h) Clemens, A. J. L.; Burke, S. D. J. Org. Chem. 2012, 77, 2983-2985. 
[29] (a) Giordano, C.; Villa, M.; Panossian, S. In Chirality in Industry;  Collins, A. N., Sheldrake, G. N., Crosby, J., 
Eds; WILEY-VCH: Chichester, U. K., 1992; pp 303-312. (b) Tanaka, R.; Nakano, K.; Nozaki, K. J. Org. Chem. 
2007, 72, 8671-8676. 
[30] (a) Jeulin, S.; Ayad, T.; Ratovelomanana-Vidal, V.; Genêt, J.-P. Adv. Synth. Catal. 2007, 349, 1592-1596. (b) Holz, 
J.; Schäffner, B.; Zayas, O.; Spannenberg, A.; Börner, A. Adv. Synth. Catal. 2008, 350, 2533-2543. 
[31] Wong, G. W.; Landis, C. R. Org. Synth. 2012, 89, 243-254. 
[32] Lambers-Verstappen, M. M. H.; de Vries, J. G. Adv. Synth. Catal. 2003, 345, 478-482. 
[33] Thomas, P. J.; Axtell, A. T.; Klosin, J.; Peng, W.; Rand, C. L.; Clark, T. P.; Landis, C. R.; Abboud, K. A. Org. Lett. 
2007, 9, 2665-2668. 
[34] (a) Consiglio, G.; Morandini, F.; Scalone, M.; Pino, P. J. Organomet. Chem. 1985, 279, 193-202. (b) Ojima, I.; 
Takai, M.; Takahashi, T.; Mitsubishi Chemical Corporation, Iwao Ojima, Takayoshi Takahashi, Masaki Takai, 
Research Foundation for the State University of New York WO2004078766, 2004. (c) Parrinello, G.; Stille, J. K. J. 
Am. Chem. Soc. 1987, 109, 7122-7127. (d) Kollár, L.; Consiglio, G.; Pino, P. J. Organomet. Chem. 1987, 330, 
305-314. (e) Kollár, L.; Bakos, J.; Tóth, I.; Heil, B. J. Organomet. Chem. 1988, 350, 277-284. (f) Consiglio, G.; 
Kollár, L.; Kölliker, R. J. Organomet. Chem. 1990, 396, 375-383. (g) Uhlemann, M.; Börner, A. ChemCatChem 
2012, 4, 753-754. (h) Breit, B. Angew. Chem. Int. Ed. 1996, 35, 2835-2837. (i) Alper, H.; Zhou, J.-Q. J. Org. 
Chem. 1992, 57, 3729-3731. (j) Lee, C. W.; Alper, H. J. Org. Chem. 1995, 60, 499-503. 
[35] Achiwa, K. J. Am. Chem. Soc. 1976, 98, 8265-8266. 
[36] Knowles, W. S.; Sabacky, M. J. Chem. Commun. (London) 1968, 1445-1446. 
[37] (a) Knowles, W. S.; Sabacky, M. J.; Vineyard, B. D. J. Chem. Soc., Chem. Commun. 1972, 10-11. (b) Vineyard, B. 
D.; Knowles, W. S.; Sabacky, M. J.; Bachmann, G. L.; Weinkauff, D. J. J. Am. Chem. Soc. 1977, 99, 5946-5952. 
[38] (a) Fryzuk, M. D.; Bosnich, B. J. Am. Chem. Soc. 1977, 99, 6262-6267. (b) Dang, T. P.; Kagan, H. B. Chem. 
Commun. 1971, 481-481. 
[39] (a) Trost, B. M.; Vaultier, M.; Santiago, M. L. J. Am. Chem. Soc. 1980, 102, 7932-7934. (b) Sayo, N.; Zhang, X.; 
Ohmoto, T.; Yoshida, A.; Yokozawa, T.; Takasago International Corporation; US005693868, 1997. 
[40] (a) Schmid, R.; Foricher, J.; Cereghetti, M.; Schönholzer, P. Helv. Chim. Acta 1991, 74, 370-389. (b) Zhang, Z.; 
Qian, H.; Longmire, J.; Zhang, X. J. Org. Chem. 2000, 65, 6223-6226. (c) Duprat de Paule, S.; Jeulin, S.; 
Ratovelomanana-Vidal, V.; Genêt, J.-P.; Champion, N.; Dellis, P. Tetrahedron Lett. 2003, 44, 823-826. (d) Jeulin, 
S.; Duprat de Paule, S.; Ratovelomanana-Vidal, V.; Genêt, J.-P.; Champion, N.; Dellis, P. Angew. Chem. Int. Ed. 
2004, 43, 320-325. 
[41] (a) Burk, M. J.; Feaster, J. E.; Harlow, R. L. Organometallics 1990, 9, 2653-2655. (b) Burk, M. J. J. Am. Chem. 
Soc. 1991, 113, 8518-8519. 
[42] Holz, J.; Quirmbach, M.; Schmidt, U.; Heller, D.; Stu, R.; Bo, A. J. Org. Chem. 1998, 63, 8031-8034. 
[43] Clark, T. P.; Landis, C. R.; Freed, S. L.; Klosin, J.; Abboud, K. A. J. Am. Chem. Soc. 2005, 127, 5040-5042. 
[44] Imamoto, T.; Nishimura, M.; Koide, A.; Yoshida, K. J. Org. Chem. 2007, 72, 7413-7416. 
[45] Yamamoto, Y.; Koizumi, T.; Katagiri, K.; Furuya, Y.; Danjo, H.; Imamoto, T.; Yamaguchi, K. Org. Lett. 2006, 8, 
6103-6106. 
[46] Babin, J. E.; Whiteker, G. T.; Union Carbide; WO1993003839, 1993. 
[47] (a) Cobley, C. J.; Klosin, J.; Qin, C.; Whiteker, G. T. Org. Lett. 2004, 6, 3277-3280. (b) Cobley, C. J.; Klosin, J.; 
Qin, C.; Whiteker, G. T. Org. Lett. 2005, 7, 1197-1197. 
[48] Sakai, N.; Satoshi, M.; Nozaki, K.; Takaya, H. J. Am. Chem. Soc. 1993, 115, 7033-7034. 
Chapter 5: Appendix 
- 144 - 
[49] (a) Higashizima, T.; Sakai, N.; Nozaki, K.; Takaya, H. Tetrahedron Lett. 1994, 35, 2023-2026. (b) Nanno, T.; 
Sakai, N.; Nozaki, K.; Takaya, H. Tetrahedron: Asymmetry 1995, 6, 2583-2591. (c) Horiuchi, T.; Ohta, T.; Takaya, 
H. Chem. Commun. 1996, 155-156. 
[50] Yan, Y.; Zhang, X. J. Am. Chem. Soc. 2006, 128, 7198-7202. 
[51] Noonan, G. M.; Fuentes, J. A.; Cobley, C. J.; Clarke, M. L. Angew. Chem. Int. Ed. 2012, 51, 2477-2480. 
[52] Noonan, G. M.; Cobley, C. J.; Mahoney, T.; Clarke, M. L. Chem. Commun. (Camb.) 2014, 50, 1475-1477. 
[53] (a) Tolman, C. A. J. Am. Chem. Soc. 1972, 94, 2994-2999. (b) Hendrix, W. T.; Rosenberg, J. L. J. Am. Chem. Soc. 
1976, 98, 4850-4852. 
[54] Casey, C. P.; Cyr, C. R. J. Am. Chem. Soc. 1973, 95, 2248-2253. 
[55] Inoue, S.-I.; Takaya, H.; Tani, K.; Otsuka, S.; Sato, T.; Noyori, R. J. Am. Chem. Soc. 1990, 112, 4897-4905. 
[56] Christiansen, A.; Börner, A. In Handbook of CH Transformations;  Dyker, G., Eds; WILEY-VCH: Weinheim, 
Germany, 2005; pp 430-438. 
[57] (a) Garlotta, D. J. Polym. Environ. 2002, 9, 63-84. (b) Gattin, R.; Copinet, A.; Bertrand, C.; Couturier, Y. J. Polym. 
Environ. 2002, 9, 11-17. (c) Numata, K.; Srivastava, R. K.; Finne-Wistrand, A.; Albertsson, A.-C.; Doi, Y.; Abe, 
H. Biomacromolecules 2007, 8, 3115-3125. 
[58] (a) Ohkuma, T.; Kitamura, M.; Noyori, R. In Catalytic Asymmetric Synthesis;  Ojima, I., Eds; WILEY-VCH: New 
York, 2000; pp 1-110. (b) Transitions Metals for Organic Synthesis; 2nd ed.; Beller, M., Bolm, C., Eds; WILEY-
VCH: Weinheim, Germany, 2004. (c) Handbook of Homogeneous Hydrogenation; de Vries, J. G., Elsevier, C. J., 
Eds; WILEY-VCH: Weinheim, Germany, 2007. 
[59] Phosphorus Ligands in Asymmetric Catalysis; 1st-3rd ed.; Börner, A., Eds; WILEY-VCH: Weinheim, Germany, 
2008. 
[60] (a) Takahashi, H.; Morimoto, T.; Achiwa, K. Chem. Lett. 1987, 16, 855-858. (b) Kitamura, M.; Ohkuma, T.; Inoue, 
S.; Sayo, N.; Kumobayashi, H.; Akutagawa, S.; Ohta, T.; Takaya, H.; Noyori, R. J. Am. Chem. Soc. 1988, 110, 
629-631. (c) Mashima, K.; Kusano, K.-H.; Sato, N.; Matsumura, Y.-I.; Nozaki, K.; Kumobayashi, H.; Hori, Y.; 
Ishizaki, T.; Akutagawa, S.; Takaya, H. J. Org. Chem. 1994, 59, 3064-3076. (d) Benincori, T.; Brenna, E.; 
Sannicolò, F.; Trimarco, L.; Antognazzab, P.; Cesarotti, E. J. Chem. Soc., Chem. Commun. 1995, 685-686. 
(e) Benincori, T.; Brenna, E.; Sannicolo, F.; Trimarco, L.; Antognazza, P.; Cesarotti, E.; Demartin, F.; Pilati, T. J. 
Org. Chem. 1996, 61, 6244-6251. (f) Naili, S.; Suisse, I.; Mortreux, A.; Agbossou, F.; Ali, M. A.; Karim, A. 
Tetrahedron Lett. 2000, 41, 2867-2870. (g) Boaz, N. W.; Debenham, S. D.; Mackenzie, E. B.; Large, S. E. Org. 
Lett. 2002, 4, 2421-2424. (h) Boaz, N. W.; Mackenzie, E. B.; Debenham, S. D.; Large, S. E.; Ponasik Jr, J. A. J. 
Org. Chem. 2005, 70, 1872-1880. (i) Qiu, L.; Kwong, F. Y.; Wu, J.; Lam, W. H.; Chan, S.; Yu, W.-Y.; Li, Y.-M.; 
Guo, R.; Zhou, Z.; Chan, A. S. C. J. Am. Chem. Soc. 2006, 128, 5955-5965. (j) Wang, C.-J.; Sun, X.; Zhang, X. 
Synlett 2006, 2006, 1169-1172. (k) Jahjah, M.; Alame, M.; Pellet-Rostaing, S.; Lemaire, M. Tetrahedron: 
Asymmetry 2007, 18, 2305-2312. 
[61] Burk, M. J.; Kalberg, C. S.; Pizzano, A. J. Am. Chem. Soc. 1998, 120, 4345-4353. 
[62] (a) Schäffner, B.; Holz, J.; Börner, A.; ThyssenKrupp Uhde GmbH; EP2141145, 2007. (b) Schäffner, B.; 
Andrushko, V.; Holz, J.; Verevkin, S. P.; Börner, A. ChemSusChem 2008, 1, 934-940. 
[63] Leijondahl, K.; Borén, L.; Braun, R.; Bäckvall, J.-E. Org. Lett. 2008, 10, 2027-2030. 
[64] Li, G.; Fronczek, F. R.; Antilla, J. C. J. Am. Chem. Soc. 2008, 130, 12216-12217. 
[65] (a) Richter, A.; Kocienski, P.; Raubo, P.; Davies, D. E. Anticancer Drug Des. 1997, 8, 217-227. (b) Jiang, X.; 
Williams, N.; De Brabander, J. K. Org. Lett. 2007, 9, 227-230. 
[66] (a) Tomita, F.; Takahashi, K.; Shimizu, K.-i. J. Antibiot. 1983, 463-467. (b) Takahashi, K.; Tomita, F. J. Antibiot. 
1983, 468-470. (c) Tomita, F.; Takahashi, K.; Tamaoki, T. J. Antibiot. 1984, 1268-1272. (d) Allan, K. M.; Stoltz, 
B. M. J. Am. Chem. Soc. 2008, 130, 17270-17271. (e) Wu, Y.-C.; Liron, M.; Zhu, J. J. Am. Chem. Soc. 2008, 130, 
7148-7152. 
[67] Mosey, R. A.; Floreancig, P. E. Nat. Prod. Rep. 2012, 29, 980-995. 
[68] (a) Burres, N. S.; Clement, J. J. Cancer Res. 1989, 49, 2935-2940. (b) Venturi, V.; Davies, C.; Singh, A. J.; 
Matthews, J. H.; Bellows, D. S.; Northcote, P. T.; Keyzers, R. A.; Teesdale-Spittle, P. H. J. Biochem. Mol. Toxicol. 
2012, 26, 94-100. (c) Lee, K.-H.; Nishimura, S.; Matsunaga, S.; Fusetani, N.; Horinouchi, S.; Yoshida, M. Cancer 
Sci. 2005, 96, 357-364. 
[69] Perry, N. B.; Blunt, J. W.; Munro, M. H. G. J. Am. Chem. Soc. 1988, 110, 4850-4851. 
[70] (a) Ogawara, H.; Higashi, K.; Uchino, K.; Perry, N. B. Chem. Pharm. Bull. (Tokyo) 1991, 39, 2152-2154. (b) Hood, 
K. A.; West, L. M.; Northcote, P. T.; Berridge, M. V.; Miller, J. H. Apoptosis 2001, 6, 207-219. 
[71] Galvin, F.; Freeman, G. J.; Razi-Wolf, Z.; Benacerraf, B.; Nadler, L.; Reiser, H. Eur. J. Immunol. 1993, 23, 
283-286. 
[72] (a) Tsukamoto, S.; Matsunaga, S.; Fusetani, N.; Toh-e, A. Tetrahedron 1999, 55, 13697-13702. (b) Vuong, D.; 
Capon, R. J.; Lacey, E.; Gill, J. H.; Heiland, K.; Friedel, T. J. Nat. Prod. 2001, 64, 640-642. 
[73] Troast, D. M.; Porco Jr, J. A. Org. Lett. 2002, 4, 991-994. 
[74] (a) Sasaki, M.; Tsuda, M.; Sekiguchi, M.; Mikami, Y.; Kobayashi, J. i. Org. Lett. 2005, 7, 4261-4264. (b) Lai, D.; 
Brötz-Oesterhelt, H.; Müller, W. E. G.; Wray, V.; Proksch, P. Fitoterapia 2013, 91, 100-106. 
Chapter 5: Appendix 
- 145 - 
[75] Harayama, Y.; Yoshida, M.; Kamimura, D.; Wada, Y.; Kita, Y. Chem. Eur. J. 2006, 12, 4893-4889. 
[76] (a) Bates, R. W.; Boonsombat, J.; Lu, Y.; Nemeth, J. A.; Sa-Ei, K.; Song, P.; Peiling Cai, M.; Cranwell, P. B.; 
Winbush, S. Pure Appl. Chem. 2008, 80, 681-685. (b) Rech, J. C.; Floreancig, P. E. Org. Lett. 2003, 5, 1495-1498. 
(c) Huang, X.; Shao, N.; Palani, A.; Aslanian, R. Tetrahedron Lett. 2007, 48, 1967-1971. (d) Kiren, S.; Shangguan, 
N.; Williams, L. J. Tetrahedron Lett. 2007, 48, 7456-7459. (e) Wan, S.; Green, M. E.; Park, J.-H.; Floreancig, P. E. 
Org. Lett. 2007, 9, 5385-5388. (f) Ménard-Moyon, C.; Taylor, R. J. K. Eur. J. Org. Chem. 2007, 2007, 3698-3706. 
(g) Piri, F.; Moghaddama, M. B. F.; Karimi, B. Electron. J. Chem. 2007, 4, 519-522. (h) Ko, C.; Hsung, R. P. Org. 
Biomol. Chem. 2007, 5, 431-434. 
[77] Vellalath, S.; Corić, I.; List, B. Angew. Chem. Int. Ed. 2010, 49, 9749-9752. 
[78] (a) Uraguchi, D.; Terada, M. J. Am. Chem. Soc. 2004, 126, 5356-5357. (b) Akiyama, T.; Itoh, J.; Yokota, K.; 
Fuchibe, K. Angew. Chem. Int. Ed. 2004, 43, 1566-1568. 
[79] (a) Charles, I.; Latham, D. W. S.; Hartley, D.; Oxford, A. W.; Scopes, D. I. C. J. Chem. Soc., Perkin Trans. 1 1980, 
1139-1146. (b) Dillard, R. D.; Easton, N. R. J. Org. Chem. 1966, 31, 2580-2584. 
[80] Al-Awadi, N. A.; Al-Bashir, R. F.; El-Dusouqui, O. M. E. J. Chem. Soc. Perk. Trans. 2 1989, 579-581. 
[81] Pakrashi, S. C.; Chakravarty, A. K. J. Org. Chem. 1974, 39, 3828-3831. 
[82] Lühr, S.; Holz, J.; Zayas, O.; Seidelmann, O.; Domke, L.; Börner, A. Tetrahedron: Asymmetry 2013, 24, 395-401. 
[83] (a) Enantioselective Synthesis of beta-Amino Acids; Juaristi, E., Soloshonok, V. A.: Hoboken, New Jersey, 2005. 
(b) Abele, S.; Seebach, D. Eur. J. Org. Chem. 2000, 1-15. (c) Porter, E. A.; Wang, X.; Lee, H.-s.; Weisblum, B. 
Nature 2000, 404, 2000-2000. (d) Pseudo-Peptides In Drug Discovery; Nielsen, P. E., Eds; WILEY-VCH: 
Weinheim, Germany, 2004. 
[84] (a) Barrow, R. A.; Hemscheidt, T.; Liang, J.; Paik, S.; Moore, R. E.; Tius, M. A. J. Am. Chem. Soc. 1995, 117, 
2479-2490. (b) Tius, M. A. Tetrahedron 2002, 58, 4343-4367. (c) Ding, Y.; Rath, C. M.; Bolduc, K. L.; 
Hakansson, K.; Sherman, D. H. J. Am. Chem. Soc. 2011, 133, 14492-14495. 
[85] Eggen, M.; Georg, G. I. Med. Res. Rev. 2002, 22, 85-101. 
[86] Nazaré, M.; Waldmann, H. Angew. Chem. 2000, 112, 1171-1174. 
[87] Nazaré, M.; Waldmann, H. Chem. Eur. J. 2001, 7, 3363-3376. 
[88] Stereoselective Synthesis of Drugs and Natural Products; Andrushko, V., Andrushko, N., Eds; WILEY-VCH: New 
York, 2013. 
[89] Shustov, G. V.; Rauk, A. Tetrahedron: Asymmetry 1996, 7, 699-708. 
[90] (a) Juaristi, E.; Quintana, D.; Balderas, M.; Garcia-Perez, E. Tetrahedron: Asymmetry 1996, 7, 2233-2246. 
(b) Agami, C.; Cheramy, S.; Dechoux, L.; Melaimi, M. Tetrahedron 2001, 57, 195-200. (c) Gutiérrez-Garcia, V. 
M.; Reyes-Rangel, G.; Munoz-Muniz, O.; Juaristi, E. Helv. Chim. Acta 2002, 85, 4189-4199. (d) Beddow, J. E.; 
Davies, S. G.; Ling, K. B.; Roberts, P. M.; Russell, A. J.; Smith, A. D.; Thomson, J. E. Org. Biomol. Chem. 2007, 
5, 2812-2825. 
[91] (a) Holz, J.; Zayas, O.; Jiao, H.; Baumann, W.; Spannenberg, A.; Monsees, A.; Riermeier, T. H.; Almena, J.; 
Kadyrov, R.; Börner, A. Chem. Eur. J. 2006, 12, 5001-5013. (b) Zhu, G.; Chen, Z.; Zhang, X. J. Org. Chem. 1999, 
64, 6907-6910. (c) Heller, D.; Holz, J.; Drexler, H.-J.; Lang, J.; Drauz, K.; Krimmer, H.-P.; Börner, A. J. Org. 
Chem. 2001, 66, 6816-6817. (d) Holz, J.; Monsees, A.; Jiao, H.; You, J.; Komarov, I. V.; Fischer, C.; Drauz, K.; 
Börner, A. J. Org. Chem. 2003, 68, 1701-1707. (e) Reetz, M. T.; Li, X. Angew. Chem. Int. Ed. 2005, 44, 
2959-2962. (f) Landert, H.; Spindler, F.; Wyss, A.; Blaser, H.-U.; Pugin, B.; Ribourduoille, Y.; Gschwend, B.; 
Ramalingam, B.; Pfaltz, A. Angew. Chem. Int. Ed. 2010, 49, 6873-6876. (g) Wu, Y.; Qi, S.-B.; Wu, F.-F.; Zhang, 
X.-C.; Li, M.; Wu, J.; Chan, A. S. C. Org. Lett. 2011, 13, 1754-1757. (h) Pignataro, L.; Boghi, M.; Civera, M.; 
Carboni, S.; Piarulli, U.; Gennari, C. Chem. Eur. J. 2012, 18, 1383-1400. (i) Imamoto, T.; Tamura, K.; Zhang, Z.; 
Horiuchi, Y.; Sugiya, M.; Yoshida, K.; Yanagisawa, A.; Gridnev, I. D. J. Am. Chem. Soc. 2012, 134, 1754-1769. 
[92] Eilitz, U.; Leßmann, F.; Seidelmann, O.; Wendisch, V. Tetrahedron: Asymmetry 2003, 14, 189-191. 
[93] (a) Saylik, D.; Campi, E. M.; Donohue, A. C.; Jackson, R. W.; Robinson, A. J. Tetrahedron: Asymmetry 2001, 12, 
657-667. (b) Zupancic, B.; Mohar, B.; Stephan, M. Org. Lett. 2010, 12, 1296-1299. (c) Huang, H.; Liu, X.; Deng, 
J.; Qiu, M.; Zheng, Z. Org. Lett. 2006, 8, 3359-3362. (d) Deng, J.; Hu, X.-P.; Huang, J.-D.; Yu, S.-B.; Wang, 
D.-Y.; Duan, Z.-C.; Zheng, Z. J. Org. Chem. 2008, 73, 2015-2017. (e) Wieland, J.; Breit, B. Nat. Chem. 2010, 2, 
832-837. (f) Guo, Y.; Shao, G.; Li, L.; Wu, W.; Li, R.; Li, J.; Song, J.; Qiu, L.; Prashad, M.; Kwong, F. Y. Adv. 
Synth. Catal. 2010, 352, 1539-1553. (g) Zupancic, B.; Mohar, B.; Stephan, M. Org. Lett. 2010, 12, 3022-3025. 
(h) Elaridi, J.; Thaqi, A.; Prosser, A.; Jackson, W. R.; Robinson, A. J. Tetrahedron: Asymmetry 2005, 16, 
1309-1319. (i) Lühr, S.; Holz, J.; Zayas, O.; Wendisch, V.; Börner, A. Tetrahedron: Asymmetry 2012, 23, 
1301-1319. 
[94] (a) Yu, C.; Liu, B.; Hu, L. J. Org. Chem. 2001, 66, 5413-5418. (b) Aranha, R. M.; Bowser, A. M.; Madalengoitia, 
J. S. Org. Lett. 2009, 11, 575-578. 
[95] (a) Basavaiah, D.; Satyanarayana, T. Chem. Commun. (Camb.) 2004, 32-33. (b) Hoen, R.; Tiemersma-Wegman, T.; 
Procuranti, B.; Lefort, L.; de Vries, J. G.; Minnaard, A. J.; Feringa, B. L. Org. Biomol. Chem. 2007, 5, 267-275. 
[96] (a) Kippo, T.; Fukuyama, T.; Ryu, I. Org. Lett. 2011, 13, 3864-3867. (b) Tong, X.; Lai, J.; Guo, B.-H.; Huang, Y. 
J. Polym. Sci. A Polym. Chem. 2011, 49, 1513-1516. 
Chapter 5: Appendix 
- 146 - 
[97] (a) Huck, J.; Duru, C.; Roumestant, M. L.; Martinez, J. Synthesis 2003, 2003, 2165-2168. (b) Huck, J.; Receveur, 
J.-M.; Roumestant, M.-L.; Martinez, J. Synlett 2001, 2001, 1467-1469. 
[98] Takagi, M.; Yamamoto, K. Tetrahedron 1991, 47, 8869-8882. 
[99] Brown, P.; Southgate, R. Tetrahedron Lett. 1986, 27, 247-250. 
[100] (a) Moonen, K.; Laureyn, I.; Stevens, C. V. Chem. Rev. 2004, 104, 6177-6215. (b) Xu, B.; Hammond, G. B. 
Angew. Chem. 2005, 117, 7570-7573. (c) Palacios, F.; Alonso, C.; de Los Santos, J. M. Chem. Rev. 2005, 105, 
899-931. (d) Ma, J.-A. Chem. Soc. Rev. 2006, 35, 630-636. 
[101] (a) Ibrahem, I.; Hammar, P.; Vesely, J.; Rios, R.; Eriksson, L.; Córdova, A. Adv. Synth. Catal. 2008, 350, 
1875-1884. (b) Ibrahem, I.; Rios, R.; Vesely, J.; Hammar, P.; Eriksson, L.; Himo, F.; Córdova, A. Angew. Chem. 
2007, 119, 4591-4594. (c) Carlone, A.; Bartoli, G.; Bosco, M.; Sambri, L.; Melchiorre, P. Angew. Chem. Int. Ed. 
2007, 46, 4504-4506. (d) Chen, Y.-R.; Duan, W.-L. Org. Lett. 2011, 13, 5824-5826. 
[102] Henry, J. C.; Lavergne, D.; Ratovelomanana-Vidal, V.; Genêt, J. P. Tetrahedron Lett. 1998, 39, 3473-3476. 
[103] Dong, K.; Wang, Z.; Ding, K. J. Am. Chem. Soc. 2012, 134, 12474-12477. 
[104] Cheruku, P.; Paptchikhine, A.; Church, T. L.; Andersson, P. G. J. Am. Chem. Soc. 2009, 131, 8285-8289. 
[105] Uozumi, Y.; Tanahashi, A.; Lee, S.-Y.; Hayashi J. Org. Chem. 1993, 58, 1945-1948. 
[106] Kabat, M. M.; Garofalo, L. M.; Daniewski, a. R.; Hutchings, S. D.; Liu, W.; Okabe, M.; Radinov, R.; Zhou, Y. J. 
Org. Chem. 2001, 66, 6141-6150. 
[107] Korostylev, A.; Selent, D.; Monsees, A.; Borgmann, C.; Börner, A. Tetrahedron: Asymmetry 2003, 14, 1905-1909. 
[108] Straub, B. F.; Wrede, M.; Schmid, K.; Rominger, F. Eur. J. Inorg. Chem. 2010, 2010, 1907-1911. 
[109] van der Vlugt, J. I.; Hewat, A. C.; Neto, S.; Sablong, R.; Mills, A. M.; Lutz, M.; Spek, A. L.; Müller, C.; Vogt, D. 
Adv. Synth. Catal. 2004, 346, 993-1003. 
[110] (a) Piras, I.; Jennerjahn, R.; Jackstell, R.; Baumann, W.; Spannenberg, A.; Franke, R.; Wiese, K.-D.; Beller, M. J. 
Organomet. Chem. 2010, 695, 479-486. (b) Mikhel, I. S.; Dubrovina, N. V.; Shuklov, I. A.; Baumann, W.; Selent, 
D.; Jiao, H.; Christiansen, A.; Franke, R.; Börner, A. J. Organomet. Chem. 2011, 696, 3050-3057. 
[111] Pàmies, O.; Diéguez, M. Chem. Eur. J. 2008, 14, 944-960. 
[112] (a) Diéguez, M.; Ruiz, A.; Claver, C. Tetrahedron: Asymmetry 2001, 12, 2827-2834. (b) Raluy, E.; Claver, C.; 
Pàmies, O.; Diéguez, M. Org. Lett. 2007, 9, 49-52. (c) Diéguez, M.; Ruiz, A.; Claver, C. Tetrahedron: Asymmetry 
2001, 12, 2861-2866. 
[113] Kartha, K. P. R. Tetrahedron Lett. 1986, 27, 3415-3416. 
[114] (a) Stereochemistry of Carbon Compounds; Eliel, E. L., Wilen, S. H., Eds; McGraw Hill Book Company: New 
York, 1962. (b) Aksnes, G.; Albriktsen Acta Chem. Scand. 1965, 19, 920-930. 
[115] Tipson, S. R.; Isbell, H. S.; Stewart, J. E. J. Res. Natl. Bur. Stand. 1959, 62, 257-282. 
[116] Loh, W.; Chevron Research Company; US4554010, 1984. 
[117] Jin, Y.; Just, G. J. Org. Chem. 1998, 63, 3647-3654. 
[118] Nakano, H.; Yokoyama, J.-I.; Fujita, R.; Hongo, H. Tetrahedron Lett. 2002, 43, 7761-7764. 
[119] Aikawa, K.; Mikami, K. Chem. Commun. (Camb.) 2012, 48, 11050-11069. 
[120] (a) Buisman, G. J. H.; Martin, M. E.; Vos, E. J.; Klootwijk, A.; Kamer, P. C. J.; van Leeuwen, P. W. N. M. 
Tetrahedron: Asymmetry 1995, 6, 719-738. (b) van der Slot, S. C.; Kamer, P. C. J.; van Leeuwen, P. W. N. M.; 
Fraanje, J.; Goubitz, K.; Lutz, M.; Spek, A. L. Organometallics 2000, 19, 2504-2515. (c) Diéguez, M.; Pàmies, O.; 
Ruiz, a.; Castillón, S.; Claver, C. Chem. Eur. J. 2001, 7, 3086-3094. 
[121] Shulgina, G. I. Pavlov. J. Biol. Sci. 1986, 21, 129-140. 
[122] (a) Mezler, M.; Müller, T.; Raming, K. Eur. J. Neurosci. 2001, 13, 477-486. (b) Dzitoyeva, S.; Dimitrijevic, N.; 
Manev, H. Proc. Natl. Acad.Sci. USA 2003, 100, 5485-5490. 
[123] (a) Wachtel, H. Neuropharmacology 1983, 22, 267-272. (b) Bobon, D.; Breulet, M.; Gerad-Vandenhove, M. A.; 
Guiot-Goffioul, F.; Plomteux, G.; Sastre-y-Hermández, M.; Schratzer, M.; Troisfontaines, B.; von Frenckell, R.; 
Wachtel, H. Eur. Arch. Psychiatry Neurol. Sci. 1988, 238, 2-6. (c) Zhu, J.; Mix, E.; Winblad, B. CNS Drug Rev. 
2001, 7, 387-398. 
[124] (a) Maxwell, C. R.; Kanes, S. J.; Abel, T.; Siegel, S. J. Neuroscience 2004, 129, 101-107. (b) Kanes, S. J.; 
Tokarczyk, J.; Siegel, S. J.; Bilker, W.; Abel, T.; Kelly, M. P. Neuroscience 2007, 144, 239-246. 
[125] Sommer, N.; Löschmann, P. A.; Northoff, G. H.; Weller, M.; Steinbrecher, A.; Steinbach, J. P.; Lichtenfels, R.; 
Meyermann, R.; Riethmüller, A.; Fontana, A. Nat. Med. 1995, 1, 244-248. 
[126] (a) Semmler, J.; Wachtel, H.; Endres, S. Int. J. Immunopharmacol 1993, 15, 409-413. (b) Chen, T. C.; Wadsten, P.; 
Su, S.; Rawlinson, N.; Hofman, F. M.; Hill, C. K.; Schönthal, A. H. Cancer Biol. Ther. 2002, 1, 268-276. 
[127] Ahlbrecht, H.; Bonnet, G.; Enders, D.; Zimmermann, G. Tetrahedron Lett. 1980, 21, 3175-3178. 
[128] Mukaiyama, T.; Hayashi, H.; Miwa, T.; Narasaka, K. Chem. Lett. 1982, 1637-1640. 
[129] (a) Hashimoto, S.-I.; Yamada, S.-I.; Koga, K. Chem. Pharm. Bull. (Tokyo) 1979, 27, 771-782. (b) Tomioka, K.; 
Shindo, M.; Koga, K. J. Am. Chem. Soc. 1989, 111, 8266-8268. (c) Shindo, M.; Koga, K.; Tomioka, K. J. Org. 
Chem. 1998, 63, 9351-9357. 
[130] Mangeney, P.; Alexakis, A.; Normant, J. F. Tetrahedron Lett. 1986, 27, 3143-3146. 
Chapter 5: Appendix 
- 147 - 
[131] (a) Besace, Y.; Berlan, J.; Pourcelot, G.; Huche, M. J. Org. Chem. 1983, 247, 11-13. (b) Berlan, J.; Besace, J.; 
Stephan, E.; Cresson, P. Tetrahedron Lett. 1985, 26, 5765-5768. (c) Berlan, J.; Besace, Y. Tetrahedron 1986, 42, 
4767-4776. 
[132] Palais, L.; Babel, L.; Quintard, A.; Belot, S.; Alexakis, A. Org. Lett. 2010, 12, 1988-1991. 
[133] (a) Tanaka, K.; Qiao, S.; Tobisu, M.; Lo, M. M.; Fu, G. C. J. Am. Chem. Soc. 2000, 122, 9870-9871. (b) Tanaka, 
K.; Fu, G. C. J. Org. Chem. 2001, 66, 8177-8186. 
[134] Arai, N.; Sato, K.; Azuma, K.; Ohkuma, T. Angew. Chem. Int. Ed. 2013, 52, 7500-7504. 
[135] (a) Mantilli, L.; Gérard, D.; Torche, S.; Besnard, C.; Mazet, C. Angew. Chem. Int. Ed. 2009, 48, 5143-5147. (b) Li, 
J.-Q.; Peters, B.; Andersson, P. G. Chem. Eur. J. 2011, 17, 11143-11145. 
[136] (a) Yang, J. W.; Hechavarria Fonseca, M. T.; Vignola, N.; List, B. Angew. Chem. Int. Ed. 2004, 44, 108-110. 
(b) Zhao, G.-L.; Córdova, A. Tetrahedron Lett. 2006, 47, 7417-7421. (c) MacMillan, D.; Ouellet, S.; Tuttle, J.; 
California Institute Of Technology; US20080125310, 2006. (d) Akagawa, K.; Akabane, H.; Sakamoto, S.; Kudo, 
K. Org. Lett. 2008, 10, 2035-2037. (e) Maeda, H.; Hori, Y.; Takasago International Corporation; WO2010140636, 
2010. (f) Ebner, C.; Pfaltz, A. Tetrahedron 2011, 67, 10287-10290. 
[137] Ouellet, S. G.; Tuttle, J. B.; MacMillan, D. W. C. J. Am. Chem. Soc. 2005, 127, 32-33. 
[138] (a) Kanazawa, Y.; Nishiyama, H. Synlett 2006, 2006, 3343-3345. (b) Maeda, H.; Yamada, S.; Itoh, H.; Hori, Y. 
Chem. Commun. (Camb.) 2012, 48, 1772-1774. 
[139] Hock, H.; Lang, S. Ber. Dtsch. Chem. Ges. 1944, 77, 257-264. 
[140] Hoffman, R. V.; Johnson, M. C.; Okonya, J. F. J. Org. Chem. 1997, 62, 2458-2465. 
[141] Nuñez, S. A.; Yeung, K.; Fox, N. S.; Phillips, S. T. J. Org. Chem. 2011, 76, 10099-10113. 
[142] Pautigny, C.; Jeulin, S.; Ayad, T.; Zhang, Z.; Genêt, J.-P.; Ratovelomanana-Vidal, V. Adv. Synth. Catal. 2008, 350, 
2525-2532. 
[143] Janecki, T.; Wasek, T.; Olczak, J. Synlett 2006, 2006, 1507-1510. 
[144] Salamonczyk, G. M.; Han, K.; Guo, Z.-w.; Sih, C. J. J. Org. Chem. 1996, 61, 6893-6900. 
[145] Zhang, X.; Cao, B.; Yu, S.; Zhang, X. Angew. Chem. Int. Ed. 2010, 49, 4047-4050. 
[146] Wang, D.-Y.; Hu, X.-P.; Deng, J.; Yu, S.-B.; Duan, Z.-C.; Zheng, Z. J. Org. Chem. 2009, 74, 4408-4410. 
[147] Kawaguchi, S.-i.; Nagat, S.; Nomoto, A.; Sonoda, M.; Ogawa, A. J. Org. Chem. 2008, 73, 7928-7933. 
[148] Baker, M. J.; Pringle, P. G. J. Chem. Soc., Chem. Commun. 1991, 1292-1293. 
[149] Ferreira, S. B.; Sodero, A. C. R.; Cardoso, M. F. C.; Lima, E. S.; Kaiser, C. R.; Silva Jr, F. P.; Ferreira, V. F. J. 
Med. Chem. 2010, 53, 2364-2375. 
[150] Cho, B. T.; Kim, N. J. Chem. Soc., Perkin Trans. 1 1996, 2901-2907. 
[151] Denmark, S. E.; Amishiro, N. J. Org. Chem. 2003, 68, 6997-7003. 
[152] Iwama, T.; Ogawa, M.; Kataoka, T.; Muraoka, O.; Tanabe, G. Tetrahedron 1998, 54, 8941-8974. 
[153] Cahiez, G.; Foulgoc, L.; Moyeux, A. Angew. Chem. Int. Ed. 2009, 48, 2969-2972. 
 
